%PDF-1.6%
184 0 obj<</AcroForm 206 0 R/Lang(EN-US)/Metadata 181 0 R/OCProperties<</D<</Order[]/RBGroups[]>>/OCGs[207 0 R]>>/Pages 171 0 R/Type/Catalog>>endobj206 0 obj<</DA(/Helv 0 Tf 0 g )/DR<</Encoding<</PDFDocEncoding 208 0 R>>/Font<</Helv 209 0 R/ZaDb 210 0 R>>>>/Fields 211 0 R>>endobj181 0 obj<</Length 4039/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="﻿" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c001 79.675d0f7, 2023/06/11-19:21:16        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/">
         <xmp:CreateDate>2002-06-21T14:55:23-04:00</xmp:CreateDate>
         <xmp:CreatorTool>AdobePS5.dll Version 5.1</xmp:CreatorTool>
         <xmp:ModifyDate>2024-06-13T11:04:47-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2024-06-13T11:04:47-04:00</xmp:MetadataDate>
         <dc:format>application/pdf</dc:format>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>HHS/FDA</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Accutane (isotretinoin) Capsules Label</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:description>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">label</rdf:li>
            </rdf:Alt>
         </dc:description>
         <dc:subject>
            <rdf:Bag>
               <rdf:li>accutane</rdf:li>
               <rdf:li>isotretinoin</rdf:li>
               <rdf:li>casules</rdf:li>
               <rdf:li>roche</rdf:li>
            </rdf:Bag>
         </dc:subject>
         <pdf:Producer>Etymon PJ 1.10, Copyright (C) 1998-2000 Etymon Systems, Inc. &lt;http://www.etymon.com/&gt;. </pdf:Producer>
         <pdf:Keywords>accutane, isotretinoin, casules, roche</pdf:Keywords>
         <xmpMM:DocumentID>uuid:9597d45c-c64b-430b-955d-77fadb77ffdb</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:8d8d6c51-e690-4bb1-8043-69befb1d1b18</xmpMM:InstanceID>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>
endstreamendobj171 0 obj<</Count 46/Kids[172 0 R 173 0 R 174 0 R 175 0 R 176 0 R 177 0 R 178 0 R 179 0 R 180 0 R]/Type/Pages>>endobj172 0 obj<</Count 6/Kids[185 0 R 1 0 R 6 0 R 8 0 R 10 0 R 12 0 R]/Parent 171 0 R/Type/Pages>>endobj173 0 obj<</Count 5/Kids[15 0 R 17 0 R 19 0 R 21 0 R 23 0 R]/Parent 171 0 R/Type/Pages>>endobj174 0 obj<</Count 5/Kids[25 0 R 27 0 R 29 0 R 31 0 R 33 0 R]/Parent 171 0 R/Type/Pages>>endobj175 0 obj<</Count 5/Kids[35 0 R 37 0 R 39 0 R 41 0 R 43 0 R]/Parent 171 0 R/Type/Pages>>endobj176 0 obj<</Count 5/Kids[45 0 R 47 0 R 49 0 R 51 0 R 53 0 R]/Parent 171 0 R/Type/Pages>>endobj177 0 obj<</Count 5/Kids[55 0 R 57 0 R 59 0 R 61 0 R 63 0 R]/Parent 171 0 R/Type/Pages>>endobj178 0 obj<</Count 5/Kids[65 0 R 67 0 R 69 0 R 71 0 R 73 0 R]/Parent 171 0 R/Type/Pages>>endobj179 0 obj<</Count 5/Kids[75 0 R 77 0 R 79 0 R 81 0 R 87 0 R]/Parent 171 0 R/Type/Pages>>endobj180 0 obj<</Count 5/Kids[91 0 R 93 0 R 95 0 R 97 0 R 101 0 R]/Parent 171 0 R/Type/Pages>>endobj91 0 obj<</Contents 212 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 180 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 213 0 R>>/Font<</T1_0 188 0 R/TT0 105 0 R/TT1 187 0 R/TT2 186 0 R/TT3 122 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 214 0 R>>>>/Rotate 0/Thumb 167 0 R/Type/Page>>endobj93 0 obj<</Contents 215 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 180 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 216 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 122 0 R/TT2 187 0 R/TT3 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 217 0 R>>>>/Rotate 0/Thumb 168 0 R/Type/Page>>endobj95 0 obj<</Contents 218 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 180 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 219 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 186 0 R/TT2 112 0 R/TT3 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 220 0 R>>>>/Rotate 0/Thumb 169 0 R/Type/Page>>endobj97 0 obj<</Contents 221 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 180 0 R/Resources<</ColorSpace<</CS0 190 0 R/CS1 123 0 R>>/ExtGState<</GS0 196 0 R/GS1 222 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 186 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 223 0 R/Im0 100 0 R>>>>/Rotate 0/Thumb 170 0 R/Type/Page>>endobj101 0 obj<</Contents 224 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 180 0 R/Resources<</ExtGState<</GS0 225 0 R>>/Font<</T1_0 125 0 R/T1_1 124 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 226 0 R>>>>/Rotate 0/Type/Page>>endobj224 0 obj<</Length 973>>stream
q
1 0 0 1 -5.995239 -295.526367 cm
0 0 612 792 re
W n
1 0 0 1 5.995239 295.526367 cm
BT
/T1_0 12 Tf
66.005 424.474 Td
(------------------------------------------------------------------------\---------------------------------------------)Tj
0 -12 TD
(This is a representation of an electronic record that was signed electro\nically and)Tj
T*
(this page is the manifestation of the electronic signature.)Tj
T*
(------------------------------------------------------------------------\---------------------------------------------)Tj
/T1_1 12 Tf
T*
( /s/)Tj
T*
(---------------------)Tj
T*
(Jonathan Wilkin)Tj
T*
(6/20/02 03:41:51 PM)Tj
T*
(minor formatting changes needed by sponsor in consent document )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS0 gs
/Fm0 Do
Q
EMC 

endstreamendobj226 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 228 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 229 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj227 0 obj<</OCGs 207 0 R/Type/OCMD>>endobj229 0 obj<</Font 230 0 R>>endobj230 0 obj<</ArialRoundedMTBold 231 0 R>>endobj231 0 obj<</BaseFont/ArialRoundedMTBold/Encoding/WinAnsiEncoding/FirstChar 0/FontDescriptor 232 0 R/LastChar 255/Subtype/TrueType/Type/Font/Widths[500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 500 250 333 479 552 594 854 760 240 354 354 438 583 313 333 313 281 594 594 594 594 594 594 594 594 594 594 313 313 583 583 583 573 979 719 719 740 740 667 604 792 760 313 573 740 604 833 760 792 667 792 719 667 625 760 688 938 604 625 646 354 281 354 583 500 333 594 625 594 625 594 333 625 604 271 271 573 271 885 604 604 625 625 438 542 354 604 542 813 521 542 521 385 281 385 583 354 594 354 313 594 458 1000 594 594 333 1208 667 365 1031 354 500 354 354 313 313 458 458 354 500 1000 333 1000 542 365 958 354 500 625 250 333 594 594 552 625 281 594 333 740 375 594 583 333 740 500 396 583 354 354 333 615 563 313 333 354 385 594 854 854 854 573 719 719 719 719 719 719 990 740 667 667 667 667 313 313 313 313 740 760 792 792 792 792 792 583 792 760 760 760 760 625 667 594 594 594 594 594 594 594 927 594 594 594 594 594 271 271 271 271 604 604 604 604 604 604 604 583 604 604 604 604 604 542 625 542]>>endobj232 0 obj<</Ascent 946/CapHeight 728/Descent -211/Flags 32/FontBBox[-174 -211 1185 946]/FontFamily(Arial Rounded MT Bold)/FontFile2 233 0 R/FontName/ArialRoundedMTBold/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 132/Type/FontDescriptor/XHeight 530>>endobj233 0 obj<</Filter/FlateDecode/Length 31995/Length1 45260>>stream
HVyXG9P@\5r@79"Hs4:	3EEj0F"(EŬG+o4[Qt]comW_{ޫ߫ P@-{uj ?KRk $rT , ) 0=Y4X jTbqPKSO2q XPNHMC}&+*:G4:v-:C|x Դu2 C`4G˲`@,{FCT-Uɕ5 ״46PC\:B[d1τߌo|/b~-R#	Ra9#ם`1Uc4;@H2@Pа76}3˲]zpaE˵{Kf׹\i+VPs:4ZM5$h1C$L$4Z-18v{9kT*B''J4QJgKu)ST:P"'
8G@o{=o0 /DzA	qKlا'"Gd^._l[u=&ZwlwmGv=kǞ\l%IdSq}^\|V4햦Mዜ_ξi6ߙot?6qΓ&GTT&u̹;)r2uV|إ`SN<!fڰDihԦxӂ[|"3>7xGֱ)`Vף掎ʺå׃qZ3xHP=ߺ􊞪o6*hvjN}0H1(ʈuN%ln˚ު s5I4:M$tY@4ݧơSCâD?DC#őE菾9G?1_78K_$zrUXY̸ؕyۡfzyJÂ[뗏yq%57I]ld=ʬ%眓<ϵK(66`%#˕1Mskw3va ʗǟlṽ6r5QB&y٪*ȗ#%Le;v]e;w넬|v"3{lcϛ.T&nj.v-w[,]U/c˞TYظ%^W<U~p)o+~8fBϢ6GO#>|,6f a̔L-q[ߢJXFJWKo_U,*Xk5͕sֶ
FuF<˙u[Oqu<5vw_/Rؾqm#.^9}~ucmstcoۂzs$t&UN>SaV<+h'iBlc:/lhIg5u{VVMJdl53pnL)uzF Ƀx]9>QSJuז7IKnNF	K0i-#*A,[<4@W:[y㯝<qx14.;;#:RCQy["ingB|qN	Dk)#X@2hRJQ7*DcINCA8$R%ҤFfy<ϱF'֘Q0ΐRp5nX
BҨ#`06!F?q;߻v:ə=G%W$[dFkӺnzf+W䴤Juڝsv3>1-<?82aVS&cOd9+OC:!g'[-iκS1绺q0}}nJ[Wf5 3~eӗ%K_<˅׀u}a`{H#*c[-ݖЄ`0o^]QPT76TtB儎&SI&PƢ:"j9!@jJIA3
h)Tl.!QZ#@t\WqI`GM5@$\2$KJ*2ɛ@t]QG
U0CBIP`ʣ80" uc|*B,h@,dQֺևQ\yTj[\0j.g=} ;ΛÐowwLZvv^O2lFTJ4;BIiZ*4>z'FiT"KHK35+w%$"B*hKj+ㅉJLJT$U"6D@D.Pʆx&k+0$Dy ^*3ȊEj	[ZɊDD-7MJ beDլX D"Sۦ%XJF$W/'U>KJJE:Y2T`B!8o;Xʕ$ULZD"QDQ**y0V*%2/1$'2dgERO"clhgJID!	QI$<OL3F*TZ2!ǼX!u$IdJhm#pgDE䞭MH&qZ̃$}&Qz|3hS6**=mS{7fV+5	XWl|`poPGAKM0;2=m(S;zE$t7Nk}cRS_~-x\v+B><,8^ھTmӚj͉GP!E?ۜ:aҴQs=㬇<?ypٖGڟpo)ݞ77NySËy\ln(.T
r8h
^-D\(>)pxR7kygvuS.=cfS1f'W1]̭BϬ! -$ %!@x5m5=LiOHǦh2;}0N\^_w[~E L2AWˬ2]?=<rl~<\dXéxeB!>;cwDq~ocyI5W}*tnmy4c>,5Kr[Y8rH.*ߖC]7Ys8)UXK,5y0w<
moǣBa#"˝?S"|1bb1o)T06ջq9>AǻZ~9P0lvA#:hiwiS"n5ʸs7zbDيϭ$37"zcA`[̽\aѩ-=u@.Xq7r}  :1d8\|b!r<Z:7tu/W#]qkaiՍݺ]Ozӷ]+mA9[ 3|Q}ǌD I 6x4D&WLRԚаS~>m-DFcbg~O>{܌y__0+;g%K.j+W^v7!ۍ6o)Zm{юv[}~wPYyEe8rcO<uLs/]t
\vO7oݾpv:dB)!\j]Cw9I/H>Hd)q|-'7ߑߟG{JHII0#AG	1#IHhN4cQlD_[ ^i%Myxl٘a3l70v'v̑Ěyl?)"XKIKa-v|`|-Vȅ@1<)l}P5"!
`5>5,Kp"܃

Xxk\WX3XP_=̂dd=f<Ȁ/a̇*1Y!zhpn]	ʡr$,SYZ`. a:5xqa&qܗL$3C9u|CiA-h<(Wʉrx*@Zp_Pf\%d|gUA(Emv]Q{ꚍґq":`*(y[9XZqS:+2f90'Ɓ14O+s5'C7*zEGSiͣRTD ;B}lї쐍YSY	sjjkbU\N %=%٬X,0{n e6=YYZjU
QwHⴺRW^Mg}lqLısIy_ql_|N$!8)m VئܴE	ֵt-PZobTIc"?ZVN۴kwl{72V"]x	zS\(*eJ=%wT]:]%,oAs.8#ѷ,^}21zoNh|1mJ2-PzQoSJ{礞{R[^^Jo"=j@M\N0CW# ؏;nH:l$1US&M1]hܔ/qmON3p[dƱ_vFGS]CB2Y"K/`uW:J$j(ʢT+iMa'#Y'?[8׏$
g'DP9ERѪMj"!?48י3\llmW)@
ŤA:F27t@i	qChJG:y|/U3;cKX=|ϾWoM74s6+q]AL~Жiy>`9OgjqH/[\ 0y[?-W(%sePg6L0Zr`qSN:u:\-`wI0DLV0[N75;3-P3򘭄Y#$fCARv5F}
¬ήqo`?쉶Wop)%:i82=٧vU>y<GON~A/v0.hvL]#Û˽!e+Hă).Fb%>ZB h]!'){/*3^%Y&Q洙RJ(KŀPJPn iCj)D\(1눕'RGw,\u3q)K.=>{`D&jV$s٧syX}=\z}Ϯ13˅}/z(N7Y`,yf65TH=	Z-tb@C;۬]Q\А
GoɻЦ !\n*ܢ0wsNW,@aQd$㗊:oCv]:R	G?q\_H_?X:L7~>9ٹf%/l=91	[kYf{v'=Ͼ2w`v=}'䜶gOF
m,-ZX(g7a0Uo5\]'!鐦"U5DD9rcb9p^M;_<WZ{nSoQ\C˗^[]K $j_ՂZ-pi_	Q,!Up($	vm$V~էb[?_~$l|줜5$rWBp5oT+%IThCF@ZDJcy	
,<'!C%>ٱeCoq:2rɑ^9dߐӭFr^匿ݲ@RtY8ydjhLil27D߷:a{G7nJ
wq:$HDQb (zPnƁK/n\^"nśp dP,/a+Kp񻤉ӚeZ%e#]i<hln{vζZZk;_"^$^B-rPRTe'+N"\_O/|$co݁{S!YBEC.2n krɱTwﶬ!bTR3O³U5[W-]gc)Tq5af#Ɍ2#'rc͎z֠VӬL"(8ܨֈ-@Y"vE+zdևW	)̴D[z[S⏧v-z6왛Zs7V,jj߹7!$Hx`B$$<B O & *WC*Zjh2ʴn]qtݙw;u|u][߽I\?̝;^'8{z'<Z1>}3_W1\ylΣd<ӘDHHD<
ɃWR~|6p1ӳ	;ݢQ=5a WfP4Ȱl;ޟŨ.8NTS
HtOI,&$aeg3QH϶ v	f_\Q5KAesH@Sj.}^gwP$yHM&ŀ|̒RXve7;S[_U{9/2=DB @R9ʐ^ǐ<ĸJvH1H<c*k,O	%v!#	5Юn<º{n]e<=?֚uDX"{M-$͠lnJu{j}Ó%U7ZǢRT\	Dr2PO!Mǡpze4D/UI8NC21@::D˥DBs,TM.IPd9^*_xp0S؂^H*r	Y*\@*D#CXfZD3bpi@X_UDc&Ã^olZ*g[Zy#_>"3O_u_O?:4t_aա5U\+|(v\G?fD6!9	rCPdRL	.¡e2Z XoaЉ[Bʁ9.Tq{ocj8ooVTtʷ;߭;|l?_T*j֎8?csWu;(KT ><6Kix`Hc`%w'̒D	?|o񁷩;[POby뛛5bbs4؂vVt	Br8 		vEҐȴ	r/B@B,qQ4,I8,Al!C_y8J[,7<9p^ >=MSg;9No˷LV3۷s I=;xlALR}u^iƎlAF7J PeH00*AU0^",@l	Bc0H])H?Mx~ycOy䍔y_Yf*^EL{G~qwEoxRmj˪K=2-<}`m/µލWvLJL d-x<0@C#+'#/Dldiy*Oʜ53_YHdT4S"2Q$&	`zONQYr,ě	6ڡIС85m9cyK(Lqp*+1q'-V<}}~B '<=?I'*Hu (@?
WB8qs=Kg|>{_utC"A*azڊi)kZ	IdZLV4*fS@"
D(/M+	/D$/af% ?v;:ĘJ竦ʁSܷmVc>s9ض5STj7UVx(٩Zu[w뫬>չ^TVT 6%JB)3JJ$/A-\;Еv	2`wSz!r'%aϪaÁQFFgya ު`4("%F䑢a-9an<n, DR!(%3_:,paǃ k֝'ݙg.aہ΋O5.[͑=9GkGjR)79m29%m雃7O4׿YI޾aoAߞ=@\0Wy$a10|NM]6=,C
J*"<E?^WduiFIQ)a"FSUb7S` .RT˲ų^Q'%U4WjSse8t
{/2T	3k!B~<*cRTWkPSg>	pBbn!!!pK!-.I(Peҵ&Em]:huێmu٭]/vwv:lYۙiWj]wt	 !{}}	ZzQ2'i0L"*8&f="K2o'̀R-_Du}U1{Ikݹu
d@2-Cqso@Y5J.ZgG6ff(is"H0=5#4	r|4$g\gMaE+eٷbQRCwxЯ? )<ʷF?{oKyy[uӟRo[{MiʆFȏ{aR0LTP_' 
U- pHjR,IvJZGOIќJ:]`W]65Xˌw(:od-WM:+,':ϩ2;AW6SBP6
M8)HYہH"%^X.I7q߉u58%g](~]_;x:b9jX*k:/ݞ(.q*AuVt2OqU@E21E6rZW|5N<<a/.bԡ`18,!ʱjڪZ+CJ)9/kwQ	hJxA(sDEg5
*+glcɆDO٬T;fg{W];Ufؒʚ#O;@WwZq?sU8i>ԺήW_b^塥Niw<	3xGGp ^-L!Ed@lR*RQ(/_vwڢZaBT0t'?0rNO0)M&0 >˖xhߛ?sO}vNFǓ	JP+d/J7zF`?K-wNamUif[ںv&lۻrXi	94SHe9BIHHN̝VUL lx,BYoѭ.2[d|Ely7zXve/CyF7D I
P%"Ka	SeK47D|Gt(ֹ_=iČCNC
e"!2)	*S0<p:ټE $<qiX<VqMU)|@|R{J<y7w~/@s{麼鮾[{<	T)ةC&ta2)MD@=	^B`dIj՗q
ᶆjq*.7Fozf8"+ťuΝw>#6xJ';YNPՓlR rrAXb^WB G,
䠜$!Bx?<9GA2}d=ܽ/o^bƑρY>]q6WƎ87?MAf`m+1L"!iR`&>5 bEX* R=RZX@ u9,O:ٞx-gM6Vиtϯ+/]|m[J1;]b5YF{B*7EhZLD"CNiXX/[*a[*g	u1tX! 	oN3Ȃ|m1\hNX{>2
2hq@7 p(ΝK7XG% Q3H>f S s8ɌaKۀ[ΫŧhÉ)p{;*/tٴR[dx^;<[JQF&:JWN]N]:RWh=Û 3R)h!Ua.ܠ829j]@K)22"Bӱy!Oa&%/	#L0?}8;90TYXCj>='g^{ت۴ct\ϓ[[;lzK[lsZ].u(7&BxVou|i F@Iቀ^`Ls:rscKｖfӿE*p֖esG6B(P{P.${PbQ$b+Facuqٲ[҄lwֵy6muc|%~n`lWmlSｶ;N8vlvl'N'?c;А4MXIXhQԩjc[iuMEf[$N`Z=y94Ư6mZq_lc?	Hz 
{H)[FxE%*+%Z,1ʡdƫ&+ԋUSH5U*~q+-'1Qn|m<lhو_Lv9=HT%XelBHbhP+k3e ;ZBS#Zk
U4!֫V6Ԗt':F~G u	="'[6Zd]+bho(;M"屼zp?3Wy;iATC6B,%5|#7Z۶';)3q(L%N O6
8o}QעioRMQ:{l㗍rEK6ԢƩEEU|JNUvF?FLqjh>`YGP:fX1ú!``NIQe2u];nTSSgXFH{{}5n0&)z(}q>L0ys0Z]MB˫W.(c#3R%+@eRǏA5?=;+4'*%~0ݧ]fkcHSw1n:\TcOf/a\6Yfd+*:p}g\S	'#v,_]pyXh\݂,v󷨦zRZ)nbPmed:F)Jh T$B%Qf .<lΤ]c_n7t<Dߍ_g|V3)P5 2F')wDCsxw*"W'0d'pGCX$fOؿʱ2$s!7t2v;tkNG~47	=;r6!	;xz40dO1LǚϙĴ]Ea,#H/D@t7vo{){콓Yv4u[Ӆe2MH$1ߨFSS?'T'gߣnf~yzdtFF:5B3sǌFq&Me[GΕjxPz>PܗՏ*e=w_t]_M=˶QdfrTbG(J*{g?_zr1@(܍Szdjc˔Hf$y¦'z )aOͤ1֨V?W^;YZӎtyMpK:S2Ao |5`[?Gbm^ uɣ+5ᕍ+rXIxkĪB:|&dDz݋""g~li\`Wghe9//-3it2Gb	tkb<|vώS c|+0xIx<ۄv(ThIU0Y1(i1eM9jC519
BDc,vS[c;p]{W'ǃcMrn>ps?Zw@iư20+ݡ@XǅbRFи
Y\B# Czcs{vIY|/G:yT`ZAnLxG|M+D&?m dXNOk/G" û,j R-upJO>kFPVˣ_WX8[e^[)=qoX9g>78t{)kSs5k[wN"'O/_qVM[={vpsK~;/6I._ܶ4?-l(J^md%Md=[I!lJ4/SmN`q0?acАK8L9-[/Չ®؎t8xCl=ѫLs񕯓хTйHJd.ΧRiet.ǤXG,P@x,.GwVYJht.pGl+Ytv'{=_<|Q/U PE^	 Σ*loJ8<|#l^v&?6~U$Xٝ.ئ3Kq;v;qv؉v|%؉s
ˀ$BC!Te4^U
uLn+S&PMVM=EVȑ~ｴ.ϫv+	Ŕ>Q[(t
V)h`!*HTXub捆8tHKpQ#v:{AO_vvhoe\~kX>jH	)pCBMb$׌ǓL]9ڵL_6d,7ǌKm.G`HU\\hbWil=:f8)qG<gr@Xcbje2hϓ{3Y޼)telr>mJϿ-bTo"Pߛį3G'>[e2P_3>6b"!J6D*àxGVOбn	;ۯdЩuhԣCs{4'p$jB%APX'ǐTV*%1&朔m58KO;<Wf?YH$}:=D@fvMv3]gmkf`%
HZ j%<*u'Yu-g8#ygtB3'=`潗u&2{cޫRA#K{#So^&ށ;í_̧6r:Փof/UϕrV̀b9FRUE)+(z3,cJ
*&Ѕ)9L=sC#?D{+_EtǦd|̶wpO|d:N%L|4NmJ]ٓ9:@~yrJ:RpHc)Uܟ(Bh)r&]yK.jnu%h03wr}}\蝽>1fK 3n-t(g؄4&QyC[AT(/	I8t//eg&$/d^z'sbƔ;T}xtz롷(9VvD7Ţ1c4Ԥn\hFlIVKy6<6f,Z&sJܬ\BpP3$oJ+22ʇN-dYR2++]VB0pu5Wh?@Bj5Ha.]:s;I	&t6904rd*mYumk=1o{5%$병дBta%x@cw(	e~XOXtƒsJ)5!y9uJ:TA5J?Za[c<aE
58Bj])-EDn*rZ]kE!S2a>QGVղ+9"KZJK)@1"*P( Y\B|WTm5/C.OA2<hُaKR!_#>pm]ٸ3+16hZ)x~J$lb8B]Rq+8Rⴱ(DګRU^~&QUOXvWh)~vHd/GM9eu.]AJVOz(zB5ѵ1YL!`GcV#hQSyt^R^0iiUZo%}Vo*_j\ٿZR[eN75.m"2O%sJu*}al2ZE!ե 2Z#v,wLljj 0:WڱH]duAC؋,Esq?()[,?ٗ#&:5щqgJgb&Lj|&f(R<MTdB\%"AOibqxHo=[Ծ~>CmvD21h98.E/8yYg/ݓwFKݼyGtƞ_eF.3*3ZGn3P;Lqj} a)pBMP|}V08*)
])ZO0Kڂ"VhY[J q\8QZL\EɅڄtǶ/qf(WuX;ҿN_8v%o9 ΢H,o>(^TMa(?={mc0`ƀc_cLxWBx$@&4J۔PRRdنVNH6֭]"eʦv:Fu,iV4uԮٹ7}x"v-U,<?9?vBiO^ߠ684~b!ʴ#KT+M9<0-<gc6p#%A6TU;y9X$ӤSp
/A>r7,X"]9wY|T;K1v݋m3tP0tktcѲ㹸pAn#/͠MP׬:=<;iVؙ݆Pz6hVg~Q㳷C05X,%lEiX|\/usU:OO\vwjkbok7|i8| gAz0zu"Gx񯘸T%_G(-q~M"c?ܛ|#G|!\ELs'Ap"Z8v\t*i56!;Χ3$B9xJaMrr:3.aP'l*^&՟;\1XJMzuj/b})w-e*rL-#z{Y[! M(ED~bgj?ޭ@t!}Iqy{Zo$ho%$59k9<B4\C=Ĝ>D9	cݔofcNnNܛ|#G|![e}~Gs$I<|Ɖq{@ThEK2BdA+gq3hkoحyN$IsR_ehNc-/M*:Fzkhl 0!IX(_*uy10lìwU09Gmg#3'n^ptjjnbtl{digG,7ӎ16~pYL	 .(!ӱӨ\z9&2Bt*,>K/<^4*j5Vpߕg21k)^ѵ𕞆qGXnѬjRt5ntJ7uό?ߥOm%bdrwN9؟9}jVocTEn՜~g(ʛK@Z~s;J\C;u>qBV$Z @4e<!ip^Yk$N6Тl-lubydk+#fM@5s&u6)+]G
Mz?i6ݔbԵ[\mPݳ6SSoFÕ}:"G^J]}6%uB4t02E[$;le;TwM>dLh?1<0c@YӈQ tfW*tr " fJC>^[3QG59c)w.Ļph6t/-D'FŲ,NO/9奺o}w:N=웵ALP!Zl7RS8ݯx/lS绩!cC3@ڽbiϱ֞'|<<aNL{U?8Sy\kwnWej55\o< n<2^boML\jk>ZY|qV,v$L VIpbIg[/X(*DH{P͡ý%370<|O-g~Y[A<	CPr Sb$jʤy [,: >p&ę(A垰vcJPF' ]qG3+؝XBl?zFڮ#rSY	9L緋͍xc_wOV.wH`H;!q̛ƎbΗt	.oz{$¥%Bx^UU /^%	v*	
ay2(W-#!ĈBv*@d
UT2<52ͽ^ǣ/i(l}l5vU؃0U>6\kKlNwz|8l)waK˱K0w
̍#]>bt".,ex*>AZZGIR%Dk«yfئ3~suHGމ_?;~	qBIB3$Y!1
F"XHxV@GEBEщuJ[Ii$u!w m\~s^u[zbU6pdg!ɑuџ_n<6|텯ܖZ0/B%}nqK~G~ԍ:sOÆۙ///@YAD3O$m5QSMUKQp媰uJ{Q}o1#,J8:9+WGg?2g[ ppzo't:=:8&%
j8|C#LZYQt7Q%-bAN99(Ϲߤ) eq#s@@x*פ:%ei:KOL*cx[6XW*oMؒH}PY}SSw^	Ǐ=iwYNyB0mpUAEةթsTعQ͈笅bdo:}9K>zR^Mߣo;^y;l'sYҋUW8cBoZ[T5{Pઔڼ.Iɋ~R~wqD%[g_ĐΤ9`O4.rikm+uSc[-~HtxhWg`v@YTͻ5TFX4h"hz8KOcnf9T@o&w9MkaemԨ9oFB\A5vNDĄ$s~ߑUjٙgS
Rf$`K[uuP^:ro8k^)0>}G'
ҩ?1YG/Co$>;_zC*)]oxC{?c_^bRO8µBqs>BPD9<5n]9$hħ4JárZ`/
*UFJK [޲NOrfw\vtҽ{.S]g:<ʵꚟ]j֕Oo#&,uNvpbWOEitwb")ަ/3+*#4ئDKFS>R4j(fxD%;O	dT\g0Eʹxy߾Xޑey>9<Q&\b#T᭫9^/Tt9H1* R (9Ƚ8>N?Lg)y%T	*̜8-	\vJgA>R^?8I5)8	R?u,L"q@*DD)t1k"Nmn%A^R  kVLDEn3?fY3eTܽ;3M1 Xrր+*w/HmY},.fWi+֭aSf~*3pEyn^R&H$?,0hJas<EUk	f(̑A0Mnso!\sP{%zugQpS"2]YY׊Qg>OzasͱkKpE4i];hE`*^C
K'FlwՆ5cwVy)o84M<)(ܳ2ƕ=zj\z[\RM?=cwGt=F;s\٩]V!ܶ-kJstEقMqXIb(QNTBSPT,-"8(kҀ8C:mXX$ ]xHV&JPט+
7K;|goǣlwǺtchݯ:|y΄BѪ xF4*bWr dB/Wq9	jJ'E$=ly̹a-Sñ*f}kZӣ#ikLm)W(d:M囹t[	)rhJ)XCkc%g,pĵZM^<0j*.ѡebw	TȆUr;}X]D	\^}g.{kbfiCMe:+6yY.*7p΅e>Rjm,{w;c;9l_ⳝ$v'qL>'Mi|-H?+c0!UJmBB4
M!&	V`˕i,}eA/1<9n%!t\cfѐcQm9Kml?9$@BMHex'.oQ~-ԉڀIq;	-fi[*jJn9Nxú/Eie"]0jLS)u`P4(ŘwTX-~:yx;w2qNY~Kp^_覦6q{q/tJ6'6T-j
nU 2?Pa/|Tox[&Wƶ&aD)a{>f0ɞK|B&y!&#3HF|KU90G'嵧;Qa4ײ0bQ!<eԄAʫx?Zj1_K |[(H⁴ݙziuS;7'&J؁?}fgvͩ( ')ĺCV)d<vP*8JQ!k AUS7}=ex2Ú6e[$`X遹1fF(*QWJP$',-˒tO1ƱSmOt.b9G+=6{p@i	h6w&c&3
ee^vCӡX)4wƻ'rXQjoxqHKʿrg9A4@ܮFwqW 0$Ь:3jCbP fǠ݌eL=
ؙ*z߄k4B .jV40eQN5qFEޡ6ЯuUK__?&fWϿ/>ܞBckm_a~'O)JLyqvl$6ezhOWp0+uf2	md>RO~sgwv7wj"._@+$BHi !HJE]<!*	-boQ[O[@Y)V#wXIP݆^3Ɗ fy|l8dy)>{bM^7S>PJKm}_[9_L>cpk=t<{fXJ&h)*`}xo^eD)В>2gf֑(c`dT2 Ҍm(۔,ihFk1ZV׏f~;G^aOKś
li'udq鵥ʴtgh+?7!N=[	p-|;fuy(jPCZIN↊U]Qje[t6{Ea<C
dXDfڝZU|ߐK_w"+#DsF,C HiMض#DYQ 2GUd7Tpe@K$Q@[h8 (g!ѧPjr~G}2O?{GLk$Ҩ(8$$DPghkCQ+n i~Y"@	aUדiGpÏ|u9B}aKGXi]?b+.GSl)Ŷɑ3R4MaGx&zXkO+`A(Wgk]6sC"]GC0}j.X$IU~뜲o~V?:y~P0\lwf$@C}?Rvxm/d7gՍ!WG8>1SE-H7v+(xQw'g*rρb|ZP|dܵcuɱÌ?N*Ka
mC5VFQqX߫׽G'RQvkWI/^D^K2e#-F&eh.hMG<x_-S@浠."(7>ǀBFEy\kjdq>v/ֆG1^.ķ)q׮kS6iNVƮ]A LKKcv8mr; 뻔;2gvITAݿyhGu{wWHZ@ H BB<+ZI6BDy&8mcR8\Ojuܦcփn0uړL>v&Ӵ!4mK]錴{s{=AFTC%vXA!('t쌜fg
sY:d3yh Y6@R&aMu`="-KNHUp5(Su}펌.>I-t@(</Nyk>`Nk*![5!hmd	!]Fm7@)E 
DAvD;E[菾?gnsW/.\>?g%׃./,:~Pؗƾ|\kЮJG]V>9qD72yM EE.~gr['Г,k)wS)Y*a[.[<oR5_TD"'dyI-Y|HI_'>:QYƹsK}ݓ3zĵoS+v<>:Nű;\!wM7uWt&S';0B/.=~QxQP{aEX^ O\Fq}/yJЧdOޗ=E*D7n"JZTȥ5E"@iݨYM͠dZbJ#_쟲WTY\Z=*2|c/e	@0c':uyxO㢧6dAeR#?YOYy|3PsPlwdcjK
nH(>;0[9/0ʃW{_g)+,WeEvPI|G%K/VG7Ho2ZN]."sB
:f^p,\˄5!Ӌه^'֐ͰUb*8&PP=XȔtP&uO(cy8cz)z6c׷-XŃ\?ɱ	.7<(!G[.ˢ%-os@d`c'6)nJ8OOGxI4C}>z2Amk̛R؛vR.ݦfa󐜧
?×88jb5z5ݡ-(>}c,-Krd;[
|Jg8[*YWIeEF(%w t^a7Q;7w*vy;KU9XHJvfop00C)ϒjU_֤GxȤI?>oI1Sp}$,<٠)Ky
&E((c}֝kN[-)w4cu꒲,
P bT̫ XDmIHZLHgvyi2Qt
oߦr5+Udga$9d^نYnoG'eJkw`g 
KDj6rI%%.+Ngkzy0ZF0:m#&l13f"	,(VV+JLdN|,MDN|isH]v=>679=ܮx1\y11%9dz{u~e%K]C/	OCӄye֝`Ԁ٥'܈ezl(i,SB@ʍI?kqmc+!K{DO2ɼ%|^p9"yA~C	)P(iCٌb-t5v+ÓXA:RX:[`0p(vz|Foز[M{x_j诀[A3RnlK],uGu`{Ro`uh QQ!d)ٴtH<n39RMQPZ$L+,Iq^+2z1js!=]^.}aFjN{=$EkS7P.(b-P}C^.C6ø MN6j>[paO@8/GlG5x*OC ;ױa<dy3YҚ@WoP=%% @E}E^au[ygfޟ8Sz.gg{1q^q/ܨ&Vd(כMbv\׹H<L˓_q>v&unz\WilT͛y3<̛ͳox챟`q^RB00(Fi	JRQPJhTMQժT!hf؞o=s}~rӣƎ?Hhܾkv̠oʕ|ÂoV^k'>YKO82-=Ɵ/ۧ}_8Ws%
~]<.3ϕ+[8z~'HT"'ƕl]]a	qI cb4h0"
4n}~;^qu6
H7~mGTMc]Pi'וyB2{GRT@| @"MnhQ+¹jZBmQ
zE-T#kB[环OTOJӕ|B˻e<@|N>y1'2$=E9/ZVWwnMt!Vnffff&D^@L/AgHI.WmG-;[Ik{:n4Q`rQ\V֧Qa_+JʏfqE<40GGj'#L]1)^mzdd:=Q;2-fרر%De"Ҋ>J\Fid~Y0Xtsǩ,;UK
TO_6k,[դ%.X]	ldB1/1TnVE$ݩ){a }q>(_X4`\{<j0|x~6q%PҐUPז*udUX	vF)x1T^bɐ	.'k(UOOtna>Ю۩ygjZen%w$L1`8&wZֱVddȌ	]58zЧZ>`z6?4w:H.wO;jKUY%#O^|ƳSB+c"SF8>b1p+f (#Hw WP twabl6B-mb[-΄&CY&d0wK)_p[6_%7#fe3*+0:dbӤx}Z0@u*c<g"@b`$~u_β_y;;wO/,h[a#~&v)l:=&kq	qlMT
Ue*^D8&@fm疛񸼨#LА2ɢG#s+|f apm+R.{}썯u4[]'TJքCdԭxϟ|?#,!/g'N-t_M^W,;+sXLʐ\d@
+ U}+$-5h]/TXGXm6\(	;11:)d ab{)Bj{s{=ğ'}9_[Rwo}ٖS]]3v59z05E?fl&.YhF~`|QbG5Iq)7&<QX(Rui㐣UB4:Rx|׾gnk=\]foݾٗs	SlKk?=kׯEzzе+oc)OʐSI%bPMrUFI@;'!WSRb18.\g>fp}r=B$HPjLϫ6ƣ \y1kh]PMTUל{M1s-*s2HA+L2i@<KT>"cq	lo"mIS{ΝΏَTx]M-9_0sئkҖ Ė n"f!#D]rPUD'ꪣ$]*J F^|.] 
ҤX-"1΢vڃ;Б=8Bmǆ^ͅMX#V	mٺPK\Ӓ&bs4s`8]:muZץ7پoi[d+t_t1h u2Aᮘm	diJ'$?;q^1'qCHeq,Īv`BVUKb~tBUlP~l&MUMJccҴu8AeҦE:{r{>|[lD%U֪^گpnD̄pP_/ʂMM]8`<vBJ{"}n`⽯ãF\?m4^6'[8)Z>+#ثo,pU|dյV<;n:c)cփ߻>lHXj:XkgD֖&>Ck%>MnՍ!3f}[nJݸ=/=ZJϔ>;Y>'tOd@GޤqB49mph97Xk?:ىssZg^&&܇r^:WMVn3^.-6pl?8&Ohc;qsϘvlaFĮXD@qAѭj+'}Z@w_$'0|rqTFmvZuم6-{^BC=I"kc	:j?wuz,rwJM*2w~߶j^kMu$|{m/xV;!TaE]cwՈىtjֽHAkw5ҿ8 YC##,<3}_roj*V<rwT`"d 
X]!ݿ>l8BJD=Ȁskq05x;ֆNg"wWb^wN>HWKK1NΈ[;g|j^a>[Y`Tn<,ai"o\ﳿΈT.ͤ|b^ɘeM:mHδ&М mzQN
r.|iYPt4j-΀AG_dƺ&86dtjJnkr2%s6݅n(W!W͟*jNUAY~d*bWb/+cΘ?+&g-[ې_<O!>kbb÷\'.?oVܓ_R2wAM񗠍-߶#I2.O1VFoPyB~rsj(12sүqrT[Iu8o%CE\5RF;|U=~jt+VnLXW2%J6Aj=RqW.M>.lTsT]ixa]S-771G[\m( AˠEjz@H*_鳲(*(}ؤ;lwψ_XD_U^Q/a؈Nqc)>b:N%40Bh:0^<E< t.qgy9nhސ𗀶<Pꀭn8$D@[YNN
Lr42NP%R3O\
"F}XshG|ƺtѷ.%vJZNhvaMy`@j1+H !Jз 	4V J3(_
"%`7,X0Dэh+Iup:9uPa% # v01_!f6`QTjcn
1_!Gvց*ЉAL<Ig)W X*+ HdT.'CYX1+`(Qyf^AI2i)Gss,_!^ Cdڰ4d,O56k{`5(!$(O'~,)Ӝ5CIx+r4O\
+Ќ0](%QQُ2Q6J?J\aym5QXTT`]Hb~	h=jj&1YJϏ>~ڍbP7@;Wsns8'8:LL͐
'g⨫YV'd|	UxVPU 4r aE)_ 1Cj8F83̹qKR?I$$[%UVQD?͢PGH-Q6F]	j&#I3/Wo)pb؃)VH
U|ROZR<R;zKcAOS4%O"?M(HT35'?NI0V3*Pesjr,7ʲ<<L{&&)IG3F~crY-˝f([OQD~/ʫI_lEe[-4@\`TQc96*24'@(K,B
4RZ,-NJHYI;`̤߻.bO^HֈNέ[;:y;in2òeedeḚd9,,,#,e.ؾnw3lf{77r22rG>Sܷvsn6^3^3^3^^\Gyr3er<>1y|c<>1y僜僜僜僜C{9!;fo&k,cO^ƚ	^>:5F8ΏE#׍0x7saP[yCUUGuJ`څ>qᒺ@T}U3U=%#5֤jwii/RU-I;H_G]nBFiF<ck5q^ld>y%Y{aaplmT-ݜIބxƷz.ZdՅgE+N]+n/*^_de405>aa+6Vq#^">''_+KRJ斬2wKN(,TXyZy'.sTOjjʻ*߬TSfc;5t~	ykڬ1̢y[]Ynn3uYDKe5qI˿?RU@iՍgۭ{Ǭ^^)mz[`jgo.حzMEM5=մ;7l>hp<82e;o;3yS7|8R4	PR^  ɭ̥QӓXEI,v'IbX)sS/][/2VUYzE&c-cq*1$VZp+W'X |1WXreu`q<tu/fg\8SWeeMؠ8msny1.F̸.lq-#2֎-ƣX7Cބ[w8%DEqOwP
'',uD"_jsJ3aG 8lS
CшToճAy/$gy⋥hϭ&$P"'PDJ.yRl3{"~)Kf}PDRdTd P4mIWmVz]uWTU/`0Hm!ٽd-a7=Ts;(K0FV2k,c4'(sz6L~`>y|(@yzd.'ə{i}~E8Zt3rF_-l]L(U
I;DJFg&Vfʊ<-JsGS"0Pۛ/c-4fۅqǰ܂3L67P/
)$7![\«*qy36Vw=%{%EbHC:1bulxS5Q"%t?)C9&ҎLB%PMÄZZ:XȳXhB3MNL4.3Ȼf9Uͦ\[M9n'\@;MU42ߣM7UwK=|bCtӷ(7٫hU}Gc)TC<Vb!<UXGk(ǔ6`#61?xO)l<x,~؁c'v9%^0^>짊Tex)88BEoqo8~@63Ni_(_~qΓ7)]§۫
>^W'<X }UMFoģOwv`ZFE5&J(%!CuYM[׮VW.\!i2tiV3v~*C<,.̟V]G54 
endstreamendobj228 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj207 0 obj<</Name(Headers/Footers)/Type/OCG/Usage<</PageElement<</Subtype/HF>>>>>>endobj125 0 obj<</BaseFont/Helvetica-Bold/Encoding/PDFDocEncoding/Subtype/Type1/Type/Font>>endobj124 0 obj<</BaseFont/Courier/Encoding/PDFDocEncoding/Subtype/Type1/Type/Font>>endobj225 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj221 0 obj<</Length 3828>>stream
q
1 0 0 1 -7.004852 -19.827393 cm
0 0 612 792 re
W n
1 0 0 1 7.004852 19.827393 cm
BT
/CS0 cs 1 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0024 Tc 0.0024 Tw 12 0 0 12 65.0357 617.0126 Tm
[(Very severe b)-6 (i)-5 (rth)-6 ( d)-6 (e)1 (f)-9 (ects h)-6 (ave occu)-6 (rred)-6 ( w)-10 (i)-5 (th)-6 ( Accu)-6 (tan)-6 (e)1 ( u)-6 (s)-3 (e i)-5 (n)-6 (cl)-5 (u)-6 (d)-6 (i)-5 (n)-6 (g)-2 (:)]TJ
0 0 0  scn
0 Tc 0 Tw 29.56 0 Td
( )Tj
/T1_0 1 Tf
-29.56 -2.28 Td
(\002\003)Tj
/TT0 1 Tf
-0.0022 Tc 0.0022 Tw [(S)-6 (e)2 (vere In)-6 (tern)-6 (al)-4 ( Def)-9 (ects: )]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 11.21 0 Td
[(defects that y)29 (ou cannot see\227involving)9 ( the brain \(including)9 ( lower I)22 (Q)2 ( )]TJ
-11.21 -1.16 Td
[(scores\), heart, g)9 (l)-3 (ands and nervous sy)29 (stem. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw 0 -2.3 TD
(\002\003)Tj
/TT0 1 Tf
-0.0025 Tc 0.0025 Tw [(S)-6 (e)1 (vere E)-5 (x)-2 (tern)-6 (al)-5 ( Def)-9 (ects: )]TJ
/TT1 1 Tf
-0.0015 Tc 0.0015 Tw 11.43 0 Td
[(defect)-4 (s t)-4 (h)-1 (at)-4 ( y)29 (ou can see\227such as l)-4 (o)-1 (w-set)-4 (,)-1 ( deform)-4 (ed or absent)-4 ( ears, )]TJ
-0.0009 Tc 0.0009 Tw -11.43 -1.16 Td
[(wide-set ey)29 (es, depressed bridg)9 (e)3 ( of nose, enlarg)9 (ed head and small chin. )]TJ
ET
q
228.1199951 0 0 113.1600037 65.0357516 405.2126003 cm
/Im0 Do
Q
BT
0 Tc 0 Tw 9.96 0 0 9.96 293.1557 405.2126 Tm
( )Tj
12 0 0 12 65.0357 381.2126 Tm
( )Tj
0 0 0.5  scn
/TT0 1 Tf
0.0016 Tc -0.0016 Tw 0 -2.25 TD
[([)5 (illust)5 (r)5 (a)2 (t)5 (i)-1 (on of how)-6 ( t)5 (o)2 ( r)5 (e)5 (m)15 (ove)5 ( c)5 (a)2 (psule)5 (s)1 (])5 ( )]TJ
0 0 0  scn
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 0 -2.21 TD
[(F)6 (i)-2 (g)10 (ure AStore at controlled room temperature \(59\260 to 86\260F)6 (, 15\260 to 30\260C\). Protect from lig)10 (ht. )]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -2.19 TD
( )Tj
0 0 0.5  scn
-0.003 Tc 0.003 Tw 0 -2.17 TD
[([b)-7 (i)-5 (n)-7 (d)-7 (er cop)-7 (y)-3 (] )]TJ
1 0 0  scn
0.0028 Tc 0.0072 Tw 0 -2.35 TD
[(F)14 (EM)7 (A)5 (LE P)14 (A)5 (TIEN)5 (TS:)]TJ
0 0 0  scn
-0.0015 Tc 20.6815 Tw 9.86 0 Td
( xx )Tj
22.177 0 Td
[(MG)6 ( )]TJ
ET
q
1 0 0 1 -7.004852 -19.827393 cm
66.161 279.6 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
66.161 279.6 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
66.641 279.6 478.8 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
545.441 279.6 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
545.441 279.6 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
66.161 279.12 0.48 -14.76 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
545.441 279.12 0.48 -14.76 re
f
Q
BT
1 0 0  scn
-0.001 Tc 0.001 Tw 12 0 0 12 65.0357 233.3727 Tm
[(DO NOT)-4 ( G)7 (E)-4 (T)-4 ( P)10 (R)1 (E)-4 (G)7 (NANT)]TJ
0 0 0  scn
0 Tc 0 Tw 12.12 0 Td
( )Tj
ET
q
1 0 0 1 -7.004852 -19.827393 cm
66.161 249.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
66.161 249.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
66.641 249.48 478.8 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
545.441 249.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
545.441 249.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
66.161 264.36 0.48 -14.88 re
f
Q
q
1 0 0 1 -7.004852 -19.827393 cm
545.441 264.36 0.48 -14.88 re
f
Q
BT
/TT1 1 Tf
0.01 Tc 12 0 0 12 65.0357 205.4127 Tm
[(xxxxxxxx-)13 (xxxxxxxxxxxx-)13 (xxxx )]TJ
0 -1.15 TD
[(xxxxxxxx-)13 (xxxx )]TJ
0 Tc 0 -1.16 TD
( )Tj
-0.0004 Tc 0.0004 Tw 0 -2.22 TD
[(Copy)30 (rig)10 (ht \251 2002 by)30 ( Roche L)20 (a)3 (boratories I)23 (nc. All rig)10 (hts reserved.  )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.16 TD
[(Revised:  J)-11 (une 2002 )]TJ
0 Tc 0 Tw 0 -2.24 TD
( )Tj
0 -2.23 TD
( )Tj
0 -2.22 TD
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj170 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 196/Width 76>>stream
H u;)EҸˎV&{z/#Ͱj/F JcVæA_*UGEw\&¦]
ʲ*WOը}邐Xz,\{򜔫 ]>1	2¼Z]u5˨GzBd X
endstreamendobj103 0 obj[/Indexed/DeviceRGB 255 104 0 R]endobj104 0 obj<</Filter/FlateDecode/Length 337>>stream
HR[BA,`XXB,`d<lzM`3qYrV#v!jjGq41k:XYδ{]j=Xp"ĒK-]RV\ipkv)WCHeh
z)ʲ+} W_Φ#Aܰȣ	rԇTfa]3jVcGTRB:,]z8؁\ӧDFF_Φ(<Ң]
:[]Z;E*i7@FiNI,FF_Φ|I'3T||q;w|(҇%,iv|>z^|? qc
endstreamendobj223 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 234 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 235 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj100 0 obj<</BitsPerComponent 8/ColorSpace 123 0 R/Filter/FlateDecode/Height 447/Length 24062/Subtype/Image/Type/XObject/Width 897>>stream
H엋z FMpvP4v5oF0                                                                                        ! x* _BA@ p _P ~|
 " @   8@@ p  Aç]7햚tZ>F)'gҙt{ƪ/SJi`JQ˧A5keAje[nҁܑۇGW6GX(Pmѭ{ߍdޤr7(MĪQaӾ=
k/U*`ekPAk#[NwG:w9y	Y GEs M݆ڋMVAk#u_#@b5H@2/0pI}*ᣀ-[No	N@jiK[n, iX\ՐH뇡H9?ϵO[fG@JdNj-mF*j!չ>e_oDȋPC)?z㞀n_Y׻g0,^VN@^;)Ri2Z.*y/Dj%=ԸSćlKR6L	;
$c[&0P,{0g&3%/"ʦ4=IUǇpҟ	ݢpQ')G`"0 oBjH_S8
3wX3u^9&aWT*R0mdUv/+,bsB972^8!P)E+,emν4^>`JHXfG[ZӢ\La[e&fF@._7o/^YSV(zNd\i(Rx^w\\e(	ax
p]!}V<
H{G{|.^Ʀޤ)7ٽt
釩 ^~FWLE|g
~F)/h)@Ǐ.9Z5Vޢ~,a&M	:wSF\߉\j?}ӯH6vJ_zU :W;B-o;G	hT@|rT]uÜ$k"lY91UCbb,ְ~f_1R+e4jұug	
mߺ~N}NC[NDEʳ~}t:浧&Ɣk,O֏{@{۞5q+/r:\~d$)䷫7e- cڥкY7!qn'v~!GTT}(kuJm,Vv\q&;TvԉF>vs2/vmr:F4io_nrFNKefP1Jb}VkżL1ql	H)Oy+1ߪ&^#Y8pT8@WI맞h35YQm_5,	4ҭ}-NayV,N#k]^Dp44!ƐH5vQ**DZ\eB
a'%[QRzY_TʴRvDv,k5tΎ.F6SUvj%?vw{ד'{P&fAؔKt$h7s/>z!@h3,VʖNLZ0o|Zjw*F=S;I+8oJ)UFL\l4''Wtʫ\㴚;RّtƆ.~Hs?|c (sʗa#R.ڞ4f*W&IG-FzᲟX~?UثY끪/A(C Z)t ~#r]ؾKyڣ=9Uoq]$iuz,m+a3Qg2ʘƔ')qi]ۨ0uY[i.KjhkO'M~*m>^+Qۄ_*J羛ޭ5oKuoX,IiċKt_q*e6Xv/Fr
R3.tnhmni]I]mgt_ApQ[CӴX/fM[+-(u<*:฿8D@~zh;闏,kN7nM|yܶCm]WA,QOYEMpYkʨ*i;NYrPՋ&d|{v)
&o8/H-iy>g%lrPƗze_"[%AAyy0Lr7QS6ñFb1[<JkԮX7ҌD@'<:@7E@'wcvJ1^E%hD6Qj$֡45;bMTҐ'oHmǢ*T3)ȶՄMlep,czSըgysI98߇ԡ~h9PXO;jQgF ^qIÌ킳0I3FM6M44O@gzWWfBg_1콻I*z4qv	
o{Y21djӀ%"ۻyBgR3$F1υK4(3s :s\R<w3ܒ.8V{@FA?03OQhF%ic@-ev
<<k|+KCW{ t52h,pšIWqZEUPK79f2W&E[m(Rmh
c@U/]\S^ !hchH+umm.iojgff\m%%tEEPz#SED-H~VG pkqKF!{Jw	jwPmةp)yMJ~tQڭѦ[hh}F RoPt/vple]&[eLE Hkfea `	1l2q*yč{!BlHN5 	$0&`N Z?wѩ{9FE34~않7dA7Z?	</p@p4v *D߃F,6Tр_tW" GAR&% *Iejl~qow'E3Z)J7悠3UnJ}8̮z^=sxݘXhk&.v ˢ}Cf@؛lmMЇRr@V5zP sF"EXP#{69SVgf: ]EŌ\%b BnZ<*tRfi.iG})a41=X6o 6~תuJ*+O`ij|X@dP5zv 0"tvq%mjI_u&SN,*q'jmn1h6ge@!;Ոep%M47jB NgH^7{MbIWHI)K\/+3f(՟]G%יΏ ʐUm<:7=gͤzLC[ Ts 	f~:L­d{?fStzk	@ ? iWN.T&%xnGPu GZnGuF㬒7-rTtH:S|[d.tnybQ :k=qa\X_ԈTn]q295hf40-yaØ
ݩ:5P	0M&;-%7~g{8UUgc[8g" ¥yߺGHhH]Dlfc7Ft~$zIF5ĩ_eQ%'螇=J"n} [A vc$Fʗ:NprVIFK*9R'*O!1S:ŢMd0Kt,E y3$uQ2GSL݌whgv5R؟o~SU*9 z8j;ʭg5
`b '@)ȭW+#^K.ۓe~F *) ҫǲ40-bz*6@1Kc`Z S6Fl0Ȅ^PISUUus3	[FZ7s6WQGgr"5Z'ր*ۀt[(~g_5t qK5e^P`ڼj:;UM`	I&vF%~TUtwmOJ.+-,6Lj8ڽۃO-9.
ϙ),Ҝ
nf)4nހfU~V%ѽ1<V RD" +~,BRHM4˥	`X(@0Xd9*_i lE3qX5O@]۹}zTyL`i/J~He@W@ 5	7&@ +tA5EG .<T { K K̭(h&/Pu:xo :HLYU?w# 0%T))s`) .T:Y^n" @hT%T
 e&3!;3FrJ<c~n:vs$ +Lnc`Atk U6
H"o_O `F6m(@ $	2'BT9q݄d
V
=Wr83{T?oHЏJCM >ݵ[9/_ b\'tÉB&RtSC[7N`O] `{ј/q"W Pۘ)m~e(" Cԡ@vѯ}}Teɑ"OP ZԮ__dϢe!l!`XbhE BGZ!mz9Wt@&	
`ISvWj?!o`uP^,qZ ذ:(J 9mt zl V"r_+G2}ұ d 2m< )'G>ꀃFBop?*qWDbtY~}'p4ʵ'S΋=x$#(6Q;]@`G83>zXd Bn 	lO,>cԣv IN/0:K8o@o ?.ux,>2BǬ, 	$T|4qnI]
EtZSE!ȯ`j`b~77L#/:t F+@0S-NgNAK/2ƽ] ~}rNO'R!*{@$[)e9# C!QmAMyH~S*r8U#"+N[oy	 %W@[oI/So>l ǳ x͚!V@1s$)0p#N6G2Lqo"]ie*-\M*wrXgi~-QTyQN6Pj׻T@N}<T6wvF- v ~_'n	g)ԣx- w\r u>`0zbg@Cm<QClx@ɭaʵ ˫omGcb `uj,W. ܜ3؊: _uJ))FC c!|^(|j^[Iq\;!| Hs0ȣ>X PSr9'^;Fo*^n' (D+,FqO!JMVr3wG8jr 煭m#O D
EPZA=YGry?̬~W^WYW ޥ?-Z\0Ft{#(B^U u&JpAÛTݼS|uZh`"Fu.R3 vy"*rk-cvοkCv['Ek"MME hñWi%1ox}̧5[%9ͭ5
榅b>`sx B},Fm:
ɸs_qyJtSwFqFTИ=С;v[+Ǻon AR0E:e'{P7 yhpNd}(}j}^}NJ(< " Xo R>P~|*:x{9Gi@jc$6Z8I"$763	_Z͕Z% \FWS˸PN' m|9(`r`)E 3hJW_Ep 9k<@09@68`UsrAZ~ļG@l.=n|p@Q -+T~U/;^0=}5.<io#% e͠r #u	]n6TBmJu٣=֥j6ؔHq+ ͆K("Ԓ+9g&<s@XHު~fRG#T,eB yKyTO60^^h7ȴ<-yh*u3vMySWsۨX,"NTHbp!4@Ro~ $6M$*A2v8 d98
@''[\. t8ˏc,#Ȇh# Bk Ϊ2垖t~&7 qkM34f1\"\40pIZc"uČp#-v!>&tD.? kQaALxG`,?SZ#KdM⍖M+F'=] V@J~Ջu7[P	UD4!:;
S1J{z9RӵД{`Cuz O❍XvGHÅ*;ٰ]@aG}Y>Y8=(J3 tn8.'
%UGpVw !1k~4p̥p[OarܽmZ{0qi_m.>D;T,1\Ϡc_<AkQs gRXY qՊb"V 06rq 8_h)KaOZS:d YRW̒/"[fs;L>P3 ;s, \z$.ۙ*KTsTv(*P٠6*?lY =,x8SMU|r6
. \82 \iC Fn3aB(m-4Na:XW
n pnp3
K78YHKp>6="*ZpJɥuBSm(%Ao&s%\E4hZv^4mtf:؁bJ4r'y׃{s5=7֭p=x@90K]9K@v%m .5ZHFcT6;㛺@$/xF`!I18zm}&W}@03ueV04^1{ 08qp]] "do[7M+=ym}"G66ԺOJǏ*(8ۺ@k|a92߶)YK&ں8/l)\횿:&|kLGz+eHll0X?h=K^bH5'E䊱cKǉ?UjܧW/:QjѰU/#@8KTu;s%(耽bJW׮-=uFrbQЉ|	l3܎H p֑zB||@]IQvt/*?	"YRP^,r@8:toӆa d:Tc:@%6EVl9霋h5y/@p)CpӄE-V޳CxHmeg} ɀJDc+G 	pύ;* -̶JzRscg	J_c|աE*z}%Pje'Q"CN7
'uܪc!ͮ@tD@o;8Z]EQc"(=sksFA),т%҄4cIR)%#Tyy)C2c2J@!1e10#Mр}QCpFAcݚrMO!#RO~m.˅2Q
ʉ~#rE0glzG=eD[&,m{Cj)=}Z\ݭrX|@{mms1BcZXoޑPBJ'4[{dSQ3Ԧi#``k9N*Xt`-H)sBwL˟p.=<W`,ʐ*?bLT*%2h7si|eIZ|*J%ADl%7@!6رV3){u3](9S0])ռdWVh*_h65K:D^S:]g{~@}eA\xa!'@=L38;PĈ.O.b֘J>}#"ۖ͛g#t_pUA+ؖ=^tgBl;J2U[j~֝iڠ˟=E>+z  V	i_0)LI?lW'|NpfuQC(ΎB>t駠aoG	g-!PT_ SAwb/_	(p\jRM."Pӳ,44ȞESr%'n|BF=HȝT;lsԣC!}Yӄ؞N,pW]e.oBzv:cQ	EÆrЌxwj[v,B@
@UVahK	:4{Ix&0#χXfgZ4/Fmj fu)pgZd1e8je@g\@Iޠsp /P#X~hdZ|S
ED*(u{!ÁF{s@:@fԙnc;a6~[h
k%qʁ/p	G\^2_ZY]iAfA{NAT,tDՁq[OЀް-/(/Q})A5^	tԭ!ĦK
 M@\$fgg37nb+Y:mڐ_+8/L j0hh]OAg[<){pZf_1fV0:-ݐpZ%&6aNCl纅EAu"/':Nܓ+	ٕ:p~5XiqsfZW4S,(eHvFL	4qxGyѿЁ%oz=ʍ)g#4m(r(#vHVT*|5侅IoGi9SFg[>jR-;%g9/~ RŦꄀ]>|FhH
-svsR0Y1s݄2-|7``82]0+-qVaF@Cyl-0}?I7+uF@4z}aJ>-A7qMwL!_!.%@8a)9˂-AT@]/qM)ﾞc3L&8ʳd%j	x5yeNj|| ܵM_F@Ht=f14)G=|?O1T៦tGB&._skv>"TV\Vf5|pZO:Оc<6N@ axbh{S^o *w~e.&i`Kq&ʊk":A9f]-ʛ[/nulnepx۷H*22dL<aOǔmpTu[fރƊD@=7oݰm5x/x'hyxxN0EL]e>O hl%譙m$2Q`]%FK$;dј-O?:T6{?NlR?@Al낱l3 4uOpw{9]ccী?Ka'|@Kf:~~CdVDEL>X	ɮIS!NN5ֲRڤFґ-bb,A^Y50k5Co6m 4lJŘw$/ہu3>?j	C0t	@I-ns/fPatB% Kf(6"_h9А]0N$`*@npS/sրpw#&j_/VmR5'ML&PjtZaMT
;1YXb ;X"["KGPߪ#	rO]%ōs0/*	_3\eWzCŬPeQ{,dG81Smk3(j "K ŗbCxސ=<	}`*֟t^s6a	z@K&yJ]BY+`! d|R$/[kʔw0|vj܆͠X"IKy"ւnIoJ@鳟'U7{-#O?X'Z?hy߬m873{	>XާObݔ	hvI%3/-GA &N13Kw֭zFeJWpz=bqF:Jm^86(RHh@|p	!$el/fH}R/~	i6 {@;zZOnlc?22q=.t_8 G̻3ٙxgZBʡ$@y`75:$gWR{"B`:ЃSfzO,%r6Ph&1N#I*{ K5l;#+|xi 5qNF*
ΑàؾTw+ެn!K0`|(MaZ+@7e@к3,; = gvj. NOcACmڶC@|jS
:o  P:}	0C
<#eh(s%K Y;
_LC;]H qѸǼ#Lb[HA8<ƍj\GP0[t!4$\2](.-}% 8iPi,ͬI0ǎP%C
X&F6TVft֬@> hEӆ=~@3rMlE9bL
_qOVX<ۜ9 <*@B^U?+װ*-pUm.ď
`m{*5b 	ܧA2zB`x
Ͽ;[(X9a5RaPq%XKR>e.n[CAFLb.Kw)Gߧ(]^QC0عP%sR
Tw"PM)jH0,J;<LCm T2.ڸNOs
ڄA
bo~J' HlU8T'_lh& (d2,L] OQ?e Z7	 ҡV.dAQW!TK_ď翨O}\ |zj@M\ݍ^B] 7a^-Q j#Ƚs ĶO<"_LߕY>q8 UQM@xRTiЍk/7=TS0Hx~/$	mxg^tΐ+T=ߑ"㳚$8*-cIM NT:l8@YTU0|
._¯*#`;:sHal). P4HK,RptCLSI:{yà?T 1[P
?^'Еb,@~Wӗ+ N!xF0fAh y k)|U5@-󮮓qw0f&rw!y|{tÍ,/Z~/O"N<VTeaAa%zg_<`DY 6(\ /#"Y4^"VyX|bcpqWEPqs TK }SDX
D۵~ :ȕ2bc?ŪaоJrzDr%@רlp&8GKwwi#ɗB9bmڼ	q @@ ~"hB`XU]ţ|Mpb7ޠ~ѭnDlOBJդ3l77h=kK.	0eKB[G$#4T @_ MEB
|ң3A->~`.6h$s^_\a2ο[uh8ـOa}@]ks"_`¬֑L7N Sa.|RZ8~ȴG <@ j-Ġ+ciV>/ J6 \|H&.kZz2MBt0%' 0dK P-ՈGaà]"cd96 	SKG7<y͕ιH&"X.|h)>[[nc!pqFf#Ņ% ]Vɓ
|}%ЋupHmVa߸K0Bp>ǋRQ<H`:n~Y%t+N~uuN@`:@&^RӸ|>c1N9u\}hGvK y[hX_FLjFw"pT!0F@Rpsuct%~ IY{iooIIY6@2H]xZyWϣAh岰a&y^ynhj" 	7FP$"J$WN-}JLv`#=(5U Bsi=oqI^VTו#m>P`Weuafxк|Tu՚7s1zmcS珹OsmVc#O!ܺyLR(l}Mbad(HrEE(}bܑ>r @>cP^	/~ρ2tg9^Z!hnbx\Cl7P'DSsk/w9լ ɋZfݳ;] ]4 ZqGO4ԮȋmC4|oSɝ,)0c*A 3nm}!yQ#׾rCPǗ9@TXAi ^ǟk"ǭ l=܎y*QnbڷkHB(ɋ[L\lJL%&|L8V
bjI=CZ"f
Hv+79(t#"Iye	*`>I"тXە$9-8if\Ŧ7 &3c# x*򓬴Gml
tZ=4ێhA _F~|`S1F@P>`ס8bQMOQ =~SŞSX
ݐ ۮ 7Ϟ	NU'ĦX'.@8?+2 `p{qo@A7MP1P+k<}w^&t	8Y8MV]ȝz*:;+1l){<M)4ww	ۂ 3lLnasA{bЄ(SEOlq૊Cd}1XD ;uk	8E!H&hh@tLIsJ)ߟx_	8<ʼ5a<ҹ p?-ԬFGXHFy*N@gmcQ^7'",G׳ǯ''TF/8Ȓf<^v8`[W;&b(
|]~SݶV ;<ˠ@AXx
^ѠRMEm7'Hv0cQs 	maOTl
|Tnx1.8gMB[9&;þ'	:3@TZ*  Wм4Z  Smu#72bLQyrMBF^rK,D۵" G#Mwg粋yZ ,h߷&i_ʵ7ߠy|JAn]Uwl}Q |taexƭ\0<nnN_hW8Ao%>pr׽E#u7p#[¶a5Xf=i&uEG1|;nL <c7{4h_p(fMH7Mz특$8VH(I7&ba2T	b.N?тb[5*# ~!z3:-8gxh{@Q *OfܑbCƂpʎǷPAocBD0- ҡD;԰&.f?S mRi(~<j`%5̺	8 (r6IF?|62EB:?*h}x;`kA.TyGvR?;FFa)@=We_	=(7G,}e4%nN?L=#^ZG9&d&	]52̇+v/]2y@y~bhG-jǡ
|0=;~Ayq58NU9r:(q{'PGUc$,@Si.M@0`O̒SA2 aha:dY*)e8F,h%t8Y\Yam1+PP7
qH%A2P1PR@o=wTh'n/C'D?ɝ6u*ëN=\Ј8=ꐰ͖9MQ,c0AB4Kzj~q]/K@{

OWAyΧ`	'j`0Xy
-f}jHynۃ^2s:8kb~`˚<FK./2p%qf]#X齬A3V@[*yKkX~	<2g3j
9䘂`F2NaC&f*}9	Ρv[:RM;y2jW	*h58u*L;[@9-ȴ*c?3>iiXi8W% 9U<2?*A8PűNOAH0))կ2Tt`Qɖ^2~.K3}ȵ"9Snpx	?>]#úW}i{$PКQy#^Px<& s|:k^GVu~VUZ̨ubxra4Fx[N^Yʀ]3=w]4pG_>V^2oԕ/cxL<*xy̃uQCA-ZEN3b(O+ u"@K7YE!AE$zai/էb?ޢ-RRWz]v2+®r<bMvE_=)hd֢h:0	$W!},
N_?@N<7$;ghf.1v (u	2 gj*ho^؜h' >j{؁W
!t V,y@ģf11CsW;#l-[^JF׷	GP^yz5)䟌.aceZDOV[=|^+) Nt 'K$ y2co,^wVPhOВ<%Z)ג/lI6Q*~ذ	dք#'/3Ľ6ed/ITV4_	+淇 t|'wO5͂0V@6Ee3*0Nif@*Od(ދe8L;pџnÀvYePvtnPbcGYQk4>B ך0Ol|n&"֯stu N@vO`^^S@],S:Kj0>O<qU+9 T͇%s`~И*LYn"fAu[W>ãfZw樀nQ>mNAS*}{O\@+\]~[qSryr0A@44#XiI-ŸC8 R9`ɮ &@ػ?F X{`I 4YbG!LƙzS-iȫaА鸿0?*g. gx	8}g7 v\&Hi.tKUI]@9e	M?te (ߙ$(0Tmdn,H̀YpRf˲ulO0A2fhτg`<?[ ohk
ZWke#Q~T0!q3Ď";=ye ase+%uDWGT.36U 8q`{,Ci7L+o~`6tݪն;rȂ˥	ߌlЕX,pHlX 'T;	gB*O'92J5)a)63hyCzsǫ>R%[rzH!AD+*?)!{47ĕb2DH<f<A]2V3e\68T,WaDZ+8J>
S}S}YWܥ$.Qܳ\Q0[ۈ,}vďe7Y9" ʀWϸe=&xSu$G͟PH? B1|}ٞ -#qqWjk&҅hD+*??1)B'	j^J&-5?;Ѣ?}'nS3+մ:B؈&<T,gU0 :˷<4}}ƕ_@߿s5!mo0)Hy|?*?dઃq1#;B˭jxGܸq#z
6oXO/-8;3أ,0H'BQmSxn!@(Itm@m<_<sP 2O+lOA03[RK3?SW4(w|J7F~. \60	Nx>{q-2 zEXa}y ڿaexW7B/`kNXw:&qH1.S2RZ=Jr oE>?^#ZNiV"#&_j֚u\r-@#gfIދXџA/_nnNe![tG]S\~C#eLG.+>1fĽ2Ӗ/Ezb,ʤ,zQ:@P2#%ߘ g{ՉʴЌn(<T3Hf(C`V4Xkۭ~rC	|P}a\@Oeh"pF+̃ }IR+)&ܮ7fJYŵx]CG_qDcH { .jY[9~$GfP
@ۙѳ0*%,
׍p4jWv"RTudMwEa蛟IKZOUTt:淄$Ԫ .Y]	MIdg\K^nEr	:R?
mP/D&ҫ$(mSQQg[3\!ĺ9:pԔߕ#M{[y!>/Fbz6@xy4j-ʱUol zRzEil75@::_oRzeR' DI~7pKO\誾:BGq/Rq4I.=|!UB玧B1d
Tz	 X:ۄ0U\n) .7v(HqcHK;\=Ry\}b>+x|[(e^4l`UȪJɊAWҦo;:Pi^&ˤzS/5Wc#d(x=~Pz8O`z7?WPQ%BN0B,2uYqoBX} jI/0samY{ !B'uMZ@?}Up$j_J` jo[ -k7vUR-@^eZĤHFla`8 ( P<.>1g,\z7X4 QJS
HӟnGzOBԊ I=jZTI/+R.e)!9KShï18P 5^{ð"t@r+Fz	 WI-fY4QԖ`sc&8+8hB,ׯ.*֟|O<_agL jA/riP|~_O+5 BoNj	0Jm&Vמ=.`E[fYƟlJRay{9Ew+ީ 6ULLp4_j #20KT jSήTA87:ƵaIlKl٣:RS R `XQQYg.mPݟgTS):@r]lO3mLi7v9?Z5ܔ3Ց㢾4au#DzF14toa_8.Ԓ-ߔxU݉r@U*ZJnzTJrme5e[ʜ lz|tc1aҿtKt%B|A IF
1ிGkn<r9ˆG tRV"t ZQUo+uoHst)zO  UViQזԩd^	;j7Y:U{(8[wb(SyRNtJ@dBeqDjr\Eg2a]R`4$"8O@us0<~fN+JR:]o_ p{O>Qr)muS^ʩ)%jcwNQP)`F@v}^T+,;ȟXO]yhW?}r"H.Z3`$m
gf"~τ(?MZ
!(k.R ʳuUB}tȁN=jCW6	 ߖob$vAVc@fNb
Cu	 XW1¨SvNHP/VVhRtiv6/	 \S?VD|pxlfGKdUTr~p=N QVS?^HFMyo꼢BA!MZ!	 qbC%ǳ
ۃ.kt
7 .XFƫȞV&\zQvu}ٸ[˝aqҋu?9ziR(BoSUI=mؠ0>h8oǵm ~?缾ƋpI!gxQ*api}֍>4Oʸ6]bVCX4GiTKN nMpALXBXU_}4}VPffލ	cgni(wvZ/xPioN X@PE9%)T,,W"Ѱ@%Dv2r   
Z\IpUx{b7+.ʚ>f=}S7z08&\#pm}TZdQOh)܎3}`Qw0zM 5:V#aw7Q݌pG7 U5ߎv-N ?HX8޻_!iT(O=/-.+iuL@%:˷c 0Y>M{/d-JST.h."`/8( uih=;f $W,/I
@tRSvmn/AG Wn*=l~.O^|hM>@TQVh7y=c`8<9DJfX{TpeUE M@zTO8"4
n=쥭*֙6v3qU|Z6 /˞ Io/І/2>@P}cy`F-5#dԚ87A%w@E!υ H{f7'dc@eW~y8#rM3A
?\(7i%{t YܠKp+^Ʉ7 VcJShq|#|	P
\UDBDl` HH22]?Q,x"ҸK+yd7S/xkޮd	w|!O%Dd=MZ2!`Ho)0IPV~!B\XW(d#0>"<Vs1{jkT0"l D	t`ZoD/K,$/ XRO_PknIvJnC 7WASAN!4x;Z[-z4a}Caqȅy ͔/pe蝿	=mj=11\N47U trKLKj=K% o GgWb\;_{[ ޕ.3E,(f|+i 42
LR{ԪX2rdֵrtFEM kQe-nr7*2O|pSD4pZf5ɽ uG:t@yB:4| dz0DtBk_Y2׋Ha^1Q`2%CE2eu&t/g5i:4j_2P~߷UGTA:Cڑ{E<"⤈?i!'Wz|Q7#
[õ̀ͿAL\ZHhG(ZUqL]_*[kVn}&3`g)}C+E3f~cs@e;hFN "+_DwRRC9*3]r;	Si+:[5~l25<oDidi7F1k	U+?.`P=oD1i4y$!h`RjB8|aМLYHŃ;e	J}zLMHe[$mx4|l|%FIux	۵ru QC E'O6.;R=?CՔ]n!<HԜ{_vAK/<1f,lb,)<ӹ0hh05}X4BmI}o g>`~=@+WK):B7z\ZpeV󖳬q{SŘsPU_s%-Ҵc:΁E0kֻ>LpDG*1k\޹[J:9t>7[~?ȗQ/1M]aiLթ BM&x
	"@@ !"@@ !"@@ !"@@ !"@@ !"@@ !2p"@@h?pn7@      ) *U

endstreamendobj123 0 obj[/Indexed 190 0 R 16 99 0 R]endobj190 0 obj[/ICCBased 200 0 R]endobj99 0 obj<</Length 52>>stream
XXX   񫫫ttt,,,BBBfff

endstreamendobj200 0 obj<</Alternate/DeviceRGB/Filter/FlateDecode/Length 2554/N 3>>stream
HwTG 첻,ԥ-
.,eEADT@(D=	gb9(A"1A,W?̼;73/
ܐPZK !||gWt .=  #`L)0@,%	@
#'\+pxi$"po!pG1p$8p %p\W5p {pp C`?`qx~	x
_$x7
8  	(
h	Xqf/$s?~34JW?P}:)b/W_//8L]UT)NJJ*X&j\uZ)uF'hs4Xn
2R=op]"Vob)(TbuvŇVWk*4yIbUUyk仆!+ddy#Q4R$f#GŨՠzԈZPGhAnC8GutM5a4	0C07±X,Kǲ<LUab[ub[߱q,vccSNl\ⶸ31x>x3߀wq<~"X d!'DKV&v}i*1D/I*) Ť'dREvO$¡P(~%GP:((_SNQSF(ϩT*zSjzz:Ii M6vюҮFh/,9ݍAϠkM(5ǰa1<*Fq1xeJ$fyybY|Y	,kk+0%ϖLv{%1M3c	dp*9+99'88/t:N:
.:Wts\nw6w>{;clyr^6o!w7ț*uuuw}ȧm~3s	!*bA`DHJ
aM7pB硗WץwXoHDlE
Qhh蕾~Zn+SjV=^W5"F	F5FNUƭ{o&RD:M.LFn4=a:n&26+0[gvl\`h1_g~G8D\$ >)0j1`Rbld*jUՄuuN[6|OmNLJlSm>H;v 2nkT{BMS/^t4.;R}ݎ2,DV-)v9:59:=vvp^|KKmWkkkS7ʭ;=½f=qK==*5m'ާ/7ԷK?/J~?w?&3Ae@vր@q`V_,[o)8%<)|X6Oa3b"3.X%*&juԠTRlWLD{G/>Îs?V[Eǭ3fvz)ʵʻo		]	?$&'!1gƎϓBV%NKJOdlOJK]:朶 |Q&@-#%c[gdzfdޘ%U;lEɞ/#levw\NOUrs匩kԣkr5'Q[

_-J-SL/*>k'KJjK.:/()VU̪8P),PeWj:EMJ;ZZmyyΏ:NU_oQX? dօ¹FE.X]KӚ_.k6m^`I䒝-:--KnYF.,X|79\:~mW[bÊ+sWW /n֑?zM _ɖ4
uL$h՛BdҞ@iءG&vVǥ8nRĩ7u\ЭD- u`ֲK³8%yhYѹJº;.!
zpg_XQKFAǿ=ȼ:ɹ8ʷ6˶5̵5͵6ζ7ϸ9к<Ѿ?DINU\dlvۀ܊ݖޢ)߯6DScs2F[p(@Xr4Pm8Ww)KmW

endstreamendobj235 0 obj<</Font 236 0 R>>endobj236 0 obj<</ArialRoundedMTBold 231 0 R>>endobj234 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj188 0 obj<</BaseFont/Symbol/Encoding 195 0 R/FirstChar 1/FontDescriptor 193 0 R/LastChar 7/Subtype/Type1/ToUnicode 194 0 R/Type/Font/Widths[790 460 250 713 250 549 549]>>endobj187 0 obj<</BaseFont/TimesNewRoman,Bold/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 191 0 R/LastChar 151/Subtype/TrueType/Type/Font/Widths[250 333 0 500 0 1000 833 278 333 333 500 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 333 333 0 570 0 500 930 722 667 722 722 667 611 778 778 389 500 778 667 944 722 778 611 778 722 556 667 722 722 1000 722 722 667 333 0 333 0 0 0 500 556 444 556 444 333 500 556 278 333 556 278 833 556 500 556 556 444 389 333 556 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 500 500 0 0 1000]>>endobj186 0 obj<</BaseFont/TimesNewRoman/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 197 0 R/LastChar 176/Subtype/TrueType/Type/Font/Widths[250 0 0 0 0 833 778 180 333 333 500 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 564 564 444 0 722 667 667 722 611 556 722 722 333 389 722 611 889 722 722 556 722 667 556 611 722 722 944 0 722 0 0 0 0 0 500 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 333 444 444 0 500 1000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 760 0 0 0 0 0 0 400]>>endobj197 0 obj<</Ascent 891/CapHeight 0/Descent -216/Flags 34/FontBBox[-568 -307 2028 1007]/FontName/TimesNewRoman/ItalicAngle 0/StemV 0/Type/FontDescriptor>>endobj191 0 obj<</Ascent 891/CapHeight 0/Descent -216/Flags 34/FontBBox[-558 -307 2034 1026]/FontName/TimesNewRoman,Bold/ItalicAngle 0/StemV 133/Type/FontDescriptor>>endobj195 0 obj<</Differences[1/registerserif/bullet/space/infinity/dotmath/greaterequal/plusminus]/Type/Encoding>>endobj193 0 obj<</Ascent 0/CapHeight 0/Descent 0/Flags 4/FontBBox[-180 -293 1090 1010]/FontFile3 192 0 R/FontName/Symbol/ItalicAngle 0/StemV 85/Type/FontDescriptor>>endobj194 0 obj<</Filter/FlateDecode/Length 263>>stream
HTOo ~9nB{1$&'ݻhHV }n/V7 ۡ 6bW? 8i\COIsbs-ƌ*c_^;`^f79GЮ]pF )Aᘱs݌&uLUe4-;^;zܯ' @"r!<H#I/
EuA$P&P&p7̢?duK8i)7%oswQ0Zٯ  }l

endstreamendobj192 0 obj<</Filter/FlateDecode/Length 17376/Subtype/Type1C>>stream
HLUX񁨈FiF
Uv'lfg`ښ#A#5H}EZRk&1Z5M6,߷;s@ԼFKiqh7
^K޸wÝ?cSVx2?H47%fFw2g5uP
Qh&
4-@KHAChڅ$:Ρ5!Alvȇ2U PJhއ~Kp8Ixx\Ks,`?~qބ>|w3"wC*JҨTORTb)/TBm6S;Au:K]Qש[]>6)Τ鱴ΧO/e!~Dߣ{*%9P89|KfXNjXItCr
	
csA,%Y%X(b 1~?#HK98c_`|.7ý,Ȍ1r-p,e.(xV&	IQ}F\p*HeFt^IrA#>32'k+ɲWb9x8STY(D#So ]KR$=>Z7#AR?Z#`sRKQ^Ĺ}*8H$|Ǔ	jF5Y^fΧ

k"}nA|y#}G/']
'8Wz!xWb47LaRrU^z}A>^`~sgqPeIo9u<Q()!^җZI]J?a 	-):!	+>^T9ͳ*I^"^
K#6	LFbn7URGfx
82x9FV2}|5ھu	IN.rH"Tɒzzu{' 9N?oXk/$ӊ/n*oC덈x|N;<>~'z >zRP>%j^!%UI8h4v#n/,-msL.cX`+sK.6U$ǉÝg+[6#L=YUm9a8h2(bP,šx%$LĂ"+JEi(BQ$"|c3)F[q8c>Cp	M/P)QЍCLV/o:x= Q7"çp/0F8
'D6Oj7ѿV+i6û`?#p~7;wQDlU6Tv/
~'`-'9ມ<&5Xoa~D-;`/1\.4Bϣ0 ʠ꩓DnLU&dlifV͗sQG_IY-D̍؅$7;X,	IJlIT6yHRe1YfY:aZSkR^H}H{&=6^;v7V#ʐgZu`(=tn;TSM0#dd7govԤQ]9sr]<֘c6=vضsr^7b\ոyOp=W/O?=ab#'MҤ=^+]c)S.]$*j/:]S\W^|sȩ/N]1mⴋ%%Jɻ%JRKt~CgJoZ}|r6978?t^)O/VT$_R]hHjte۶|xƍrܸ쥦˾ŹZn]xyAVMhkA矫Jβ;kGjLZgwi F[͖}a{O)!<sMftjlJcCv5`ìiy"7f9<4B!nas6iIfx|5ILk3$:D@~  dsNhti-]*ں[C-{ڽaա1Oh5]Ƽ>wZ\\5Wg/@G]TPPHy
g!3$@#<Ea+
VUV]֞_l3ۙqg3w=~@cgF'65Ӑd'3o2İNg2㌹eE#b}3dρ=g5Cu#.7[T97
{5%:+8X8^6>B- Q"?MJ:jusݨv[^˳r[hMt	)=}	S6*"Ak}ezs0ȯUOM*/`ZFdJ//gd4_?ӑ@rAg&"*1{THԥGyedAhi5i:ˢhuq<=Z~"q:QRtZQw(]+||Րt'`4u@ԆV*~H׀^VPwA=lXŵdCQޜ;չܪt;p2
oOaB"gX:b+7z-5wcM-p+=<^[a("Ws`Aڣz;Tz'΅3
t[ڠWKgs`*Z@>aŃId*π
3~0yޖr2`A \ճsqzp
˝kbｼ
T!_Lz4yjrn<u&L_>+VIhxU.*L᳥:EK\LcWzIR\LGNLUGEg)T"UEF[{/ / 8_TOTҘ~&us>ZKDJ,,h$eabҴENwkԌ*w(>SύIꔘ!	-LPS&))-҂HqiT?.ˉDFW:llj=:wỹq
"8P[p/l (r (jа2ƁńO5Ҧ;&MC%̾'
fpn*V *VU*>. 5X'I
%B! A>K]Euh[Kۈ>oep0R	'姀+u$Y}Ťb`-!-b&:"_zs $oa߭5M9ӳ;6h[FfG`__G(T՜#ݓߞgS 1{lcr<˜:	A:kwy=z}pOG2A0*|I/y9hf2./'\;V#9ͻwPUK2+xG(9}>a~@4.|3
p,tR+_`Coc=EldvD{86&zF<rF<x'?&.߂#x7a&ǿ>ހA'}<G[~CiI-bQL Z݂=\k:}א#H8us:&<q!]	Q^gC|܂O]||*vq[+<Vv|7;6luf=o[weT{?,F$|b2L!
ސO=W#6Za5XW
fW`^ȐHu|k|PNR]R%EiNB1X?^i,<BǏT@+IJlTRT(z )zLێ)F&FQH9H#U	Rپ\ 
fvPmj}5<Zħ@D{cSzG-mN@.´Y9Eee-ٕdr woXOKGE{5ugIޛNLfrcݩբEYP7򒐄 $	D 
7	o(RqkYAZuhwmNeqfoXv_ߝ{~wn3rɧo{ڰ_?N>eZ om][<{AǆZM^Sa),ȤahcWmc}	\^g~f{"'Hfp<Cy,:53]$/N`P"vtX'gt4VJ|fBC⼤ZnN\ӎ
i/wN|t/v4>!FSdtCǽko<l]0uY4Ł^s" G[ӽ(/X-_?)Dzux/!NF$TP}hȮdU^D;g3XӾVroX[tD~	-%ƻٛi4"'5F'iT/@ȈDdEL(hbnH-(T\ؓ8!kr$qw gpL0`n yu ch)ჷ-my,{=`n
Zy#qR-H#f.
!nT(.n	Nbt8
ȉmĿz5.lֳBwu9X|֟yLs uW.z|2H|~zFrv[4#7OS|+!94(:x,gQ.7*j$jsSswRϹKuod5iGvU4p'Ƌ"k?&a"۫$Pf.R]UFj(F
؅i0jud)KQ1R߸	(s[`Hʺ˕ns )u[p=>.l{2,|Z9rǏمyF҇9Y2f=S8KKOG5*4gjC}.YfLF&$9=9MvcUuYJӕM%C*UfaW 61liЮ9Ά[ACO!1*@O|QQjY{UPrwUw{JSBP#::NZS'osGk(ȉYoC\HRt;XVh>$4󰑂w
vٶ`4hIMu3Qίq1Z1Y="	 {&|)&+.!l)5J11}#ۗ`SRKtd+\o׮'HsփU2W	(٨u3ɜ)fMcԳy` oN\$rr=&=syl6e&ihMLHڨآ v͇IGԉS`Gӣ/
HJC'Od>\**[YldI.ԛE~u {Sʖ񺒳~StB-2n7R*H)d %P+&4O,B;cYE)|I^t0.+Z!.Z"pe44gk\,B%K^YVPq0,cte1ZnUݎ%o*5pR 1\q)9]u-hkGOT2.o[LCGwN41=x;`Q!D!0`?/;\Dif+]-uqڪ 
l)=B'lib^h}	MyjpxV5ov`fWi~l#{դtPE4kI2ZhIɉ	ka }X@Z O41mP}Pi\ŸТ$}&5-&ؐ!,\[d)oMו֘nJ*J&G>tqrx<ő̲r]*,[wg*Ԕg<w/} ?W&b%#ecK~xS_{į(h);,.rðhxDuL-P!bZ:pYiì9=.Btƺ3:QeU!@	܀K.I @B\-[]cΰo8~~8qw{yy25J9\}fRrg`މ=Ssow{Yl<*O.|{'*F^,@UM
V`)l\ %CYC9Kibi&j[Ӕw"xY#566@Mk8"a.&@0(u0)VZl)BrNMR䀶lb<|$ֆfjXA3$<f5el{1#$Mǽv{/p8b? 4as&酆R@ :S/mUCƆ(fѦMj=~ݥ}BgfTSvԙ@,֘H^꧑QAk]XV<"˻)$AF9Ԯx،PPO
'<dO˥8,y9JHa/meF`]:/I`UQSm9@``<ᔗsuޘ9`͝vGE	eVfTY,$qz%W'>(+8z|i%BSRT=M5ԋhJG8zAS~-꣈Z^]XsQzJTIsLknK+JLQ3 "Y>a 5
Xf!gqu|].`x5VW7D\nEUVu	ba|c!U)?],&KЭ	4Sɖ']~uU*hO}Gi4Fv1{Z1Yw6)>Rޫ1΄'m)9Gz#}>-܋"+l=PJKƽ\LSKK1kXRaG54=.heNʍbS]"Ă̩%-ncd鐡NBXUp8,Kۦ $7YmU榵 lE*ζq9ڿqPi>7l	b[IKyykOZp0Hvǳi]ES  5UiEW1R L9;"q5"}- +uhZvR\o7P눟^|V>Ȝ/Nj떱Ҡ5p^<g%P7I2ϙbwV1Z%;#4i|R=;yhc<E>;KpjtP]>Ag N'Zrѩ2FCΔ~|ګιz'ZOkKyR[Wb+Y;??nMP쉣KB$Ľ_{)L?isu:2 v݇@Eb+a*Xsdm*0G7us)lLw.aҦv?̀]`?{t%w,l "!>MH|Im4h< J5pQ'o$<Rjvo"\'|}/.'=E<0AHblQsGb54NU;i	j	[ZՔ׾|<x*4H!H5UpEҟu:GdEb.`t+^Yl(An7	!bC,HGqj'hjOIOr߳Y?zSBpS6dh5̋JȦ/.f[`aZ{`<	ө{X)(5+3rũ4	wV/Qȹwn`t?ο -
q|[JkNNaa&~1h<3//8A,uñ2fu]Pq;O&:EPJsN4hNڠfHڏ0o	lQfIE0=ʟLt,cNmRovQPn1!N/9 H	C$'	Dpx xuG\նV>q^~k|?5L#339	d(Ґfr%(h!x4elе5-tCNJ'A0qϐ/uv̊O1њzj:K'-XFj5DhÚfx.uak*Dlͷ
"_Kl ֧3_"52D,:Ϻ+55kr[Z<H}𲜄^:o2IHb>y\4507&"\ UMm܁5(CBm`qd.Xmge/?+ExL	6~%$Ȉ} oHps~NX&]6mT[Ei1SOӢZ	XH	(ǫغ{ouv|9d}L(}C?^vk9vL*xn׃RuIK]ʹ|g|xMPYtА?7>V>H5V-['N1D]Cx92@dl>Chc@aL͂x$mYNйs"
Zl1ciFˡihYY0 yΉb& bK~w\ws̆H$'񭮲%է,39,l<Bi?z_ig]zGbHA]LE󡫦eMwƶK<_Յc=&nkmOvSHGt$%UBh~C@$ΗO*SW
k9,>#n\x#)JZHg}1~9TDH!qoi
N=oLgVܲG/zq/c\".A<LW]|]Tӯ;5O_Q&g [G+ w;E,ALcxep!F|V#G/t;̘݊/ڰvQ{kNDQPUROjoFl	Om/g߭ ?q~ }.7ʌk۠ݫ-Թ[Q~ܖimtFc#Y0;$X9`)ٍDSsX$Vfl1d7)z,A:Dc)2QV-__wR	kv($v~LԐ%dgh*D$K&v=C!cyˈrw7YϫoYkm\	umՄ;5ߠ[TUjX*kVzjܲSB>
HlhA,SR;J˚Eh-%9";~ᇀnecr{Z5zLbrAYQveS쨎F~4lVߤ&Ec3gWV<i\**9<		3^}vn
ːBKd<DpN#1Z<~&)T)H=GZuXЬv]Fge7T c;u,y{<q'Y	$~	uF2W,ⰴ^F.msfC'ZjVQKEo.pσ1Ubp3Bw&[
jlQC*t2i/9]QCPR'UW23UdoPam3,&GMcS_GQQF%w>9w%}.E9UFq}ydծҍC祴|7?"lIecz%q3@uB	Ȁ-fncxv)'	,__WDF!ZRF J{lQ~/h@N9Js\@2&PCɂe`!}jjNVu0̺fWk֝G 1	لGHI IQ DBxG@!BCZܴmJmgv7;?79w~7J"2Y`LN^H,JvkVfJA!x7ݢ?@/h?a=̺BdӔrtXUs1Tt+)\#t(TQk.X>edײW{zӌ_UL=Q*l`sޣ4><pSaE1logw5*QJ;焵y0GVYnk}}8q(`TELhr	9\2OQY`[ ^6׷cHc)hh5:}9[THppvË:9L.UaMFs9\3߰/N	_8͆,5	D.ʷde42W*Q̺݀?)GVB
@v+Hr^N3wop	e&6c1D@wyA	Ox'GөgI@&}tB$Co4QMͦf39<A /zlMxݙ9:!Lb#hf/is>j]3
at?P:kK&ZX%@=<@Js)|n^<rr1;pڌ<5&^;3hRqlZkE@H2;p?ZC,Sbbn!EFIQCx#pH@F<il
q.?rÏ3{+oּqt8%m~Rjnxk͢|D|8+[VsRTft7SS_>(wguYYY֝6A:}sίWϐ0BkO_
+1+4<uj\kUUMźRV?$1ښg.X=hxuu3h]lj
 L#v2:_ov;ϻ*IcZ#꒹.Z:{{-[[8Zuy?&$7Chlc?JX䫵|N]0]
M^k;h߆d, P.(y"bGϻB(PuPS+TQMjJv{0AR۲{˱-4Z<^!XBġ%}؉!WaT΀IL<)G>Ł-HGnXt[CzXЙBf#"#M.T ?jQTi+b/c%ptDɬ$h\0Chֳ)ൊ# WKA_;{Z.dBAap3iDhqMA?C0fJLĤ@7)a'RPTr4+|8(qcr+.~/V6[oosaܷ>Kd0R<f%Q}PC !E<x#!5FOa0(K뫾q蹇30V9mÏ<bmxդqш7wgde5"g<i5sf`)5̼6 	?2;z+ݣGSiﮤݿwk>쎌ܹ̌%߿pӟI\!7!0PU *bUt4D]LS$7=#G蔛b$㼁VOS.%Ei,2KvbjHaM 2-Ij,DE11ȫq6ČG9".13/` ý^T*c,k|/?G$#$<ig`vJ?ɸYg.SCd̈9Ls]?{<cQ:-Y?"ȼ(W_)誫=ͬSZoq{}V	ډA$n	S&-jA[ZtQJ	GI$e(BL Gp)G
jkvs񋞽}ў߽|wfg;]/@]˭U'"CF;rAɡKRcv613-Q*Hܟ`0nnڦӌ/jkSVǀIG VK[.fgq=ޏszMVMۡ棤}RrTFo|
p߼xYp'irA*:G⁂	[Z[[l!	)uY*144	&6ģH Θ1`
GmρGm߁h̿OIPD#ƈfLG.3an"y	=k+8Fp1eѼG
r=nӎA1e5ysT%$0\q^)yX)ifKdd/2<c>(^zL-3 }L,ϟL|BgfWq
1S_a
yW\hb>e9  dU qi/lUZH{${dbe'ZWgS=ךn@Ê~ FjsVB9qzccaLg&j+פhi1X&oέ+X`mIDjّZ]c.J)N+O2X(Ӥ+vǉܣ"=@(}'ϵW_Ǣ;v71jSϤyI)fdfɅ]-	Rm
AChQv{vVY[S%]lA~O[CϮ,n:J>P(>.,Du6;NQO1]ds?`Td29^]PXS>K~x}Y_9d!,DL~[,%0
 oY3Zd|qiLdiVhH˴HJ(C^jg]k֜5&689mCMg&)=P;߮F.	)zp*0j՜FumQedk~2rU6Q1`,klKcG8FQȳFޥ1}>A{:"Ődw䙕EVS4Q}L1]دpVc$膭=
lJd3Xh{T|%!Q'H=P]0$ϖ=:gQj&dU]\K]NtάED8Dt1F54:>clpQ9h!էkc*$ᇬ=Sx}l_FݵQ9w#bB#U)4쬲Kӭ魻y\ț &(Α
Q?{2nC~d>@1/>	_X/ ϝ XE"I*
@N>P0I09aBgFV:	RNECnSϪY|/rQ'e/rql4'
F$pSmX.yǓlɂD8ݛzyf	~ݛv֬~ƿ$f	<G>4B8SqN]{@+udV#Ea8Dyg#IpQ+q8q@B\䃖pR""Q+
RR4H%bv/_LQ<t{@:D?En<G`$<o
]3;
|'QbFZ( NQHNlws;rY\XA_Zᔾ%	Bi}#Dk7-"4Ky`#z Gq
䎡ȁ^^|Z}3NQw.ی<H8@_n<"wlW{jL;?ԋ/S8prwvC XA@n:]6O"pgX'΋2L$\ `>3vFwoM"ޝI"4]_WmPGvffEq/w` ȇzyz$KP>V*,(Eva,⺰|.";X#F}gw%*U{}ޞ~EBc$|ww?&еJ3t7+nxuѢC]&ާM+)$}x4sgEDs.Ӕޚ7zV(U|RHIe1 F cC

WfR/="X@V1%L'$c0_30->/{vއ#$CC3fpj-~u
z7+#v$XvL'U7ɌW
/ """$("r\/?E9B*D5M=ǋ*jh,oU5k4\l=ST;vFtN~Hu֪L)1yGN%Rdi`uh%}t]GQFIL(<RVį
ϯ	+k!8VkγREmEsW]"0</뽋>O؟YduߩwSr|zA]c.;dÓ||CЃ@_k3=^/W^7^PQhe0
y;Jcr^u/̕JAB2Ki
Y:lVK<ȍfC`>kȍJ 8||se<˥N_+]#MV@9oobKh95i݀SrX*lI O5[@Ѱ?EⅤcÇr5䘛fRPrP ؜A8^A9kc^G-xjtx95nIf.hv:flH E4y$<ؑɭhցD$
Q@{$em^ˬ'aV{'^ 0+2,vz<lu,샕}E |CN&#2)#paKEw$95c( Z  A>	vrr}|3bCD".2#'&!2uRߍs	 mdRg0.ҼG1i(|M8&c@<~jcsF9{aGӒLrQ૑{	|^џ7s<CqsQF(qzv|#xW(^H4A+		Y෷	er;)\+غ`a׋iQh]iQ5ǯЯY;9	R-gO:Uy.z\fa>rt	i|YzIBڥXS=0[aQ/݀bse+݋ߏ@n̮iWOhcGs%]	^:PAtϣUy.:;		B`^/ٹy4O,4p~mi./d'4RrģgŔA_i*&ӉS&L$CRs#7u4,o1HF=nwqfdRq->Z$Gc9ѫ2Qf_eO]ࣥ&D{_L,Q1J7x\Ԃг%DŮQ8e!nK-`Gbo 0	X~5mce4¤^jF,%/^⋔pqM0Ap|R2K,FA	Gvb*v9fJZ6)!BU찠YGɴzW@3u1,tD7)< aWΘm1@[MWO?+Rl,GѬWWJc:yQvQ:X[Wr솩Z[jz*U| aɉכN۪*U<l}˵ԶXx(A/qepLf4-\KvLWn-rS&L>Ojqܔu;/tC>4Pc;{7ruߋ~g?V,g"PP!o'CZWIE@_P'@lD DhP0I(բ&}Ms6fɽv{Zo&(Gߺ;ҿ)2)reR|J/uw`쿙2\s_}gZ黩<NodRtږׯkn^dWywW-ҵk^6mSjTOjޗќ[Z&^:or|TČj:eqY/vzÜkZO:c֚9I79O!rAN[ps/_?s|)y?Mg"?ECv8

endstreamendobj196 0 obj<</BG2/Default/OP false/OPM 1/SA false/SM 0.02/TR2/Default/Type/ExtGState/UCR2/Default/op false>>endobj222 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj218 0 obj<</Length 5593>>stream
q
1 0 0 1 -5.233948 14.012665 cm
0 0 612 792 re
W n
1 0 0 1 5.233948 -14.012665 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0023 Tc -0.0023 Tw 12 0 0 12 66.8067 650.9727 Tm
[(Ot)5 (he)6 (r)6 ( Im)15 (por)6 (t)5 (ant)5 ( Infor)6 (m)15 (at)5 (ion is found in t)5 (h)-1 (e)6 ( )]TJ
1 0 0  scn
0.002 Tc -0.002 Tw 19.31 0 Td
[(M)6 (e)6 (d)-2 (ic)6 (at)5 (ion G)10 (u)-2 (ide)]TJ
0 0 0  scn
0.0005 Tc -0.0005 Tw 7.69 0 Td
[( and in the booklet f)-6 (r)4 (om)14 ( )]TJ
-0.0026 Tc 0.0026 Tw -27 -1.16 Td
[(you)-6 (r p)-6 (rescri)-5 (b)-6 (er: )]TJ
/T1_0 1 Tf
0 Tc 0 Tw 0 -2.28 TD
(\002\003)Tj
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 1.5 0 Td
[(Common side effects that are not serious but that y)30 (ou should tell y)30 (our prescriber about. )]TJ
/TT2 1 Tf
0 Tc 0 Tw 35.01 0 Td
( )Tj
/T1_0 1 Tf
-36.51 -2.31 Td
(\002\003)Tj
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 1.5 0 Td
(How to take Accutane.  )Tj
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(Thing)10 (s)-1 ( to avoid during)10 ( Accutane treatment. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT1 1 Tf
0.0013 Tc -0.0013 Tw 1.5 0 Td
[(Wa)5 (y)31 (s)1 ( to g)11 (e)5 (t mor)4 (e)5 ( inf)4 (o)1 (r)4 (m)-1 (a)5 (tion if)4 ( y)31 (ou ne)5 (e)5 (d)1 ( it. )]TJ
1 0 0  scn
/TT0 1 Tf
0.0003 Tc -0.0022 Tw 15.96 0 0 15.96 66.8067 495.9327 Tm
(Accutane Causes Serious Birth Defects )Tj
0 0 0.5  scn
0.0001 Tc -0.0001 Tw 12 0 0 12 66.8067 468.2127 Tm
[([text appearing on m)13 (ain back panel outside of)-7 ( card] )]TJ
1 0 0  scn
0.0706 Tc -0.0044 Tw 14.04 0 0 14.04 88.4067 439.8927 Tm
[(Highlights of Warning to F)6 (e)2 (m)15 (a)-2 (le P)6 (a)-2 (tients.)4 (  )]TJ
/TT1 1 Tf
0.0702 Tc -0.004 Tw 21.47 0 Td
(\(It is )Tj
/TT0 1 Tf
0.0705 Tc 0 Tw 2.598 0 Td
[(im)15 (portant)]TJ
/TT1 1 Tf
0.0726 Tc -0.0064 Tw 4.949 0 Td
( to )Tj
ET
q
1 0 0 1 -5.233948 14.012665 cm
93.641 424.32 424.8 -1.2 re
f
Q
BT
0.0716 Tc -0.0054 Tw 14.04 0 0 14.04 69.4467 423.8127 Tm
[(w)7 (a)3 (tch the video and read all inform)20 (a)3 (tion in the )]TJ
0 0 0  scn
/TT3 1 Tf
0.0677 Tc -0.0015 Tw 22.316 0 Td
[(Be Sm)-26 (a)-5 (r)-5 (t)-5 (,)2 ( Be Sa)-5 (fe, Be )]TJ
ET
q
1 0 0 1 -5.233948 14.012665 cm
1 0 0  scn
74.681 408.24 313.32 -0.96 re
f
Q
q
1 0 0 1 -5.233948 14.012665 cm
388.001 408.24 149.28 -0.96 re
f
Q
BT
0.0693 Tc 0 Tw 14.04 0 0 14.04 147.8067 407.6127 Tm
(Sure)Tj
1 0 0  scn
0 Tc ( )Tj
/TT1 1 Tf
0.0716 Tc -0.0054 Tw 2.538 0 Td
[(booklet given to y)16 (o)-1 (u by)16 ( y)16 (our prescriber.)5 (\))]TJ
ET
q
1 0 0 1 -5.233948 14.012665 cm
0 0 0  scn
153.041 392.04 31.2 -0.84 re
f
Q
q
1 0 0 1 -5.233948 14.012665 cm
184.241 392.04 274.8 -0.84 re
f
Q
BT
/TT0 1 Tf
0 Tc 0 Tw 14.04 0 0 14.04 453.8067 407.6127 Tm
( )Tj
0 0 0  scn
/T1_0 1 Tf
12 0 0 12 66.8067 379.5327 Tm
(\002\003)Tj
/TT1 1 Tf
-0.0014 Tc 0.0014 Tw 1.5 0 Td
[(You MUST NOT take Accutane if y)29 (ou are preg)9 (nant because any)29 ( amount can cause severe )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(birth defects, even for short periods during)9 ( preg)9 (nancy)29 (.)-1 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT1 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(You MUST NOT become preg)9 (nant while taking)9 ( Accutane, or for 1 month after y)29 (ou stop )]TJ
-0.0009 Tc 0.0009 Tw T*
[(taking)9 ( Accutane. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT1 1 Tf
0.0006 Tc -0.0006 Tw 1.5 0 Td
[(You will not g)11 (e)4 (t y)31 (our)4 ( f)4 (i)-2 (r)4 (st pr)4 (e)4 (sc)4 (r)4 (iption f)4 (o)1 (r)4 ( Ac)4 (c)4 (u)1 (ta)4 (ne)5 ( until the)4 (r)4 (e)4 ( is pr)4 (oof)4 ( y)31 (ou ha)4 (ve)4 ( ha)4 (d 2 )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.14 TD
[(neg)9 (a)3 (tive preg)9 (nancy)29 ( tests as instructed by)29 ( y)29 (our prescriber \(a neg)9 (a)3 (tive test means that it does )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.16 TD
[(not show preg)9 (nancy)29 (\))2 (. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT1 1 Tf
-0.0007 Tc 0.0007 Tw 1.5 0 Td
[(You cannot g)9 (e)3 (t monthly)29 ( refills for Accutane unless there is proof that y)29 (ou have had a )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(neg)9 (a)3 (tive preg)9 (nancy)29 ( test every)29 ( month during)9 ( Accutane treatment. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT1 1 Tf
-0.0009 Tc 0.0009 Tw 1.5 0 Td
(Even the best methods of birth control can fail. Therefore, 2 separate, \effective forms of )Tj
-0.0006 Tc 0.0006 Tw 0 -1.14 TD
[(contraception must be used at the same time for at least 1 month before \beg)9 (i)-3 (nning)9 ( therapy)29 (,)-1 ( )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.16 TD
[(during)9 ( therapy)29 (,)-1 ( and for 1 month after Accutane therapy)29 ( has stopped. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT1 1 Tf
0.0008 Tc -0.0008 Tw 1.5 0 Td
[(Stop ta)5 (king)11 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( r)4 (i)-1 (g)11 (h)1 (t a)5 (w)3 (a)5 (y)31 ( a)5 (nd c)5 (a)5 (ll y)31 (our)4 ( pr)4 (e)5 (sc)5 (r)4 (ibe)5 (r)4 ( imme)5 (dia)5 (t)-1 (e)5 (l)-1 (y)31 ( if)4 ( y)31 (ou ha)5 (ve)5 ( se)5 (x)-9 ( )]TJ
-0.0006 Tc 0.0006 Tw 0 -1.14 TD
[(without birth control, miss y)29 (our period or become preg)9 (nant while y)29 (ou are taking)9 ( Accutane. I)22 (f)2 ( )]TJ
0 -1.15 TD
[(y)29 (ou g)9 (e)3 (t preg)9 (nant in the month after y)29 (ou have stopped Accutane treatment, call y)29 (our )]TJ
0.0012 Tc -0.0012 Tw 0 -1.16 TD
[(pr)4 (e)5 (sc)5 (r)4 (ibe)5 (r)4 ( imme)5 (dia)5 (t)-1 (e)5 (l)-1 (y)31 (.)1 ( )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj169 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 155/Width 76>>stream
HK PΝ14¼-jrŞj;؟\uhjƃL,®@u؇Qk'z+>eorNx#};q[;Ì$~t?#Y\m 7
endstreamendobj220 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 237 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 238 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj238 0 obj<</Font 239 0 R>>endobj239 0 obj<</ArialRoundedMTBold 231 0 R>>endobj237 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj112 0 obj<</BaseFont/TimesNewRoman,Italic/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 113 0 R/LastChar 150/Subtype/TrueType/Type/Font/Widths[250 0 0 0 0 0 0 0 333 333 0 0 250 333 250 278 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 611 611 667 722 611 611 722 722 333 444 667 556 833 667 722 611 0 611 500 556 722 611 833 0 556 0 0 0 0 0 0 0 500 500 444 500 444 278 500 500 278 0 444 278 722 500 500 500 0 389 389 278 500 444 667 444 444 0 400 0 400 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500]>>endobj105 0 obj<</BaseFont/TimesNewRoman,BoldItalic/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 107 0 R/LastChar 122/Subtype/TrueType/Type/Font/Widths[250 0 555 0 0 0 0 0 333 333 0 0 250 0 250 0 0 500 0 0 0 0 0 0 0 0 333 0 0 0 0 500 0 667 667 667 722 0 667 722 0 389 0 0 611 889 722 0 611 0 667 556 611 722 667 889 0 611 0 0 0 0 0 0 0 500 500 444 500 444 333 500 556 278 0 500 278 778 556 500 500 500 389 389 278 556 444 667 0 444 389]>>endobj107 0 obj<</Ascent 891/CapHeight 0/Descent -216/Flags 98/FontBBox[-547 -307 1206 1032]/FontName/TimesNewRoman,BoldItalic/ItalicAngle -15/StemV 133/Type/FontDescriptor>>endobj113 0 obj<</Ascent 891/CapHeight 0/Descent -216/Flags 98/FontBBox[-498 -307 1120 1023]/FontName/TimesNewRoman,Italic/ItalicAngle -15/StemV 0/Type/FontDescriptor>>endobj219 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj215 0 obj<</Length 4291>>stream
q
1 0 0 1 -5.991425 -4.997284 cm
0 0 612 792 re
W n
1 0 0 1 5.991425 4.997284 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/T1_0 1 Tf
12 0 0 12 66.0492 631.2427 Tm
(\002\003)Tj
/TT0 1 Tf
-0.0011 Tc 0.0011 Tw 1.5 0 Td
[(Have trouble concentrating)9 (.)-1 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
0.0009 Tc -0.0009 Tw 1.5 0 Td
[(Withdr)4 (a)5 (w)3 ( f)4 (r)4 (o)1 (m y)31 (our)4 ( f)4 (r)4 (i)-1 (e)5 (nds or)4 ( f)4 (a)5 (mily)31 (. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw 1.5 0 Td
[(F)5 (eel like y)29 (ou have no energ)9 (y)29 (. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
0.0005 Tc -0.0005 Tw 1.5 0 Td
[(Ha)4 (ve)4 ( f)4 (e)4 (e)4 (ling)11 (s of)4 ( wor)4 (t)-2 (hle)4 (ssne)4 (ss or)4 ( ina)4 (ppr)4 (opr)4 (ia)4 (te)4 ( g)11 (u)1 (ilt. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0001 Tc 0.0001 Tw 1.5 0 Td
[(Start having)10 ( thoug)10 (hts about hurting)10 ( y)30 (ourself or taking)10 ( y)30 (our own life \(suicidal thoug)10 (hts\). )]TJ
0 Tc 0 Tw -1.5 -2.24 Td
( )Tj
0.0007 Tc -0.0007 Tw 0 -2.22 TD
[(Te)5 (ll y)31 (our)4 ( pr)4 (e)5 (sc)5 (r)4 (ibe)5 (r)4 ( if)4 ( y)31 (ou or)4 ( some)5 (one)5 ( in y)31 (our)4 ( f)4 (a)5 (mily)31 ( ha)5 (s e)5 (v)1 (e)5 (r)4 ( ha)5 (d a)5 ( me)5 (nta)5 (l)-1 ( illne)5 (ss or)4 ( if)4 ( y)31 (ou ta)5 (ke)5 ( )]TJ
0.0009 Tc -0.0009 Tw 0 -1.16 TD
[(a)5 (n)1 (y)31 ( me)5 (dic)5 (i)-1 (ne)5 (s f)4 (o)1 (r)4 ( a)5 ( me)5 (nta)5 (l)-1 ( illne)5 (ss \()4 (f)4 (o)1 (r)4 ( e)5 (x)-9 (a)5 (m)-1 (ple)5 (,)1 ( de)5 (pr)4 (e)5 (ssion\))4 (. )]TJ
/TT1 1 Tf
0.0021 Tc 0.0001 Tw 0 -2.25 TD
[(Ot)5 (her serious side ef)5 (f)5 (ect)5 (s t)5 (o)3 ( wat)5 (c)-2 (h f)5 (o)3 (r )]TJ
/TT2 1 Tf
0.0002 Tc -0.0002 Tw 0 -2.22 TD
[(Stop taking Accutane and call your prescriber if)-7 ( you develop any of)-7 ( the problem)13 (s)-1 ( on this )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.13 TD
[(list or any other unusual or severe problem)13 (s)-1 (. )]TJ
/TT0 1 Tf
-0.0005 Tc 0.0005 Tw 19.29 0 Td
[(I)23 (f)3 ( not treated, they)30 ( could lead to serious health )]TJ
-0.0003 Tc 0.0003 Tw -19.29 -1.16 Td
(problems. Serious permanent problems do not happen often.  )Tj
/T1_0 1 Tf
0 Tc 0 Tw 0 -2.31 TD
(\002\003)Tj
/TT0 1 Tf
0.0004 Tc -0.0004 Tw 1.5 0 Td
[(He)4 (a)4 (da)4 (c)4 (he)4 (s, na)4 (use)4 (a)4 (, vomiting)10 (, blur)3 (r)3 (e)4 (d vision \()3 (i)-2 (nc)4 (r)3 (e)4 (a)4 (se)4 (d br)3 (a)4 (i)-2 (n pr)3 (e)4 (ssur)3 (e)4 (\))3 (. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(Severe stomach pain, diarrhea, rectal bleeding)9 (,)-1 ( or trouble swallowing)9 (. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 1.5 0 Td
[(Yellowing)9 ( of y)29 (our skin or ey)29 (es and/or dark urine. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0014 Tc 0.0014 Tw 1.5 0 Td
[(C)-4 (h)-1 (ang)9 (e)2 (s i)-4 (n)-1 ( heari)-4 (n)-1 (g)9 (.)-1 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw 1.5 0 Td
[(Allerg)9 (ic reactions \(if y)29 (ou know y)29 (ou are sensitive to \223parabens\224, tell y)29 (our prescriber because )]TJ
0.0009 Tc -0.0009 Tw 0 -1.15 TD
[(it is a)5 ( pr)4 (e)5 (se)5 (r)4 (va)5 (tive)5 ( in the)5 ( g)11 (e)5 (la)5 (tin c)5 (a)5 (p)1 (sule)5 ( of)4 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 (\))4 (.)]TJ
/TT3 1 Tf
0 Tc 0 Tw 21.66 0 Td
( )Tj
/T1_0 1 Tf
-23.16 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(B)7 (one or muscle pain. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(Vision chang)10 (e)3 (s, including)10 ( trouble seeing)10 ( at nig)10 (ht \(this can start suddenly)30 (, so be very)30 ( careful )]TJ
-0.0007 Tc 0.0007 Tw T*
[(when driving)9 ( or operating)9 ( any)29 ( vehicle at nig)9 (h)-1 (t\).  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
0.001 Tc -0.001 Tw 1.5 0 Td
[(Pe)5 (r)4 (siste)5 (nt f)4 (e)5 (ve)5 (r)4 (,)1 ( c)5 (h)1 (ills, or)4 ( sor)4 (e)5 ( thr)4 (o)1 (a)5 (t)-1 (. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj168 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 131/Width 76>>stream
H ٙ2~oǲffѢؑ*WFv&eMԩ%ﶹ"B \Nw.pW;OM;D򿺠z Vj5.g33;  ޭT
endstreamendobj217 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 240 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 241 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj241 0 obj<</Font 242 0 R>>endobj242 0 obj<</ArialRoundedMTBold 231 0 R>>endobj240 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj122 0 obj<</BaseFont/Arial,BoldItalic/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 121 0 R/LastChar 119/Subtype/TrueType/Type/Font/Widths[278 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 0 0 0 278 0 0 0 833 0 778 667 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 556 611 556 611 556 333 0 611 278 0 0 278 889 611 611 611 0 389 556 333 611 0 778]>>endobj121 0 obj<</Ascent 905/CapHeight 0/Descent -211/Flags 96/FontBBox[-560 -376 1157 1031]/FontName/Arial,BoldItalic/ItalicAngle -15/StemV 133/Type/FontDescriptor>>endobj216 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj212 0 obj<</Length 5104>>stream
q
1 0 0 1 -4.587219 15.812622 cm
0 0 612 792 re
W n
1 0 0 1 4.587219 -15.812622 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 12 0 0 12 67.4534 652.7726 Tm
[(Sm)-11 (art, Be Safe, Be Sure)]TJ
/TT1 1 Tf
0 Tc 0 Tw 10.02 0 Td
( )Tj
1 0 0  scn
-0.0002 Tc 0.0002 Tw (booklet about pregnancy prevention, don\222t start taking Accutane.)Tj
0 0 0  scn
0 Tc 0 Tw 28.22 0 Td
( )Tj
-0.0021 Tc 0.0021 Tw -38.24 -1.16 Td
[(Cal)-4 (l)-4 ( you)-6 (r p)-6 (rescri)-4 (b)-6 (er.  )]TJ
/TT2 1 Tf
-0.0006 Tc 0.0006 Tw 0 -2.2 TD
[(Most people have further questions after reading)9 ( so much important information about )]TJ
-0.0011 Tc 0.0011 Tw 0 -1.15 TD
[(preg)9 (nancy)29 ( prevention and birth defects)]TJ
1 0 0  scn
0 Tc 0 Tw 15.53 0 Td
(. )Tj
0 0 0  scn
-0.0007 Tc 0.0007 Tw [(I)22 (f)2 ( there is any)29 (t)-3 (hing)9 ( y)29 (ou are not sure about, do )]TJ
/TT1 1 Tf
0.0019 Tc 0 Tw 18.85 0 Td
(not)Tj
/TT2 1 Tf
-0.0011 Tc 0.0011 Tw 1.39 0 Td
( take )Tj
0.0004 Tc -0.0004 Tw -35.77 -1.16 Td
[(Ac)4 (c)4 (uta)4 (ne)4 ( until y)30 (our)3 ( que)4 (stions ha)4 (ve)4 ( be)4 (e)4 (n a)4 (nswe)4 (r)3 (e)4 (d by)30 ( y)30 (our)3 ( pr)3 (e)4 (sc)4 (r)3 (ibe)4 (r)3 (. )]TJ
/TT3 1 Tf
-0.0025 Tc 0.0067 Tw 14.04 0 0 14.04 67.4534 555.8126 Tm
[(I)-7 (m)-2 (por)-6 (tant I)-7 (n)2 (for)-6 (m)-2 (ati)-7 (on for)-6 ( Al)-7 (l)]TJ
ET
q
1 0 0 1 -4.587219 15.812622 cm
244.481 538.56 18 -1.44 re
f
Q
BT
0.0003 Tc 0.0039 Tw 14.04 0 0 14.04 257.8934 555.8126 Tm
( Patients )Tj
1 0 0  scn
/TT1 1 Tf
-0.002 Tc 0.002 Tw 12 0 0 12 67.4534 528.5726 Tm
[(B)-5 (e)2 (f)-9 (o)-2 (re you)-6 ( start tak)-6 (i)-4 (n)-6 (g)-2 ( Accu)-6 (tan)-6 (e)2 (, tel)-4 (l)-4 ( you)-6 (r p)-6 (rescri)-4 (b)-6 (er i)-4 (f)-9 ( you)-6 (: )]TJ
0 0 0  scn
/T1_0 1 Tf
0 Tc 0 Tw 0 -2.28 TD
(\002\003)Tj
/TT2 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(Are currently)29 ( taking)9 ( an oral or injected corticosteroid or an anticonvulsant \(seiz)-7 (u)-1 (re\) )]TJ
-0.0002 Tc 0 Tw 0 -1.16 TD
(medication. )Tj
/T1_0 1 Tf
0 Tc -1.5 -2.3 Td
(\002\003)Tj
/TT2 1 Tf
-0.001 Tc 0.001 Tw 1.5 0 Td
[(Take part in sports where y)29 (ou are more likely)29 ( to break a bone. )]TJ
0 Tc 0 Tw -1.5 -1.14 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT2 1 Tf
-0.0009 Tc 0.0009 Tw 1.5 0 Td
[(Have anorex)-11 (ia nervosa \(a ty)29 (pe of eating)9 ( disorder\), back pain, a history)29 ( of problems with )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.14 TD
[(healing)10 ( of bone fractures, or problems with bone metabolism. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/TT3 1 Tf
0.0015 Tc 0.0007 Tw 0 -1.18 TD
[(M)5 (e)-2 (nt)5 (al problems and suicide )]TJ
/TT2 1 Tf
-0.0007 Tc 0 -2.21 TD
[(Some patients have become depressed or developed other serious mental pr\oblems while they)29 ( )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(were taking)9 ( Accutane or shortly)29 ( after stopping)9 ( Accutane. Some patients taking)9 ( Accutane have )]TJ
-0.0003 Tc 0.0003 Tw T*
[(had thoug)10 (hts of ending)10 ( their own lives \(suicidal thoug)10 (hts\). Some people have tried to end their )]TJ
0.0007 Tc -0.0007 Tw T*
[(own live)5 (s \()4 (a)5 (tte)5 (mpte)5 (d suic)5 (ide)5 (\))4 ( a)5 (nd some)5 ( pe)5 (ople)5 ( ha)5 (ve)5 ( e)5 (nde)5 (d the)5 (i)-1 (r)4 ( own live)5 (s \()4 (c)5 (ommitte)5 (d suic)5 (ide)5 (\))4 (. )]TJ
-0.0008 Tc 0.0008 Tw T*
[(There have been reports of patients on Accutane becoming)9 ( ag)9 (g)9 (r)2 (essive or violent. No one knows )]TJ
-0.001 Tc 0.001 Tw T*
[(if Accutane caused these problems or behaviors or if they)29 ( would have happened even if the )]TJ
-0.0007 Tc 0.0007 Tw T*
(person did not take Accutane. )Tj
1 0 0  scn
/TT1 1 Tf
0.0019 Tc 0 Tw 0 -2.26 TD
[(St)5 (op)]TJ
/TT2 1 Tf
0 Tc 1.95 0 Td
( )Tj
/TT1 1 Tf
-0.0018 Tc 0.0018 Tw [(tak)-6 (i)-4 (n)-6 (g)-2 ( Accu)-6 (tan)-6 (e)2 ( an)-6 (d)-6 ( cal)-4 (l)-4 ( you)-6 (r p)-6 (rescri)-4 (b)-6 (er ri)-4 (gh)-6 (t aw)-10 (ay i)-4 (f)-9 ( you)-6 (:)]TJ
0 0 0  scn
/TT2 1 Tf
0 Tc 0 Tw 25.62 0 Td
( )Tj
/T1_0 1 Tf
-27.57 -2.28 Td
(\002\003)Tj
/TT2 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(Start to feel sad or have cry)30 (i)-3 (ng)10 ( spells. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT2 1 Tf
0.001 Tc -0.001 Tw 1.5 0 Td
[(L)22 (o)1 (se)5 ( inte)5 (r)4 (e)5 (st in a)5 (c)5 (tivitie)5 (s y)31 (ou onc)5 (e)5 ( e)5 (n)1 (joy)31 (e)5 (d. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT2 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(Sleep too much or have trouble sleeping)10 (. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT2 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(B)6 (ecome more irritable, ang)9 (r)2 (y)29 (,)-1 ( or ag)9 (g)9 (r)2 (essive than usual \(for ex)-11 (ample, temper outbursts, )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.15 TD
[(thoug)10 (hts of violence\) )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT2 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(Have a chang)9 (e)3 ( in y)29 (our appetite or body)29 ( weig)9 (ht. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj167 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 155/Width 76>>stream
H m*mQ!p XNmM!D
+;N)ɆJ)tsB\TˍĘ/iW!#	㸁1m$SZYgL5`XWxK8yރsd7a%d[͍M~xg	 ߞ8
endstreamendobj214 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 243 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 244 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj244 0 obj<</Font 245 0 R>>endobj245 0 obj<</ArialRoundedMTBold 231 0 R>>endobj243 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj213 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj75 0 obj<</Contents 246 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 179 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 247 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 186 0 R/TT2 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 248 0 R>>>>/Rotate 0/Thumb 162 0 R/Type/Page>>endobj77 0 obj<</Contents 249 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 179 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 250 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 251 0 R>>>>/Rotate 0/Thumb 163 0 R/Type/Page>>endobj79 0 obj<</Contents 252 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 179 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 253 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 254 0 R>>>>/Rotate 0/Thumb 164 0 R/Type/Page>>endobj81 0 obj<</Contents 255 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 179 0 R/Resources<</ColorSpace<</CS0 190 0 R/CS1 84 0 R>>/ExtGState<</GS0 196 0 R/GS1 256 0 R>>/Font<</TT0 186 0 R>>/ProcSet[/PDF/Text/ImageC/ImageI]/XObject<</Fm0 257 0 R/Im0 85 0 R>>>>/Rotate 0/Thumb 165 0 R/Type/Page>>endobj87 0 obj<</Contents 258 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 179 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 259 0 R>>/Font<</T1_0 119 0 R/T1_1 120 0 R/TT0 187 0 R/TT1 186 0 R/TT2 105 0 R>>/ProcSet[/PDF/Text/ImageB]/XObject<</Fm0 260 0 R/Im0 199 0 R>>>>/Rotate 0/Thumb 166 0 R/Type/Page>>endobj258 0 obj<</Length 5176>>stream
q
1 0 0 1 -6.872375 21.993347 cm
0 0 612 792 re
W n
1 0 0 1 6.872375 -21.993347 cm
BT
/CS0 cs 0 0 0.5  scn
/GS0 gs
/T1_0 1 Tf
12 0 0 12 119.1682 660.0333 Tm
[([text)-600 (printed)-600 (on)-600 ('prescription)-600 (pak')-600 (blister)-600 (cards])]TJ
1 0 0  scn
/TT0 1 Tf
-0.0013 Tc -0.0008 Tw 14.04 0 0 14.04 65.1682 630.3933 Tm
(ALL PATIENTS:)Tj
0 0 0  scn
-0.0021 Tc 0 Tw 7.624 0 Td
(  )Tj
0.0014 Tc -0.0035 Tw -7.624 -2.068 Td
[(It is im)14 (portant for your health that you read all the inform)14 (ation you received )]TJ
0.0011 Tc -0.0032 Tw 0 -1.145 TD
[(w)-12 (i)-3 (th this prescription and from)14 ( your prescriber )]TJ
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 12 0 0 12 65.1682 558.2733 Tm
[(This packag)9 (e provides )]TJ
/TT0 1 Tf
-0.0038 Tc 0 Tw 9.22 0 Td
[(rem)9 (i)-6 (n)-8 (d)-8 (ers)]TJ
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 4.37 0 Td
[( of important safety)30 ( facts about Accutane, but it does )]TJ
/TT0 1 Tf
0.0019 Tc 0 Tw 21.35 0 Td
[(not)5 ( )]TJ
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw -34.94 -1.15 Td
[(contain all the information y)30 (ou need to know. I)23 (t)-2 ( is important for y)30 (ou to know how to take )]TJ
-0.0011 Tc 0.0011 Tw 0 -1.16 TD
[(Accutane correctly)29 ( and what side effects to watch for.  )]TJ
-0.0006 Tc 0.0006 Tw 0 -2.22 TD
[(Read all the information y)29 (ou g)9 (e)3 (t about Accutane from y)29 (our prescriber and pharmacist, including)9 ( )]TJ
0.0011 Tc 0 Tw 0 -1.16 TD
[(the)5 ( )]TJ
1 0 0  scn
/TT0 1 Tf
0.002 Tc -0.002 Tw 1.47 0 Td
[(M)6 (e)6 (d)-2 (ic)6 (at)5 (ion G)10 (u)-2 (ide)]TJ
0 0 0  scn
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 7.69 0 Td
[( provided with this packag)9 (e.  )]TJ
-0.0009 Tc 0.0009 Tw -9.16 -2.22 Td
[(The prescription y)29 (ou g)9 (o)-1 (t at y)29 (our prescriber')9 (s)-2 ( office should have had a special y)29 (e)3 (llow self-)]TJ
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(adhesive sticker on it. The sticker is YEL)20 (L)20 (O)1 (W)-7 (.)-1 ( I)22 (f)2 ( y)29 (our prescriptions for Accutane do not have )]TJ
-0.0006 Tc 0.0006 Tw T*
[(this y)29 (e)3 (llow self-adhesive sticker, call y)29 (our prescriber. The pharmacy)29 ( should not fill prescriptions )]TJ
-0.001 Tc 0.001 Tw 0 -1.16 TD
[(for Accutane unless they)29 ( have the y)29 (e)3 (llow self-adhesive sticker. )]TJ
-0.0006 Tc 0.0006 Tw 0.55 -2.23 Td
[(You should read, understand and sig)9 (n)-1 ( an )]TJ
1 0 0  scn
-0.0018 Tc 0.0018 Tw 16.52 0 Td
[(I)21 (n)-2 (form)-4 (ed C)-5 (onsent)-4 (/)-4 (P)-6 (at)-4 (i)-4 (e)2 (nt)-4 ( Ag)8 (reem)-4 (ent)]TJ
0 0 0  scn
-0.0013 Tc 0.0013 Tw [( before y)29 (ou take )]TJ
-0.0005 Tc 0.0005 Tw -16.73 -1.15 Td
[(Accutane. Contact y)30 (our prescriber if y)30 (ou have not sig)10 (ned this form \(male patients must sig)10 (n one )]TJ
-0.0003 Tc 0.0003 Tw 9.67 -1.16 Td
[(form and female patients must sig)10 (n two forms\). )]TJ
1 0 0  scn
/TT0 1 Tf
0.0006 Tc -0.0027 Tw 14.04 0 0 14.04 136.5682 338.5533 Tm
(Never share Accutane)Tj
0 0 0  scn
/TT1 1 Tf
0 Tc 0 Tw 9.96 0 0 9.96 268.4482 338.5533 Tm
( )Tj
-0.0017 Tc 0.0017 Tw 12 0 0 12 270.9682 338.5533 Tm
[(because i)-4 (t)-4 ( can cause seri)-4 (ous si)-4 (de effect)-4 (s  )]TJ
0.0003 Tc 0 Tw -3.66 -1.17 Td
[(including)10 ( )]TJ
1 0 0  scn
-0.0011 Tc 0.0011 Tw 4.02 0 Td
(severe birth defects.)Tj
0 Tc 0 Tw 9.96 0 0 9.96 371.2882 324.5133 Tm
( )Tj
0 0 0  scn
/T1_1 1 Tf
-0.0017 Tc 14.04 0 0 14.04 65.1682 296.6734 Tm
[(Special)-598 (Warning)-598 (for)-598 (Female)-598 (Patients)]TJ
/TT1 1 Tf
0 Tc 12 0 0 12 359.1682 296.6734 Tm
( )Tj
1 0 0  scn
/TT0 1 Tf
-0.0015 Tc 0.0048 Tw 9 0 0 9 65.1682 271.3533 Tm
[(CAUS)-5 (ES)-5 ( B)-14 (I)1 (RTH DEFECTS)]TJ
0 0 0  scn
/TT1 1 Tf
0.003 Tc 0 Tw 9.96 0 0 9.96 175.8082 271.3533 Tm
(  )Tj
ET
q
1 0 0 1 -6.872375 21.993347 cm
72.041 247.44 39 -67.92 re
f*
Q
q
/CS0 cs 1 1 1  scn
39 0 0 67.9199982 65.1682286 201.5134428 cm
/Im0 Do
Q
BT
1 0 0  scn
/TT0 1 Tf
0 Tc 9 0 0 9 104.1682 201.5134 Tm
( )Tj
-0.0017 Tc 0.005 Tw -4.333 -2.387 Td
(DO NOT GET PREGNANT )Tj
/TT1 1 Tf
0.0026 Tc -0.0047 Tw 14.04 0 0 14.04 65.1682 152.4333 Tm
[(A)7 (ccutane causes serious birth defects.)5 ( D)7 (o)-2 ( N)7 (O)7 (T)7 ( take A)7 (ccutane if y)15 (ou are pregnant.)]TJ
0 0 0  scn
0 Tc 0 Tw 9.96 0 0 9.96 529.4482 152.4333 Tm
( )Tj
/TT0 1 Tf
-0.0019 Tc 0.0019 Tw 12 0 0 12 65.1682 124.9534 Tm
[(It i)-4 (s)-3 ( very i)-4 (m)11 (p)-6 (o)-2 (rtan)-6 (t f)-9 (o)-2 (r you)-6 ( to read)-6 ( an)-6 (d)-6 ( u)-6 (n)-6 (d)-6 (erstan)-6 (d)-6 ( th)-6 (e i)-4 (n)-6 (f)-9 (o)-2 (rm)11 (ati)-4 (o)-2 (n)-6 ( ab)-6 (ou)-6 (t p)-6 (reven)-6 (ti)-4 (n)-6 (g)-2 ( )]TJ
0.0002 Tc -0.0002 Tw 0 -1.15 TD
[(pregnancy on the back of)-7 ( this package, in the Medication G)8 (u)-4 (ide, and in the m)13 (aterials given )]TJ
-0.0017 Tc 0.0017 Tw T*
[(to you)-5 ( b)-5 (y)-2 ( you)-5 (r p)-5 (rescri)-4 (b)-5 (er. )]TJ
1 0 0  scn
0.0005 Tc -0.0005 Tw 11.38 0 Td
[(If)-6 ( you do not have the Medication G)8 (u)-3 (ide, and a video and the)]TJ
0 0 0  scn
0 Tc 0 Tw 26.11 0 Td
( )Tj
/TT2 1 Tf
0.003 Tc [(Be)7 ( )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj166 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 176/Width 76>>stream
H0'd}B|"N }Ԛ$IDRZ-;hBv!)Ym·}+"~7w!i,Dp)הɅZƀsU\Jl"*ibe|"WB^ǺfIr "
endstreamendobj260 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 261 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 262 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj199 0 obj<</BitsPerComponent 1/DecodeParms<</BlackIs1 false/Columns 163/EncodedByteAlign true/EndOfLine false/K -1/Rows 284>>/Filter/CCITTFaxDecode/Height 284/ImageMask true/Length 577/Subtype/Image/Type/XObject/Width 163>>stream
&`<4aY<0<$ pܬpܷ< ԃ<WPܬ<g(p58`IpÀ<Ap<ܥOܫۼpVভ\¼V׀7pEx~ӷkx>|>3PQ`ذ5PqE{@߼j@@۽@Էt@@Ҁ@tҀ߄%JP%w$z@(@a@@@Ԑ<7<gxJ5 xg 
endstreamendobj262 0 obj<</Font 263 0 R>>endobj263 0 obj<</ArialRoundedMTBold 231 0 R>>endobj261 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj119 0 obj<</BaseFont/Courier-Bold/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 89 0 R/LastChar 181/Subtype/Type1/Type/Font/Widths[600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600]>>endobj120 0 obj<</BaseFont/Courier/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 90 0 R/LastChar 181/Subtype/Type1/Type/Font/Widths[600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600 600]>>endobj90 0 obj<</Ascent 629/CapHeight 562/Descent -157/Flags 35/FontBBox[-28 -250 628 805]/FontName/Courier/ItalicAngle 0/StemV 51/Type/FontDescriptor/XHeight 426>>endobj89 0 obj<</Ascent 626/CapHeight 562/Descent -142/Flags 262179/FontBBox[-113 -250 749 801]/FontName/Courier-Bold/ItalicAngle 0/StemV 106/Type/FontDescriptor/XHeight 439>>endobj259 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj255 0 obj<</Length 1263>>stream
q
1 0 0 1 55.124039 -148.877197 cm
0 0 612 792 re
W n
1 0 0 1 -55.124039 148.877197 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
12 0 0 12 127.1646 488.2028 Tm
(R)Tj
0.67 -0.25 Td
(x)Tj
0.0006 Tc -0.0006 Tw 0.51 0.25 Td
[( only)31 ( )]TJ
ET
q
159.2400055 0 0 58.1999969 127.1646426 411.1627963 cm
/Im0 Do
Q
BT
0 Tc 0 Tw 12 0 0 12 286.4046 411.1628 Tm
( )Tj
-13.27 -1.99 Td
( )Tj
-0.0002 Tc 0.0002 Tw 0 -2.24 TD
(27898276-0602  )Tj
0 -2.22 TD
[(Revised: J)-11 (une 2002 )]TJ
0 Tc 0 Tw 0 -1.16 TD
( )Tj
0.0009 Tc -0.0009 Tw 0 -2.23 TD
[(Pr)4 (inte)5 (d in USA )]TJ
-0.0004 Tc 0.0004 Tw 0 -2.24 TD
[(Copy)30 (rig)10 (ht \251 2000-2002 by)30 ( Roche L)20 (a)3 (boratories I)23 (nc. All rig)10 (hts reserved.)]TJ
0 Tc 0 Tw 9.96 0 0 9.96 470.0046 266.2028 Tm
( )Tj
12 0 0 12 127.1646 239.4428 Tm
( )Tj
0 -2.22 TD
( )Tj
0 -1.15 TD
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
T*
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj165 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 113/Width 76>>stream
HA Dѳ}z^GjqiLd3 B.'|{&-ҖOX=t$^l^^͞
    J u
endstreamendobj257 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 264 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 265 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj85 0 obj<</BitsPerComponent 8/ColorSpace 84 0 R/Filter/JPXDecode/Height 122/Length 7846/Subtype/Image/Type/XObject/Width 332>>stream
   jP  

   ftypjp2     jp2 jpxbjpx    rreq   @    -     jp2h   ihdr   z  L     colr      Jpclr fffwww   UUUDDD333"""UffDUUw   cmap           jp2cOQ )    L   z              z         R     \ @@HHPHHPHHPHHPHHP 
     0 ߀0UרM/Zl`"WͨvXhF 
     ߀h:FB 
     >|&@>@Ν;*HzT%^'xNVxLmKNHde 
    (:$D
3,tݿ[G	k41> 
     |4>F#i-ΞRw%ϯD3vm}PQ#)#̴dȋtjY14P#0;Z
z3KN+dw | 1GKMrOdKyH1=em7 
    C|&@|bAZCY(94e.:dArBL^ 
    4ApoID|[֕ۭΟ=8M蜪"~2-"مl*yl{ ˣ-w8P!hY^BHg+2.3w ^	/Y@"tEx|;6Aq@yp'`(?ΰپ]M\WCRa®5V{㔪w^%RQVk'7U	ʶi-_(.>WinZ!sƶ6vχZ[#飒KÉ#hAkʉa WJaIY699-Cb|y9JK7|gڠ|G;@?;g^;ҕN]x3s)z 
    @|40"0)V)9utQw5шBi5_)MӶGaf~12tsHq\#ZfzZ.,jcl/0Ϫ:RÑdj 
    M/IO $yԐL욎)hVq+Pxqh5U!r{w[\2i㗈*".uIa{a*pŶoܓNV۴)8mam||9E{>;y9_`oQ/,90ՑN^2<O>%w%״\lS=8MHpɸ{e%>;X< Kul~wP=eY	~C|[Ò
yhޭ{GTff bf!C8l^T.r>!zk g蛡X(g(q&uvOqiD)R)f$]gul	ZgܹR3n`>F}c1pRt?VH/,:.mjC>2+3=IfyufJ4A&R3B'<"{<r1׬wF[*OAi1 ֆD\k
ùS"n3i͜$Zěo&8uOr/\l:dW̄!֫f[sf'B+9"ytP)fYuy" 0m#љW®t~eS.0`k+ǰ\- Ǉ:,6=6(n]}ƾdB,ű UthP@my @~/_:Z7
`e]YOo;0T1E	C5TIt(ꖹjP!%ac
em?xUZSZ"!D<2L#	;Γ숄4zP؟nRʸ >W܉1}|ͪeD7E>.'Ag#֋(f@\~$*%!ݏ|fu=>zjKN>F
VCtL",`pIUȗ<'w5+%)Q(skS4ַic7=-C8\<ʳӤ0\#@n^\t&.JLe]щ	ؒokh%Y(DEmvrdX3}Kn+F:Y/*8l6iprh[:K4)	qpej5K(=Cs`ڂz(/DLhͺk^;/˲4`?DizHa{6ǏD?uWRe]\%+x' -B_ qB{} ձ	 F+^)"<ܗhz;*s"q//mb&9/\2In 
   E٠|=yPk?;_,@r/\\a3rg7-ڥ ZE<vkbGYޟ 8j^K|8TېnnԭhRm-)9#nZC, Հ(1`R\hja~YChݻ&\n>	96 Wz`y۔[A	cչvnK/9 an@ƑQ[ȤҀ}*<JH&i߰
>A 
    ?e~Jg4oiWM&_H?%sttہMsbIN =hPwC|j3oHzPNpY.k$жgDڥGg%b+y2e0OQXJ/9e_B*ZPF9ڹ:b1,ӶRgj;FG+v8˛dx
2OTW;[Ji,[Z-QD*pz'Rߡ_3d|bhgW	D1\"wQhouo7|C<juSV#^חxnߔ	oR̪QOZSg Q0*֔"UYM
J&ۦf2XIm{ߨyI\䆮'۠(<m6R}<\/  95.u-᷺7)!$I]mH*Bv2xǀl
2u05e~IspcXt	vcy?PnCor"U T%&HfQwMHHCt1er>y
 9v74YvXXj[#lc	# ,z4DEJ:TNO4 8M3r.X%-n`f,0Fk+v6s+0bLxr9igpRx C0qky;+&tFmY:b
:y
C[bU9ݘMѭI= qcC2ݠv{T®Zp
|<KHrø&u##V2enl^4aJy몜kїkaldIZ3Le.ֹlQ͡ykoGdˡ97}n=
/	vWE/ȭ?#shhIND(qC糝osXR	wJ.Њ;@KDӟ#N
CEsmpzdn6s#?hsBOry	1/.X8; A==X+EJeJ,	,HDBqh@jfs&b&sDTQ=1:7 NCuR1ΏD$:9J
˻z盫~0AؿCЍ?FJo\.}0lT24W6eh ";#Ae]c+ܥӶJ8k(0~)38NiA@1:$:s|;|U	}ΊuєTcJ|:B7]VSմLrJeGݞnUQh=Gax 6LVp\1_ũHXgKX(W+`w%S &i<(Z=v&WCi*()#Uv̽IOxQLl&6$śҾ{kfOm!pygâ)4/2y(վdViN>?<IxƍiسY<iӇ 4i;C{SB͙H9H74Ufc
3g_UpM:8ڄ!K BΒybJrcEEjԷ\"-GtsDpCh UTQ.羫FJyݱtPN'xoT(zm
!O5YMwDIM!K
kPحZ}z`YτpƳ9*K"2=M.H9lZ7B~CsM-2]n5}֚e
1זG}FRmvaMg4kֽ1-RM(	Q
#_]hfh!4[waM'iNÅA <Y{%=ve1Ǜխb(ePF$55&?W*9!E2:1X$ 0Z99DI`bmXX=^a|`@ONݙH/t
[@Q"\ӹRSazֻFt@#/"?Htj6[6&fO"h^}PT$ş@9'Hm1lŏ(R}_s-f*m_ 쵍91E2x|{ǐX=QAF?{?K$ 6V`~v'.rN+R\O"u-B | K~Кٴ|((޳gGq?b5(#E ~f31uS!톟TmC~J-m!NN  oyݴriS!
ZN;)2zRb==.oWr`K߷*PpZ=UpY"j,b1͵b"*c3Rs˞*ƬHAZbҘ02f"!yZ.i4~"L[6 ah3,k+lW4a[(dۉcF9m\M)q'xL#DAe_ #9h!53Y̧mFi=#}@_bjA8b]	h #+Qm4pcHYtN[xjڵI{j]*
8(a=pr%3 z:h#x4S!ְW0MbVrʃDXdsH`qzJ;#3PlK<Mpď82WqPy(.de#W!W]iWn8Qӏ	+%0F!)n#O
Ҿip~~>&k$&*m
5Ukju򾿸AW%urvfgb ޗQY߇#eAiuBRƧG{-p${G@iR|wvwޜיqB|P"ɋ51AaѪYR-Ag{h<[_o⋮h^NK] AO<Y=*n9p34%-4,d]!4d	`Cv);IKA$[o}8QCCsDZK]ukF̺eS0znw%
Y8ĕ~"sIE4(Rޑ3`>ceZ蹩t7Rs(q
o5	읡u"鴿*J^$EA'_NdpG̍5)B53lHtͷ))Ds(x,Z}0lD?u(Ecg:?`4E+@!]0t_T!/'6Ǻ&j.`>$X)8ˤsPO>8$89¬SFmt|s4ݢƒY)#YʳuCK\0RWFŠicG[j옠>\$Q7k;Wئ^4f/Ӧ6XOo eIli%ߛw'08u@;鍘H{a0`Ϯan[eWfP[jTLr$i* >?yb#'VS-<?T+1\jע*3Ӄo
.9xu
,Ť 
   -~K3i?kVߓ@C8M	|۷y^#EC̦5 mRc[8zYwzV´0\0a.b܏6Wgz\A&Ix ̋[eXlT<QFAcL^$xq0pbxݴmյQ 5EVr 3IaS]Ĳwa\ߦI;1Hs'|yM4)F_ϰ5Z>V$_:ȼ\)[?E0VӍ\v]KNTxy&-LfZD@m73
`.~;DZTȇHݯ9WTKOjdXJ}N0c<H$YPt[!P$(2lڗfȘd6·ͣc4Ji8e2|#-+a&\+ʇ+,)1`]K|,gN03縧g3LoADڙn@sj*ûN)~22T1G|%{`:!i7΅. @~ƕ(xԖP0mD*S.X-`;iWCͷv	#;8CLzE)iq9ld͌nSsY9<+ks|,cPQCgYSFsv[-L`PZm&SՊk9\.=!t1"!Tq2WixcKǈhĝiGp˫0ﵟe>UBesa(d=sOpYG
endstreamendobj84 0 obj[/Indexed 190 0 R 19 83 0 R]endobj83 0 obj<</Length 60>>stream
fffwww   UUUDDD333"""UffDUUw
endstreamendobj265 0 obj<</Font 266 0 R>>endobj266 0 obj<</ArialRoundedMTBold 231 0 R>>endobj264 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj256 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj252 0 obj<</Length 5018>>stream
q
1 0 0 1 -8.556702 -20.547363 cm
0 0 612 792 re
W n
1 0 0 1 8.556702 20.547363 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/T1_0 1 Tf
12 0 0 12 63.4839 615.6926 Tm
(\002\003)Tj
/TT0 1 Tf
0.0005 Tc -0.0005 Tw 1.5 0 Td
[(Signs of)-6 ( other possibly serious problem)14 (s.)]TJ
/TT1 1 Tf
-0.001 Tc 0.001 Tw 17.35 0 Td
[( Accutane may)29 ( cause other problems. Tell y)29 (our )]TJ
-17.35 -1.14 Td
[(prescriber if y)29 (ou have trouble breathing)9 ( \(shortness of breath\), are fainting)9 (,)-1 ( are very)29 ( thirsty)29 ( or )]TJ
-0.0006 Tc 0.0006 Tw 0 -1.15 TD
[(urinate a lot, feel weak, have leg)9 ( swelling)9 (,)-1 ( convulsions, slurred speech, problems moving)9 (, or )]TJ
-0.0004 Tc 0.0004 Tw T*
[(any)30 ( other serious or unusual problems. F)6 (r)3 (equent urination and thirst can be sig)10 (ns of blood )]TJ
-0.0005 Tc 0.0005 Tw T*
[(sug)10 (a)3 (r problems. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
-0.0006 Tc 0.0006 Tw T*
[(S)-4 (e)3 (rious permanent problems do not happen often. However, because the sy)29 (mptoms listed above )]TJ
-0.0003 Tc 0.0003 Tw T*
[(may)30 ( be sig)10 (ns of serious problems, if y)30 (ou g)10 (e)4 (t these sy)30 (mptoms, stop taking)10 ( Accutane and call y)30 (our )]TJ
-0.0007 Tc 0.0007 Tw T*
[(prescriber. I)22 (f)2 ( not treated, they)29 ( could lead to serious health problems. Even if these problems are )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.16 TD
[(treated, they)29 ( may)29 ( not clear up after y)29 (ou stop taking)9 ( Accutane. )]TJ
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw 0 -2.25 TD
[(Accutane has less serious possible side ef)-7 (f)-7 (ects)]TJ
ET
q
1 0 0 1 -8.556702 -20.547363 cm
72.041 483.72 230.76 -1.2 re
f
Q
BT
0 Tc 0 Tw 12 0 0 12 294.2439 464.4926 Tm
( )Tj
/TT1 1 Tf
-0.0009 Tc 0.0009 Tw -19.23 -2.21 Td
[(The common less serious side effects of Accutane are dry)29 ( skin, chapped lips, dry)29 ( ey)29 (es, and dry)29 ( )]TJ
0 -1.15 TD
[(nose that may)29 ( lead to nosebleeds. People who wear contact lenses may)29 ( have trouble wearing)9 ( )]TJ
0.0009 Tc -0.0009 Tw T*
[(the)5 (m)-1 ( while)5 ( ta)5 (king)11 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( a)5 (nd a)5 (f)4 (te)5 (r)4 ( the)5 (r)4 (a)5 (p)1 (y)31 (.)1 ( Some)5 (time)5 (s, pe)5 (ople)5 (\222)4 (s a)5 (c)5 (n)1 (e)5 ( ma)5 (y)31 ( g)11 (e)5 (t wor)4 (se)5 ( f)4 (o)1 (r)4 ( a)5 ( )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(while. They)30 ( should continue taking)10 ( Accutane unless told to stop by)30 ( their prescriber.  )]TJ
-0.0011 Tc 0.0011 Tw 0 -2.22 TD
[(These are not all of Accutane\222s possible side effects. Your prescribe\r or pharmacist can g)9 (i)-3 (ve y)29 (ou )]TJ
0.0008 Tc -0.0008 Tw 0 -1.16 TD
[(mor)4 (e)5 ( de)5 (ta)5 (ile)5 (d inf)4 (o)1 (r)4 (m)-1 (a)5 (tion tha)5 (t)-1 ( is wr)4 (itte)5 (n f)4 (o)1 (r)4 ( he)5 (a)5 (lth c)5 (a)5 (r)4 (e)5 ( pr)4 (of)4 (e)5 (ssiona)5 (ls. )]TJ
-0.0004 Tc 0.0004 Tw 0 -2.22 TD
[(This Medication Guide is only)30 ( a summary)30 ( of some important information about Accutane. )]TJ
0.0008 Tc -0.0008 Tw 0 -1.15 TD
[(Me)5 (dic)5 (i)-1 (ne)5 (s a)5 (r)4 (e)5 ( some)5 (time)5 (s pr)4 (e)5 (sc)5 (r)4 (ibe)5 (d)1 ( f)4 (o)1 (r)4 ( pur)4 (pose)5 (s othe)5 (r)4 ( tha)5 (n)1 ( those)5 ( liste)5 (d in a)5 ( Me)5 (dic)5 (a)5 (tion Guide)5 (.)1 ( )]TJ
-0.001 Tc 0.001 Tw T*
[(I)22 (f)2 ( y)29 (ou have any)29 ( concerns or questions about Accutane, ask y)29 (our prescriber. Do not use Accutane )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.16 TD
(for a condition for which it was not prescribed. )Tj
/TT0 1 Tf
-0.0011 Tc 0 Tw 0 -2.26 TD
(Active)Tj
/TT1 1 Tf
0 Tc 2.71 0 Td
( )Tj
/TT0 1 Tf
-0.0015 Tc 0.0015 Tw [(In)-5 (gred)-5 (i)-4 (e)2 (n)-5 (t: Isotreti)-4 (n)-5 (oi)-4 (n)-5 (.)-1 (   )]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw -2.71 -2.2 Td
[(I)22 (n)-1 (active I)22 (n)-1 (g)9 (r)2 (edients: beeswax)-11 (,)-1 ( buty)29 (l)-3 (ated hy)29 (drox)-11 (y)29 (a)3 (nisole, edetate disodium, hy)29 (drog)9 (enated )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.15 TD
[(soy)30 (bean oil flakes, hy)30 (drog)10 (enated veg)10 (e)3 (table oil, and soy)30 (bean oil. Gelatin capsules contain )]TJ
-0.0004 Tc 0.0004 Tw T*
[(g)10 (l)-3 (y)30 (cerin and parabens \(methy)30 (l and propy)30 (l\), with the following)10 ( dy)30 (e sy)30 (stems: 10 mg)10 ( \227 iron ox)-10 (ide )]TJ
0.0006 Tc -0.0006 Tw T*
[(\()4 (r)4 (e)4 (d\))4 ( a)4 (nd tita)4 (nium diox)-9 (ide)4 (;)-2 ( 20 mg)11 ( \227 F)7 (D)3 (&)8 (C)-2 ( Re)4 (d No. 3, F)7 (D)3 (&)8 (C)-2 ( B)8 (l)-2 (ue)4 ( No. 1, a)4 (nd tita)4 (nium diox)-9 (ide)4 (;)-2 ( )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.16 TD
[(40 mg)10 ( \227 F)6 (D)2 (&)8 (C)-3 ( Yellow No. 6, D&)8 (C Yellow No. 10, and titanium diox)-10 (ide. )]TJ
0 Tc 0 Tw 0 -2.22 TD
( )Tj
-0.0005 Tc 0.0005 Tw 0 -1.15 TD
[(This Medication Guide has been approved by)30 ( the U.S. F)6 (ood and Drug)10 ( Administration.  )]TJ
0 Tc 0 Tw T*
( )Tj
0 -1.16 TD
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj164 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 126/Width 76>>stream
H0AZOiOeeN Ř_V[T/½]eW	vَ;)OUTČ]$#+D.eOSv8FK;Iu[to4(e;y  u ^
endstreamendobj254 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 267 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 268 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj268 0 obj<</Font 269 0 R>>endobj269 0 obj<</ArialRoundedMTBold 231 0 R>>endobj267 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj253 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj249 0 obj<</Length 6010>>stream
q
1 0 0 1 -12.066406 11.682617 cm
0 0 612 792 re
W n
1 0 0 1 12.066406 -11.682617 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw 12 0 0 12 77.9742 648.8826 Tm
[(vision, diz)-6 (z)-6 (i)-2 (ness, nausea, or vomiting)10 (. Also, some patients taking)10 ( Accutane have had seizures )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.15 TD
(\(convulsions\) or stroke. )Tj
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT1 1 Tf
0.0024 Tc -0.0024 Tw 1.5 0 Td
[(A)5 (bdom)15 (e)6 (n \()5 (s)2 (t)5 (o)2 (m)15 (a)2 (c)6 (h)-1 ( ar)6 (e)6 (a)2 (\))5 ( pr)6 (oble)6 (m)15 (s)2 (.)]TJ
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw 15.23 0 Td
[( Certain sy)30 (mptoms may)30 ( mean that y)30 (our internal org)10 (a)4 (ns )]TJ
-0.0009 Tc 0.0009 Tw -15.23 -1.14 Td
[(are being)9 ( damag)9 (e)3 (d. These org)9 (a)3 (ns include the liver, pancreas, bowel \(intestines\), and )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(esophag)9 (u)-1 (s \(connection between mouth and stomach\). I)22 (f)2 ( y)29 (our org)9 (a)3 (ns are damag)9 (e)3 (d, they)29 ( may)29 ( )]TJ
-0.0006 Tc 0.0006 Tw T*
[(not g)9 (e)3 (t better even after y)29 (ou stop taking)9 ( Accutane. Stop taking)9 ( Accutane and call y)29 (our )]TJ
T*
[(prescriber if y)29 (ou g)9 (e)3 (t severe stomach, chest or bowel pain, trouble swallowing)9 ( or painful )]TJ
T*
[(swallowing)9 (, new or worsening)9 ( heartburn, diarrhea, rectal bleeding)9 (,)-1 ( y)29 (e)3 (llowing)9 ( of y)29 (our skin or )]TJ
-0.0013 Tc 0.0013 Tw T*
[(ey)29 (es, or dark urine. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT1 1 Tf
0.0022 Tc -0.0022 Tw 1.5 0 Td
[(Bone)6 ( and m)15 (u)-2 (sc)6 (le)6 ( pr)6 (oble)6 (m)15 (s)1 (.)]TJ
/TT0 1 Tf
-0.0009 Tc 0.0009 Tw 11.71 0 Td
[( Accutane may)29 ( affect bones, muscles, and lig)9 (aments and cause )]TJ
-0.0002 Tc 0.0002 Tw -11.71 -1.14 Td
[(pain in y)30 (our joints or muscles. Tell y)30 (our prescriber if y)30 (ou plan vig)10 (orous phy)30 (sical activity)30 ( )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(during)9 ( treatment with Accutane. Tell y)29 (our prescriber if y)29 (ou develop pain, particularly)29 ( back )]TJ
T*
[(pain or joint pain. There are reports that some patients have had stunte\d g)9 (r)2 (owth after taking)9 ( )]TJ
-0.0014 Tc 0.0014 Tw T*
(Accutane for acne as directed.  There are also some reports of broken bo\nes or reduced )Tj
-0.001 Tc 0.001 Tw T*
[(healing)9 ( of broken bones after taking)9 ( Accutane for acne as directed.  No one knows if taking)9 ( )]TJ
T*
[(Accutane for acne will affect y)29 (our bones.  I)22 (f)2 ( y)29 (ou have a broken bone, tell y)29 (our provider that )]TJ
-0.0008 Tc 0.0008 Tw T*
[(y)29 (ou are taking)9 ( Accutane. Muscle weakness with or without pain can be a sig)9 (n)-1 ( of serious )]TJ
-0.0007 Tc 0.0007 Tw T*
[(muscle damag)9 (e)3 (. I)22 (f)2 ( this happens, stop taking)9 ( Accutane and call y)29 (our prescriber rig)9 (h)-1 (t away)29 (.  )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 1.5 0 Td
[(Hearing problem)13 (s)-1 (.)]TJ
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 7.99 0 Td
[( Some people taking)9 ( Accutane have developed hearing)9 ( problems. I)22 (t)-3 ( is )]TJ
-7.99 -1.14 Td
[(possible that hearing)9 ( loss can be permanent. Stop using)9 ( Accutane and call y)29 (our prescriber if )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(y)29 (our hearing)9 ( g)9 (e)3 (ts worse or if y)29 (ou have ring)9 (ing)9 ( in y)29 (our ears. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT1 1 Tf
0.0007 Tc -0.0007 Tw 1.5 0 Td
[(Vision problem)14 (s.)]TJ
/TT0 1 Tf
-0.0005 Tc 0.0005 Tw [( W)-7 (hile taking)10 ( Accutane y)30 (ou may)30 ( develop a sudden inability)30 ( to see in the )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.14 TD
[(dark, so driving)10 ( at nig)10 (ht can be dang)10 (erous. This condition usually)30 ( clears up after y)30 (ou stop )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(taking)9 ( Accutane, but it may)29 ( be permanent. Other serious ey)29 (e effects can occur. Stop taking)9 ( )]TJ
T*
[(Accutane and call y)29 (our prescriber rig)9 (h)-1 (t away)29 ( if y)29 (ou have any)29 ( problems with y)29 (our vision or )]TJ
-0.0005 Tc 0.0005 Tw T*
[(dry)30 (ness of the ey)30 (es that is painful or constant. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT1 1 Tf
0.0006 Tc -0.0006 Tw 1.5 0 Td
[(Lipid \(f)-6 (ats and cholesterol in blood\) problem)14 (s.)]TJ
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 19.77 0 Td
[( Many)29 ( people taking)9 ( Accutane develop hig)9 (h)-1 ( )]TJ
-0.0005 Tc 0.0005 Tw -19.77 -1.15 Td
(levels of cholesterol and other fats in their blood. This can be a serio\us problem. Return to )Tj
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(y)29 (our prescriber for blood tests to check y)29 (our lipids and to g)9 (e)3 (t any)29 ( needed treatment. These )]TJ
T*
[(problems g)9 (e)3 (nerally)29 ( g)9 (o)-1 ( away)29 ( when Accutane treatment is finished. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT1 1 Tf
-0.0024 Tc 0.0024 Tw 1.5 0 Td
[(Al)-5 (l)-5 (ergi)-5 (c)1 ( reacti)-5 (o)-2 (n)-6 (s)-3 (.)]TJ
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 7.76 0 Td
[( I)22 (n)-1 ( some people, Accutane can cause serious allerg)9 (ic reactions. Stop )]TJ
-0.0017 Tc 0.0017 Tw -7.76 -1.14 Td
[(t)-4 (a)2 (ki)-4 (ng)8 ( Accut)-4 (a)2 (ne and g)8 (e)2 (t)-4 ( em)-4 (erg)8 (e)2 (ncy)28 ( care ri)-4 (g)8 (h)-2 (t)-4 ( away)28 ( i)-4 (f)1 ( y)28 (ou devel)-4 (op hi)-4 (ves, a swol)-4 (l)-4 (e)2 (n face or )]TJ
-0.0006 Tc 0.0006 Tw 0 -1.15 TD
[(mouth, or have trouble breathing)9 (. Stop taking)9 ( Accutane and call y)29 (our prescriber if y)29 (ou )]TJ
-0.001 Tc 0.001 Tw T*
[(develop a fever, rash, or red patches or bruises on y)29 (our leg)9 (s)-2 (. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj163 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 142/Width 76>>stream
H gwJ>nxޥRH,tc5i$rNכTKS}\.FL'v4='.6#Q
7Wƻ^%BxZ{Eh0ðT23 t-
endstreamendobj251 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 270 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 271 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj271 0 obj<</Font 272 0 R>>endobj272 0 obj<</ArialRoundedMTBold 231 0 R>>endobj270 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj250 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj246 0 obj<</Length 7727>>stream
q
1 0 0 1 -8.215332 12.992645 cm
0 0 612 792 re
W n
1 0 0 1 8.215332 -12.992645 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/T1_0 1 Tf
12 0 0 12 63.8253 649.2326 Tm
(\002\003)Tj
/TT0 1 Tf
-0.0012 Tc 0.0012 Tw 1.5 0 Td
[(Do n)-5 (o)-1 (t tak)-5 (e)3 ( vi)-3 (tam)12 (i)-3 (n)-5 ( A)]TJ
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 9.43 0 Td
[( supplements. Vitamin A in hig)10 (h doses has many)30 ( of the same side )]TJ
0.0006 Tc -0.0006 Tw -9.43 -1.14 Td
[(e)4 (f)4 (f)4 (e)4 (c)4 (t)-2 (s a)4 (s Ac)4 (c)4 (u)1 (ta)4 (ne)4 (. Ta)4 (king)11 ( both tog)11 (e)4 (the)4 (r)4 ( ma)4 (y)31 ( inc)4 (r)4 (e)4 (a)4 (se)4 ( y)31 (our)4 ( c)4 (h)1 (a)4 (n)1 (c)4 (e)4 ( of)4 ( g)11 (e)5 (tting)11 ( side)4 ( e)4 (f)4 (f)4 (e)4 (c)4 (t)-2 (s. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.25 Td
(\002\003)Tj
/TT0 1 Tf
0.0001 Tc -0.0001 Tw 1.5 0 Td
[(Do not have cosm)13 (etic procedures to sm)13 (ooth your skin, including w)-8 (axing, derm)13 (abrasion, )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.14 TD
[(or laser procedures, w)-8 (h)-4 (ile you are using Accutane and f)-7 (or at least 6 m)13 (onths af)-7 (ter you )]TJ
0.0004 Tc 0 Tw 0 -1.13 TD
(stop.)Tj
/TT1 1 Tf
-0.0018 Tc 0.0018 Tw [( Accut)-4 (a)2 (ne can i)-4 (n)-2 (crease y)28 (our chance of scarri)-4 (ng)8 ( from)-4 ( t)-4 (h)-2 (ese procedures. C)-5 (h)-2 (eck wi)-4 (t)-4 (h)-2 ( y)28 (our )]TJ
-0.0013 Tc 0.0013 Tw 0 -1.15 TD
[(prescriber for advice about when y)29 (ou can have cosmetic procedures. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
0.0021 Tc -0.0021 Tw 1.5 0 Td
[(A)4 (void sunlight)5 ( and ult)5 (r)6 (aviole)6 (t)5 ( light)5 (s)]TJ
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 15.42 0 Td
[( as much as possible. Tanning)10 ( machines use ultraviolet )]TJ
0.0009 Tc -0.0009 Tw -15.42 -1.14 Td
[(lig)11 (hts. Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( ma)5 (y)31 ( ma)5 (ke)5 ( y)31 (our)4 ( skin mor)4 (e)5 ( se)5 (nsitive)5 ( to lig)11 (ht. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
0.0019 Tc -0.0019 Tw 1.5 0 Td
[(Do not)5 ( use)6 ( bir)6 (t)5 (h c)6 (o)2 (nt)5 (r)6 (o)2 (l pills t)5 (h)-2 (at)5 ( do not)5 ( c)6 (o)2 (nt)5 (ain e)6 (s)1 (t)5 (r)6 (oge)6 (n \()5 (\223)2 (m)15 (inipills\224\))5 (.)]TJ
/TT1 1 Tf
-0.0007 Tc 0.0007 Tw 30.34 0 Td
[( They)29 ( may)29 ( not )]TJ
-0.0009 Tc 0.0009 Tw -30.34 -1.15 Td
[(work while y)29 (ou take Accutane. Ask y)29 (our prescriber or pharmacist if y)29 (ou are not sure what )]TJ
-0.0006 Tc 0.0006 Tw T*
[(ty)29 (pe y)29 (ou are using)9 (.)-1 (  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
1.5 0 Td
[(Talk w)-8 (i)-2 (th your doctor if)-7 ( you plan to take other drugs or herbal products)]TJ
/TT1 1 Tf
0.0006 Tc -0.0006 Tw 30.89 0 Td
(. This is )Tj
0.0009 Tc -0.0009 Tw -30.89 -1.14 Td
[(e)5 (spe)5 (c)5 (i)-1 (a)5 (lly)31 ( impor)4 (ta)5 (nt f)4 (o)1 (r)4 ( pa)5 (tie)5 (nts using)11 ( bir)4 (t)-1 (h c)5 (ontr)4 (o)1 (l pills a)5 (nd othe)5 (r)4 ( hor)4 (mona)5 (l ty)31 (pe)5 (s of)4 ( bir)4 (t)-1 (h )]TJ
-0.0014 Tc 0.0014 Tw T*
[(cont)-4 (rol)-4 ( because t)-4 (h)-1 (e bi)-4 (rt)-4 (h cont)-4 (rol)-4 ( m)-4 (a)2 (y)29 ( not)-4 ( work as effect)-4 (i)-4 (v)-1 (el)-4 (y)29 ( i)-4 (f)2 ( y)29 (ou are t)-4 (a)2 (ki)-4 (ng)9 ( cert)-4 (a)2 (i)-4 (n)-1 ( drug)9 (s )]TJ
-0.0005 Tc 0.0005 Tw T*
[(or herbal products. You should not take the herbal supplement S)-4 (t)-3 (. J)-11 (ohn\222s W)-7 (ort because this )]TJ
-0.0004 Tc 0.0004 Tw T*
[(herbal supplement may)30 ( make birth control pills not work as effectively)30 (.  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.25 Td
(\002\003)Tj
/TT0 1 Tf
-0.0018 Tc 0.0018 Tw 1.5 0 Td
[(T)-5 (a)-2 (l)-4 (k)-6 ( w)-10 (i)-4 (th)-6 ( you)-6 (r d)-6 (o)-2 (ctor i)-4 (f)-9 ( you)-6 ( are cu)-6 (rren)-6 (tl)-4 (y tak)-6 (i)-4 (n)-6 (g)-2 ( an)-6 ( oral)-4 ( or i)-4 (n)-6 (jected)-6 ( corti)-4 (c)2 (osteroi)-4 (d)-6 ( or )]TJ
0 -1.12 TD
[(an)-6 (ti)-4 (con)-6 (v)-2 (u)-6 (l)-4 (san)-6 (t)1 ( \(sei)-4 (zu)-6 (re\) m)11 (e)2 (d)-6 (i)-4 (cati)-4 (on)-6 ( p)-6 (r)2 (i)-4 (o)-2 (r to u)-6 (s)-3 (i)-4 (n)-6 (g Accu)-6 (tan)-6 (e)2 (.  )]TJ
/TT1 1 Tf
-0.0015 Tc 0.0015 Tw 26.23 0 Td
[(These drug)9 (s m)-4 (a)2 (y)29 ( weaken )]TJ
-0.0005 Tc 0.0005 Tw -26.23 -1.15 Td
[(y)30 (our bones.)]TJ
/TT2 1 Tf
0 Tc 0 Tw 4.63 0 Td
( )Tj
/T1_0 1 Tf
-6.13 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
-0.002 Tc 0.002 Tw 1.5 0 Td
[(Do n)-6 (o)-2 (t sh)-6 (are Accu)-6 (tan)-6 (e)2 ( w)-10 (i)-4 (th)-6 ( oth)-6 (er p)-6 (e)2 (op)-6 (l)-4 (e)2 (.)]TJ
/TT1 1 Tf
-0.001 Tc 0.001 Tw [( I)22 (t)-3 ( can cause birth defects and other serious )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.14 TD
(health problems. )Tj
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw 1.5 0 Td
[(Do not take Accutane w)-8 (i)-2 (th antibiotics unless you talk to your prescriber.)]TJ
/TT1 1 Tf
-0.0046 Tc 0.0046 Tw 30.89 0 Td
[( Fo)-5 (r s)-5 (o)-5 (m)-7 (e)-1 ( )]TJ
0.001 Tc -0.001 Tw -30.89 -1.14 Td
[(a)5 (n)1 (tibiotic)5 (s, y)31 (ou ma)5 (y)31 ( ha)5 (ve)5 ( to stop ta)5 (king)11 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( until the)5 ( a)5 (n)1 (tibiotic)5 ( tr)4 (e)5 (a)5 (tme)5 (nt is f)4 (i)-1 (nishe)5 (d. )]TJ
0.0005 Tc -0.0005 Tw 0 -1.15 TD
[(Use)4 ( of)4 ( both dr)4 (ug)11 (s tog)11 (e)4 (the)4 (r)4 ( c)4 (a)4 (n)1 ( inc)4 (r)4 (e)4 (a)4 (se)4 ( the)4 ( c)4 (h)1 (a)4 (n)1 (c)4 (e)4 (s of)4 ( g)11 (e)4 (tting)11 ( inc)4 (r)4 (e)4 (a)4 (se)4 (d)1 ( pr)4 (e)4 (ssur)4 (e)4 ( in the)4 ( br)4 (a)4 (i)-2 (n. )]TJ
/TT0 1 Tf
0 Tc 0 Tw -1.5 -1.17 Td
( )Tj
-0.0016 Tc 0.0016 Tw T*
[(Wh)-5 (at are th)-5 (e p)-5 (o)-2 (ssi)-4 (b)-5 (l)-4 (e si)-4 (d)-5 (e)2 ( ef)-9 (f)-9 (ects of)-9 ( Accu)-5 (tan)-5 (e)2 (?  )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0014 Tc 0.0014 Tw T*
[(Accu)-5 (tan)-5 (e)2 ( h)-5 (a)-1 (s p)-5 (o)-1 (ssi)-4 (b)-5 (l)-4 (e seri)-4 (ou)-5 (s si)-4 (d)-5 (e)2 ( ef)-8 (f)-8 (ects)]TJ
ET
q
1 0 0 1 -8.215332 12.992645 cm
72.041 256.2 209.76 -1.2 re
f
Q
BT
0 Tc 0 Tw 12 0 0 12 273.5853 270.5127 Tm
( )Tj
/TT1 1 Tf
9.96 0 0 9.96 63.8253 258.7527 Tm
( )Tj
/T1_0 1 Tf
12 0 0 12 63.8253 244.4727 Tm
(\002\003)Tj
/TT0 1 Tf
0.0025 Tc -0.0025 Tw 1.5 0 Td
[(A)5 (c)6 (c)6 (u)-1 (t)6 (a)3 (ne)6 ( c)6 (a)3 (n c)6 (a)3 (use)6 ( bir)6 (t)6 (h de)6 (fe)6 (c)6 (t)6 (s, pr)6 (e)6 (m)16 (at)6 (ur)6 (e)6 ( bir)6 (t)6 (hs, and de)6 (at)6 (h in babie)6 (s)]TJ
/TT1 1 Tf
-0.0007 Tc 0.0007 Tw 30.6 0 Td
( whose mothers )Tj
-30.6 -1.14 Td
[(took Accutane while they)29 ( were preg)9 (nant. See \223W)-7 (hat is the most important information I)22 ( )]TJ
-0.0009 Tc 0.0009 Tw T*
[(should know about Accutane?)-17 (\224)3 ( and \223W)-7 (hat are the important warning)9 (s)-2 ( for females taking)9 ( )]TJ
-0.0023 Tc 0 Tw T*
[(Accut)-4 (a)2 (ne?)-18 (\224)2 ( )]TJ
0 Tc -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT0 1 Tf
0.0005 Tc -0.0005 Tw 1.5 0 Td
[(Serious m)14 (e)4 (ntal health problem)14 (s.)]TJ
/TT1 1 Tf
-0.0002 Tc 0.0002 Tw [( See \223W)-6 (hat is the most important information I)23 ( should )]TJ
-0.001 Tc 0.001 Tw 0 -1.14 TD
[(know about Accutane?)-17 (\224)3 ( )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 1.5 0 Td
[(Serious brain problem)14 (s. )]TJ
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 10.5 0 Td
[(Accutane can increase the pressure in y)29 (our brain. This can lead to )]TJ
-0.0007 Tc 0.0007 Tw -10.5 -1.14 Td
[(permanent loss of sig)9 (h)-1 (t, or in rare cases, death. Stop taking)9 ( Accutane and call y)29 (our prescriber )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(rig)9 (h)-1 (t away)29 ( if y)29 (ou g)9 (e)3 (t any)29 ( of these sig)9 (n)-1 (s of increased brain pressure: bad headache, blurred )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj162 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 154/Width 76>>stream
H :SNR ,DEQRݗ,4cw'?V]\l{<5*/̰9sWM"eSrxb	%Jy&^I'vU`(w֋mU cl
endstreamendobj248 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 273 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 274 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj274 0 obj<</Font 275 0 R>>endobj275 0 obj<</ArialRoundedMTBold 231 0 R>>endobj273 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj247 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj65 0 obj<</Contents 276 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 178 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 277 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 112 0 R/TT2 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 278 0 R>>>>/Rotate 0/Thumb 157 0 R/Type/Page>>endobj67 0 obj<</Contents 279 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 178 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 280 0 R>>/Font<</TT0 186 0 R/TT1 187 0 R/TT2 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 281 0 R>>>>/Rotate 0/Thumb 158 0 R/Type/Page>>endobj69 0 obj<</Contents 282 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 178 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 283 0 R>>/Font<</TT0 105 0 R/TT1 186 0 R/TT2 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 284 0 R>>>>/Rotate 0/Thumb 159 0 R/Type/Page>>endobj71 0 obj<</Contents 285 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 178 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 286 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 105 0 R/TT2 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 287 0 R>>>>/Rotate 0/Thumb 160 0 R/Type/Page>>endobj73 0 obj<</Contents 288 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 178 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 289 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 290 0 R>>>>/Rotate 0/Thumb 161 0 R/Type/Page>>endobj288 0 obj<</Length 6281>>stream
q
1 0 0 1 -7.93158 27.64267 cm
0 0 612 792 re
W n
1 0 0 1 7.93158 -27.64267 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
12 0 0 12 64.109 664.8427 Tm
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 1.5 0 Td
[(Do not take Accutane unless y)30 (ou completely)30 ( understand its possible risks and are willing)10 ( to )]TJ
0.0008 Tc -0.0008 Tw 0 -1.14 TD
[(f)4 (o)1 (llow a)5 (ll of)4 ( the)5 ( instr)4 (u)1 (c)5 (tions in this Me)5 (dic)5 (a)5 (tion Guide)5 (.)1 ( )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
0.0006 Tc -0.0006 Tw 0 -1.15 TD
[(Te)4 (ll y)31 (our)4 ( pr)4 (e)4 (sc)4 (r)4 (ibe)4 (r)4 ( if)4 ( y)31 (ou or)4 ( some)4 (one)4 ( in y)31 (our)4 ( f)4 (a)4 (mily)31 ( ha)4 (s ha)4 (d a)4 (n)1 (y)31 ( kind of)4 ( me)4 (nta)4 (l)-2 ( pr)4 (oble)4 (m)-2 (s, )]TJ
-0.0007 Tc 0.0007 Tw T*
[(asthma, liver disease, diabetes, heart disease, osteoporosis \(bone loss\\), weak bones, anorex)-11 (ia )]TJ
0.0007 Tc -0.0007 Tw T*
[(ne)5 (r)4 (vosa)5 ( \()4 (a)5 (n e)5 (a)5 (ting)11 ( disor)4 (d)1 (e)5 (r)4 ( whe)5 (r)4 (e)5 ( pe)5 (ople)5 ( e)5 (a)5 (t)-1 ( too little)5 (\))4 (,)1 ( or)4 ( a)5 (n)1 (y)31 ( othe)5 (r)4 ( impor)4 (ta)5 (nt he)5 (a)5 (lth pr)4 (oble)5 (m)-1 (s. )]TJ
-0.0008 Tc 0.0008 Tw T*
[(Tell y)29 (our prescriber about any)29 ( food or drug)9 ( allerg)9 (ies y)29 (ou have had in the past. These problems )]TJ
-0.0006 Tc 0.0006 Tw T*
[(do not necessarily)29 ( mean y)29 (ou cannot take Accutane, but y)29 (our prescriber needs this information to )]TJ
-0.0005 Tc 0.0005 Tw T*
[(discuss if Accutane is rig)10 (ht for y)30 (ou. )]TJ
0 Tc 0 Tw T*
( )Tj
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 0 -1.17 TD
[(How)-8 ( should I take Accutane? )]TJ
0 Tc 0 Tw 0 -1.15 TD
( )Tj
/T1_0 1 Tf
0 -1.21 TD
(\002\003)Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(You will g)9 (e)3 (t no more than a 30-day)29 ( supply)29 ( of Accutane at a time, to be sure y)29 (ou check in )]TJ
-0.0013 Tc 0.0013 Tw 0 -1.14 TD
[(wi)-3 (t)-3 (h)-1 ( y)29 (our prescri)-3 (b)-1 (er each m)-3 (ont)-3 (h t)-3 (o)-1 ( di)-3 (scuss si)-3 (de effect)-3 (s. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(Your prescription should have a special y)29 (e)3 (llow self-adhesive sticker attached to it. The )]TJ
-0.0005 Tc 0.0005 Tw T*
[(sticker is YEL)20 (L)20 (O)2 (W)-7 (. I)23 (f)3 ( y)30 (our prescription does not have this y)30 (e)3 (llow self-adhesive sticker, call )]TJ
0 -1.15 TD
[(y)30 (our prescriber. The pharmacy)30 ( should not fill y)30 (our prescription unless it has the y)30 (e)3 (llow self-)]TJ
-0.0008 Tc 0.0008 Tw T*
(adhesive sticker. )Tj
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
-0.0009 Tc 0.0009 Tw 1.5 0 Td
[(The amount of Accutane y)29 (ou take has been specially)29 ( chosen for y)29 (ou and may)29 ( chang)9 (e)3 ( during)9 ( )]TJ
0.0015 Tc 0 Tw T*
[(tr)5 (e)5 (a)5 (tme)5 (nt. )]TJ
/TT1 1 Tf
0 Tc 4.27 0 Td
( )Tj
/T1_0 1 Tf
-5.77 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 1.5 0 Td
[(You will ta)5 (ke)5 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( 2 time)5 (s a)5 ( da)5 (y)31 ( with a)5 ( me)5 (a)5 (l)-1 (, unle)5 (ss y)31 (our)4 ( pr)4 (e)5 (sc)5 (r)4 (ibe)5 (r)4 ( te)5 (lls y)31 (ou othe)5 (r)4 (w)3 (ise)5 (.)1 ( )]TJ
0 -1.14 TD
[(Swa)5 (llow y)31 (our)4 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( c)5 (a)5 (p)1 (sule)5 (s with a)5 ( f)4 (u)1 (ll g)11 (l)-1 (a)5 (ss of)4 ( liquid. This will he)5 (lp pr)4 (e)5 (v)1 (e)5 (n)1 (t the)5 ( )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(medication inside the capsule from irritating)10 ( the lining)10 ( of y)30 (our esophag)10 (us \(connection )]TJ
-0.0008 Tc 0.0008 Tw T*
[(between mouth and stomach\). F)5 (o)-1 (r the same reason, do not chew or suck on the capsule. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
1.5 0 Td
[(I)23 (f)3 ( y)30 (ou miss a dose, just skip that dose. Do )]TJ
/TT1 1 Tf
0.0019 Tc 16.89 0 Td
(not)Tj
/TT0 1 Tf
0.0008 Tc -0.0008 Tw 1.39 0 Td
[( ta)5 (ke)5 ( 2 dose)5 (s the)5 ( ne)5 (x)-9 (t)-1 ( time)5 (.)]TJ
/TT1 1 Tf
0 Tc 0 Tw 10.86 0 Td
( )Tj
/T1_0 1 Tf
-30.64 -1.22 Td
(\002\003)Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(You should return to y)29 (our prescriber as directed to make sure y)29 (ou don\222t have sig)9 (n)-1 (s of serious )]TJ
0 -1.14 TD
[(side effects. B)6 (ecause some of Accutane\222s serious side effects show up in blood tests\, some of )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.15 TD
[(these visits may)30 ( involve blood tests \(monthly)30 ( visits for female patients should alway)30 (s)-1 ( include )]TJ
-0.0013 Tc 0.0013 Tw T*
[(a urine or serum preg)9 (nancy)29 ( test\). )]TJ
/TT1 1 Tf
0 Tc 0 Tw 13.34 0 Td
( )Tj
-14.84 -1.17 Td
( )Tj
0.0006 Tc -0.0006 Tw T*
[(What should I avoid w)-7 (h)-3 (ile taking Accutane?  )]TJ
0 Tc 0 Tw T*
( )Tj
/T1_0 1 Tf
0 -1.21 TD
(\002\003)Tj
/TT1 1 Tf
0.0019 Tc -0.0019 Tw 1.5 0 Td
[(D)4 (o)2 ( not)5 ( ge)6 (t)5 ( pr)6 (e)6 (g)2 (nant)]TJ
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 8.52 0 Td
[( while taking)10 ( Accutane. See \223W)-7 (hat is the most important information I)23 ( )]TJ
-0.0009 Tc 0.0009 Tw -8.52 -1.14 Td
[(should know about Accutane?)-17 (\224)3 ( and \223W)-7 (hat are the important warning)9 (s)-2 ( for females taking)9 ( )]TJ
-0.0023 Tc 0 Tw 0 -1.15 TD
[(Accut)-4 (a)2 (ne?)-18 (\224)2 ( )]TJ
/T1_0 1 Tf
0 Tc -1.5 -1.23 Td
(\002\003)Tj
/TT1 1 Tf
-0.0021 Tc 0.0021 Tw 1.5 0 Td
[(Do n)-6 (o)-2 (t b)-6 (reast f)-9 (eed)]TJ
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 7.8 0 Td
[( while taking)9 ( Accutane and for 1 month after stopping)9 ( Accutane. W)-7 (e)3 ( do )]TJ
-7.8 -1.14 Td
[(not know if Accutane can pass throug)9 (h y)29 (our milk and harm the baby)29 (. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT1 1 Tf
1.5 0 Td
(Do not give blood)Tj
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 7.48 0 Td
[( while y)29 (ou take Accutane and for 1 month after stopping)9 ( Accutane. I)22 (f)2 ( )]TJ
-7.48 -1.14 Td
[(someone who is preg)9 (nant g)9 (e)3 (ts y)29 (our donated blood, her baby)29 ( may)29 ( be ex)-11 (posed to Accutane and )]TJ
-0.0006 Tc 0.0006 Tw T*
[(may)29 ( be born with birth defects. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj161 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 157/Width 76>>stream
H	0gϔ^RhW}8'<̆a_laԔm>HR1jeԮMdз,
i<eN-\=k"_nFYB'24~^L/t:dDu)/GEԠ{*[˽K 1
endstreamendobj290 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 291 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 292 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj292 0 obj<</Font 293 0 R>>endobj293 0 obj<</ArialRoundedMTBold 231 0 R>>endobj291 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj289 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj285 0 obj<</Length 5290>>stream
q
1 0 0 1 -5.139526 21.395599 cm
0 0 612 792 re
W n
1 0 0 1 5.139526 -21.395599 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
12 0 0 12 66.9011 658.3556 Tm
( )Tj
/TT1 1 Tf
0.0028 Tc -0.0049 Tw 14.04 0 0 14.04 133.0211 642.5156 Tm
[(All patients should read the rest of this Medication G)7 (u)3 (ide)]TJ
0 Tc 0 Tw 12 0 0 12 465.6611 642.5156 Tm
(. )Tj
-13.73 -1.17 Td
( )Tj
/TT0 1 Tf
-0.0001 Tc 0.0001 Tw -19.5 -1.15 Td
[(What are the signs of)-7 ( m)13 (e)4 (ntal problem)13 (s)-1 (? )]TJ
0 Tc 0 Tw 0 -1.15 TD
( )Tj
/TT2 1 Tf
-0.0006 Tc 0.0006 Tw 0 -1.13 TD
[(Tell y)29 (our prescriber if, to the best of y)29 (our knowledg)9 (e, y)29 (ou or someone in y)29 (our family)29 ( has ever )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.15 TD
[(had any)30 ( mental illness, including)10 ( depression, suicidal behavior, or psy)30 (c)4 (hosis. Psy)30 (c)4 (hosis means a )]TJ
0.0007 Tc -0.0007 Tw T*
[(loss of)4 ( c)5 (onta)5 (c)5 (t)-1 ( with r)4 (e)5 (a)5 (lity)31 (, suc)5 (h)1 ( a)5 (s he)5 (a)5 (r)4 (ing)11 ( voic)5 (e)5 (s or)4 ( se)5 (e)5 (i)-1 (ng)11 ( thing)11 (s tha)5 (t)-1 ( a)5 (r)4 (e)5 ( not the)5 (r)4 (e)5 (.)1 ( Also, te)5 (ll )]TJ
-0.0009 Tc 0.0009 Tw T*
[(y)29 (our prescriber if y)29 (ou take medicines for any)29 ( of these problems. )]TJ
0 Tc 0 Tw T*
( )Tj
/TT0 1 Tf
0.0001 Tc -0.0001 Tw 0 -1.17 TD
[(Stop using Accutane and tell your provider right aw)-8 (ay if)-7 ( you: )]TJ
/TT2 1 Tf
0 Tc 0 Tw 0 -1.13 TD
( )Tj
/T1_0 1 Tf
0 -1.23 TD
(\002\003)Tj
/TT2 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(Start to feel sad or have cry)29 (i)-3 (ng)9 ( spells )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT2 1 Tf
0.001 Tc -0.001 Tw 1.5 0 Td
[(L)22 (o)1 (se)5 ( inte)5 (r)4 (e)5 (st in a)5 (c)5 (tivitie)5 (s y)31 (ou onc)5 (e)5 ( e)5 (n)1 (joy)31 (e)5 (d )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT2 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(Sleep too much or have trouble sleeping)10 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT2 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(B)6 (ecome more irritable, ang)9 (r)2 (y)29 (,)-1 ( or ag)9 (g)9 (r)2 (essive than usual \(for ex)-11 (ample, temper outbursts, )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.14 TD
[(thoug)10 (hts of violence\) )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT2 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(Have a chang)9 (e)3 ( in y)29 (our appetite or body)29 ( weig)9 (ht  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT2 1 Tf
-0.0011 Tc 0.0011 Tw 1.5 0 Td
[(Have trouble concentrating)9 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT2 1 Tf
0.001 Tc -0.001 Tw 1.5 0 Td
[(Withdr)4 (a)5 (w)3 ( f)4 (r)4 (o)1 (m y)31 (our)4 ( f)4 (r)4 (i)-1 (e)5 (nds or)4 ( f)4 (a)5 (mily)31 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT2 1 Tf
-0.0011 Tc 0.0011 Tw 1.5 0 Td
[(F)5 (eel like y)29 (ou have no energ)9 (y)29 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT2 1 Tf
0.0006 Tc -0.0006 Tw 1.5 0 Td
[(Ha)4 (ve)4 ( f)4 (e)4 (e)4 (ling)11 (s of)4 ( wor)4 (t)-2 (hle)4 (ssne)4 (ss or)4 ( ina)4 (ppr)4 (opr)4 (ia)4 (te)4 ( g)11 (u)1 (ilt  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT2 1 Tf
-0.0001 Tc 0.0001 Tw 1.5 0 Td
[(Start having)10 ( thoug)10 (hts about hurting)10 ( y)30 (ourself or taking)10 ( y)30 (our own life \(suicidal thoug)10 (hts\) )]TJ
0 Tc 0 Tw -1.5 -1.14 Td
( )Tj
0 -1.15 TD
( )Tj
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw 0 -1.17 TD
(What is Accutane?)Tj
/TT2 1 Tf
0 Tc 0 Tw ( )Tj
0 -1.13 TD
( )Tj
-0.0011 Tc 0.0011 Tw 0 -1.15 TD
(Accutane is used to treat the most severe form of acne \(nodular acne\) \that cannot be cleared up )Tj
-0.0007 Tc 0.0007 Tw T*
[(by)29 ( any)29 ( other acne treatments, including)9 ( antibiotics. I)22 (n)-1 ( severe nodular acne, many)29 ( red, swollen, )]TJ
-0.0009 Tc 0.0009 Tw T*
[(tender lumps form in the skin. These can be the siz)-7 (e)3 ( of pencil erasers or larg)9 (er. I)22 (f)2 ( untreated, )]TJ
-0.0012 Tc 0.0012 Tw T*
(nodular acne can lead to permanent scars. However, because Accutane can \have serious side )Tj
-0.0007 Tc 0.0007 Tw T*
[(effects, y)29 (ou should talk with y)29 (our prescriber about all of the possible treatments for y)29 (our acne, )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
[(and whether Accutane\222s possible benefits outweig)10 (h its possible risks.  )]TJ
/TT0 1 Tf
0.0001 Tc -0.0001 Tw 0 -2.24 TD
(Who should not take Accutane?)Tj
/TT2 1 Tf
0 Tc 0 Tw 13.62 0 Td
( )Tj
-13.62 -1.13 Td
( )Tj
/T1_0 1 Tf
0 -1.25 TD
(\002\003)Tj
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw 1.5 0 Td
[(Do not take Accutane if)-7 ( you are pregnant, plan to becom)13 (e)4 ( pregnant, or becom)13 (e)4 ( )]TJ
-0.0024 Tc 0.0024 Tw 0 -1.12 TD
[(p)-6 (regn)-6 (a)-2 (n)-6 (t)1 ( d)-6 (u)-6 (r)1 (i)-5 (n)-6 (g Accu)-6 (tan)-6 (e)1 ( treatm)11 (en)-6 (t.)]TJ
/TT2 1 Tf
-0.001 Tc 0.001 Tw ( Accutane causes severe birth defects. All females )Tj
0 -1.15 TD
[(should read the section \223W)-7 (hat are the important warning)9 (s)-2 ( for females taking)9 ( Accutane?)-17 (\224)3 ( for )]TJ
T*
[(more information and warning)9 (s)-2 ( about Accutane and preg)9 (nancy)29 (.)-1 ( )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj160 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 143/Width 76>>stream
H kJL^XYilBHI:֪TecV ijRz2VxYj]]?}u:dG6VzY!^n\QPv]($jFp݃EJG?19K . 
endstreamendobj287 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 294 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 295 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj295 0 obj<</Font 296 0 R>>endobj296 0 obj<</ArialRoundedMTBold 231 0 R>>endobj294 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj286 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj282 0 obj<</Length 6273>>stream
q
1 0 0 1 -8.989197 16.032654 cm
0 0 612 792 re
W n
1 0 0 1 8.989197 -16.032654 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0006 Tc -0.0006 Tw 12 0 0 12 117.0514 652.9927 Tm
[(of m)-12 (e)4 (ntal problem)-12 (s?" )]TJ
0 Tc 0 Tw 0 -1.15 TD
( )Tj
-0.0001 Tc 0.0001 Tw T*
(For other possible serious side effects of Accutane, see "What are the p\ossible side )Tj
0.0016 Tc -0.0016 Tw T*
[(e)5 (f)5 (f)5 (e)5 (c)5 (t)-1 (s of)5 ( Ac)5 (c)5 (u)-2 (tane)5 (?" in this Me)5 (dic)5 (a)2 (tion Guide)5 (.)]TJ
/TT1 1 Tf
0 Tc 0 Tw 19.7 0 Td
( )Tj
-24.2 -1.13 Td
( )Tj
/TT2 1 Tf
-0.0019 Tc 0.0019 Tw 0 -1.17 TD
[(Wh)-6 (at are th)-6 (e i)-4 (m)11 (p)-6 (o)-2 (rtan)-6 (t w)-10 (a)-2 (rn)-6 (i)-4 (n)-6 (gs f)-9 (o)-2 (r f)-9 (e)2 (m)11 (a)-2 (l)-4 (e)2 (s tak)-6 (i)-4 (n)-6 (g)-2 ( Accu)-6 (tan)-6 (e)2 (? )]TJ
/TT1 1 Tf
0 Tc 0 Tw 0 -1.13 TD
( )Tj
-0.0006 Tc 0.0006 Tw 0 -1.15 TD
[(You must not become preg)9 (nant while taking)9 ( Accutane, or for 1 month after y)29 (ou stop taking)9 ( )]TJ
-0.0011 Tc 0.0011 Tw T*
[(Accutane. Accutane can cause severe birth defects in babies of women who\ take it while they)29 ( are )]TJ
0.0008 Tc -0.0008 Tw T*
[(pr)4 (e)5 (g)11 (na)5 (nt, e)5 (v)1 (e)5 (n)1 ( if)4 ( the)5 (y)31 ( ta)5 (ke)5 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( f)4 (o)1 (r)4 ( only)31 ( a)5 ( shor)4 (t time)5 (. )]TJ
/TT2 1 Tf
-0.0019 Tc 0.0019 Tw 23.46 0 Td
[(T)-5 (h)-6 (ere i)-4 (s)-3 ( an)-6 ( extrem)11 (el)-4 (y h)-6 (i)-4 (gh)-6 ( ri)-4 (sk)-6 ( th)-6 (at )]TJ
0.002 Tc -0.002 Tw -23.46 -1.15 Td
[(your)6 ( baby w)-6 (ill be)6 ( de)6 (for)6 (m)15 (e)6 (d)-2 ( or)6 ( w)-6 (ill die)]TJ
/TT1 1 Tf
-0.0009 Tc 0.0009 Tw 16.33 0 Td
[( if y)29 (ou are preg)9 (nant while taking)9 ( Accutane. Taking)9 ( )]TJ
-0.0022 Tc 0.0022 Tw -16.33 -1.15 Td
[(Accut)-4 (a)2 (ne al)-4 (so i)-4 (n)-2 (creases t)-4 (h)-2 (e chance of m)-4 (i)-4 (s)-3 (carri)-4 (ag)8 (e and prem)-4 (at)-4 (ure bi)-4 (rt)-4 (hs. )]TJ
0 Tc 0 Tw T*
( )Tj
0.0008 Tc -0.0008 Tw T*
[(F)7 (e)5 (ma)5 (le)5 ( pa)5 (tie)5 (nts will not g)11 (e)5 (t the)5 (i)-1 (r)4 ( f)4 (i)-1 (r)4 (st pr)4 (e)5 (sc)5 (r)4 (iption f)4 (o)1 (r)4 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( unle)5 (ss the)5 (r)4 (e)5 ( is pr)4 (oof)4 ( the)5 (y)31 ( ha)5 (ve)5 ( )]TJ
-0.0008 Tc 0.0008 Tw T*
[(had 2 neg)9 (a)3 (tive preg)9 (nancy)29 ( tests. The first test must be done when y)29 (our prescriber decides to )]TJ
-0.001 Tc 0.001 Tw T*
[(prescribe Accutane. The second preg)9 (nancy)29 ( test must be done during)9 ( the first 5 day)29 (s)-2 ( of the )]TJ
-0.0008 Tc 0.0008 Tw T*
[(menstrual period rig)9 (h)-1 (t before starting)9 ( Accutane therapy)29 (,)-1 ( or as instructed by)29 ( y)29 (our prescriber. Each )]TJ
-0.0007 Tc 0.0007 Tw T*
[(month of treatment, y)29 (ou must have a neg)9 (a)3 (tive result from a urine or serum preg)9 (nancy)29 ( test. )]TJ
-0.0008 Tc 0.0008 Tw T*
[(F)5 (e)3 (male patients cannot g)9 (e)3 (t another prescription for Accutane unless there is proof that they)29 ( have )]TJ
-0.0013 Tc 0.0013 Tw T*
[(had a neg)9 (a)3 (tive preg)9 (nancy)29 ( test. )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0007 Tc 0.0007 Tw T*
[(A y)29 (e)3 (llow self-adhesive Accutane Qualification Sticker on y)29 (our prescription indicates to the )]TJ
-0.0008 Tc 0.0008 Tw T*
[(pharmacist that y)29 (ou are qualified by)29 ( y)29 (our prescriber to g)9 (e)3 (t Accutane. )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0009 Tc 0.0009 Tw T*
[(W)-7 (h)-1 (ile y)29 (ou are taking)9 ( Accutane, y)29 (ou )]TJ
/TT2 1 Tf
-0.013 Tc 0 Tw 14.6 0 Td
[(mu)-17 (s)-14 (t)]TJ
/TT1 1 Tf
-0.001 Tc 0.001 Tw 2.1 0 Td
( use effective birth control. )Tj
/TT2 1 Tf
0.0015 Tc -0.0015 Tw 11.03 0 Td
[(Y)4 (o)2 (u m)15 (u)-2 (st)5 ( use)5 ( 2 se)5 (par)5 (a)2 (t)5 (e)5 ( )]TJ
-0.0021 Tc 0.0021 Tw -27.73 -1.15 Td
[(ef)-9 (f)-9 (ecti)-4 (v)-2 (e f)-9 (o)-2 (rm)11 (s of)-9 ( b)-6 (i)-4 (rth)-6 ( con)-6 (t)1 (rol)-4 ( at th)-6 (e sam)11 (e)2 ( ti)-4 (m)11 (e)]TJ
/TT1 1 Tf
-0.0008 Tc 0.0008 Tw 20.28 0 Td
[( for at least 1 month before starting)9 ( Accutane, )]TJ
-0.0005 Tc 0.0005 Tw -20.28 -1.15 Td
[(while y)30 (ou take it, and for 1 month after y)30 (ou stop taking)10 ( it. You can either discuss effective birth )]TJ
T*
[(control methods with y)30 (our prescriber or g)10 (o for a free visit to discuss birth control with another )]TJ
0.0005 Tc -0.0005 Tw T*
[(phy)31 (sic)4 (i)-2 (a)4 (n)1 ( or)4 ( f)4 (a)4 (mily)31 ( pla)4 (nning)11 ( e)4 (x)-9 (pe)4 (r)4 (t)-2 (. Your)4 ( pr)4 (e)4 (sc)4 (r)4 (ibe)4 (r)4 ( c)4 (a)4 (n)1 ( a)4 (r)4 (r)4 (a)4 (ng)11 (e)4 ( this f)4 (r)4 (e)4 (e)]TJ
ET
q
1 0 0 1 -8.989197 16.032654 cm
405.401 249.48 18.48 -0.6 re
f
Q
BT
0.0008 Tc -0.0008 Tw 12 0 0 12 414.8914 266.8327 Tm
[( visit, whic)5 (h will be)5 ( )]TJ
-0.0012 Tc 0.0012 Tw -29.32 -1.15 Td
[(paid for by)29 ( the manufacturer. )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0006 Tc 0.0006 Tw T*
[(You must use 2 separate forms of effective birth control because any)29 ( method, including)9 ( birth )]TJ
-0.0005 Tc 0.0005 Tw T*
[(control pills and steriliz)-7 (ation, can fail. There are only)30 ( 2 reasons y)30 (ou would not need to use 2 )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.16 TD
(separate methods of effective birth control: )Tj
-0.0009 Tc 0.0009 Tw 0 -2.22 TD
[(1. )-500 (You have had y)29 (our womb removed by)29 ( surg)9 (ery)29 ( \(a hy)29 (sterectomy)29 (\). )]TJ
0.0011 Tc 0.1389 Tw 0 -1.15 TD
[(2. )-360 (You )-10 (a)5 (r)4 (e)5 ( )-10 (a)5 (b)1 (solute)5 (ly)31 ( )-10 (c)5 (e)5 (r)4 (ta)5 (in )-10 (y)31 (ou )-10 (will )-10 (not ha)5 (ve)5 ( g)11 (e)5 (nita)5 (l-)4 (to-)4 (g)11 (e)5 (n)1 (ita)5 (l se)5 (x)-9 (u)1 (a)5 (l)-1 ( c)5 (onta)5 (c)5 (t)-1 ( with a)5 ( ma)5 (le)5 ( )]TJ
-0.001 Tc 0.001 Tw 1.5 -1.15 Td
[(before, during)9 (,)-1 ( and for 1 month after Accutane treatment. )]TJ
0 Tc 0 Tw -1.5 -1.15 Td
( )Tj
/TT2 1 Tf
-0.0003 Tc 0.0003 Tw 0 -1.17 TD
[(If)-7 ( you have sex at any tim)13 (e)4 ( w)-8 (i)-2 (thout using 2 f)-7 (orm)13 (s of)-7 ( ef)-7 (f)-7 (ective birth control, get pregnant, or )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.15 TD
[(m)13 (i)-2 (ss your period, stop using Accutane and call your prescriber right aw)-8 (ay.  )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj159 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 145/Width 76>>stream
H0z:*i7@8;)kcA2ot3Ub j*I􂻑j&Mb{Tψ:K$9o̜ŚkU./I)4<oD'c l
endstreamendobj284 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 297 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 298 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj298 0 obj<</Font 299 0 R>>endobj299 0 obj<</ArialRoundedMTBold 231 0 R>>endobj297 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj283 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj279 0 obj<</Length 5934>>stream
q
1 0 0 1 -7.333282 21.685944 cm
0 0 612 792 re
W n
1 0 0 1 7.333282 -21.685944 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
12 0 0 12 64.7073 659.246 Tm
( )Tj
/TT1 1 Tf
-0.0014 Tc 0.0014 Tw 0 -1.13 TD
[(ME)-4 (DICAT)-4 (ION G)6 (U)1 (IDE)-4 (:)2 ( )]TJ
0 Tc 0 Tw 0 -1.15 TD
( )Tj
/TT0 1 Tf
0.0011 Tc 0.0019 Tw 9.96 0 0 9.96 64.7073 620.1259 Tm
[(Read)-5 ( th)7 (is Med)-5 (i)2 (catio)-5 (n)7 ( Gu)7 (id)-5 (e ev)7 (ery)19 ( tim)20 (e y)19 (o)-5 (u)7 ( g)7 (e)-1 (t a p)-5 (r)-3 (escrip)-5 (tio)-5 (n)7 ( o)-5 (r)-3 ( a ref)9 (ill f)9 (o)-5 (r A)12 (ccu)7 (tan)7 (e)-1 ( \(A)12 (CK-)9 (u)7 (-)9 (t)2 (an)7 (e\). T)-15 (h)7 (ere m)20 (a)-1 (y)19 ( b)-5 (e)-1 ( )]TJ
0.0022 Tc 0.0008 Tw 0 -1.157 TD
[(n)8 (ew)26 ( in)8 (f)10 (o)-4 (rm)21 (ation)8 (.)-1 ( T)-13 (h)8 (is)6 ( in)8 (f)10 (o)-4 (rm)21 (ation)8 ( does)6 ( n)8 (o)-4 (t tak)8 (e th)8 (e place of)10 ( talk)8 (in)8 (g)8 ( w)26 (ith)8 ( y)20 (o)-4 (u)8 (r)-2 ( pres)6 (criber \(doctor or oth)8 (er h)8 (ealth)8 ( )]TJ
0.0035 Tc -0.0005 Tw T*
[(care prov)10 (ider\). )]TJ
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 12 0 0 12 64.7073 577.5259 Tm
[(What is the m)13 (ost im)13 (portant inf)-7 (orm)13 (ation I should know)-8 ( about Accutane? )]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -1.13 TD
( )Tj
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(Accutane is used to treat a ty)29 (pe of severe acne \(nodular acne\) that has not been helped by)29 ( other )]TJ
-0.0008 Tc 0.0008 Tw T*
[(treatments, including)9 ( antibiotics. However, Accutane can cause serious side effects. B)6 (e)3 (fore )]TJ
T*
[(starting)9 ( Accutane, discuss with y)29 (our prescriber how bad y)29 (our acne is, the possible benefits of )]TJ
T*
[(Accutane, and its possible side effects, to decide if Accutane is rig)9 (h)-1 (t for y)29 (ou. Your prescriber )]TJ
-0.0004 Tc 0.0004 Tw T*
[(will ask y)30 (ou to read and sig)10 (n a form or forms indicating)10 ( y)30 (ou understand some of the serious risks )]TJ
-0.0014 Tc 0.0014 Tw T*
(of Accutane. )Tj
0 Tc 0 Tw T*
( )Tj
/TT1 1 Tf
-0.0014 Tc 0.0014 Tw 0.58 -1.17 Td
[(P)9 (o)-1 (ssi)-4 (b)-5 (l)-4 (e seri)-4 (ou)-5 (s si)-4 (d)-5 (e)2 ( ef)-8 (f)-8 (ects of)-8 ( tak)-5 (i)-4 (n)-5 (g)-1 ( Accu)-5 (tan)-5 (e)2 ( i)-4 (n)-5 (cl)-4 (u)-5 (d)-5 (e)2 ( )]TJ
/TT2 1 Tf
0.0001 Tc -0.0001 Tw 23.51 0 Td
(birth defects)Tj
/TT1 1 Tf
0.0023 Tc -0.0023 Tw 5.08 0 Td
( and )Tj
/TT2 1 Tf
0.0007 Tc -0.0007 Tw 2.12 0 Td
[(m)-11 (e)5 (ntal disorders.)]TJ
/TT1 1 Tf
0 Tc 0 Tw ( )Tj
-11.79 -1.15 Td
( )Tj
0.0025 Tc -0.0025 Tw -16.5 -1.15 Td
[(1. )-500 (Bir)6 (t)6 (h de)6 (fe)6 (c)6 (t)6 (s. A)5 (c)6 (c)6 (u)-1 (t)6 (a)3 (ne)6 ( c)6 (a)3 (n c)6 (a)3 (use)6 ( bir)6 (t)6 (h de)6 (fe)6 (c)6 (t)6 (s \()6 (d)-1 (e)6 (f)-4 (or)6 (m)16 (e)6 (d babie)6 (s)2 (\))6 ( if t)6 (a)3 (ke)6 (n by a )]TJ
0.0031 Tc -0.0031 Tw 1.5 -1.13 Td
[(pr)7 (e)7 (g)3 (nant)6 ( wom)16 (a)3 (n.)]TJ
/TT0 1 Tf
-0.0011 Tc 0.0011 Tw 7.5 0 Td
[( I)22 (t)-3 ( can also cause miscarriag)9 (e \(losing)9 ( the baby)29 ( before birth\), )]TJ
-7.5 -1.15 Td
[(premature \(early)29 (\) birth, or death of the baby)29 (. Do not take Accutane if y)29 (ou are )]TJ
-0.0008 Tc 0.0008 Tw T*
[(preg)9 (nant or plan to become preg)9 (nant while y)29 (ou are taking)9 ( Accutane. Do not g)9 (e)3 (t )]TJ
-0.0007 Tc 0.0007 Tw T*
[(preg)9 (nant for 1 month after y)29 (ou stop taking)9 ( Accutane. Also, if y)29 (ou g)9 (e)3 (t preg)9 (nant while )]TJ
T*
[(taking)9 ( Accutane, stop taking)9 ( it rig)9 (h)-1 (t away)29 ( and call y)29 (our prescriber.  )]TJ
0 Tc 0 Tw T*
( )Tj
/TT2 1 Tf
0.0017 Tc -0.0017 Tw 0 -1.17 TD
[(All f)5 (e)6 (m)-10 (a)2 (le)6 (s should re)6 (ad the)6 ( se)6 (c)6 (tion in this Me)6 (dic)6 (a)2 (tion Guide)6 ( "What are)6 ( the)6 ( )]TJ
0.0006 Tc -0.0006 Tw 0 -1.15 TD
[(im)-12 (portant warnings for fem)-12 (a)1 (les taking Accutane?")]TJ
/TT0 1 Tf
0 Tc 0 Tw 21.14 0 Td
( )Tj
-21.14 -1.13 Td
( )Tj
/TT1 1 Tf
0.0021 Tc -0.0021 Tw -1.5 -1.15 Td
[(2. )-500 (M)6 (e)6 (n)-2 (t)5 (a)2 (l pr)6 (oble)6 (m)15 (s)1 ( and suic)6 (ide)6 (.)]TJ
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 14.11 0 Td
[( Some patients, while taking)9 ( Accutane or soon after )]TJ
-0.0009 Tc 0.0009 Tw -12.61 -1.15 Td
[(stopping)9 ( Accutane, have become depressed or developed other serious mental )]TJ
-0.0003 Tc 0.0003 Tw T*
[(problems. Sy)30 (mptoms of these problems include sad, \223anx)-10 (i)-2 (ous\224 or empty)30 ( mood, )]TJ
0.0009 Tc -0.0009 Tw T*
[(ir)4 (r)4 (ita)5 (bility)31 (, a)5 (n)1 (g)11 (e)5 (r)4 (,)1 ( loss of)4 ( ple)5 (a)5 (sur)4 (e)5 ( or)4 ( inte)5 (r)4 (e)5 (st in soc)5 (i)-1 (a)5 (l)-1 ( or)4 ( spor)4 (ts a)5 (c)5 (tivitie)5 (s, sle)5 (e)5 (p)1 (ing)11 ( too )]TJ
-0.0005 Tc 0.0005 Tw T*
[(much or too little, chang)10 (e)3 (s in weig)10 (ht or appetite, school or work performance g)10 (oing)10 ( )]TJ
T*
[(down, or trouble concentrating)10 (. Some patients taking)10 ( Accutane have had thoug)10 (hts )]TJ
-0.0001 Tc 0.0001 Tw T*
[(about hurting)10 ( themselves or putting)10 ( an end to their own lives \(suicidal thoug)10 (hts\). )]TJ
-0.0007 Tc 0.0007 Tw T*
(Some people tried to end their own lives. And some people have ended the\ir own )Tj
-0.0011 Tc 0.0011 Tw T*
(lives. There were reports that some of these people did not appear depre\ssed. There )Tj
-0.0008 Tc 0.0008 Tw 0 -1.14 TD
[(have been reports of patients on Accutane becoming)9 ( ag)9 (g)9 (r)2 (essive or violent. No one )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(knows if Accutane caused these behaviors or if they)29 ( would have happened even if the )]TJ
-0.0007 Tc 0.0007 Tw T*
(person did not take Accutane. )Tj
0 Tc 0 Tw T*
( )Tj
/TT2 1 Tf
0.0017 Tc -0.0017 Tw 0 -1.17 TD
[(All patie)6 (nts should re)6 (ad the)6 ( se)6 (c)6 (tion in this Me)6 (dic)6 (a)2 (tion Guide)6 ( "What are)6 ( the)6 ( signs )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj158 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 134/Width 76>>stream
H0gwʮ?hvB86}uu׸xH+ӈR_[1oDKL<IYV2 9T^M9vtR!<Ƌ5a'ޣZ)Շ0s |'
endstreamendobj281 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 300 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 301 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj301 0 obj<</Font 302 0 R>>endobj302 0 obj<</ArialRoundedMTBold 231 0 R>>endobj300 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj280 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj276 0 obj<</Length 1942>>stream
q
1 0 0 1 -2.404266 -188.83728 cm
0 0 612 792 re
W n
1 0 0 1 2.404266 188.83728 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0005 Tc 0.0005 Tw 12 0 0 12 69.6363 448.7228 Tm
[(I)23 ( have: )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
/T1_0 1 Tf
0 -1.09 TD
(\002\003)Tj
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 1.5 0 Td
[(fully)29 ( ex)-11 (plained to the patient, __________________, the nature and purpose of Ac\cutane )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.08 TD
[(treatment, including)10 ( its benefits and risks )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.08 Td
(\002\003)Tj
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 1.5 0 Td
[(g)9 (i)-3 (ven the patient the appropriate educational materials, )]TJ
/TT1 1 Tf
22.17 0 Td
(Be Smart, Be Safe, Be Sure)Tj
/TT0 1 Tf
-0.0015 Tc 0.0015 Tw 10.84 0 Td
(, for )Tj
-0.0007 Tc 0.0007 Tw -33.01 -1.09 Td
[(Accutane and asked the patient if he/she has any)29 ( questions reg)9 (a)3 (rding)9 ( his/her treatment with )]TJ
-0.0017 Tc 0.0017 Tw T*
(Accutane  )Tj
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.08 Td
(\002\003)Tj
/TT0 1 Tf
0.0008 Tc -0.0008 Tw 1.5 0 Td
[(a)5 (n)1 (swe)5 (r)4 (e)5 (d)1 ( those)5 ( que)5 (stions to the)5 ( be)5 (st of)4 ( my)31 ( a)5 (b)1 (ility)31 (  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.09 Td
(\002\003)Tj
/TT0 1 Tf
-0.0017 Tc 0.0017 Tw 1.5 0 Td
[(pl)-4 (aced t)-4 (h)-2 (e y)28 (e)2 (l)-4 (l)-4 (o)-2 (w sel)-4 (f-adhesi)-4 (ve Accut)-4 (a)2 (ne Qual)-4 (i)-4 (f)1 (i)-4 (cat)-4 (i)-4 (on S)-5 (t)-4 (i)-4 (c)2 (ker on t)-4 (h)-2 (e prescri)-4 (p)-2 (t)-4 (i)-4 (on.)]TJ
/TT2 1 Tf
0 Tc 0 Tw 33.12 0 Td
( )Tj
/TT0 1 Tf
( )Tj
-34.62 -1.08 Td
( )Tj
T*
( )Tj
-0.0003 Tc 0.0003 Tw 0 -1.09 TD
[(Prescriber Sig)10 (nature: ___________________________________ Date:______________ )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj157 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 80/Width 76>>stream
H	 Eڭv5&8sj`r?)X`-%72e^ҽ[;"^^}     p?/
endstreamendobj278 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 303 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 304 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj304 0 obj<</Font 305 0 R>>endobj305 0 obj<</ArialRoundedMTBold 231 0 R>>endobj303 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj277 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj55 0 obj<</Contents 306 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 177 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 307 0 R>>/Font<</T1_0 116 0 R/T1_1 188 0 R/TT0 186 0 R/TT1 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 308 0 R>>>>/Rotate 0/Thumb 152 0 R/Type/Page>>endobj57 0 obj<</Contents 309 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 177 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 310 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 311 0 R>>>>/Rotate 0/Thumb 153 0 R/Type/Page>>endobj59 0 obj<</Contents 312 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 177 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 313 0 R>>/Font<</TT0 187 0 R/TT1 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 314 0 R>>>>/Rotate 0/Thumb 154 0 R/Type/Page>>endobj61 0 obj<</Contents 315 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 177 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 316 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 317 0 R>>>>/Rotate 0/Thumb 155 0 R/Type/Page>>endobj63 0 obj<</Contents 318 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 177 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 319 0 R>>/Font<</T1_0 108 0 R/TT0 186 0 R/TT1 187 0 R/TT2 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 320 0 R>>>>/Rotate 0/Thumb 156 0 R/Type/Page>>endobj318 0 obj<</Length 5397>>stream
q
1 0 0 1 -7.579071 27.222656 cm
0 0 612 792 re
W n
1 0 0 1 7.579071 -27.222656 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
12 0 0 12 64.4615 664.7828 Tm
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itials: ______ )]TJ
/TT1 1 Tf
0 Tc 0 Tw -1.5 -1.09 Td
( )Tj
-0.0018 Tc 0.0018 Tw 0 -1.08 TD
[(8. )-500 (I agree to retu)-6 (r)2 (n)-6 ( to see m)11 (y)-2 ( p)-6 (rescri)-4 (b)-6 (er every m)11 (o)-2 (n)-6 (t)1 (h)-6 ( I tak)-6 (e)2 ( Accu)-6 (tan)-6 (e)2 ( to get a n)-6 (e)2 (w)-10 ( )]TJ
-0.0016 Tc 0.0016 Tw 1.5 -1.08 Td
[(p)-5 (rescri)-4 (p)-5 (t)1 (i)-4 (o)-2 (n)-5 ( f)-9 (o)-2 (r Accu)-5 (tan)-5 (e)2 (, to ch)-5 (eck)-5 ( m)11 (y)-2 ( p)-5 (r)2 (ogress, an)-5 (d)-5 ( to ch)-5 (eck)-5 ( f)-9 (o)-2 (r si)-4 (gn)-5 (s of)-9 ( si)-4 (d)-5 (e)2 ( ef)-9 (f)-9 (e)2 (cts.  )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(I)24 (n)1 (itials: ______ )]TJ
0 Tc 0 Tw T*
( )Tj
/TT1 1 Tf
0.0018 Tc -0.0018 Tw -1.5 -1.09 Td
[(9. )-500 (Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( w)-6 (ill be)6 ( pr)6 (e)6 (s)1 (c)6 (r)6 (ibe)6 (d j)5 (u)-2 (st)5 ( for)6 ( m)15 (e)6 (\227I w)-6 (ill not)5 ( shar)6 (e)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( w)-6 (it)5 (h)-2 ( ot)5 (he)6 (r)6 ( pe)6 (ople)6 ( )]TJ
-0.0018 Tc 0.0018 Tw 1.5 -1.08 Td
[(b)-6 (ecau)-6 (s)-3 (e i)-4 (t)1 ( m)11 (ay cau)-6 (s)-3 (e seri)-4 (ou)-6 (s si)-4 (d)-6 (e)2 ( ef)-9 (f)-9 (ects, i)-4 (n)-6 (cl)-4 (u)-6 (d)-6 (i)-4 (n)-6 (g)-2 ( b)-6 (i)-4 (rth)-6 ( d)-6 (e)2 (f)-9 (ects. )]TJ
0 Tc 0 Tw T*
( )Tj
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 0 -1.09 TD
[(I)24 (n)1 (itials: ______ )]TJ
/TT1 1 Tf
0 Tc 0 Tw 0 -1.08 TD
( )Tj
-1.5 -1.08 Td
[(10. I w)-8 (ill not give blood w)-8 (h)-4 (ile taking Accutane or f)-7 (or 1 m)13 (onth af)-7 (ter I stop taking Accutane. )]TJ
0.0019 Tc -0.0019 Tw 1.5 -1.09 Td
[(I unde)6 (r)6 (s)1 (t)5 (a)2 (nd t)5 (h)-2 (at)5 ( if som)15 (e)6 (one)6 ( who is pr)6 (e)6 (g)2 (nant)5 ( ge)6 (t)5 (s)1 ( m)15 (y)2 ( donat)5 (e)6 (d blood, he)6 (r)6 ( baby m)15 (ay be)6 ( )]TJ
0.0022 Tc -0.0022 Tw T*
[(e)6 (x)2 (pose)6 (d t)5 (o)2 ( A)4 (c)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( and m)15 (ay be)6 ( bor)6 (n)-2 ( wit)5 (h)-2 ( se)6 (r)6 (ious bir)6 (t)5 (h de)6 (fe)6 (c)6 (t)5 (s. )]TJ
/TT0 1 Tf
0 Tc 0 Tw T*
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.09 TD
[(I)24 (n)1 (itials: ______ )]TJ
/TT1 1 Tf
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0003 Tc 0.0003 Tw 0 -1.08 TD
(11. I have read the )Tj
/TT2 1 Tf
0.0015 Tc -0.0015 Tw 8.16 0 Td
[(Patie)5 (nt Produc)5 (t)-1 ( Inf)5 (o)2 (rm)-11 (ation, Im)-11 (portant Inf)5 (o)2 (rm)-11 (ation Conc)5 (e)5 (r)1 (ning Y)-8 (o)2 (ur )]TJ
0.0021 Tc -0.0021 Tw -6.66 -1.09 Td
[(Tre)6 (a)2 (tm)-10 (e)6 (n)-2 (t with Ac)6 (c)6 (u)-2 (tane)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 10.49 0 Td
(\002)Tj
-0.02 -0.02 Td
[(\002)780 (\002)]TJ
0 0.02 TD
(\002)Tj
/TT2 1 Tf
0.0018 Tc -0.0018 Tw [( \()5 (isotre)6 (tinoin\))5 (,)]TJ
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 6.7 0 Td
[( and other m)13 (aterials m)13 (y provider gave m)13 (e)3 ( )]TJ
0.0023 Tc -0.0023 Tw -17.17 -1.08 Td
[(c)6 (o)2 (nt)5 (aining im)15 (por)6 (t)5 (ant)5 ( safe)6 (t)5 (y)2 ( infor)6 (m)15 (at)5 (ion about)5 ( A)5 (c)6 (c)6 (u)-1 (t)5 (a)2 (ne)6 (. I unde)6 (r)6 (s)2 (t)5 (a)2 (nd all t)5 (h)-1 (e)6 ( )]TJ
-0.0024 Tc 0.0024 Tw 0 -1.08 TD
[(i)-5 (n)-6 (f)-9 (o)-2 (rm)11 (ati)-5 (o)-2 (n)-6 ( I recei)-5 (ved)-6 (.)-2 ( )]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -1.09 TD
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(I)24 (n)1 (itials: ______ )]TJ
0 Tc 0 Tw T*
( )Tj
/TT1 1 Tf
0.0014 Tc -0.0014 Tw -1.5 -1.14 Td
[(12. M)5 (y)1 ( pr)5 (e)5 (s)1 (c)5 (r)5 (i)-1 (be)5 (r)5 ( and I have)5 ( de)5 (c)5 (i)-1 (de)5 (d I should take)5 ( Ac)5 (c)5 (u)-2 (tane)5 (. I unde)5 (r)5 (s)1 (tand that e)5 (a)1 (c)5 (h)-2 ( of)-6 ( m)14 (y)1 ( )]TJ
-0.0001 Tc 0.0001 Tw 1.5 -1.15 Td
[(Accutane prescriptions m)13 (u)-4 (st have a yellow)-8 ( self)-7 (-adhesive Accutane Qualif)-7 (ication Sticker )]TJ
-0.0012 Tc 0.0012 Tw 0 -1.15 TD
[(on)-5 ( i)-3 (t)2 (. I u)-5 (n)-5 (d)-5 (erstan)-5 (d)-5 ( th)-5 (at I can)-5 ( stop)-5 ( tak)-5 (i)-3 (n)-5 (g)-1 ( Accu)-5 (tan)-5 (e)3 ( at an)-5 (y ti)-3 (m)12 (e)3 (. I agree to tel)-3 (l)-3 ( m)12 (y)-1 ( )]TJ
-0.0018 Tc 0.0018 Tw T*
[(p)-6 (rescri)-4 (b)-6 (er i)-4 (f)-9 ( I stop)-6 ( tak)-6 (i)-4 (n)-6 (g)-2 ( Accu)-6 (tan)-6 (e)2 (. )]TJ
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 0 -1.1 TD
[(I)24 (n)1 (itials: ______ )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
-0.0003 Tc 0.0003 Tw -1.5 -1.08 Td
[(I)23 ( now authoriz)-6 (e my)30 ( prescriber ___________________________ to beg)10 (i)-2 (n my)30 ( treatment with )]TJ
-0.0015 Tc 0 Tw 0 -1.09 TD
(Accutane. )Tj
0 Tc 0 -1.08 TD
( )Tj
T*
[(Patient Sig)10 (nature: __________________________________________ Date: _________ )]TJ
0 -1.09 TD
( )Tj
-0.0007 Tc 0.0007 Tw 0 -1.08 TD
[(Parent/Guardian Sig)9 (n)-1 (ature \(if under ag)9 (e 18\): _____________________ Date: _________ )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0002 Tc 0.0002 Tw 0 -1.09 TD
(Patient Name \(print\) ___________________________________ )Tj
0 Tc 0 Tw 0 -1.08 TD
( )Tj
-0.0003 Tc 0.0003 Tw T*
(Patient address  ____________________________________    Telephone \(___\.___.___\) )Tj
0 Tc 0 Tw 0 -1.09 TD
( )Tj
0 -1.08 TD
[( )-5380 (     ______________________________________ )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj156 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 139/Width 76>>stream
H ٝu׏^gJ0o  ED0;	KCMlS9S@H(4:O$.v
luE~
X-ך.V3|kwKr$3׿SV\hǥIK=GO {A(
endstreamendobj320 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 321 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 322 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj322 0 obj<</Font 323 0 R>>endobj323 0 obj<</ArialRoundedMTBold 231 0 R>>endobj321 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj108 0 obj<</BaseFont/KFIEBN+TT67AoI00/Encoding 111 0 R/FirstChar 1/FontDescriptor 106 0 R/LastChar 2/Subtype/Type1/Type/Font/Widths[780 800]>>endobj111 0 obj<</Differences[1/Ge4/Ge2]/Type/Encoding>>endobj106 0 obj<</Ascent 0/CapHeight 0/CharSet(/Ge2/Ge4)/Descent 0/Flags 4/FontBBox[0 -16 962 677]/FontFile3 109 0 R/FontName/KFIEBN+TT67AoI00/ItalicAngle 0/StemV 0/Type/FontDescriptor>>endobj109 0 obj<</Filter/FlateDecode/Length 502/Subtype/Type1C>>stream
HDoHq~6Fٵd6EceۑrUZQPqB%ȡ.(Z֚1A׽LꍅѫDE/}8EaYӥ;_TN}k/^x3׳h庣nb,,k9j 0%Xb.0n6)`nL%hGѬQ<]ī -Cj!zqRyho`H` _\pFx~s/lO8D4p5ih_Tsz/j~exA]8W:9|d$v&;{j 1"ߘ<y-_\0q<XGqnМ9*hszfQgp(C/>gLMM?xZ.枍fq$SΫt0@.LQt1FݰjB`J}lEkkZězտUcp0 A

endstreamendobj319 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj315 0 obj<</Length 6639>>stream
q
1 0 0 1 -9.460907 20.584259 cm
0 0 612 792 re
W n
1 0 0 1 9.460907 -20.584259 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0696 Tc -0.0034 Tw 14.04 0 0 14.04 85.4997 655.6243 Tm
[(reports of patients on Accutane becom)14 (i)-3 (ng aggressive or violent. )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
94.961 633.48 440.04 -1.32 re
f
Q
BT
0.0695 Tc -0.0033 Tw 14.04 0 0 14.04 100.7397 639.5443 Tm
[(No one k)19 (n)2 (ow)-12 (s if Accutane caused these behaviors or if they )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
110.201 617.4 409.56 -1.32 re
f
Q
BT
0.0689 Tc -0.0027 Tw 14.04 0 0 14.04 87.1797 623.4643 Tm
[(w)-12 (o)-4 (uld have happened even if the person did not tak)18 (e Accutane. )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
96.641 601.32 436.8 -1.32 re
f
Q
BT
0.0702 Tc -0.004 Tw 14.04 0 0 14.04 96.0597 607.3843 Tm
[(Som)14 (e)1 ( people have had other signs of depression w)-11 (h)2 (ile tak)20 (i)-2 (ng )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
105.521 585.24 418.92 -1.32 re
f
Q
BT
0.0693 Tc -0.0031 Tw 14.04 0 0 14.04 220.4997 591.1843 Tm
[(Accutane \(see #7 below)-12 (\). )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
229.961 569.04 170.04 -1.32 re
f
Q
BT
0 Tc 0 Tw 14.04 0 0 14.04 394.9797 591.1843 Tm
( )Tj
/TT1 1 Tf
12 0 0 12 62.5797 577.6243 Tm
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itials: ______ )]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -1.13 TD
( )Tj
0.0695 Tc -0.0033 Tw 14.04 0 0 14.04 70.3797 535.3843 Tm
[(5. )-77 (Before I start tak)19 (i)-3 (ng Accutane, I agree to tell m)14 (y)-3 ( prescriber if, )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
97.841 513.24 434.28 -1.32 re
f
Q
BT
14.04 0 0 14.04 106.6197 519.4243 Tm
[(to the best of m)14 (y)-3 ( k)19 (n)2 (ow)-12 (ledge, I have )]TJ
/TT1 1 Tf
0.0699 Tc 0 Tw 17.718 0 Td
(ever)Tj
/TT0 1 Tf
0.0697 Tc -0.0035 Tw 2 0 Td
[( had sym)14 (p)2 (tom)14 (s)-3 ( of )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
116.081 497.28 397.8 -1.32 re
f
Q
BT
0.0699 Tc -0.0037 Tw 14.04 0 0 14.04 94.9797 503.1043 Tm
[(depression \(see #7 below)-11 (\),)4 ( been psychotic,)4 ( attem)14 (p)2 (ted suicide,)4 ( )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
104.441 480.96 421.2 -1.32 re
f
Q
BT
0.0702 Tc -0.004 Tw 14.04 0 0 14.04 99.2997 487.0243 Tm
[(had any other m)14 (e)1 (ntal problem)14 (s)-2 (,)4 ( or tak)20 (e)1 ( m)14 (e)1 (dicine for any of )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
108.761 464.88 412.44 -1.32 re
f
Q
BT
0.0705 Tc -0.0043 Tw 14.04 0 0 14.04 87.7797 470.9443 Tm
[(these problem)15 (s)-2 (.)4 ( Being psychotic m)15 (e)2 (ans having a loss of contact )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
97.241 448.8 435.48 -1.32 re
f
Q
BT
0.0704 Tc -0.0042 Tw 14.04 0 0 14.04 83.6997 454.8643 Tm
[(w)-11 (i)-2 (th reality,)4 ( such as hearing voices or seeing things that are not )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
93.161 432.72 443.76 -1.32 re
f
Q
BT
0.0683 Tc 0 Tw 14.04 0 0 14.04 285.2997 438.7843 Tm
(there. )Tj
ET
q
1 0 0 1 -9.460907 20.584259 cm
294.761 416.64 40.44 -1.32 re
f
Q
BT
0 Tc 14.04 0 0 14.04 330.1797 438.7843 Tm
( )Tj
/TT1 1 Tf
12 0 0 12 62.5797 425.1043 Tm
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itials: ______ )]TJ
/TT0 1 Tf
0 Tc 0 Tw T*
( )Tj
0.0695 Tc -0.0033 Tw 14.04 0 0 14.04 70.3797 382.8643 Tm
[(6. )-77 (Before I start tak)19 (i)-3 (ng Accutane, I agree to tell m)14 (y)-3 ( prescriber if, )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
97.841 360.72 434.28 -1.32 re
f
Q
BT
0.0702 Tc -0.004 Tw 14.04 0 0 14.04 88.7397 366.7843 Tm
[(to the best of m)14 (y)-2 ( k)20 (n)2 (ow)-11 (ledge,)4 ( anyone in m)14 (y)-2 ( fam)14 (ily has ever had )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
98.201 344.64 433.56 -1.32 re
f
Q
BT
0.0694 Tc -0.0032 Tw 14.04 0 0 14.04 90.5397 350.7043 Tm
[(sym)14 (p)2 (tom)14 (s)-3 ( of depression, been psychotic, attem)14 (p)2 (ted suicide, or )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
100.001 328.56 430.08 -1.32 re
f
Q
BT
0.0702 Tc -0.004 Tw 14.04 0 0 14.04 168.6597 334.5043 Tm
[(had any other serious m)14 (e)1 (ntal problem)14 (s)-2 (.)4 ( )]TJ
ET
q
1 0 0 1 -9.460907 20.584259 cm
178.121 312.36 273.84 -1.32 re
f
Q
BT
0 Tc 0 Tw 14.04 0 0 14.04 446.9397 334.5043 Tm
( )Tj
/TT1 1 Tf
12 0 0 12 62.5797 320.9443 Tm
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itials: ______ )]TJ
/TT0 1 Tf
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
/TT1 1 Tf
-0.0008 Tc 0.0008 Tw 0 -1.09 TD
[(7. )-500 (Once I)22 ( start taking)9 ( Accutane, I)22 ( ag)9 (ree to stop using)9 ( Accutane and tell my)29 ( prescriber rig)9 (h)-1 (t )]TJ
-0.0009 Tc 0.0009 Tw 1.5 -1.08 Td
[(away)29 ( if any)29 ( of the following)9 ( happen. I)22 (:)-3 ( )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
/T1_0 1 Tf
0 -1.2 TD
(\002\003)Tj
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(Start to feel sad or have cry)29 (i)-3 (ng)9 ( spells )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT1 1 Tf
0.0011 Tc -0.0011 Tw 1.5 0 Td
[(L)22 (o)1 (se)5 ( inte)5 (r)4 (e)5 (st in a)5 (c)5 (tivitie)5 (s I)24 ( onc)5 (e)5 ( e)5 (n)1 (joy)31 (e)5 (d )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(Sleep too much or have trouble sleeping)10 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT1 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(B)6 (ecome more irritable, ang)9 (r)2 (y)29 (,)-1 ( or ag)9 (g)9 (r)2 (essive than usual \(for ex)-11 (ample, temper outbursts, )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.14 TD
[(thoug)10 (hts of violence\) )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(Have a chang)9 (e)3 ( in my)29 ( appetite or body)29 ( weig)9 (ht  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 1.5 0 Td
[(Have trouble concentrating)9 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT1 1 Tf
0.0013 Tc -0.0013 Tw 1.5 0 Td
[(Withdr)4 (a)5 (w)4 ( f)4 (r)4 (o)1 (m my)31 ( f)4 (r)4 (i)-1 (e)5 (nds or)4 ( f)4 (a)5 (mily)31 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT1 1 Tf
-0.0013 Tc 0.0013 Tw 1.5 0 Td
[(F)5 (eel like I)22 ( have no energ)9 (y)29 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT1 1 Tf
0.0006 Tc -0.0006 Tw 1.5 0 Td
[(Ha)4 (ve)4 ( f)4 (e)4 (e)4 (ling)11 (s of)4 ( wor)4 (t)-2 (hle)4 (ssne)4 (ss or)4 ( ina)4 (ppr)4 (opr)4 (ia)4 (te)4 ( g)11 (u)1 (ilt  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT1 1 Tf
1.5 0 Td
[(Start having)10 ( thoug)10 (hts about hurting)10 ( my)30 (self or taking)10 ( my)30 ( own life \(suicidal thoug)10 (hts\) )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj155 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 187/Width 76>>stream
H; zNu |$htuAxI$*:@xe"}2~0W慮	gy{	*tz_b|uψ.@e2A]J?_,*ʘ.;l\ ?F36k\|y?_Ve6B5Fr.۰Ey5r9]~1/m砇4I [
endstreamendobj317 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 324 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 325 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj325 0 obj<</Font 326 0 R>>endobj326 0 obj<</ArialRoundedMTBold 231 0 R>>endobj324 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj316 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj312 0 obj<</Length 6714>>stream
q
1 0 0 1 -10.800964 18.40625 cm
0 0 612 792 re
W n
1 0 0 1 10.800964 -18.40625 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.002 Tc 0.005 Tw 9.96 0 0 9.96 61.2396 657.1662 Tm
[(INF)-6 (O)-7 (RM)-22 (ED CO)-7 (NSENT/P)-6 (A)-3 (TIENT AGREEM)-22 (ENT \()-6 (f)-6 (o)-8 (r)-4 ( a)-8 (ll pa)-8 (t)-6 (i)-1 (e)-4 (nt)-6 (s)2 (\))-6 (:)-6 ( )]TJ
/TT1 1 Tf
0.0038 Tc -0.0008 Tw 0 -1.735 TD
[(T)-12 (o)-2 ( be com)23 (p)-2 (l)5 (e)2 (t)5 (e)2 (d by)22 ( pat)5 (i)5 (e)2 (n)10 (t)5 ( \(paren)10 (t)5 ( or g)10 (u)10 (a)2 (rdi)5 (a)2 (n)10 ( i)5 (f)12 ( pat)5 (i)5 (e)2 (n)10 (t)5 ( i)5 (s)7 ( u)10 (n)10 (d)-2 (er ag)10 (e 18\) an)10 (d s)7 (i)5 (g)10 (n)10 (e)2 (d by)22 ( t)5 (h)10 (e pres)7 (cri)5 (b)-2 (er.)]TJ
/TT0 1 Tf
0 Tc 0 Tw 41.229 0 Td
( )Tj
-0.0016 Tc 0.0016 Tw 12 0 0 12 61.2396 620.3262 Tm
[(Read)-5 ( each)-5 ( i)-4 (t)1 (em)11 ( b)-5 (e)2 (l)-4 (o)-2 (w)-9 ( an)-5 (d)-5 ( i)-4 (n)-5 (i)-4 (t)1 (i)-4 (a)-2 (l)-4 ( i)-4 (n)-5 ( th)-5 (e sp)-5 (ace p)-5 (r)2 (ovi)-4 (d)-5 (e)2 (d)-5 ( i)-4 (f)-9 ( you)-5 ( u)-5 (n)-5 (d)-5 (erstan)-5 (d)-5 ( each)-5 ( i)-4 (t)1 (em)11 ( an)-5 (d)-5 ( )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(agree to f)-7 (ollow)-8 ( your prescriber\222s instructions. A parent or guardian of)-7 ( a patient under age )]TJ
-0.0017 Tc 0.0017 Tw T*
[(18 m)11 (u)-5 (st al)-4 (so read)-5 ( an)-5 (d)-5 ( u)-5 (n)-5 (d)-5 (erstan)-5 (d)-5 ( each)-5 ( i)-4 (t)1 (em)11 ( b)-5 (e)2 (f)-9 (o)-2 (re si)-4 (gn)-5 (i)-4 (n)-5 (g th)-5 (e agreem)11 (en)-5 (t. )]TJ
0 -1.1 TD
[(Do n)-5 (o)-2 (t si)-4 (gn)-5 ( th)-5 (i)-4 (s)-2 ( agreem)11 (en)-5 (t an)-5 (d)-5 ( d)-5 (o)-2 ( n)-5 (o)-2 (t tak)-5 (e)2 ( Accu)-5 (tan)-5 (e)2 ( i)-4 (f)-9 ( th)-5 (ere i)-4 (s)-2 ( an)-5 (yth)-5 (i)-4 (n)-5 (g)-2 ( th)-5 (at you)-5 ( d)-5 (o)-2 ( n)-5 (o)-2 (t )]TJ
0 -1.08 TD
[(u)-5 (n)-5 (d)-5 (erstan)-5 (d)-5 ( ab)-5 (ou)-5 (t al)-4 (l)-4 ( th)-5 (e i)-4 (n)-5 (f)-9 (o)-2 (rm)11 (ati)-4 (o)-2 (n)-5 ( you)-5 ( h)-5 (ave recei)-4 (ved)-5 ( ab)-5 (ou)-5 (t u)-5 (s)-2 (i)-4 (n)-5 (g Accu)-5 (tan)-5 (e)2 (. )]TJ
/TT1 1 Tf
0 Tc 0 Tw T*
( )Tj
0.5 Tw 0 -1.09 TD
[(1. I)23 (, )500 (____________________________________________________________, )]TJ
-0.002 Tc 0.002 Tw 16.1 -1.08 Td
[(\(P)-6 (at)-4 (i)-4 (e)2 (nt)-4 (\222s Nam)-4 (e)2 (\) )]TJ
-0.0009 Tc 0.0009 Tw -14.6 -1.08 Td
(understand that Accutane is a medicine used to treat severe nodular acne\ that cannot be )Tj
-0.0008 Tc 0.0008 Tw T*
[(cleared up by)29 ( any)29 ( other acne treatments, including)9 ( antibiotics. I)22 (n)-1 ( severe nodular acne, many)29 ( )]TJ
0 -1.08 TD
[(red, swollen, tender lumps form in the skin. I)22 (f)2 ( untreated, severe nodular acne can lead to )]TJ
-0.0018 Tc 0.0018 Tw T*
[(perm)-4 (anent)-4 ( scars.  )]TJ
0 Tc 0 Tw -1.5 -1.09 Td
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itials: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0006 Tc 0.0006 Tw 0 -1.09 TD
[(2. )-500 (My)29 ( prescriber has told me about my)29 ( choices for treating)9 ( my)29 ( acne. )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itials: ______ )]TJ
0 Tc 0 Tw -1.5 -1.09 Td
( )Tj
-0.0009 Tc 0.0009 Tw T*
[(3. )-500 (I)22 ( understand that there are serious side effects that may)29 ( happen while I)22 ( am taking)9 ( Accutane. )]TJ
1.5 -1.08 Td
[(These have been ex)-11 (plained to me. These side effects include serious birth defects in babie\s of )]TJ
0 -1.09 TD
[(preg)9 (nant females. \(Note: There is a second I)22 (n)-1 (formed Consent form for female patients )]TJ
-0.001 Tc 0.001 Tw 0 -1.08 TD
[(concerning)9 ( birth defects.\)  )]TJ
0 Tc 0 Tw T*
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.09 TD
[(I)24 (n)1 (itials: ______ )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
/TT0 1 Tf
0.0694 Tc -0.0032 Tw 14.04 0 0 14.04 66.9996 278.0863 Tm
[(4. )-77 (I understand that som)14 (e patients, w)-12 (h)2 (ile tak)19 (i)-3 (ng Accutane or soon )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
95.801 258.12 438.36 -1.32 re
f
Q
BT
0.0692 Tc -0.003 Tw 14.04 0 0 14.04 90.3996 262.0063 Tm
[(after stopping Accutane, have becom)13 (e depressed or developed )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
101.201 242.04 427.56 -1.32 re
f
Q
BT
0.0701 Tc -0.0039 Tw 14.04 0 0 14.04 96.2796 245.8063 Tm
[(other serious m)14 (e)1 (ntal problem)14 (s)-2 (.)4 ( Sym)14 (p)2 (tom)14 (s)-2 ( of these problem)14 (s)-2 ( )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
107.081 225.84 219 -1.32 re
f
Q
q
1 0 0 1 -10.800964 18.40625 cm
326.081 225.84 196.8 -1.32 re
f
Q
BT
0.0707 Tc -0.0045 Tw 14.04 0 0 14.04 79.5996 229.7263 Tm
[(include sad,)5 ( \223anxious\224 or em)15 (pty m)15 (o)-2 (od,)5 ( irritability,)5 ( anger,)5 ( loss of )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
90.401 209.76 449.28 -1.32 re
f
Q
BT
0.0702 Tc -0.004 Tw 14.04 0 0 14.04 92.5596 213.6463 Tm
(pleasure or interest in social or sports activities, sleeping too )Tj
ET
q
1 0 0 1 -10.800964 18.40625 cm
103.361 193.68 423.36 -1.32 re
f
Q
BT
0.0704 Tc -0.0042 Tw 14.04 0 0 14.04 82.1196 197.5662 Tm
[(m)15 (u)3 (ch or too little,)4 ( changes in w)-11 (e)1 (ight or appetite,)4 ( school or w)-11 (o)-2 (rk)20 ( )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
92.921 177.6 444.24 -1.32 re
f
Q
BT
0.0696 Tc -0.0034 Tw 14.04 0 0 14.04 106.4796 181.4862 Tm
[(perform)14 (a)-3 (nce going dow)-12 (n)2 (, or trouble concentrating. Som)14 (e)1 ( )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
117.281 161.52 359.04 -1.32 re
f
Q
q
1 0 0 1 -10.800964 18.40625 cm
476.321 161.52 36.48 -1.32 re
f
Q
BT
0.0693 Tc -0.0031 Tw 14.04 0 0 14.04 102.5196 165.4062 Tm
[(patients tak)19 (i)-3 (ng Accutane have had thoughts about hurting )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
113.321 145.44 403.32 -1.32 re
f
Q
BT
0.0703 Tc -0.0041 Tw 14.04 0 0 14.04 110.0796 149.2062 Tm
[(them)14 (selves or putting an end to their ow)-11 (n lives \(suicidal )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
120.881 129.24 388.32 -1.32 re
f
Q
BT
0.0698 Tc -0.0036 Tw 14.04 0 0 14.04 89.9196 133.1262 Tm
[(thoughts\).)4 ( Som)14 (e)1 ( people tried to end their ow)-11 (n lives.)4 ( A)6 (nd som)14 (e)1 ( )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
100.721 113.16 428.64 -1.32 re
f
Q
BT
0.0694 Tc -0.0032 Tw 14.04 0 0 14.04 81.1596 117.0463 Tm
[(people have ended their ow)-12 (n lives. There w)-12 (ere reports that som)14 (e )]TJ
ET
q
1 0 0 1 -10.800964 18.40625 cm
91.961 97.08 446.16 -1.32 re
f
Q
BT
0.0691 Tc -0.0029 Tw 14.04 0 0 14.04 102.2796 100.9664 Tm
(of these people did not appear depressed. There have been )Tj
ET
q
1 0 0 1 -10.800964 18.40625 cm
113.081 81 403.8 -1.32 re
f
Q
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj154 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 181/Width 76>>stream
HA :;&u"vLދ(
VJ|09]Z6ם "Z؊WPf?,G\ih/U;+h\vjè|/~NKkkl&Eu+-5/fG͋uYjB[%F,-μH2( H8v
endstreamendobj314 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 327 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 328 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj328 0 obj<</Font 329 0 R>>endobj329 0 obj<</ArialRoundedMTBold 231 0 R>>endobj327 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj313 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj309 0 obj<</Length 3223>>stream
q
1 0 0 1 -4.453796 -78.37738 cm
0 0 612 792 re
W n
1 0 0 1 4.453796 78.37738 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/T1_0 1 Tf
12 0 0 12 67.5868 559.1827 Tm
(\002\003)Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw 1.5 0 Td
[(have been informed of the purpose and importance of participating)9 ( in the Accutane Survey)29 ( )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.08 TD
[(and g)10 (i)-2 (ven the opportunity)30 ( to enroll.  )]TJ
0 Tc 0 Tw -1.5 -1.09 Td
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
0 -1.09 TD
( )Tj
/TT1 1 Tf
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(My prescriber has answered all m)-11 (y)5 ( questions about Accutane and I understand that it is m)-11 (y)5 ( )]TJ
ET
q
1 0 0 1 -4.453796 -78.37738 cm
489.041 558.24 35.52 -1.2 re
f
Q
BT
0.0015 Tc -0.0015 Tw 12 0 0 12 67.5868 468.2226 Tm
[(re)5 (sponsibility)5 ( not to ge)5 (t pre)5 (g)2 (nant)]TJ
ET
q
1 0 0 1 -4.453796 -78.37738 cm
72.041 545.28 162.96 -1.2 re
f
Q
BT
0.0007 Tc -0.0007 Tw 12 0 0 12 230.5468 468.2226 Tm
[( during Accutane treatm)-11 (ent or for 1 m)-11 (o)1 (nth after I stop taking )]TJ
ET
q
1 0 0 1 -4.453796 -78.37738 cm
374.681 545.28 164.04 -1.2 re
f
Q
BT
-0.0038 Tc 0 Tw 12 0 0 12 67.5868 455.1426 Tm
[(A)-7 (ccu)-8 (t)-6 (a)-4 (n)-8 (e)]TJ
ET
q
1 0 0 1 -4.453796 -78.37738 cm
72.041 532.2 46.68 -1.2 re
f
Q
BT
0 Tc 12 0 0 12 114.2668 455.1426 Tm
(. )Tj
-3.89 -1.08 Td
( )Tj
/TT0 1 Tf
0.0007 Tc -0.0007 Tw T*
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
-0.0005 Tc 0.0005 Tw 0 -1.08 TD
[(I)23 ( now authoriz)-7 (e my)30 ( prescriber ________________ to beg)10 (i)-3 (n my)30 ( treatment with Accutane. )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0001 Tc 0.0001 Tw 0 -1.09 TD
[(Patient sig)10 (nature:________________________________ Date:____________________ )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
-0.0007 Tc 0.0007 Tw T*
[(Parent/g)9 (uardian sig)9 (n)-1 (ature \(if under ag)9 (e 18\):____________________ Date:___________ )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
0 -1.08 TD
( )Tj
-0.0002 Tc 0.0002 Tw T*
(Please print: Patient name and address__________________________________\______ )Tj
0 Tc 0 Tw 0 -1.09 TD
( )Tj
-0.0001 Tc 0.0001 Tw 0 -1.08 TD
(______________________________________ Telephone _______________________\ )Tj
0 Tc 0 Tw T*
( )Tj
-0.0006 Tc 0.0006 Tw 0 -1.09 TD
[(I)22 ( have fully)29 ( ex)-11 (plained to the patient, __________________, the nature and purpose of th\e )]TJ
0 -1.08 TD
[(treatment described above and the risks to females of childbearing)9 ( potential.  I)22 ( have asked the )]TJ
-0.0009 Tc 0.0009 Tw T*
[(patient if she has any)29 ( questions reg)9 (a)3 (rding)9 ( her treatment with Accutane and have answered those )]TJ
0.0008 Tc -0.0008 Tw 0 -1.09 TD
[(que)5 (stions to the)5 ( be)5 (st of)4 ( my)31 ( a)5 (b)1 (ility)31 (.   )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
-0.0003 Tc 0.0003 Tw T*
[(Prescriber sig)10 (nature: ______________________________ Date:__________________ )]TJ
0 Tc 0 Tw 9.96 0 0 9.96 67.5868 183.5827 Tm
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj153 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 114/Width 76>>stream
H9 D\S:(mJ`<!" CM|kS]:K=/maiqgb劫tK}#qW0'S_JaNVFk   t_
endstreamendobj311 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 330 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 331 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj331 0 obj<</Font 332 0 R>>endobj332 0 obj<</ArialRoundedMTBold 231 0 R>>endobj330 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj310 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj306 0 obj<</Length 5004>>stream
q
1 0 0 1 -7.939697 -0.37735 cm
0 0 612 792 re
W n
1 0 0 1 7.939697 0.37735 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw 12 0 0 12 64.1009 637.1828 Tm
[(11. I)23 ( understand that I)23 ( should not start taking)10 ( Accutane until I)23 ( am sure that I)23 ( am not preg)10 (nant and )]TJ
-0.0008 Tc 0.0008 Tw 1.5 -1.08 Td
[(have neg)9 (a)3 (tive results from 2 preg)9 (nancy)29 ( tests.  )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0007 Tc 0.0007 Tw 0 -1.09 TD
[(12. I)22 ( have read and understand the materials my)29 ( prescriber has g)9 (i)-3 (ven to me, including)9 ( the )]TJ
/TT1 1 Tf
0.0011 Tc 0 Tw 35.86 0 Td
[(Patie)5 (nt )]TJ
0.0002 Tc -0.0002 Tw -34.36 -1.08 Td
[(Product Information, Important Information Concerning Y)-14 (our Treatment with)]TJ
/TT0 1 Tf
0 Tc 0 Tw 31.3 0 Td
( )Tj
/TT1 1 Tf
-0.0008 Tc (Accutane)Tj
/T1_0 1 Tf
0 Tc 3.96 0 Td
(\001)Tj
/TT1 1 Tf
( )Tj
0.0005 Tc -35.26 -1.08 Td
[(\()14 (i)-2 (sotretinoin\))14 (. )]TJ
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw [(My)29 ( prescriber g)9 (a)3 (ve me and asked me to watch the video about contraception. I)22 ( )]TJ
-0.0004 Tc 0.0004 Tw T*
[(was told about a confidential counseling)10 ( line that I)23 ( may)30 ( call for more information about birth )]TJ
-0.0016 Tc 0.0016 Tw 0 -1.08 TD
[(cont)-4 (rol)-4 (.)-2 ( I)21 ( have recei)-4 (ved i)-4 (n)-2 (form)-4 (at)-4 (i)-4 (on on em)-4 (erg)8 (e)2 (ncy)28 ( cont)-4 (racept)-4 (i)-4 (on \(bi)-4 (r)1 (t)-4 (h)-2 ( cont)-4 (rol)-4 (\))1 (.  )]TJ
0 Tc 0 Tw T*
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.09 TD
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0004 Tc 0.0004 Tw 0 -1.08 TD
[(13. I)23 ( understand that I)23 ( must stop taking)10 ( Accutane rig)10 (ht away)30 ( and inform my)30 ( prescriber if I)23 ( g)10 (e)3 (t )]TJ
1.5 -1.09 Td
[(preg)10 (nant, miss my)30 ( menstrual period, stop using)10 ( birth control, or have sex)-10 (ual intercourse )]TJ
0.0002 Tc -0.0002 Tw T*
[(without using)10 ( my)30 ( 2 birth control methods at any)30 ( time.  )]TJ
0 Tc 0 Tw T*
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.09 TD
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0007 Tc 0.0007 Tw 0 -1.08 TD
[(14. My)29 ( prescriber g)9 (a)3 (ve me information about the confidential Accutane Survey)29 ( and ex)-11 (plained to )]TJ
-0.0004 Tc 0.0004 Tw 1.5 -1.09 Td
[(me how important it is to take part in the Accutane Survey)30 (. )]TJ
0 Tc 0 Tw T*
( )Tj
0.0007 Tc -0.0007 Tw T*
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.09 Td
( )Tj
-0.0006 Tc 0.0006 Tw T*
[(15. I)22 ( understand that the y)29 (e)3 (llow self-adhesive Accutane Qualification Sticker on my)29 ( prescription )]TJ
-0.0011 Tc 0.0011 Tw 1.5 -1.08 Td
[(for Accutane means that I)22 ( am qualified to receive an Accutane prescription, because I)22 (:)-3 ( )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
/T1_1 1 Tf
-1.5 -1.08 Td
(\002\003)Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw 1.5 0 Td
[(have had 2 neg)9 (a)3 (tive urine or serum preg)9 (nancy)29 ( tests before receiving)9 ( the initial Accutane )]TJ
0 -1.08 TD
[(prescription. I)22 ( must have a neg)9 (a)3 (tive result from a urine or serum preg)9 (nancy)29 ( test repeated each )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.09 TD
[(month prior to my)30 ( receiving)10 ( each subsequent prescription. )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
/T1_1 1 Tf
-1.5 -1.08 Td
(\002\003)Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(have selected and committed to use 2 forms of effective contraception si\multaneously)29 (, at )]TJ
0 -1.09 TD
[(least 1 of which must be a primary)29 ( form, unless absolute abstinence is the chosen method, or )]TJ
0 -1.08 TD
[(I)22 ( have underg)9 (one a hy)29 (sterectomy)29 (.)-1 ( I)22 ( must use 2 forms of contraception for at least 1 month )]TJ
0.0007 Tc -0.0007 Tw T*
[(pr)4 (ior)4 ( to initia)5 (tion of)4 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( the)5 (r)4 (a)5 (p)1 (y)31 (,)1 ( dur)4 (ing)11 ( the)5 (r)4 (a)5 (p)1 (y)31 (,)1 ( a)5 (nd f)4 (o)1 (r)4 ( 1 month a)5 (f)4 (te)5 (r)4 ( disc)5 (ontinuing)11 ( )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.09 TD
[(therapy)29 (.)-1 ( I)22 ( must receive counseling)9 (,)-1 ( repeated on a monthly)29 ( basis, about contraception and )]TJ
-0.001 Tc 0.001 Tw 0 -1.08 TD
[(behaviors associated with an increased risk of preg)9 (nancy)29 (.)-1 ( )]TJ
0 Tc 0 Tw T*
( )Tj
/T1_1 1 Tf
-1.5 -1.09 Td
(\002\003)Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 1.5 0 Td
[(have sig)10 (ned a Patient I)23 (nformation/Consent form that contains warning)10 (s)-1 ( about the risk of )]TJ
-0.0007 Tc 0.0007 Tw T*
[(potential birth defects if I)22 ( am preg)9 (nant or become preg)9 (nant and my)29 ( unborn baby)29 ( is ex)-11 (posed )]TJ
0.0004 Tc -0.0004 Tw T*
(to isotretinoin. )Tj
0 Tc 0 Tw 0 -1.09 TD
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj152 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 141/Width 76>>stream
H얁 ggJq E$OBc(4fgGQ._읬D9hFeodmhך{8]!+L![=;ܒD`جvڻ@L8#_J oc5 7
endstreamendobj308 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 333 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 334 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj334 0 obj<</Font 335 0 R>>endobj335 0 obj<</ArialRoundedMTBold 231 0 R>>endobj333 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj116 0 obj<</BaseFont/TT67FoI00/Encoding 117 0 R/FirstChar 1/FontDescriptor 115 0 R/LastChar 1/Subtype/Type1/Type/Font/Widths[790]>>endobj117 0 obj<</Differences[1/Ge2]/Type/Encoding>>endobj115 0 obj<</Ascent 0/CapHeight 0/Descent 0/Flags 4/FontBBox[0 -16 886 677]/FontFile3 114 0 R/FontName/TT67FoI00/ItalicAngle 0/StemV 0/Type/FontDescriptor>>endobj114 0 obj<</Length 406/Subtype/Type1C>>stream
  
TT67FoI00 *kk H H) Ge2TT67FoI00      6R9HY:NNRGZW$/0~:YW;N MSXY$F ;IW;A(9:CB=M98(PAPC)NBC?99)C+vec[vQwLaWLb]lPwCz}rgfmsltstt^GL(:2ӐxyI%

endstreamendobj307 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj45 0 obj<</Contents 336 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 176 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 337 0 R>>/Font<</TT0 186 0 R/TT1 187 0 R/TT2 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 338 0 R>>>>/Rotate 0/Thumb 147 0 R/Type/Page>>endobj47 0 obj<</Contents 339 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 176 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 340 0 R>>/Font<</TT0 186 0 R/TT1 112 0 R/TT2 187 0 R/TT3 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 341 0 R>>>>/Rotate 0/Thumb 148 0 R/Type/Page>>endobj49 0 obj<</Contents 342 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 176 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 343 0 R>>/Font<</TT0 186 0 R/TT1 187 0 R/TT2 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 344 0 R>>>>/Rotate 0/Thumb 149 0 R/Type/Page>>endobj51 0 obj<</Contents 345 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 176 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 346 0 R>>/Font<</TT0 187 0 R/TT1 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 347 0 R>>>>/Rotate 0/Thumb 150 0 R/Type/Page>>endobj53 0 obj<</Contents 348 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 176 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 349 0 R>>/Font<</TT0 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 350 0 R>>>>/Rotate 0/Thumb 151 0 R/Type/Page>>endobj348 0 obj<</Length 5350>>stream
q
1 0 0 1 -8.003784 13.842712 cm
0 0 612 792 re
W n
1 0 0 1 8.003784 -13.842712 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0001 Tc 0.0001 Tw 12 0 0 12 64.0368 651.4028 Tm
[(5. )-500 (I)23 ( understand that birth control pills and injectable/implantable/insertab\le hormonal birth )]TJ
-0.0007 Tc 0.0007 Tw 1.5 -1.08 Td
[(control products are among)9 ( the most effective forms of birth control. However, any)29 ( sing)9 (le )]TJ
0 -1.09 TD
[(form of birth control can fail. Therefore, I)22 ( must use 2 different methods at the same time, )]TJ
0 -1.08 TD
[(every)29 ( time I)22 ( have sex)-11 (u)-1 (al intercourse, even if 1 of the methods I)22 ( choose is birth control pills or )]TJ
0.0002 Tc -0.0002 Tw T*
(injections.  )Tj
0 Tc 0 Tw 0 -1.09 TD
(  )Tj
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0003 Tc 0.0003 Tw 0 -1.12 TD
[(6.   I)23 ( will talk with my)30 ( prescriber about any)30 ( drug)10 (s or herbal products I)23 ( plan to take during)10 ( my)30 ( )]TJ
-0.0006 Tc 0.0006 Tw 1.5 -1.15 Td
[(Accutane treatment because hormonal birth control methods \(for ex)-11 (ample, birth control pills\) )]TJ
0 -1.15 TD
[(may)29 ( not work if I)22 ( am taking)9 ( certain drug)9 (s or herbal products \(for ex)-11 (ample, St. J)-11 (ohn\222s W)-7 (o)-1 (rt\).  )]TJ
0 Tc 0 Tw -1.5 -1.12 Td
( )Tj
0.0007 Tc -0.0007 Tw 1.5 -1.08 Td
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0007 Tc 0.0007 Tw 0 -1.09 TD
[(7. )-500 (I)22 ( understand that the following)9 ( are considered effective forms of birth control: )]TJ
0 Tc 0 Tw 0 -1.08 TD
( )Tj
0.001 Tc -0.001 Tw 1.5 -1.08 Td
[(Pr)4 (ima)5 (r)4 (y)31 (: )-1530 (Tuba)5 (l lig)11 (a)5 (tion \()4 (t)-1 (y)31 (i)-1 (ng)11 ( my)31 ( tube)5 (s\))4 (, pa)5 (r)4 (t)-1 (ne)5 (r)4 (\222)4 (s va)5 (se)5 (c)5 (t)-1 (omy)31 (,)1 ( bir)4 (t)-1 (h c)5 (ontr)4 (o)1 (l pills, )]TJ
-0.0003 Tc 0.0003 Tw 5.25 -1.09 Td
[(injectable/implantable/insertable hormonal birth control products, and a\n I)23 (UD )]TJ
-0.0012 Tc 0.0012 Tw T*
(\(intrauterine device\). )Tj
-0.0008 Tc 0.0008 Tw -4.87 -1.08 Td
[(Secondary)29 (:  )90 (Diaphrag)9 (ms, latex)-11 ( condoms, and cervical caps. Each must be used with a )]TJ
0.0009 Tc -0.0009 Tw 4.87 -1.09 Td
[(spe)5 (r)4 (mic)5 (ide)5 (,)1 ( whic)5 (h is a)5 ( spe)5 (c)5 (i)-1 (a)5 (l)-1 ( c)5 (r)4 (e)5 (a)5 (m)-1 ( or)4 ( je)5 (lly)31 ( tha)5 (t)-1 ( kills spe)5 (r)4 (m. )]TJ
-0.0003 Tc 0.0003 Tw -5.25 -1.08 Td
[(I)23 ( understand that at least 1 of my)30 ( 2 methods of birth control must be a primary)30 ( method. )]TJ
0 Tc 0 Tw T*
( )Tj
0.0006 Tc -0.0006 Tw 0 -1.09 TD
[(I)24 (n)1 (itial: ________ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0009 Tc 0.0009 Tw 0 -1.08 TD
[(8. )-500 (I)22 ( understand that I)22 ( may)29 ( receive a free contraceptive \(birth control\) counseling)9 ( session and )]TJ
0.0007 Tc -0.0007 Tw 1.5 -1.09 Td
[(pr)4 (e)5 (g)11 (na)5 (nc)5 (y)31 ( te)5 (sting)11 ( f)4 (r)4 (o)1 (m a)5 ( doc)5 (tor)4 ( or)4 ( othe)5 (r)4 ( f)4 (a)5 (mily)31 ( pla)5 (nning)11 ( e)5 (x)-9 (pe)5 (r)4 (t)-1 (. My)31 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( pr)4 (e)5 (sc)5 (r)4 (ibe)5 (r)4 ( c)5 (a)5 (n)1 ( )]TJ
0.0012 Tc -0.0012 Tw T*
[(g)11 (i)-1 (ve)5 ( me)5 ( a)5 (n)1 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( Pa)5 (tie)5 (nt Re)5 (f)4 (e)5 (r)4 (r)4 (a)5 (l F)7 (o)1 (r)4 (m)-1 ( f)4 (o)1 (r)4 ( this f)4 (r)4 (e)5 (e)5 ( )]TJ
ET
q
1 0 0 1 -8.003784 13.842712 cm
338.321 282.84 21.48 -0.6 re
f
Q
BT
0.0001 Tc -0.0001 Tw 12 0 0 12 351.7968 298.0027 Tm
(consultation.  )Tj
0 Tc 0 Tw -22.48 -1.08 Td
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.09 TD
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0004 Tc 0.0004 Tw 0 -1.08 TD
[(9. )-500 (I)23 ( understand that I)23 ( must beg)10 (i)-3 (n using)10 ( the birth control methods I)23 ( have chosen as described )]TJ
-0.0006 Tc 0.0006 Tw 1.5 -1.09 Td
[(above at least 1 month before I)22 ( start taking)9 ( Accutane.  )]TJ
0 Tc 0 Tw T*
( )Tj
0.0007 Tc 1.2493 Tw -1.5 -1.08 Td
[( I)24 (n)1 (itial: )1250 (______ )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
-0.0009 Tc 0.0009 Tw 0 -1.08 TD
[(10. I)22 ( understand that I)22 ( cannot g)9 (e)3 (t a prescription for Accutane unless I)22 ( have 2 neg)9 (a)3 (tive preg)9 (nancy)29 ( )]TJ
-0.0008 Tc 0.0008 Tw 1.5 -1.08 Td
[(test results. The first preg)9 (nancy)29 ( test should be done when my)29 ( prescriber decides to prescribe )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.09 TD
[(Accutane. The second preg)9 (nancy)29 ( test should be done during)9 ( the first 5 day)29 (s)-1 ( of my)29 ( menstrual )]TJ
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(pe)5 (r)4 (i)-1 (od r)4 (i)-1 (g)11 (h)1 (t be)5 (f)4 (o)1 (r)4 (e)5 ( sta)5 (r)4 (ting)11 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( the)5 (r)4 (a)5 (p)1 (y)31 (,)1 ( or)4 ( a)5 (s instr)4 (u)1 (c)5 (t)-1 (e)5 (d)1 ( by)31 ( my)31 ( pr)4 (e)5 (sc)5 (r)4 (ibe)5 (r)4 (. I)24 ( will the)5 (n)1 ( )]TJ
-0.0009 Tc 0.0009 Tw T*
[(have 1 preg)9 (nancy)29 ( test every)29 ( month during)9 ( my)29 ( Accutane therapy)29 (.)-1 (  )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(I)24 (n)1 (itial: ______  )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj151 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 141/Width 76>>stream
H0SQS  1PbHO2b(:3iAi)|@(H5@]^e_]BWԁ4Zk#ᙓ@KlW 3+;}Az< y/
endstreamendobj350 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 351 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 352 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj352 0 obj<</Font 353 0 R>>endobj353 0 obj<</ArialRoundedMTBold 231 0 R>>endobj351 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj349 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj345 0 obj<</Length 4108>>stream
q
1 0 0 1 -3.858582 -19.227356 cm
0 0 612 792 re
W n
1 0 0 1 3.858582 19.227356 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0021 Tc 0.0021 Tw 12 0 0 12 68.182 617.6126 Tm
[(P)9 (AT)-5 (I)-3 (E)-5 (NT)-5 ( INF)9 (O)-4 (RMAT)-5 (IO)-4 (N/)-4 (CO)-4 (NS)-6 (E)-5 (NT)-5 ( \(f)-9 (or f)-9 (e)2 (m)11 (a)-2 (l)-4 (e)2 ( p)-6 (a)-2 (ti)-4 (en)-6 (ts con)-6 (cern)-6 (i)-4 (n)-6 (g b)-6 (i)-4 (rth)-6 ( d)-6 (e)2 (f)-9 (e)2 (cts\): )]TJ
0.0018 Tc -0.0018 Tw 8.06 -2.17 Td
[(To be)6 ( c)6 (o)2 (m)15 (p)-2 (le)6 (t)5 (e)6 (d by t)5 (h)-2 (e)6 ( pat)5 (ie)6 (n)-2 (t)5 (,)2 ( he)6 (r)6 ( par)6 (e)6 (n)-2 (t)5 (/guar)6 (dian* )]TJ
-0.0021 Tc 0.0021 Tw 5.17 -1.09 Td
[(an)-6 (d)-6 ( si)-4 (gn)-6 (ed)-6 ( b)-6 (y)-2 ( h)-6 (er p)-6 (rescri)-4 (b)-6 (er. )]TJ
/TT1 1 Tf
0 Tc 0 Tw 6.27 -1.08 Td
( )Tj
-0.0005 Tc 0.0005 Tw -19.5 -1.08 Td
[(Read each item below and initial in the space provided to show that y)30 (ou understand each item )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.09 TD
[(and ag)9 (ree to follow y)29 (our prescriber')9 (s)-2 ( instructions.  )]TJ
/TT0 1 Tf
0.0019 Tc -0.0019 Tw [(D)4 (o)2 ( not)5 ( sign t)5 (h)-2 (is c)6 (o)2 (nse)6 (n)-2 (t)5 ( and do not)5 ( t)5 (a)2 (ke)6 ( )]TJ
0.0001 Tc -0.0001 Tw 0 -1.08 TD
[(Accutane if)-7 ( there is anything that you do not understand. )]TJ
/TT1 1 Tf
0 Tc 0 Tw 24.66 0 Td
( )Tj
-24.66 -1.08 Td
( )Tj
-0.0008 Tc 0.0008 Tw 0 -1.09 TD
[(*A parent or g)9 (u)-1 (ardian of a minor patient \(under ag)9 (e 18\) must also read and initial each item )]TJ
0 -1.08 TD
[(before sig)9 (n)-1 (ing)9 ( the consent. )]TJ
0 Tc 0 Tw T*
( )Tj
0 -1.09 TD
(____________________________________________________________ )Tj
-0.002 Tc 0.002 Tw 16.1 -1.08 Td
[(\(P)-6 (at)-4 (i)-4 (e)2 (nt)-4 (\222s Nam)-4 (e)2 (\) )]TJ
0 Tc 0 Tw -16.1 -1.08 Td
(  )Tj
19.5 -1.09 Td
( )Tj
-18 -1.08 Td
( )Tj
0 -1.08 TD
( )Tj
-0.0006 Tc 0.0006 Tw -1.5 -1.09 Td
[(1. )-500 (I)22 ( understand that there is a very)29 ( hig)9 (h)-1 ( risk that my)29 ( unborn baby)29 ( could have severe birth )]TJ
-0.001 Tc 0.001 Tw 1.5 -1.08 Td
[(defects if I)22 ( am preg)9 (nant or become preg)9 (nant while taking)9 ( Accutane in any)29 ( amount even for )]TJ
0.0006 Tc -0.0006 Tw T*
[(shor)4 (t pe)4 (r)4 (i)-2 (ods of)4 ( time)4 (. This is why)31 ( I)24 ( must not be)4 ( pr)4 (e)4 (g)11 (na)5 (nt while)5 ( ta)4 (king)11 ( Ac)4 (c)4 (u)1 (ta)4 (ne)5 (.  )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0005 Tc 0.0005 Tw 0 -1.09 TD
[(2. )-500 (I)23 ( understand that I)23 ( must not take Accutane \(isotretinoin\) if I)23 ( am preg)10 (nant.  )]TJ
0 Tc 0 Tw 1.5 -1.08 Td
( )Tj
0.0007 Tc -0.0007 Tw 0 -1.08 TD
[(I)24 (n)1 (itial: ______ )]TJ
0 Tc 0 Tw -1.5 -1.09 Td
( )Tj
-0.0004 Tc 0.0004 Tw T*
[(3. )-500 (I)23 ( understand that I)23 ( must not g)10 (e)3 (t preg)10 (nant during)10 ( the entire time of my)30 ( treatment and for 1 )]TJ
-0.0007 Tc 0.0007 Tw 1.5 -1.08 Td
[(month after the end of my)29 ( treatment with Accutane.  )]TJ
0 Tc 0 Tw 0 -1.09 TD
( )Tj
0.0006 Tc -0.0006 Tw 0 -1.08 TD
[(I)24 (n)1 (itial: ________ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
-0.0005 Tc 0.0005 Tw 0 -1.09 TD
[(4. )-500 (I)23 ( understand that I)23 ( must avoid sex)-10 (ual intercourse completely)30 (, or I)23 ( must use 2 separate, )]TJ
-0.0018 Tc 0.0018 Tw 1.5 -1.08 Td
[(effect)-4 (i)-4 (v)-2 (e form)-4 (s of bi)-4 (rt)-4 (h cont)-4 (rol)-4 ( \(cont)-4 (racept)-4 (i)-4 (on\) )]TJ
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 18.95 0 Td
[(at the sam)12 (e)3 ( tim)12 (e)]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 6.93 0 Td
[(.  The only)29 ( ex)-11 (ception is if I)22 ( )]TJ
-0.001 Tc 0.001 Tw -25.88 -1.08 Td
[(have had surg)9 (ery)29 ( to remove the womb \(a hy)29 (sterectomy)29 (\))2 (. )]TJ
0 Tc 0 Tw T*
( )Tj
0.0006 Tc -0.0006 Tw 0 -1.08 TD
[(I)24 (n)1 (itial: ________ )]TJ
0 Tc 0 Tw -1.5 -1.08 Td
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj150 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 120/Width 76>>stream
Hԉ0Cٙ0 E(7@qLڵ  !.
"jw]5xT!VZJ|i/X}"N+>AalnkL ` 
endstreamendobj347 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 354 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 355 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj355 0 obj<</Font 356 0 R>>endobj356 0 obj<</ArialRoundedMTBold 231 0 R>>endobj354 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj346 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj342 0 obj<</Length 4306>>stream
q
1 0 0 1 -6.57431 -102.85733 cm
0 0 612 792 re
W n
1 0 0 1 6.57431 102.85733 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0001 Tc 0.0001 Tw 12 0 0 12 65.4663 534.3427 Tm
[(Soft g)10 (e)4 (latin capsules, 20 mg)10 ( \(maroon\), imprinted ACCUTANE 20 ROCHE. B)7 (ox)-10 (e)4 (s of 100 )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(containing)10 ( 10 Prescription Paks of 10 capsules \(NDC 0004-0169-49\). )]TJ
-0.0001 Tc 0.0001 Tw 0 -2.22 TD
[(Soft g)10 (e)4 (latin capsules, 40 mg)10 ( \(y)30 (ellow\), imprinted ACCUTANE 40 ROCHE. B)7 (ox)-10 (e)4 (s of 100 )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(containing)10 ( 10 Prescription Paks of 10 capsules \(NDC 0004-0156-49\). )]TJ
0 -2.24 TD
[(Store at controlled room temperature \(59\260 to 86\260F)6 (, 15\260 to 30\260C\). Protect from lig)10 (ht. )]TJ
/TT1 1 Tf
-0.0022 Tc 0 Tw 0 -2.25 TD
[(RE)-5 (F)9 (E)-5 (RE)-5 (NCE)-5 (S)-6 (:)1 ( )]TJ
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 0 -2.2 TD
[(1. Peck GL)20 (, Olsen TG, Yoder F)6 (W)-7 (, et al. Prolong)9 (ed remissions of cy)29 (stic and cong)9 (lobate acne )]TJ
0.0003 Tc -0.0003 Tw 0 -1.15 TD
(with 13-)Tj
/TT2 1 Tf
-0.0038 Tc 0 Tw 3.36 0 Td
[(ci)-6 (s)]TJ
/TT0 1 Tf
-0.001 Tc 0.001 Tw 1.11 0 Td
(-retinoic acid. )Tj
/TT2 1 Tf
-0.0005 Tc 0.0005 Tw (N Engl J Med )Tj
/TT0 1 Tf
0.0002 Tc -0.0002 Tw 11.56 0 Td
[(300:329-333, 1979. 2. Pochi PE, Shalita AR, Strauss J)-11 (S)-4 (, )]TJ
-0.0009 Tc 0.0009 Tw -16.03 -1.15 Td
[(W)-7 (e)3 (bster SB)6 (. Report of the consensus conference on acne classification. )]TJ
/TT2 1 Tf
-0.001 Tc 0.001 Tw 28.82 0 Td
(J Am Acad Dermatol )Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw -28.82 -1.15 Td
[(24:495-500, 1991. 3. F)6 (a)3 (rrell L)20 (N)2 (, Strauss J)-11 (S)-4 (, Stranieri AM. The treatment of severe cy)29 (stic acne )]TJ
0.0003 Tc -0.0003 Tw T*
(with 13-)Tj
/TT2 1 Tf
-0.0038 Tc 0 Tw 3.36 0 Td
[(ci)-6 (s)]TJ
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 1.11 0 Td
(-retinoic acid: evaluation of sebum production and the clinical response\ in a multiple-)Tj
0.0013 Tc -0.0013 Tw -4.47 -1.15 Td
[(dose)5 ( tr)4 (ia)5 (l. )]TJ
/TT2 1 Tf
-0.001 Tc 0.001 Tw 4.19 0 Td
(J Am Acad Dermatol )Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw [(3:602-611, 1980. 4. J)-11 (ones H, B)7 (l)-3 (anc D, Cunliffe W)-7 (J)-11 (. 13-)]TJ
/TT2 1 Tf
-0.0038 Tc 0 Tw 31.01 0 Td
[(ci)-6 (s)]TJ
/TT0 1 Tf
0 Tc 1.11 0 Td
(-)Tj
-0.002 Tc 0.002 Tw -36.31 -1.15 Td
[(ret)-4 (i)-4 (noi)-4 (c aci)-4 (d and acne. )]TJ
/TT2 1 Tf
-0.0023 Tc 0 Tw 9.22 0 Td
[(L)-6 (ancet)-4 ( )]TJ
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 2.97 0 Td
[(2:1048-1049, 1980. 5.  Katz)-7 ( RA, J)-11 (org)10 (ensen H, Nig)10 (r)3 (a TP. )]TJ
-12.19 -1.15 Td
[(Elevation of serum trig)10 (ly)30 (ceride levels from oral isotretinoin in disorders of keratiniz)-6 (ation. )]TJ
/TT2 1 Tf
-0.001 Tc 0 Tw 36.06 0 Td
(Arch )Tj
-0.0004 Tc -36.06 -1.15 Td
(Dermatol )Tj
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw 4.08 0 Td
[(116:1369-1372, 1980. 6. Ellis CN, Madison KC, Pennes DR, Martel W)-6 (, Voorhees J)-11 (J)-11 (. )]TJ
-0.0017 Tc 0.0017 Tw -4.08 -1.15 Td
[(I)21 (s)-2 (ot)-4 (ret)-4 (i)-4 (noi)-4 (n t)-4 (h)-2 (erapy)28 ( i)-4 (s)-2 ( associ)-4 (at)-4 (ed wi)-4 (t)-4 (h)-2 ( earl)-4 (y)28 ( skel)-4 (et)-4 (al)-4 ( radi)-4 (og)8 (raphi)-4 (c chang)8 (e)2 (s. )]TJ
/TT2 1 Tf
-0.001 Tc 0.001 Tw 29.84 0 Td
(J Am Acad Dermatol )Tj
/TT0 1 Tf
-0.0001 Tc 0.0001 Tw -29.84 -1.15 Td
[(10:1024-1029, 1984. 7. Dicken CH, Connolly)30 ( SM. Eruptive x)-10 (a)4 (nthomas associated with )]TJ
0.0001 Tc -0.0001 Tw T*
(isotretinoin \(13-)Tj
/TT2 1 Tf
-0.0038 Tc 0 Tw 6.47 0 Td
[(ci)-6 (s)]TJ
/TT0 1 Tf
-0.0011 Tc 0.0011 Tw 1.11 0 Td
(-retinoic acid\). )Tj
/TT2 1 Tf
-0.0005 Tc 0.0005 Tw 6.12 0 Td
(Arch Dermatol )Tj
/TT0 1 Tf
0.0003 Tc -0.0003 Tw 6.27 0 Td
[(116:951-952, 1980. 8. Strauss J)-10 (S)-3 (, Rapini RP, )]TJ
-0.0006 Tc 0.0006 Tw -19.97 -1.15 Td
[(Shalita AR, et al. I)22 (s)-1 (otretinoin therapy)29 ( for acne: results of a multicenter dose-response study)29 (. )]TJ
/TT2 1 Tf
-0.0038 Tc 0 Tw 36.89 0 Td
(J )Tj
-0.0007 Tc 0.0007 Tw -36.89 -1.16 Td
(Am Acad Dermatol )Tj
/TT0 1 Tf
0 Tc 0 Tw 7.96 0 Td
(10:490-496, 1984. )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj149 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 94/Width 76>>stream
Hҁ	  ٝ8%(m X.C՞t~;v˔U#{oTK;#B8|Ƅ.oղ,   Ls ]`
endstreamendobj344 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 357 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 358 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj358 0 obj<</Font 359 0 R>>endobj359 0 obj<</ArialRoundedMTBold 231 0 R>>endobj357 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj343 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj339 0 obj<</Length 9049>>stream
q
1 0 0 1 -6.502411 2.502686 cm
0 0 612 792 re
W n
1 0 0 1 6.502411 -2.502686 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0012 Tc 0.0012 Tw 12 0 0 12 65.5382 639.7027 Tm
[(if warranted by)29 ( persistent or recurring)9 ( severe nodular acne, a second course of therapy)29 ( may)29 ( be )]TJ
0.0008 Tc -0.0008 Tw 0 -1.15 TD
[(initia)5 (te)5 (d. The)5 ( optima)5 (l inte)5 (r)4 (v)1 (a)5 (l)-1 ( be)5 (f)4 (o)1 (r)4 (e)5 ( r)4 (e)5 (tr)4 (e)5 (a)5 (tme)5 (nt ha)5 (s not be)5 (e)5 (n)1 ( de)5 (f)4 (i)-1 (ne)5 (d f)4 (o)1 (r)4 ( pa)5 (tie)5 (nts who ha)5 (ve)5 ( not )]TJ
-0.0006 Tc 0.0006 Tw T*
[(completed skeletal g)9 (r)2 (owth. L)20 (ong)9 (-term use of Accutane, even in low doses, has not been studied, )]TJ
T*
[(and is not recommended.  I)22 (t)-3 ( is important that Accutane be g)9 (i)-3 (ven at the recommended doses for )]TJ
-0.0008 Tc 0.0008 Tw T*
[(no long)9 (er than the recommended duration. The effect of long)9 (-term use of Accutane on bone loss )]TJ
-0.0009 Tc 0.0009 Tw T*
[(is unknown \(see W)-7 (A)1 (RNI)22 (NGS)]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 12.11 0 Td
(: Skeletal: Bone Mineral Density, Hyperostosis, )Tj
/TT0 1 Tf
-0.0019 Tc 0 Tw 19.36 0 Td
(and)Tj
/TT1 1 Tf
-0.001 Tc 0.001 Tw 1.44 0 Td
( Premature )Tj
0.0002 Tc -0.0002 Tw -32.91 -1.16 Td
(Epiphyseal Closure)Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw 7.86 0 Td
(\).  )Tj
-0.0015 Tc 0.0015 Tw -7.86 -2.22 Td
[(C)-4 (ont)-4 (racept)-4 (i)-4 (v)-1 (e m)-4 (easures m)-4 (u)-1 (st)-4 ( be fol)-4 (l)-4 (o)-1 (wed for any)29 ( subsequent)-4 ( course of t)-4 (h)-1 (erapy)29 ( \(see box)-11 (ed )]TJ
-0.0018 Tc 0.0018 Tw 0 -1.16 TD
[(C)-5 (ONTR)-5 (AI)21 (NDI)21 (C)-5 (ATI)21 (ONS)-6 ( AND W)-8 (AR)-5 (NI)21 (NGS)-6 (\). )]TJ
/TT2 1 Tf
0 Tc 0 Tw 18.34 -2.25 Td
( )Tj
0.0002 Tc -0.0002 Tw -17.23 -1.15 Td
[(Table 4. Accutane Dosing by Body Weight \(Based on Adm)13 (i)-2 (nistration With F)11 (ood\) )]TJ
/TT0 1 Tf
0 Tc 0 Tw 17.23 -1.13 Td
( )Tj
/TT2 1 Tf
0.0015 Tc -0.0015 Tw -14.07 -1.17 Td
[(Body We)5 (ight)5 ( )]TJ
18.739 0 Td
[(Tot)5 (a)2 (l m)15 (g)2 (/day )]TJ
/TT0 1 Tf
0.0007 Tc -0.0007 Tw -21.699 -1.17 Td
[(kilog)11 (r)4 (ams )-3820 (pounds )-3800 (0.5 mg)11 (/kg)11 ( )-3600 (1 mg)11 (/kg)11 ( )-3730 (2 mg)11 (/kg)11 (*)1 ( )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.281 442.56 90.12 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
156.401 442.56 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
156.881 442.56 89.76 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
246.641 442.56 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
247.121 442.56 89.64 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
336.761 442.56 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
337.241 442.56 89.76 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
427.001 442.56 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
427.481 442.56 89.76 -0.48 re
f
Q
BT
0 Tc 2.13 Tw 12 0 0 12 65.5382 419.5027 Tm
[( 40 )-1750 ( )-360 (88 )-1400 ( )-340 (20 )-1410 ( )-330 (40 )-1430 ( )-310 (80 )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.281 428.28 90.12 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
156.401 428.28 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
156.881 428.28 89.76 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
246.641 428.28 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
247.121 428.28 89.64 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
336.761 428.28 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
337.241 428.28 89.76 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
427.001 428.28 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
427.481 428.28 89.76 -0.48 re
f
Q
BT
12 0 0 12 65.5382 405.7027 Tm
[( 50 )-1750 ( )140 (110 )-1400 ( )-340 (25 )-1410 ( )-330 (50 )-1430 ( )190 (100 )]TJ
0 -1.15 TD
[( 60 )-1750 ( )140 (132 )-1400 ( )-340 (30 )-1410 ( )-330 (60 )-1430 ( )190 (120 )]TJ
T*
[( 70 )-1750 ( )140 (154 )-1400 ( )-340 (35 )-1410 ( )-330 (70 )-1430 ( )190 (140 )]TJ
T*
[( 80 )-1750 ( )140 (176 )-1400 ( )-340 (40 )-1410 ( )-330 (80 )-1430 ( )190 (160 )]TJ
T*
[( 90 )-1750 ( )140 (198 )-1400 ( )-340 (45 )-1410 ( )-330 (90 )-1430 ( )190 (180 )]TJ
1.63 Tw T*
[( 100 )-2250 ( )-360 (220 )-1900 ( )-840 (50 )-1910 ( )-330 (100 )-1930 ( )-310 (200 )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.281 331.2 90.12 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
156.401 331.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
156.881 331.2 89.76 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
246.641 331.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
247.121 331.2 89.64 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
336.761 331.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
337.241 331.2 89.76 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
427.001 331.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
427.481 331.2 89.76 -0.48 re
f
Q
BT
-0.0011 Tc 0.0011 Tw 12 0 0 12 65.5382 322.4227 Tm
[(*See DOSAGE AND ADMI)22 (N)1 (I)22 (S)-5 (TRATI)22 (ON: the recommended dosag)9 (e rang)9 (e is 0.5 to )]TJ
0.0003 Tc -0.0003 Tw 0 -1.16 TD
[(1.0 mg)10 (/kg)10 (/)-2 (day)30 (. )]TJ
/TT3 1 Tf
0.0008 Tc -0.0008 Tw 0 -2.35 TD
[(Inform)-11 (ation for Pharm)-11 (a)1 (cists:)]TJ
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 12.26 0 Td
[( Accutane must only)29 ( be dispensed in no more than a 30-day)29 ( )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 290.16 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
66.161 290.16 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
66.641 290.16 478.8 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 290.16 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 290.16 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
66.161 289.68 0.48 -14.88 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 289.68 0.48 -14.88 re
f
Q
BT
12 0 0 12 65.5382 266.5028 Tm
[(supply)29 ( and only)29 ( on presentation of an Accutane prescription with a y)29 (e)3 (llow self-adhesive )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 274.8 0.48 -13.8 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 274.8 0.48 -13.8 re
f
Q
BT
0.0007 Tc -0.0007 Tw 12 0 0 12 65.5382 252.7028 Tm
[(Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( Qua)5 (lif)4 (ic)5 (a)5 (tion Stic)5 (ke)5 (r)4 ( wr)4 (itte)5 (n within the)5 ( pr)4 (e)5 (v)1 (ious 7 da)5 (y)31 (s. )]TJ
/TT2 1 Tf
-0.0013 Tc 0.0013 Tw 26.71 0 Td
[(RE)-4 (F)10 (I)-2 (L)-4 (L)-4 (S)-5 ( RE)-4 (QUIRE)-4 ( A )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 261 0.48 -13.8 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 261 0.48 -13.8 re
f
Q
BT
0.0005 Tc -0.0005 Tw 12 0 0 12 65.5382 238.6627 Tm
[(NEW WRITTEN P)11 (R)3 (ESCRIP)11 (T)-2 (ION WITH A YELLOW SELF)11 (-ADHESIVE ACCUTANE )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 247.2 0.48 -13.8 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 247.2 0.48 -13.8 re
f
Q
BT
-0.0007 Tc 0.0007 Tw 12 0 0 12 65.5382 225.1028 Tm
[(QUAL)-4 (IF)10 (ICAT)-4 (ION S)-4 (T)-4 (ICK)7 (E)-4 (R WIT)-4 (H)-3 (IN T)-4 (H)-3 (E)-4 ( P)10 (R)2 (E)-4 (V)2 (IOUS)-4 ( 7 DAYS)-4 (. )]TJ
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 29.22 0 Td
(No telephone or )Tj
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 233.4 0.48 -13.8 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 233.4 0.48 -13.8 re
f
Q
BT
0.0012 Tc -0.0012 Tw 12 0 0 12 65.5382 211.1828 Tm
[(c)5 (o)1 (mpute)5 (r)4 (ize)5 (d)1 ( pr)4 (e)5 (sc)5 (r)4 (iptions a)5 (r)4 (e)5 ( pe)5 (r)4 (mitte)5 (d. )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 219.6 0.48 -26.76 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 219.6 0.48 -26.76 re
f
Q
BT
-0.0007 Tc 0.0007 Tw 12 0 0 12 65.5382 184.5428 Tm
[(An Accutane Medication Guide must be g)9 (i)-3 (ven to the patient each time Accutane is dispensed, as )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 192.84 0.48 -13.8 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 192.84 0.48 -13.8 re
f
Q
BT
12 0 0 12 65.5382 170.7428 Tm
[(required by)29 ( law. This Accutane Medication Guide is an important part of the risk ma\nag)9 (e)3 (ment )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 179.04 0.48 -13.8 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 179.04 0.48 -13.8 re
f
Q
BT
-0.0008 Tc 0.0008 Tw 12 0 0 12 65.5382 156.8228 Tm
[(prog)9 (ram for the patient. )]TJ
ET
q
1 0 0 1 -6.502411 2.502686 cm
66.161 150.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
66.161 150.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
66.641 150.36 478.8 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 150.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 150.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
66.161 165.24 0.48 -14.88 re
f
Q
q
1 0 0 1 -6.502411 2.502686 cm
545.441 165.24 0.48 -14.88 re
f
Q
BT
/TT2 1 Tf
0.0005 Tc -0.0005 Tw 12 0 0 12 65.5382 128.6228 Tm
[(HOW SUP)11 (P)11 (L)-2 (IED:)]TJ
/TT0 1 Tf
0.0001 Tc -0.0001 Tw [( Soft g)10 (e)4 (latin capsules, 10 mg)10 ( \(lig)10 (ht pink\), imprinted ACCUTANE 10 )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.16 TD
[(ROCHE. B)7 (ox)-10 (e)4 (s of 100 containing)10 ( 10 Prescription Paks of 10 capsules \(NDC 0004-0155-49\). )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj148 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 165/Width 76>>stream
H C])YGO>ЃXU!D%Wv^<k9
~:)O" bbHazcVvG~5^SA7<;Q>{55Z֓pq/ 伉reTOB! h`
endstreamendobj341 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 360 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 361 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj361 0 obj<</Font 362 0 R>>endobj362 0 obj<</ArialRoundedMTBold 231 0 R>>endobj360 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj340 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj336 0 obj<</Length 6206>>stream
q
1 0 0 1 -8.468994 14.622742 cm
0 0 612 792 re
W n
1 0 0 1 8.468994 -14.622742 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 12 0 0 12 63.5716 651.7027 Tm
[(W)-7 (h)-1 (ite cells in the urine, proteinuria, microscopic or g)9 (r)2 (oss hematuria  )]TJ
/TT1 1 Tf
-0.0004 Tc 0 Tw 0 -2.22 TD
[(OVE)-3 (RDOS)-4 (A)2 (G)7 (E)-3 (:)]TJ
/TT0 1 Tf
-0.0019 Tc 0.0019 Tw 7.44 0 Td
[( The oral)-4 ( L)19 (D)]TJ
0.0075 Tc 0 Tw 8.04 0 0 8.04 214.7716 621.5827 Tm
(50)Tj
-0.0003 Tc 0.0003 Tw 12 0 0 12 222.9316 625.0627 Tm
[( of isotretinoin is g)10 (r)3 (eater than 4000 mg)10 (/kg)10 ( in rats and mice )]TJ
-0.0007 Tc 0.0007 Tw -13.28 -1.32 Td
[(\(>)3 (600 times the recommended clinical dose of 1.0 mg)9 (/kg)9 (/)-3 (day)29 ( after normaliz)-7 (ation of the rat dose )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(for total body)29 ( surface area and >300 times the recommended clinical dose of 1.0 mg)9 (/kg)9 (/)-3 (day)29 ( after )]TJ
-0.0006 Tc 0.0006 Tw T*
[(normaliz)-7 (ation of the mouse dose for total body)29 ( surface area\) and is approx)-11 (imately)29 ( 1960 mg)9 (/kg)9 ( in )]TJ
-0.0005 Tc 0.0005 Tw T*
[(rabbits \(653 times the recommended clinical dose of 1.0 mg)10 (/kg)10 (/)-3 (day)30 ( after normaliz)-7 (ation for total )]TJ
-0.0008 Tc 0.0008 Tw T*
[(body)29 ( surface area\). I)22 (n)-1 ( humans, overdosag)9 (e has been associated with vomiting)9 (,)-1 ( facial flushing)9 (, )]TJ
-0.0003 Tc 0.0003 Tw T*
[(cheilosis, abdominal pain, headache, diz)-6 (z)-6 (i)-2 (ness, and atax)-10 (ia. All sy)30 (mptoms quickly)30 ( resolved )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.16 TD
(without apparent residual effects. )Tj
-0.0013 Tc 0.0013 Tw 0 -2.22 TD
[(Accutane causes serious birth defects at any)29 ( dosag)9 (e \(see box)-11 (ed C)-4 (ONTR)-4 (A)1 (I)22 (NDI)22 (C)-4 (A)1 (TI)22 (ONS)-5 ( AND )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.15 TD
[(W)-6 (A)2 (RNI)23 (NGS\). F)6 (e)4 (males of childbearing)10 ( potential who present with isotretinoin overdose must be )]TJ
-0.0009 Tc 0.0009 Tw T*
[(evaluated for preg)9 (nancy)29 (.)-1 ( Patients who are preg)9 (nant should receive counseling)9 ( about the risks to )]TJ
-0.0012 Tc 0.0012 Tw T*
[(the fetus, as described in the box)-11 (ed C)-4 (ONTR)-4 (A)1 (I)22 (NDI)22 (C)-4 (A)1 (TI)22 (ONS)-5 ( AND W)-7 (A)1 (R)-4 (N)1 (I)22 (NGS)-5 (. Non-preg)9 (nant )]TJ
-0.0016 Tc 0.0016 Tw T*
[(pat)-4 (i)-4 (e)2 (nt)-4 (s m)-4 (u)-2 (st)-4 ( be warned t)-4 (o)-2 ( avoi)-4 (d preg)8 (nancy)28 ( for at)-4 ( l)-4 (east)-4 ( one m)-4 (ont)-4 (h and recei)-4 (ve cont)-4 (racept)-4 (i)-4 (v)-2 (e )]TJ
-0.0006 Tc 0.0006 Tw T*
[(counseling)9 ( as described in the box)-11 (ed CONTRAI)22 (NDI)22 (CATI)22 (ONS AND W)-7 (A)2 (RNI)22 (NGS. Educational )]TJ
-0.001 Tc 0.001 Tw T*
[(materials for such patients can be obtained by)29 ( calling)9 ( the manufacturer. B)6 (ecause an overdose )]TJ
-0.0004 Tc 0.0004 Tw T*
[(would be ex)-10 (pected to result in hig)10 (her levels of isotretinoin in semen than found during)10 ( a normal )]TJ
-0.0006 Tc 0.0006 Tw T*
[(treatment course, male patients should use a condom, or avoid reproducti\ve sex)-11 (u)-1 (al activity)29 ( with a )]TJ
T*
[(female who is or mig)9 (ht become preg)9 (nant, for 30 day)29 (s)-1 ( after the overdose. All patients with )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.16 TD
[(isotretinoin overdose should not donate blood for at least 30 day)30 (s)-1 (. )]TJ
/TT1 1 Tf
-0.0012 Tc 0.0012 Tw 0 -2.22 TD
[(DOS)-5 (A)1 (G)7 (E)-4 ( AND ADMINIS)-5 (T)-4 (RAT)-4 (ION:)]TJ
/TT0 1 Tf
-0.0009 Tc 0.0009 Tw 16.32 0 Td
( Accutane should be administered with a meal \(see )Tj
0 Tw -16.32 -1.16 Td
[(P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT2 1 Tf
0.0001 Tc -0.0001 Tw (Information for Patients and Prescribers)Tj
/TT0 1 Tf
-0.0015 Tc 0 Tw 23.79 0 Td
(\). )Tj
-0.0008 Tc 0.0008 Tw -23.79 -2.23 Td
[(The recommended dosag)9 (e rang)9 (e for Accutane is 0.5 to 1.0 mg)9 (/kg)9 (/)-3 (day)29 ( g)9 (i)-3 (ven in two divided doses )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.15 TD
[(with food for 15 to 20 weeks. I)23 (n studies comparing)10 ( 0.1, 0.5, and 1.0 mg)10 (/kg)10 (/)-2 (day)30 (,)]TJ
0 Tc 0 Tw 8.04 0 0 8.04 445.2916 285.9428 Tm
(8)Tj
-0.0001 Tc 0.0001 Tw 12 0 0 12 449.3716 280.4227 Tm
( it was found )Tj
0.0008 Tc -0.0008 Tw -32.15 -1.15 Td
[(tha)5 (t)-1 ( a)5 (ll dosa)5 (g)11 (e)5 (s pr)4 (ovide)5 (d initia)5 (l c)5 (l)-1 (e)5 (a)5 (r)4 (ing)11 ( of)4 ( dise)5 (a)5 (se)5 (,)1 ( but the)5 (r)4 (e)5 ( wa)5 (s a)5 ( g)11 (r)4 (e)5 (a)5 (t)-1 (e)5 (r)4 ( ne)5 (e)5 (d)1 ( f)4 (o)1 (r)4 ( r)4 (e)5 (tr)4 (e)5 (a)5 (tme)5 (nt )]TJ
-0.0009 Tc 0.0009 Tw T*
[(with the lower dosag)9 (es. During)9 ( treatment, the dose may)29 ( be adjusted according)9 ( to response of the )]TJ
-0.0011 Tc 0.0011 Tw T*
[(disease and/or the appearance of clinical side effects \227 some of whic\h may)29 ( be dose related. )]TJ
-0.0006 Tc 0.0006 Tw T*
[(Adult patients whose disease is very)29 ( severe with scarring)9 ( or is primarily)29 ( manifested on the trunk )]TJ
-0.0005 Tc 0.0005 Tw T*
[(may)30 ( require dose adjustments up to 2.0 mg)10 (/kg)10 (/)-3 (day)30 (, as tolerated. F)6 (a)3 (ilure to take Accutane with )]TJ
-0.0008 Tc 0.0008 Tw T*
[(food will sig)9 (n)-1 (ificantly)29 ( decrease absorption. B)6 (e)3 (fore upward dose adjustments are made, the )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.16 TD
(patients should be questioned about their compliance with food instructi\ons. )Tj
-0.0005 Tc 0.0005 Tw 0 -2.22 TD
[(The safety)30 ( of once daily)30 ( dosing)10 ( with Accutane has not been established. Once daily)30 ( dosing)10 ( is )]TJ
/TT1 1 Tf
0.0019 Tc 0 Tw 37.36 0 Td
(not)Tj
/TT0 1 Tf
0 Tc 1.39 0 Td
( )Tj
-0.0011 Tc 0.0011 Tw -38.75 -1.16 Td
(recommended.  )Tj
-0.0006 Tc 0.0006 Tw T*
[(I)22 (f)2 ( the total nodule count has been reduced by)29 ( more than 70% prior to completing)9 ( 15 to 20 weeks )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(of treatment, the drug)9 ( may)29 ( be discontinued. After a period of 2 months or more off therapy)29 (,)-1 ( and )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj147 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 145/Width 76>>stream
H얁 fwJqL	W1B0_z0km<ѫVyFVTK;?t1{t__y.ܯ	i1C)/ބCko[VwkJ^]£6V^#
  .BA
endstreamendobj338 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 363 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 364 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj364 0 obj<</Font 365 0 R>>endobj365 0 obj<</ArialRoundedMTBold 231 0 R>>endobj363 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj337 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj35 0 obj<</Contents 366 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 175 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 367 0 R>>/Font<</T1_0 188 0 R/TT0 112 0 R/TT1 186 0 R/TT2 187 0 R/TT3 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 368 0 R>>>>/Rotate 0/Thumb 142 0 R/Type/Page>>endobj37 0 obj<</Contents 369 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 175 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 370 0 R>>/Font<</T1_0 188 0 R/TT0 112 0 R/TT1 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 371 0 R>>>>/Rotate 0/Thumb 143 0 R/Type/Page>>endobj39 0 obj<</Contents 372 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 175 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 373 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 105 0 R/TT2 187 0 R/TT3 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 374 0 R>>>>/Rotate 0/Thumb 144 0 R/Type/Page>>endobj41 0 obj<</Contents 375 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 175 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 376 0 R>>/Font<</TT0 187 0 R/TT1 112 0 R/TT2 105 0 R/TT3 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 377 0 R>>>>/Rotate 0/Thumb 145 0 R/Type/Page>>endobj43 0 obj<</Contents 378 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 175 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 379 0 R>>/Font<</TT0 112 0 R/TT1 186 0 R/TT2 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 380 0 R>>>>/Rotate 0/Thumb 146 0 R/Type/Page>>endobj378 0 obj<</Length 7061>>stream
q
1 0 0 1 -7.947876 18.942719 cm
0 0 612 792 re
W n
1 0 0 1 7.947876 -18.942719 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0012 Tc 12 0 0 12 64.0927 656.1427 Tm
[(Psy)5 (c)5 (h)1 (iatric)5 (:)]TJ
/TT1 1 Tf
-0.0002 Tc 0.0002 Tw 4.88 0 Td
[( suicidal ideation, suicide attempts, suicide, depression, psy)30 (c)4 (hosis, ag)10 (g)10 (r)3 (ession, )]TJ
-0.0004 Tc 0.0004 Tw -4.88 -1.16 Td
[(violent behaviors \(see W)-7 (A)2 (RNI)23 (NGS: )]TJ
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 14.91 0 Td
[(Psy)5 (c)5 (h)1 (iatric)5 ( Disorde)5 (rs)]TJ
/TT1 1 Tf
0.0013 Tc -0.0013 Tw [(\))4 (,)1 ( e)5 (m)-1 (otiona)5 (l insta)5 (b)1 (ility)31 (  )]TJ
-0.0005 Tc 0.0005 Tw -14.91 -2.22 Td
[(Of the patients reporting)10 ( depression, some reported that the depression subsided with )]TJ
0.0007 Tc -0.0007 Tw 0 -1.16 TD
[(disc)5 (ontinua)5 (tion of)4 ( the)5 (r)4 (a)5 (p)1 (y)31 ( a)5 (nd r)4 (e)5 (c)5 (u)1 (r)4 (r)4 (e)5 (d with r)4 (e)5 (institution of)4 ( the)5 (r)4 (a)5 (p)1 (y)31 (.)1 ( )]TJ
/TT0 1 Tf
-0.0011 Tc 0.0011 Tw 0 -2.24 TD
(Reproductive System:)Tj
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 8.67 0 Td
( abnormal menses  )Tj
/TT0 1 Tf
0 Tw -8.67 -2.22 Td
(Respiratory:)Tj
/TT1 1 Tf
0.0005 Tw 5.05 0 Td
[( bronchospasms \(with or without a history)30 ( of asthma\), respiratory)30 ( infection, voice )]TJ
0.0014 Tc -0.0014 Tw -5.05 -1.16 Td
[(a)5 (lte)5 (r)4 (a)5 (tion  )]TJ
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 0 -2.22 TD
(Skin and Appendages:)Tj
/TT1 1 Tf
0.0009 Tc -0.0009 Tw 8.93 0 Td
[( a)5 (c)5 (n)1 (e)5 ( f)4 (u)1 (lmina)5 (n)1 (s, a)5 (l)-1 (ope)5 (c)5 (i)-1 (a)5 ( \()4 (w)3 (hic)5 (h)1 ( in some)5 ( c)5 (a)5 (se)5 (s pe)5 (r)4 (sists\))4 (,)1 ( br)4 (uising)11 (, c)5 (h)1 (e)5 (ilitis )]TJ
-0.0003 Tc 0.0003 Tw -8.93 -1.15 Td
[(\(dry)30 ( lips\), dry)30 ( mouth, dry)30 ( nose, dry)30 ( skin, epistax)-10 (i)-2 (s, eruptive x)-10 (a)4 (nthomas,)]TJ
0 Tc 0 Tw 8.04 0 0 8.04 405.9727 499.3027 Tm
(7)Tj
0.0008 Tc -0.0008 Tw 12 0 0 12 410.0527 493.7827 Tm
[( f)4 (l)-1 (ushing)11 (, f)4 (r)4 (a)5 (g)11 (ility)31 ( of)4 ( )]TJ
0 Tc 0 Tw -28.83 -1.15 Td
[(skin, hair abnormalities, hirsutism, hy)30 (perpig)10 (mentation and hy)30 (popig)10 (m)-2 (entation, infections )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.15 TD
[(\(including)10 ( disseminated herpes simplex)-10 (\))3 (, nail dy)30 (strophy)30 (, parony)30 (chia, peeling)10 ( of palms and soles, )]TJ
T*
[(photoallerg)10 (ic/photosensitiz)-6 (ing)10 ( reactions, pruritus, py)30 (og)10 (enic g)10 (r)3 (anuloma, rash \(including)10 ( facial )]TJ
-0.0009 Tc 0.0009 Tw T*
[(ery)29 (t)-3 (hema, seborrhea, and ecz)-7 (ema\), sunburn susceptibility)29 ( increased, sweating)9 (,)-1 ( urticaria, )]TJ
0.0011 Tc -0.0011 Tw T*
[(va)5 (sc)5 (ulitis \()4 (i)-1 (nc)5 (luding)11 ( We)5 (g)11 (e)5 (ne)5 (r)4 (\222)4 (s g)11 (r)4 (a)5 (nuloma)5 (t)-1 (osis; se)5 (e)]TJ
/TT0 1 Tf
0 Tc 0 Tw 20.84 0 Td
( )Tj
/TT1 1 Tf
-0.0017 Tc [(P)-5 (R)-5 (EC)-5 (AUTI)21 (ONS)-5 (:)]TJ
/TT0 1 Tf
0.0008 Tc -0.0008 Tw 7.4 0 Td
[( Hy)5 (pe)5 (rse)5 (nsitiv)5 (ity)]TJ
/TT1 1 Tf
-0.0015 Tc 0 Tw 6.74 0 Td
(\), )Tj
-0.0007 Tc 0.0007 Tw -34.98 -1.15 Td
[(abnormal wound healing)9 ( \(delay)29 (ed healing)9 ( or ex)-11 (uberant g)9 (r)2 (anulation tissue with crusting)9 (;)-3 ( see )]TJ
-0.0017 Tc 0 Tw 0 -1.16 TD
[(P)-5 (R)-5 (EC)-5 (AUTI)21 (ONS)-5 (:)]TJ
/TT0 1 Tf
0.0001 Tc -0.0001 Tw 7.15 0 Td
( Information for Patients and Prescribers)Tj
/TT1 1 Tf
-0.003 Tc 0 Tw 16.64 0 Td
(\) )Tj
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw -23.79 -2.23 Td
(Special Senses:)Tj
/TT1 1 Tf
0 Tc 0 Tw 6.18 0 Td
( )Tj
/TT0 1 Tf
-0.0004 Tc (Hearing:)Tj
/TT1 1 Tf
-0.0025 Tc 0.0025 Tw 3.91 0 Td
[( heari)-5 (n)-2 (g)8 ( i)-5 (m)-5 (p)-2 (ai)-5 (rm)-5 (ent)-5 ( \(see W)-9 (AR)-5 (NI)21 (NGS)-6 (:)-5 ( )]TJ
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 16.09 0 Td
(Hearing Impairment)Tj
/TT1 1 Tf
0.0009 Tc -0.0009 Tw 8.24 0 Td
[(\))4 (,)1 ( tinnitus.  )]TJ
/TT0 1 Tf
0.0006 Tc 0 Tw -34.42 -1.15 Td
(Vision:)Tj
/TT1 1 Tf
0.001 Tc -0.001 Tw 2.89 0 Td
[( c)5 (o)1 (r)4 (n)1 (e)5 (a)5 (l)-1 ( opa)5 (c)5 (itie)5 (s \()4 (se)5 (e)5 ( WARNI)24 (NGS: )]TJ
/TT0 1 Tf
[(Corne)5 (a)1 (l Opac)5 (itie)5 (s)]TJ
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 22.34 0 Td
[(\), decreased nig)10 (ht vision which )]TJ
0.0012 Tc -0.0012 Tw -25.23 -1.14 Td
[(ma)5 (y)31 ( pe)5 (r)4 (sist \()4 (se)5 (e)5 ( WARNI)24 (NGS: )]TJ
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw 12.55 0 Td
(Decreased Night Vision)Tj
/TT1 1 Tf
-0.0008 Tc 0.0008 Tw 9.55 0 Td
(\), cataracts, color vision disorder, )Tj
-0.0001 Tc 0.0001 Tw -22.1 -1.15 Td
[(conjunctivitis, dry)30 ( ey)30 (es, ey)30 (elid inflammation, keratitis, optic neuritis, photophobia, visual )]TJ
-0.0007 Tc 0 Tw T*
(disturbances )Tj
/TT0 1 Tf
-0.0009 Tc 0.0009 Tw 0 -2.23 TD
(Urinary System:)Tj
/TT1 1 Tf
0.0007 Tc -0.0007 Tw 6.57 0 Td
[( g)11 (l)-1 (ome)5 (r)4 (ulone)5 (phr)4 (itis \()4 (se)5 (e)5 ( PRECAUTI)24 (ONS: )]TJ
/TT0 1 Tf
0.0009 Tc 0 Tw [(Hy)5 (pe)5 (rse)5 (nsitiv)5 (ity)]TJ
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 23.84 0 Td
(\), nonspecific )Tj
-0.0001 Tc 0.0001 Tw -30.41 -1.16 Td
[(urog)10 (enital finding)10 (s \(see PRECAUTI)23 (ONS: )]TJ
/TT0 1 Tf
0.0002 Tc -0.0002 Tw 17.06 0 Td
(Laboratory Tests)Tj
/TT1 1 Tf
-0.0013 Tc 0.0013 Tw 6.87 0 Td
[( for other urolog)9 (ical parameters\) )]TJ
/TT2 1 Tf
0.0003 Tc 0 Tw -23.93 -2.22 Td
(Laboratory)Tj
/TT0 1 Tf
0 Tc 4.61 0 Td
(:)Tj
/TT1 1 Tf
0.0011 Tc -0.0011 Tw 0.33 0 Td
[( Ele)5 (v)1 (a)5 (tion of)4 ( pla)5 (sma)5 ( tr)4 (ig)11 (ly)31 (c)5 (e)5 (r)4 (ide)5 (s \()4 (se)5 (e)5 ( WARNI)24 (NGS: )]TJ
/TT0 1 Tf
0.0014 Tc 0 Tw 21.44 0 Td
(Lipids)Tj
/TT1 1 Tf
-0.002 Tc 0.002 Tw 2.51 0 Td
[(\), decrease i)-4 (n)-2 ( serum)-4 ( )]TJ
-0.0004 Tc 0.0004 Tw -28.89 -1.16 Td
[(hig)10 (h-density)30 ( lipoprotein \(HDL)20 (\) levels, elevations of serum cholesterol during)10 ( treatment  )]TJ
-0.0008 Tc 0.0008 Tw 0 -2.22 TD
[(I)22 (n)-1 (creased alkaline phosphatase, SGOT \(AST\), SGPT \(AL)20 (T\), GGTP or L)20 (DH \(see W)-7 (A)1 (RNI)22 (NGS: )]TJ
/TT0 1 Tf
0 Tc 0 Tw 0 -1.16 TD
(Hepatotoxicity)Tj
/TT1 1 Tf
-0.003 Tc 0.003 Tw 5.88 0 Td
(\)  )Tj
-0.0003 Tc 0.0003 Tw -5.88 -2.23 Td
[(Elevation of fasting)10 ( blood sug)10 (a)4 (r, elevations of CPK \(see PRECAUTI)23 (ONS: )]TJ
/TT0 1 Tf
0.0002 Tc -0.0002 Tw 30.13 0 Td
(Laboratory Tests)Tj
/TT1 1 Tf
-0.0015 Tc 0 Tw 6.87 0 Td
(\), )Tj
-0.0011 Tc -37 -1.16 Td
[(hy)29 (peruricemia )]TJ
-0.0008 Tc 0.0008 Tw 0 -2.22 TD
[(Decreases in red blood cell parameters, decreases in white blood cell co\unts \(including)9 ( severe )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(neutropenia and rare reports of ag)9 (ranulocy)29 (t)-3 (osis; see PRECAUTI)22 (ONS:)]TJ
/TT0 1 Tf
0.0008 Tc -0.0008 Tw 27.97 0 Td
[( I)4 (n)1 (formation for Patie)5 (nts )]TJ
-0.0005 Tc 0.0005 Tw -27.97 -1.16 Td
(and Prescribers)Tj
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 6.41 0 Td
[(\), elevated sedimentation rates, elevated platelet counts, thrombocy)29 (t)-3 (openia )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj146 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 147/Width 76>>stream
H g/$Ncc+Q=UbIՒ+zA{r1H)t24sܭIxne7ay $N^P^jFI)0_sn!;U>	!H2Fw T
endstreamendobj380 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 381 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 382 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj382 0 obj<</Font 383 0 R>>endobj383 0 obj<</ArialRoundedMTBold 231 0 R>>endobj381 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj379 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj375 0 obj<</Length 7334>>stream
q
1 0 0 1 -7.882782 5.792664 cm
0 0 612 792 re
W n
1 0 0 1 7.882782 -5.792664 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0017 Tc 0.0017 Tw 12 0 0 12 64.1578 642.9927 Tm
[(ADVE)-5 (RS)-5 (E)-5 ( RE)-5 (ACT)-5 (IONS)-5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw 11.31 0 Td
( )Tj
/TT2 1 Tf
0.0015 Tc -0.0015 Tw [(Clinic)5 (al Trials and Postm)-11 (a)2 (rke)5 (ting Surv)5 (e)5 (illanc)5 (e)5 (:)]TJ
/TT3 1 Tf
-0.002 Tc 0.002 Tw 20.07 0 Td
( The adverse )Tj
-0.0008 Tc 0.0008 Tw -31.38 -1.15 Td
[(reactions listed below reflect the ex)-11 (perience from investig)9 (ational studies of Accutane, and the )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(postmarketing)9 ( ex)-11 (perience. The relationship of some of these events to Accutane therapy)29 ( is )]TJ
-0.0011 Tc 0.0011 Tw T*
[(unknown. Many)29 ( of the side effects and adverse reactions seen in patients receiving)9 ( Accutane are )]TJ
0.0007 Tc -0.0007 Tw T*
[(simila)5 (r)4 ( to those)5 ( de)5 (sc)5 (r)4 (i)-1 (be)5 (d in pa)5 (tie)5 (nts ta)5 (king)11 ( ve)5 (r)4 (y)31 ( hig)11 (h)1 ( dose)5 (s of)4 ( vita)5 (min A \()4 (d)1 (r)4 (y)31 (ne)5 (ss of)4 ( the)5 ( skin )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.16 TD
[(and mucous membranes, eg)9 (, of the lips, nasal passag)9 (e)3 (, and ey)29 (es\).  )]TJ
/TT2 1 Tf
0.0013 Tc -0.0013 Tw 0 -2.22 TD
[(Dose)5 ( Re)5 (lationship:)]TJ
/TT3 1 Tf
0.0009 Tc -0.0009 Tw 7.87 0 Td
[( Che)5 (ilitis a)5 (nd hy)31 (pe)5 (r)4 (t)-1 (r)4 (i)-1 (g)11 (l)-1 (y)31 (c)5 (e)5 (r)4 (ide)5 (mia)5 ( a)5 (r)4 (e)5 ( usua)5 (lly)31 ( dose)5 ( r)4 (e)5 (la)5 (te)5 (d. Most a)5 (dve)5 (r)4 (se)5 ( )]TJ
-0.0008 Tc 0.0008 Tw -7.87 -1.15 Td
[(reactions reported in clinical trials were reversible when therapy)29 ( was discontinued; however, )]TJ
-0.0013 Tc 0.0013 Tw 0 -1.16 TD
[(some persisted after cessation of therapy)29 ( \(see W)-7 (A)1 (R)-4 (N)1 (I)22 (NGS)-5 ( and ADVER)-4 (S)-5 (E R)-4 (EAC)-4 (TI)22 (ONS)-5 (\).)]TJ
/TT1 1 Tf
0 Tc 0 Tw ( )Tj
-0.0006 Tc 0.0006 Tw 0 -2.23 TD
[(Body as a W)22 (hole:)]TJ
/TT3 1 Tf
0.001 Tc -0.001 Tw 7.05 0 Td
[( a)5 (lle)5 (r)4 (g)11 (ic)5 ( r)4 (e)5 (a)5 (c)5 (tions, inc)5 (l)-1 (uding)11 ( va)5 (sc)5 (ulitis, sy)31 (ste)5 (mic)5 ( hy)31 (pe)5 (r)4 (se)5 (n)1 (sitivity)31 ( \()4 (se)5 (e)5 ( )]TJ
-0.0009 Tc 0 Tw -7.05 -1.16 Td
[(P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
0.0009 Tc [(Hy)5 (pe)5 (rse)5 (nsitiv)5 (ity)]TJ
/TT3 1 Tf
-0.0003 Tc 0.0003 Tw 13.89 0 Td
[(\), edema, fatig)10 (ue, ly)30 (mphadenopathy)30 (, weig)10 (ht loss )]TJ
/TT1 1 Tf
0 Tc 0 Tw 19.56 0 Td
( )Tj
0.0002 Tc -33.45 -2.23 Td
(Cardiovascular:)Tj
/TT3 1 Tf
-0.0006 Tc 0.0006 Tw 6.61 0 Td
[( palpitation, tachy)29 (cardia, vascular thrombotic disease, stroke )]TJ
/TT1 1 Tf
-0.0004 Tc 0 Tw -6.61 -2.22 Td
(Endocrine/Metabolic:)Tj
/TT3 1 Tf
-0.0023 Tc 0.0023 Tw 8.82 0 Td
[( hy)28 (pert)-4 (ri)-4 (g)8 (l)-4 (y)28 (ceri)-4 (d)-2 (em)-4 (i)-4 (a)2 ( \(see W)-8 (AR)-5 (NI)21 (NGS)-6 (:)-4 ( )]TJ
/TT1 1 Tf
0.0014 Tc 0 Tw 16.55 0 Td
(Lipids)Tj
/TT3 1 Tf
-0.0003 Tc 0.0003 Tw 2.51 0 Td
[(\), alterations in blood sug)10 (a)4 (r )]TJ
-0.0011 Tc 0.0011 Tw -27.88 -1.16 Td
[(levels \(see P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 11.83 0 Td
(Laboratory Tests)Tj
/TT3 1 Tf
-0.003 Tc 0 Tw 6.87 0 Td
(\) )Tj
/TT1 1 Tf
0.001 Tc -18.7 -2.23 Td
[(Gastrointe)5 (stinal:)]TJ
/TT3 1 Tf
-0.002 Tc 0.002 Tw 6.84 0 Td
[( i)-4 (n)-2 (fl)-4 (am)-4 (m)-4 (a)2 (t)-4 (o)-2 (ry)28 ( bowel)-4 ( di)-4 (sease \(see W)-8 (AR)-5 (NI)21 (NGS)-6 (:)-4 ( )]TJ
/TT1 1 Tf
0.0007 Tc -0.0007 Tw 19.48 0 Td
[(I)4 (n)1 (flammatory)5 ( Bowe)5 (l Dise)5 (ase)]TJ
/TT3 1 Tf
-0.0015 Tc 0 Tw 11.6 0 Td
(\), )Tj
0.001 Tc -0.001 Tw -37.92 -1.15 Td
[(he)5 (pa)5 (titis \()4 (se)5 (e)5 ( WARNI)24 (NGS: )]TJ
/TT1 1 Tf
0 Tc 0 Tw (Hepatotoxicity)Tj
/TT3 1 Tf
0.0009 Tc -0.0009 Tw 17.27 0 Td
[(\))4 (,)1 ( pa)5 (nc)5 (r)4 (e)5 (a)5 (titis \()4 (se)5 (e)5 ( WARNI)24 (NGS: )]TJ
/TT1 1 Tf
0.0014 Tc 0 Tw 13.43 0 Td
(Lipids)Tj
/TT3 1 Tf
-0.0006 Tc 0.0006 Tw 2.51 0 Td
[(\), bleeding)9 ( )]TJ
-0.0003 Tc 0.0003 Tw -33.21 -1.15 Td
[(and inflammation of the g)10 (ums, colitis, esophag)10 (itis/esophag)10 (eal ulceration, ileitis, nausea, other )]TJ
0 Tc 0 Tw 0 -1.16 TD
[(nonspecific g)10 (a)4 (strointestinal sy)30 (mptoms  )]TJ
/TT1 1 Tf
-0.0008 Tc 0 -2.22 TD
(Hematologic:)Tj
/TT3 1 Tf
0.001 Tc -0.001 Tw [( a)5 (lle)5 (r)4 (g)11 (ic)5 ( r)4 (e)5 (a)5 (c)5 (tions \()4 (se)5 (e)5 ( PRECAUTI)24 (ONS: )]TJ
/TT1 1 Tf
0.0009 Tc 0 Tw 22.07 0 Td
[(Hy)5 (pe)5 (rse)5 (nsitiv)5 (ity)]TJ
/TT3 1 Tf
-0.0013 Tc 0.0013 Tw 6.49 0 Td
[(\), anem)-3 (i)-3 (a)3 (, )]TJ
-0.0008 Tc 0.0008 Tw -28.56 -1.15 Td
[(thrombocy)29 (t)-3 (openia, neutropenia, rare reports of ag)9 (ranulocy)29 (t)-3 (osis \(see PRECAUTI)22 (ONS: )]TJ
/TT1 1 Tf
0.0001 Tc -0.0001 Tw 0 -1.15 TD
(Information for Patients and Prescribers)Tj
/TT3 1 Tf
-0.0015 Tc 0.0015 Tw 16.39 0 Td
[(\). S)-5 (ee P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
0.0002 Tc -0.0002 Tw (Laboratory Tests)Tj
/TT3 1 Tf
-0.0017 Tc 0.0017 Tw 16.79 0 Td
[( for ot)-4 (her )]TJ
0.001 Tc -0.001 Tw -33.18 -1.16 Td
[(he)5 (ma)5 (tolog)11 (i)-1 (c)5 (a)5 (l)-1 ( pa)5 (r)4 (a)5 (me)5 (te)5 (r)4 (s.  )]TJ
/TT1 1 Tf
-0.0005 Tc 0 Tw 0 -2.22 TD
(Musculoskeletal:)Tj
/TT3 1 Tf
0.0005 Tw 6.82 0 Td
[( skeletal hy)30 (perostosis, calcification of tendons and lig)10 (aments, premature )]TJ
-0.0007 Tc 0.0007 Tw -6.82 -1.15 Td
[(epiphy)29 (seal closure, decreases in bone mineral density)29 ( \(see W)-7 (A)2 (RNI)22 (NGS: )]TJ
/TT1 1 Tf
-0.0024 Tc 0 Tw 29.31 0 Td
[(Skel)-5 (et)-5 (al)]TJ
/TT3 1 Tf
-0.0015 Tc 3.16 0 Td
(\), )Tj
0.001 Tc -0.001 Tw -32.47 -1.15 Td
[(musc)5 (uloske)5 (le)5 (ta)5 (l sy)31 (mptoms \()4 (some)5 (time)5 (s se)5 (ve)5 (r)4 (e)5 (\))4 ( inc)5 (l)-1 (uding)11 ( ba)5 (c)5 (k)1 ( pa)5 (in a)5 (nd a)5 (r)4 (thr)4 (a)5 (lg)11 (ia)5 ( \()4 (se)5 (e)5 ( )]TJ
-0.0009 Tc 0 Tw 0 -1.15 TD
[(P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
0.0001 Tc -0.0001 Tw (Information for Patients and Prescribers)Tj
/TT3 1 Tf
0.0012 Tc -0.0012 Tw 23.79 0 Td
[(\))4 (,)1 ( tr)4 (a)5 (n)1 (sie)5 (n)1 (t pa)5 (in in the)5 ( c)5 (h)1 (e)5 (st \()4 (se)5 (e)5 ( )]TJ
-0.0009 Tc 0 Tw -23.79 -1.15 Td
[(P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
0.0001 Tc -0.0001 Tw (Information for Patients and Prescribers)Tj
/TT3 1 Tf
-0.0001 Tc 0.0001 Tw 23.79 0 Td
[(\), arthritis, tendonitis, other ty)30 (pes of )]TJ
-0.0004 Tc 0.0004 Tw -23.79 -1.15 Td
[(bone abnormalities, elevations of CPK/rare reports of rhabdomy)30 (oly)30 (sis \(see PRECAUTI)23 (ONS: )]TJ
/TT1 1 Tf
0.0003 Tc -0.0003 Tw 0 -1.16 TD
(Laboratory Tests\))Tj
/TT3 1 Tf
0 Tc 0 Tw 7.19 0 Td
(  )Tj
/TT1 1 Tf
0.0004 Tc -7.19 -2.22 Td
(Neurological:)Tj
/TT3 1 Tf
-0.0008 Tc 0.0008 Tw 5.61 0 Td
[( pseudotumor cerebri \(see W)-7 (A)1 (RNI)22 (NGS: )]TJ
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 16.48 0 Td
(Pseudotumor Cerebri)Tj
/TT3 1 Tf
-0.0001 Tc 0.0001 Tw 8.69 0 Td
[(\), diz)-6 (z)-6 (iness, )]TJ
-0.0006 Tc 0.0006 Tw -30.78 -1.15 Td
[(drowsiness, headache, insomnia, letharg)9 (y)29 (, malaise, nervousness, paresthesias, seiz)-7 (ures, stroke, )]TJ
-0.001 Tc 0.001 Tw T*
[(sy)29 (ncope, weakness )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj145 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 138/Width 76>>stream
H 1k*5<b-@ƇkBazLvjI=Jw?KE5󱹿syb,׌M^ⵥu{!^'nk%PjIUmx6?7
! V
endstreamendobj377 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 384 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 385 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj385 0 obj<</Font 386 0 R>>endobj386 0 obj<</ArialRoundedMTBold 231 0 R>>endobj384 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj376 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj372 0 obj<</Length 6485>>stream
q
1 0 0 1 -7.872955 15.58902 cm
0 0 612 792 re
W n
1 0 0 1 7.872955 -15.58902 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0027 Tc 0.0003 Tw 9.96 0 0 9.96 64.1676 654.589 Tm
[(50 m)22 (e)1 (n)9 ( \(ag)9 (e)1 (s)6 ( 17 to 32 y)21 (ears)6 (\))-2 ( receiv)9 (i)3 (n)9 (g)9 ( A)14 (ccu)9 (tan)9 (e)1 ( \(is)6 (o)-3 (tretin)9 (oin)9 (\))-2 ( th)9 (erapy)21 ( f)10 (o)-3 (r n)9 (odu)9 (lar acn)9 (e, n)9 (o)-3 ( s)6 (i)3 (g)9 (n)9 (i)3 (f)10 (i)3 (can)9 (t ef)10 (f)10 (ects)6 ( w)26 (e)1 (re )]TJ
0.0008 Tc 0.0022 Tw 0 -1.157 TD
[(seen)7 ( o)-5 (n)7 ( ej)-10 (acu)7 (late v)7 (o)-5 (lu)7 (m)20 (e)-1 (, sp)-5 (erm)20 ( co)-5 (u)7 (n)7 (t)2 (, to)-5 (tal sp)-5 (erm)20 ( m)20 (o)-5 (tility)19 (, m)20 (o)-5 (rp)-5 (h)7 (o)-5 (lo)-5 (g)7 (y)19 ( o)-5 (r)-3 ( sem)20 (i)2 (n)7 (a)-1 (l p)-5 (l)2 (asm)20 (a)-1 ( f)9 (r)-3 (u)7 (c)-1 (to)-5 (se. )]TJ
/TT1 1 Tf
-0.0022 Tc 0 Tw 12 0 0 12 64.1676 623.389 Tm
[(Pregn)-6 (a)-2 (n)-6 (cy:)]TJ
/TT2 1 Tf
-0.0014 Tc 0.0014 Tw 4.77 0 Td
[( Category X. S)-5 (ee b)-5 (oxed)-5 ( CONT)-4 (RAINDICAT)-4 (IONS)-5 ( AND WARNING)6 (S)-5 (.)-1 ( )]TJ
/TT1 1 Tf
0.0009 Tc -0.0009 Tw -4.77 -2.2 Td
(Nursing Mothers:)Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 7.43 0 Td
[( I)22 (t)-3 ( is not known whether this drug)9 ( is ex)-11 (creted in human milk. B)6 (ecause of the )]TJ
-0.0008 Tc 0.0008 Tw -7.43 -1.16 Td
[(potential for adverse effects, nursing)9 ( mothers should not receive Accutane. )]TJ
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 0 -2.22 TD
(Pediatric Use)Tj
/TT2 1 Tf
0 Tc 0 Tw 5.52 0 Td
(:)Tj
/TT1 1 Tf
0.33 0 Td
( )Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw [(The use of Accutane in pediatric patients less than 12 y)29 (ears of ag)9 (e has not been )]TJ
-0.0012 Tc 0.0012 Tw -5.85 -1.15 Td
(studied. The use of Accutane for the treatment of severe recalcitrant no\dular acne in pediatric )Tj
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(patients ag)9 (es 12 to 17 y)29 (ears should be g)9 (i)-3 (ven careful consideration, especially)29 ( for those patients )]TJ
-0.0008 Tc 0.0008 Tw T*
[(where a known metabolic or structural bone disease ex)-11 (ists \(see PRECAUTI)22 (ONS: )]TJ
/TT3 1 Tf
-0.0015 Tc 0 Tw 32.74 0 Td
(General)Tj
/TT0 1 Tf
-0.0017 Tc 0.0017 Tw 3.27 0 Td
(\). Use )Tj
-0.001 Tc 0.001 Tw -36.01 -1.15 Td
[(of Accutane in this ag)9 (e g)9 (r)2 (oup for severe recalcitrant nodular acne is supported by)29 ( evidence from )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.23 TD
[(a clinical study)30 ( comparing)10 ( 103 pediatric patients \(13 to 17 y)30 (ears\) to 197 adult patients \()]TJ
/T1_0 1 Tf
0 Tc 0 Tw 34.86 0 Td
(\006)Tj
/TT0 1 Tf
0.55 0 Td
(18 )Tj
-0.0005 Tc 0.0005 Tw -35.41 -1.15 Td
[(y)30 (ears\). Results from this study)30 ( demonstrated that Accutane, at a dose of 1 mg)10 (/kg)10 (/)-3 (day)30 ( g)10 (i)-3 (ven in )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(two divided doses, was equally)29 ( effective in treating)9 ( severe recalcitrant nodular acne in both )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
(pediatric and adult patients.  )Tj
0.0007 Tc -0.0007 Tw 0 -2.22 TD
[(I)24 (n)1 ( studie)5 (s with Ac)5 (c)5 (u)1 (ta)5 (ne)5 (, a)5 (dve)5 (r)4 (se)5 ( r)4 (e)5 (a)5 (c)5 (tions r)4 (e)5 (por)4 (te)5 (d in pe)5 (dia)5 (t)-1 (r)4 (i)-1 (c)5 ( pa)5 (tie)5 (nts we)5 (r)4 (e)5 ( simila)5 (r)4 ( to those)5 ( )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(described in adults ex)-11 (cept for the increased incidence of back pain and arthralg)9 (ia \(both of which )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.16 TD
[(were sometimes severe\) and my)29 (alg)9 (i)-3 (a in pediatric patients \(see ADVERSE REACTI)22 (ONS\).   )]TJ
-0.001 Tc 0.001 Tw 0 -2.22 TD
[(I)22 (n)-1 ( an open-label clinical trial \(N=217\) of a sing)9 (le course of therapy)29 ( with Accutane for severe )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(recalcitrant nodular acne, bone density)29 ( measurements at several skeletal sites were not )]TJ
-0.0011 Tc 0.0011 Tw T*
[(sig)9 (n)-1 (ificantly)29 ( decreased \(lumbar spine chang)9 (e)3 ( >-4% and total hip chang)9 (e)3 ( >-5%\) or were increased )]TJ
-0.0006 Tc 0.0006 Tw T*
[(in the majority)29 ( of patients.  One patient had a decrease in lumbar spine bone mineral d\ensity)29 ( )]TJ
-0.0008 Tc 0.0008 Tw T*
[(>4% based on unadjusted data.  Six)-11 (t)-3 (een \(7.9%\) patients had decreases in lumbar spine bone )]TJ
-0.0007 Tc 0.0007 Tw T*
[(mineral density)29 ( >4%, and all the other patients \(92%\) did not have sig)9 (n)-1 (ificant decreases or had )]TJ
-0.0008 Tc 0.0008 Tw T*
[(increases \(adjusted for body)29 ( mass index)-11 (\))2 (.  Nine patients \(4.5%\) had a decrease in total hip bone )]TJ
-0.0007 Tc 0.0007 Tw T*
[(mineral density)29 ( >5% based on unadjusted data.  Twenty)29 (-one \(10.6%\) patients had decreases in )]TJ
-0.0003 Tc 0.0003 Tw T*
[(total hip bone mineral density)30 ( >5%, and all the other patients \(89%\) did not have sig)10 (nificant )]TJ
-0.0008 Tc 0.0008 Tw T*
[(decreases or had increases \(adjusted for body)29 ( mass index)-11 (\))2 (.  F)5 (o)-1 (llow-up studies performed in 8 of )]TJ
-0.0006 Tc 0.0006 Tw T*
[(the patients with decreased bone mineral density)29 ( for up to 11 months thereafter demonstrated )]TJ
-0.0004 Tc 0.0004 Tw T*
[(increasing)10 ( bone density)30 ( in 5 patients at the lumbar spine, while the other 3 patients had lumba\r )]TJ
T*
[(spine bone density)30 ( measurements below baseline values.  Total hip bone mineral densities )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.16 TD
[(remained below baseline \(rang)9 (e \2261.6% to -7.6%\) in 5 of 8 patients \(62.5%\). )]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 0 -2.23 TD
(Geriatric Use)Tj
/TT2 1 Tf
0 Tc 0 Tw (:)Tj
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw 5.85 0 Td
[( Clinical studies of isotretinoin did not include sufficient numbers of \subjects ag)10 (ed )]TJ
-0.0009 Tc 0.0009 Tw -5.85 -1.15 Td
[(65 y)29 (ears and over to determine whether they)29 ( respond differently)29 ( from y)29 (oung)9 (er subjects. )]TJ
0 -1.15 TD
[(Althoug)9 (h reported clinical ex)-11 (perience has not identified differences in responses between elderly)29 ( )]TJ
-0.0007 Tc 0.0007 Tw T*
[(and y)29 (oung)9 (er patients, effects of ag)9 (ing)9 ( mig)9 (ht be ex)-11 (pected to increase some risks associated with )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(isotretinoin therapy)30 ( \(see W)-7 (A)2 (RNI)23 (NGS and PRECAUTI)23 (ONS\). )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj144 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 149/Width 76>>stream
H얁 g4i>r5qB;/U#FXQEE^31fAGzWe]K#}^j=c'M,YچvVR>
6rĨb. #
endstreamendobj374 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 387 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 388 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj388 0 obj<</Font 389 0 R>>endobj389 0 obj<</ArialRoundedMTBold 231 0 R>>endobj387 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj373 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj369 0 obj<</Length 7854>>stream
q
1 0 0 1 -8.187561 15.073547 cm
0 0 612 792 re
W n
1 0 0 1 8.187561 -15.073547 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/T1_0 1 Tf
12 0 0 12 63.853 651.3135 Tm
(\002\003)Tj
/TT0 1 Tf
-0.0012 Tc 1.5 0 Td
(Glucose: )Tj
/TT1 1 Tf
-0.0017 Tc 0.0017 Tw 3.85 0 Td
[(S)-5 (o)-2 (m)-4 (e)2 ( pat)-4 (i)-4 (e)2 (nt)-4 (s recei)-4 (vi)-4 (ng)8 ( Accut)-4 (a)2 (ne have ex)-12 (peri)-4 (enced probl)-4 (em)-4 (s i)-4 (n)-2 ( t)-4 (h)-2 (e cont)-4 (rol)-4 ( of t)-4 (h)-2 (ei)-4 (r )]TJ
-0.0008 Tc 0.0008 Tw -3.85 -1.14 Td
[(blood sug)9 (a)3 (r. I)22 (n)-1 ( addition, new cases of diabetes have been diag)9 (nosed during)9 ( Accutane )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
[(therapy)30 (, althoug)10 (h no causal relationship has been established.)]TJ
/TT0 1 Tf
0 Tc 0 Tw 24.56 0 Td
( )Tj
/T1_0 1 Tf
-26.06 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
0.0021 Tc 1.5 0 Td
[(CPK:)5 ( )]TJ
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 2.53 0 Td
[(Some patients underg)10 (oing)10 ( vig)10 (orous phy)30 (sical activity)30 ( while on Accutane therapy)30 ( have )]TJ
-0.001 Tc 0.001 Tw -2.53 -1.15 Td
[(ex)-11 (perienced elevated CPK levels; however, the clinical sig)9 (n)-1 (ificance is unknown. There have )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.15 TD
[(been rare postmarketing)10 ( reports of rhabdomy)30 (oly)30 (sis, some associated with strenuous phy)30 (sical )]TJ
-0.0006 Tc 0.0006 Tw T*
[(activity)29 (. I)22 (n)-1 ( a clinical trial of 217 pediatric patients \(12 to 17 y)29 (ears\) with severe recalcitrant )]TJ
-0.0005 Tc 0.0005 Tw T*
[(nodular acne, transient elevations in CPK were observed in 12% of patien\ts, including)10 ( those )]TJ
-0.0004 Tc 0.0004 Tw T*
[(underg)10 (oing)10 ( strenuous phy)30 (sical activity)30 ( in association with reported musculoskeletal adverse )]TJ
0.0008 Tc -0.0008 Tw T*
[(e)5 (v)1 (e)5 (n)1 (ts suc)5 (h)1 ( a)5 (s ba)5 (c)5 (k)1 ( pa)5 (in, a)5 (r)4 (thr)4 (a)5 (lg)11 (ia)5 (, limb injur)4 (y)31 (, or)4 ( musc)5 (le)5 ( spr)4 (a)5 (in.  I)24 (n)1 ( the)5 (se)5 ( pa)5 (tie)5 (nts, )]TJ
-0.0005 Tc 0.0005 Tw T*
[(approx)-10 (imately)30 ( half of the CPK elevations returned to normal within 2 weeks and half )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(returned to normal within 4 weeks.  No cases of rhabdomy)30 (oly)30 (sis were reported in this trial.)]TJ
/TT0 1 Tf
0 Tc 0 Tw 36.3 0 Td
( )Tj
-0.0001 Tc 0.0001 Tw -37.8 -2.22 Td
(Carcinogenesis, Mutagenesis and Impairment of Fertility:)Tj
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 23.32 0 Td
[( I)22 (n)-1 ( male and female F)5 (i)-3 (scher 344 rats )]TJ
-0.0004 Tc 0.0004 Tw -23.32 -1.15 Td
[(g)10 (i)-3 (ven oral isotretinoin at dosag)10 (es of 8 or 32 mg)10 (/kg)10 (/)-3 (day)30 ( \(1.3 to 5.3 times the recommended )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(clinical dose of 1.0 mg)9 (/kg)9 (/)-3 (day)29 (,)-1 ( respectively)29 (,)-1 ( after normaliz)-7 (ation for total body)29 ( surface area\) for )]TJ
-0.0012 Tc 0.0012 Tw T*
[(g)9 (r)2 (eater than 18 months, there was a dose-related increased incidence of ph\eochromocy)29 (t)-3 (oma )]TJ
-0.0018 Tc 0.0018 Tw T*
[(rel)-4 (a)2 (t)-4 (i)-4 (v)-2 (e t)-4 (o)-2 ( cont)-4 (rol)-4 (s)-3 (.  The i)-4 (n)-2 (ci)-4 (dence of adrenal)-4 ( m)-4 (e)2 (dul)-4 (l)-4 (a)2 (ry)28 ( hy)28 (perpl)-4 (a)2 (si)-4 (a was al)-4 (so i)-4 (n)-2 (creased at)-4 ( t)-4 (h)-2 (e )]TJ
-0.0006 Tc 0.0006 Tw T*
[(hig)9 (h)-1 (er dosag)9 (e in both sex)-11 (e)3 (s. The relatively)29 ( hig)9 (h)-1 ( level of spontaneous pheochromocy)29 (t)-3 (omas )]TJ
-0.0004 Tc 0.0004 Tw T*
[(occurring)10 ( in the male F)6 (i)-3 (scher 344 rat makes it an equivocal model for study)30 ( of this tumor; )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.16 TD
(therefore, the relevance of this tumor to the human population is uncert\ain.  )Tj
-0.0004 Tc 0.0004 Tw 0 -2.22 TD
(The Ames test was conducted with isotretinoin in two laboratories. The r\esults of the tests in one )Tj
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(laboratory)29 ( were neg)9 (a)3 (tive while in the second laboratory)29 ( a weakly)29 ( positive response \(less than 1.6 )]TJ
-0.0007 Tc 0.0007 Tw T*
[(x)-11 ( backg)9 (r)2 (ound\) was noted in )]TJ
/TT0 1 Tf
0.0001 Tc -0.0001 Tw 11.34 0 Td
(S. typhimurium)Tj
/TT1 1 Tf
-0.0008 Tc 0.0008 Tw 6.11 0 Td
[( TA100 when the assay)29 ( was conducted with )]TJ
-0.0009 Tc 0.0009 Tw -17.45 -1.15 Td
[(metabolic activation. No dose-response effect was seen and all other str\ains were neg)9 (a)3 (tive. )]TJ
-0.0002 Tc 0.0002 Tw T*
[(Additionally)30 (, other tests desig)10 (ned to assess g)10 (e)4 (notox)-10 (icity)30 ( \(Chinese hamster cell assay)30 (, mouse )]TJ
-0.0003 Tc 0.0003 Tw T*
(micronucleus test, )Tj
/TT0 1 Tf
-0.0013 Tc 0.0013 Tw 7.52 0 Td
[(S. cerevi)-3 (si)-3 (ae)]TJ
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 5.04 0 Td
[( D7 assay)30 (, in vitro clastog)10 (e)3 (nesis assay)30 ( with human-derived )]TJ
-0.0006 Tc 0.0006 Tw -12.56 -1.16 Td
[(ly)29 (mphocy)29 (t)-3 (es, and unscheduled DNA sy)29 (nthesis assay)29 (\))2 ( were all neg)9 (a)3 (tive. )]TJ
-0.0005 Tc 0.0005 Tw 0 -2.22 TD
[(I)23 (n rats, no adverse effects on g)10 (onadal function, fertility)30 (, conception rate, g)10 (e)3 (station or parturition )]TJ
0 -1.15 TD
[(were observed at oral dosag)10 (es of isotretinoin of 2, 8, or 32 mg)10 (/kg)10 (/)-3 (day)30 ( \(0.3, 1.3, or 5.3 times the )]TJ
-0.0006 Tc 0.0006 Tw T*
[(recommended clinical dose of 1.0 mg)9 (/kg)9 (/)-3 (day)29 (,)-1 ( respectively)29 (,)-1 ( after normaliz)-7 (ation for total body)29 ( )]TJ
-0.0025 Tc 0.0025 Tw 0 -1.16 TD
(surface area\). )Tj
0.0039 Tc -0.0009 Tw 9.96 0 0 9.96 63.853 159.5535 Tm
[(In)10 ( dog)10 (s)8 (,)1 ( t)5 (e)2 (s)8 (t)5 (i)5 (c)2 (u)10 (l)5 (ar at)5 (roph)10 (y)22 ( w)27 (a)2 (s)8 ( n)10 (o)-2 (t)5 (e)2 (d af)12 (t)5 (e)2 (r t)5 (reat)5 (m)23 (e)2 (n)10 (t)5 ( w)27 (i)5 (t)5 (h)10 ( oral)5 ( i)5 (s)8 (ot)5 (ret)5 (i)5 (n)10 (oi)5 (n)10 ( f)12 (o)-2 (r approx)10 (i)5 (m)23 (at)5 (el)5 (y)22 ( 30 w)27 (eek)10 (s)8 ( at)5 ( dos)8 (ag)10 (es)8 ( of)12 ( )]TJ
0.004 Tc -0.001 Tw 0 -1.157 TD
[(20 or 60 m)23 (g)10 (/)5 (k)10 (g)10 (/)5 (day)22 ( \(10 or 30 t)5 (i)5 (m)23 (es)8 ( t)5 (h)10 (e recom)23 (m)23 (e)2 (n)10 (d)-2 (ed cl)5 (i)5 (n)10 (i)5 (cal)5 ( dos)8 (e of)12 ( 1.0 m)23 (g)10 (/)5 (k)10 (g)10 (/)5 (day)22 (,)1 ( res)8 (p)-2 (ect)5 (i)5 (v)10 (el)5 (y)22 (,)1 ( af)12 (t)5 (e)2 (r )]TJ
0.0029 Tc 0.0001 Tw 0 -1.145 TD
[(n)9 (o)-3 (rm)22 (alization)9 ( f)11 (o)-3 (r total body)21 ( s)7 (u)9 (rf)11 (ace area\). In)9 ( g)9 (e)1 (n)9 (e)1 (ral, th)9 (ere w)26 (a)1 (s)7 ( m)22 (i)4 (cros)7 (copic ev)9 (iden)9 (ce f)11 (o)-3 (r appreciable depres)7 (s)7 (i)4 (on)9 ( of)11 ( )]TJ
0.0023 Tc 0.0007 Tw 0 -1.157 TD
[(s)6 (p)-4 (erm)21 (atog)8 (en)8 (es)6 (i)3 (s)6 ( bu)8 (t s)6 (o)-4 (m)21 (e s)6 (p)-4 (erm)21 ( w)26 (ere obs)6 (erv)8 (ed in)8 ( all tes)6 (t)3 (es)6 ( ex)8 (am)21 (in)8 (ed an)8 (d in)8 ( n)8 (o)-4 ( in)8 (s)6 (t)3 (an)8 (ce w)26 (ere com)21 (p)-4 (letely)20 ( atroph)8 (ic )]TJ
0.0039 Tc -0.0009 Tw T*
[(t)5 (u)10 (bu)10 (l)5 (e)2 (s)8 ( s)8 (een)10 (. In)10 ( s)8 (t)5 (u)10 (d)-2 (i)5 (e)2 (s)8 ( of)12 ( 66 m)23 (e)2 (n)10 (,)1 ( 30 of)12 ( w)27 (h)10 (om)23 ( w)27 (e)2 (re pat)5 (i)5 (e)2 (n)10 (t)5 (s)8 ( w)27 (i)5 (t)5 (h)10 ( n)10 (odu)10 (l)5 (a)2 (r acn)10 (e u)10 (n)10 (d)-2 (er t)5 (reat)5 (m)23 (e)2 (n)10 (t)5 ( w)27 (i)5 (t)5 (h)10 ( oral)5 ( )]TJ
0.0009 Tc 0.0021 Tw T*
[(iso)-5 (t)2 (retin)7 (o)-5 (i)2 (n)7 (,)-2 ( n)7 (o)-5 ( sig)7 (n)7 (i)2 (f)9 (i)2 (can)7 (t ch)7 (an)7 (g)7 (e)-1 (s w)24 (e)-1 (re n)7 (o)-5 (ted)-5 ( in)7 ( th)7 (e co)-5 (u)7 (n)7 (t)2 ( o)-5 (r)-3 ( m)20 (o)-5 (tility)19 ( o)-5 (f)9 ( sp)-5 (erm)20 (a)-1 (to)-5 (zo)-5 (a in)7 ( th)7 (e ej)-10 (acu)7 (late. In)7 ( a stu)7 (d)-5 (y)19 ( o)-5 (f)9 ( )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj143 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 141/Width 76>>stream
H0gY"n U!$Z(j3?^"2ЛkBQ݇z5uxfQhMz}`{^y'"h9u}l|OY4?o&4v2\C5 
endstreamendobj371 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 390 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 391 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj391 0 obj<</Font 392 0 R>>endobj392 0 obj<</ArialRoundedMTBold 231 0 R>>endobj390 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj370 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj366 0 obj<</Length 6979>>stream
q
1 0 0 1 -7.195709 -1.037292 cm
0 0 612 792 re
W n
1 0 0 1 7.195709 1.037292 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/T1_0 1 Tf
12 0 0 12 64.8449 635.2027 Tm
(\002\003)Tj
/TT0 1 Tf
0.0012 Tc -0.0012 Tw 1.5 0 Td
[(Sy)5 (ste)5 (m)3 (ic)5 ( Cortic)5 (oste)5 (roids)]TJ
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 9.97 0 Td
[(: Sy)30 (stemic corticosteroids are known to cause osteoporosis.  No )]TJ
-0.0008 Tc 0.0008 Tw -9.97 -1.14 Td
(formal clinical studies have been conducted to assess if there is an int\eractive effect on bone )Tj
0 -1.15 TD
[(loss between sy)29 (stemic corticosteroids and Accutane.  Therefore, caution should be ex)-11 (ercised )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
[(when using)10 ( these drug)10 (s tog)10 (e)3 (ther. )]TJ
0.0011 Tc -0.0011 Tw -1.5 -2.22 Td
[(Pr)4 (e)5 (sc)5 (r)4 (ibe)5 (r)4 (s a)5 (r)4 (e)5 ( a)5 (dvise)5 (d to c)5 (onsult the)5 ( pa)5 (c)5 (k)1 (a)5 (g)11 (e)5 ( inse)5 (r)4 (t)-1 ( of)4 ( me)5 (dic)5 (a)5 (tion a)5 (d)1 (ministe)5 (r)4 (e)5 (d c)5 (onc)5 (omita)5 (ntly)31 ( )]TJ
-0.0017 Tc 0.0017 Tw 0 -1.15 TD
[(wi)-4 (t)-4 (h)-2 ( horm)-4 (onal)-4 ( cont)-4 (racept)-4 (i)-4 (v)-2 (es, si)-4 (nce som)-4 (e)2 ( m)-4 (e)2 (di)-4 (cat)-4 (i)-4 (ons m)-4 (a)2 (y)28 ( decrease t)-4 (h)-2 (e effect)-4 (i)-4 (v)-2 (eness of t)-4 (h)-2 (ese )]TJ
-0.0001 Tc 0.0001 Tw T*
(birth control products. )Tj
/TT2 1 Tf
-0.0016 Tc 0.0016 Tw 9.16 0 Td
[(Accu)-5 (tan)-5 (e)2 ( u)-5 (s)-2 (e i)-4 (s)-2 ( associ)-4 (ated)-5 ( w)-9 (i)-4 (th)-5 ( d)-5 (e)2 (p)-5 (ressi)-4 (on)-5 ( i)-4 (n)-5 ( som)11 (e)2 ( p)-5 (a)-2 (ti)-4 (en)-5 (ts \(see )]TJ
0 Tw -9.16 -1.15 Td
[(WARNING)6 (S)-5 (:)2 ( )]TJ
/TT3 1 Tf
0.0012 Tc 6.18 0 Td
[(Psy)5 (c)5 (h)-3 (iatric)]TJ
/TT2 1 Tf
-0.0017 Tc 0.0017 Tw 4.61 0 Td
[( an)-5 (d)-5 ( ADVE)-5 (RS)-5 (E)-5 ( RE)-5 (ACT)-5 (IONS)-5 (: )]TJ
/TT3 1 Tf
0.0012 Tc 0 Tw 13.68 0 Td
[(Psy)5 (c)5 (h)-3 (iatric)]TJ
/TT2 1 Tf
-0.003 Tc 4.61 0 Td
(\).)Tj
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 0.58 0 Td
( Patients should be )Tj
-0.0006 Tc 0.0006 Tw -29.66 -1.15 Td
[(prospectively)29 ( cautioned not to self-medicate with the herbal supplement S)-4 (t)-3 (. J)-11 (ohn\222s W)-7 (o)-1 (rt because )]TJ
-0.0012 Tc 0.0012 Tw T*
[(a possi)-3 (bl)-3 (e i)-3 (n)-1 (t)-3 (e)3 (ract)-3 (i)-3 (on has been sug)9 (g)9 (e)3 (st)-3 (ed wi)-3 (t)-3 (h)-1 ( horm)-3 (onal)-3 ( cont)-3 (racept)-3 (i)-3 (v)-1 (es based on report)-3 (s)-2 ( of )]TJ
-0.0007 Tc 0.0007 Tw T*
[(breakthroug)9 (h bleeding)9 ( on oral contraceptives shortly)29 ( after starting)9 ( S)-4 (t)-3 (. J)-11 (ohn')10 (s W)-7 (o)-1 (rt. P)-4 (r)2 (eg)9 (nancies )]TJ
-0.0012 Tc 0.0012 Tw T*
[(have been report)-3 (e)3 (d by)29 ( users of com)-3 (b)-1 (i)-3 (n)-1 (ed horm)-3 (onal)-3 ( cont)-3 (racept)-3 (i)-3 (v)-1 (es who al)-3 (so used som)-3 (e)3 ( form)-3 ( of )]TJ
0.0005 Tc -0.0005 Tw 0 -1.16 TD
[(St. J)-10 (ohn')11 (s W)-6 (o)1 (rt.  )]TJ
/TT3 1 Tf
-0.0005 Tc 0.0005 Tw 0 -2.26 TD
(Laboratory Tests: )Tj
/TT0 1 Tf
-0.0011 Tc 0.0011 Tw 0 -2.2 TD
(Pregnancy Test: )Tj
/TT1 1 Tf
0.0011 Tc -0.0011 Tw 6.82 0 Td
[(F)7 (e)5 (ma)5 (le)5 ( pa)5 (tie)5 (nts of)4 ( c)5 (h)1 (ildbe)5 (a)5 (r)4 (ing)11 ( pote)5 (n)1 (tia)5 (l must ha)5 (ve)5 ( ne)5 (g)11 (a)5 (tive)5 ( r)4 (e)5 (sults f)4 (r)4 (o)1 (m 2 )]TJ
-0.0005 Tc 0.0005 Tw -6.82 -1.15 Td
[(urine or serum preg)10 (nancy)30 ( tests with a sensitivity)30 ( of at least 25 mI)23 (U/mL)20 ( before receiving)10 ( the )]TJ
0 -1.15 TD
[(initial Accutane prescription. The first test is obtained by)30 ( the prescriber when the decision is )]TJ
-0.001 Tc 0.001 Tw T*
[(made to pursue qualification of the patient for Accutane \(a screening)9 ( test\).  The second )]TJ
-0.0006 Tc 0.0006 Tw T*
[(preg)9 (nancy)29 ( test \(a confirmation test\) should be done during)9 ( the first 5 day)29 (s)-1 ( of the menstrual )]TJ
-0.0009 Tc 0.0009 Tw T*
[(period immediately)29 ( preceding)9 ( the beg)9 (i)-3 (nning)9 ( of Accutane therapy)29 (.)-1 ( F)5 (o)-1 (r patients with amenorrhea, )]TJ
-0.0008 Tc 0.0008 Tw T*
[(the second test should be done at least 11 day)29 (s)-2 ( after the last act of unprotected sex)-11 (u)-1 (al intercourse )]TJ
T*
[(\(without using)9 ( 2 effective forms of contraception\).)]TJ
/TT2 1 Tf
0 Tc 0 Tw 20.2 0 Td
(  )Tj
/TT1 1 Tf
-20.2 -1.15 Td
( )Tj
-0.0056 Tc 0.0086 Tw 9.96 0 0 9.96 64.8449 280.7228 Tm
[(E)-9 (a)-7 (c)-7 (h m)13 (o)-12 (nt)-5 (h o)-12 (f)2 ( t)-5 (he)-7 (r)-10 (a)-7 (p)-12 (y)13 (,)-9 ( t)-5 (he)-7 ( p)-12 (a)-7 (t)-5 (i)-5 (e)-7 (nt)-5 ( m)13 (ust)-5 ( ha)-7 (ve)-7 ( a)-7 ( ne)-7 (ga)-7 (t)-5 (i)-5 (ve)-7 ( r)-10 (e)-7 (sul)-5 (t)-5 ( fr)-10 (o)-12 (m)13 ( a)-7 ( ur)-10 (i)-5 (ne)-7 ( o)-12 (r)-10 ( se)-7 (r)-10 (um)13 ( p)-12 (r)-10 (e)-7 (gna)-7 (nc)-7 (y)13 ( t)-5 (e)-7 (st)-5 (.)-9 ( A)6 ( p)-12 (r)-10 (e)-7 (gna)-7 (nc)-7 (y)13 ( )]TJ
0.0024 Tc 0.0006 Tw 0 -1.157 TD
[(tes)6 (t)3 ( m)21 (u)8 (s)6 (t)3 ( be repeated each)8 ( m)21 (o)-4 (n)8 (t)3 (h)8 ( prior to th)8 (e f)10 (e)1 (m)21 (a)1 (le patien)8 (t)3 ( receiv)8 (i)3 (n)8 (g)8 ( each)8 ( pres)6 (cription)8 (.)-1 (  )]TJ
/TT0 1 Tf
0 Tc 0 Tw T*
( )Tj
/T1_0 1 Tf
12 0 0 12 64.8449 243.5228 Tm
(\002\003)Tj
/TT0 1 Tf
0.0004 Tc 1.5 0 Td
(Lipids: )Tj
/TT1 1 Tf
-0.0002 Tc 0.0002 Tw 3.09 0 Td
[(Pretreatment and follow-up blood lipids should be obtained under fasting\)10 ( conditions. )]TJ
-0.0007 Tc 0.0007 Tw -3.09 -1.15 Td
(After consumption of alcohol, at least 36 hours should elapse before the\se determinations are )Tj
0.0008 Tc -0.0008 Tw 0 -1.15 TD
[(ma)5 (de)5 (. I)24 (t)-1 ( is r)4 (e)5 (c)5 (o)1 (mme)5 (nde)5 (d tha)5 (t)-1 ( the)5 (se)5 ( te)5 (sts be)5 ( pe)5 (r)4 (f)4 (o)1 (r)4 (m)-1 (e)5 (d)1 ( a)5 (t)-1 ( we)5 (e)5 (k)1 (ly)31 ( or)4 ( biwe)5 (e)5 (k)1 (ly)31 ( inte)5 (r)4 (v)1 (a)5 (l)-1 (s until )]TJ
-0.0007 Tc 0.0007 Tw T*
[(the lipid response to Accutane is established. The incidence of hy)29 (pertrig)9 (l)-3 (y)29 (ceridemia is 1 )]TJ
0 -1.16 TD
[(patient in 4 on Accutane therapy)29 ( \(see W)-7 (A)2 (RNI)22 (NGS: )]TJ
/TT0 1 Tf
0.0014 Tc 0 Tw 20.97 0 Td
(Lipids)Tj
/TT1 1 Tf
-0.003 Tc 2.51 0 Td
(\).)Tj
/TT0 1 Tf
0 Tc 0.58 0 Td
( )Tj
/T1_0 1 Tf
-25.56 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
1.5 0 Td
(Liver Function Tests: )Tj
/TT1 1 Tf
-0.0007 Tc 0.0007 Tw 8.86 0 Td
[(Since elevations of liver enz)-7 (y)29 (mes have been observed during)9 ( clinical )]TJ
-0.0004 Tc 0.0004 Tw -8.86 -1.14 Td
(trials, and hepatitis has been reported, pretreatment and follow-up live\r function tests should )Tj
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(be performed at weekly)29 ( or biweekly)29 ( intervals until the response to Accutane has been )]TJ
0.001 Tc -0.001 Tw 0 -1.16 TD
[(e)5 (sta)5 (blishe)5 (d \()4 (se)5 (e)5 ( WARNI)24 (NGS: )]TJ
/TT0 1 Tf
0 Tc 0 Tw 12.44 0 Td
(Hepatotoxicity)Tj
/TT1 1 Tf
-0.003 Tc 5.88 0 Td
(\).)Tj
/TT0 1 Tf
0 Tc 0.58 0 Td
( )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj142 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 133/Width 76>>stream
H엉0gϔؘ7@8C*SB`/唔g3]`)eq narG3#Vz@7[=37kxR 
endstreamendobj368 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 393 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 394 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj394 0 obj<</Font 395 0 R>>endobj395 0 obj<</ArialRoundedMTBold 231 0 R>>endobj393 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj367 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj25 0 obj<</Contents 396 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 174 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 397 0 R>>/Font<</TT0 112 0 R/TT1 186 0 R/TT2 105 0 R/TT3 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 398 0 R>>>>/Rotate 0/Thumb 137 0 R/Type/Page>>endobj27 0 obj<</Contents 399 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 174 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 400 0 R>>/Font<</TT0 186 0 R/TT1 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 401 0 R>>>>/Rotate 0/Thumb 138 0 R/Type/Page>>endobj29 0 obj<</Contents 402 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 174 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 403 0 R>>/Font<</T1_0 188 0 R/T1_1 116 0 R/TT0 105 0 R/TT1 112 0 R/TT2 186 0 R/TT3 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 404 0 R>>>>/Rotate 0/Thumb 139 0 R/Type/Page>>endobj31 0 obj<</Contents 405 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 174 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 406 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 407 0 R>>>>/Rotate 0/Thumb 140 0 R/Type/Page>>endobj33 0 obj<</Contents 408 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 174 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 409 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 112 0 R/TT2 105 0 R/TT3 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 410 0 R>>>>/Rotate 0/Thumb 141 0 R/Type/Page>>endobj408 0 obj<</Length 5808>>stream
q
1 0 0 1 -8.17688 1.602692 cm
0 0 612 792 re
W n
1 0 0 1 8.17688 -1.602692 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw 12 0 0 12 81.8637 638.8027 Tm
[(Consideration should be g)10 (i)-2 (ven to discontinuation of Accutane if any)30 ( sig)10 (nificant abnormality)30 ( )]TJ
0 Tc 0 Tw 0 -1.16 TD
(is found. )Tj
/T1_0 1 Tf
-1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0012 Tc 0.0012 Tw 1.5 0 Td
[(Neutropenia and rare cases of ag)9 (ranulocy)29 (t)-3 (osis have been reported.  Accutane should be )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(discontinued if clinically)30 ( sig)10 (nificant decreases in white cell counts occur. )]TJ
/TT1 1 Tf
0.0009 Tc 0 Tw -1.5 -2.23 Td
[(Hy)5 (pe)5 (rse)5 (nsitiv)5 (ity)5 (:)4 ( )]TJ
/TT0 1 Tf
-0.0011 Tc 0.0011 Tw 7.07 0 Td
[(Anaphy)29 (lactic reactions and other allerg)9 (ic reactions have been reported. )]TJ
0.0008 Tc -0.0008 Tw -7.07 -1.15 Td
[(Cuta)5 (ne)5 (ous a)5 (lle)5 (r)4 (g)11 (ic)5 ( r)4 (e)5 (a)5 (c)5 (tions a)5 (nd se)5 (r)4 (i)-1 (ous c)5 (a)5 (se)5 (s of)4 ( a)5 (lle)5 (r)4 (g)11 (ic)5 ( va)5 (sc)5 (ulitis, of)4 (te)5 (n with pur)4 (pur)4 (a)5 ( \()4 (b)1 (r)4 (u)1 (ise)5 (s )]TJ
-0.0009 Tc 0.0009 Tw T*
[(and red patches\) of the ex)-11 (tremities and ex)-11 (tracutaneous involvement \(including)9 ( renal\) have been )]TJ
-0.0008 Tc 0.0008 Tw T*
[(reported. Severe allerg)9 (ic reaction necessitates discontinuation of therapy)29 ( and appropriate medical )]TJ
-0.0005 Tc 0 Tw 0 -1.16 TD
[(manag)10 (e)3 (ment. )]TJ
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 0 -2.23 TD
(Drug Interactions)Tj
/TT2 1 Tf
0 Tc 0 Tw 7.19 0 Td
(:)Tj
/TT3 1 Tf
0.33 0 Td
(   )Tj
/T1_0 1 Tf
-7.52 -2.3 Td
(\002\003)Tj
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 1.5 0 Td
(Vitamin A:)Tj
/TT0 1 Tf
-0.0005 Tc 0.0005 Tw 4.36 0 Td
[( B)7 (ecause of the relationship of Accutane to vitamin A, patients should be \advised )]TJ
-0.0002 Tc 0.0002 Tw -4.36 -1.16 Td
[(ag)10 (ainst taking)10 ( vitamin supplements containing)10 ( vitamin A to avoid additive tox)-10 (i)-2 (c effects.)]TJ
/TT1 1 Tf
0 Tc 0 Tw 35.24 0 Td
( )Tj
/T1_0 1 Tf
-36.74 -2.3 Td
(\002\003)Tj
/TT1 1 Tf
0.0019 Tc 1.5 0 Td
[(Te)6 (trac)6 (y)6 (c)6 (line)6 (s)1 (:)]TJ
/TT0 1 Tf
-0.0005 Tc 0.0005 Tw 5.71 0 Td
[( Concomitant treatment with Accutane and tetracy)30 (c)3 (lines should be avoided )]TJ
-0.0012 Tc 0.0012 Tw -5.71 -1.14 Td
(because Accutane use has been associated with a number of cases of pseud\otumor cerebri )Tj
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
[(\(benig)10 (n intracranial hy)30 (pertension\), some of which involved concomitant use of tetracy)30 (c)3 (lines. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 1.5 0 Td
(Micro-dosed Progesterone Preparations:)Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw 16.59 0 Td
[( Micro-dosed prog)9 (esterone preparations )]TJ
-0.0006 Tc 0.0006 Tw -16.59 -1.15 Td
[(\(\223minipills\224 that do not contain an estrog)9 (en\) may)29 ( be an inadequate method of contraception )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(during)9 ( Accutane therapy)29 (.)-1 ( Althoug)9 (h other hormonal contraceptives are hig)9 (h)-1 (ly)29 ( effective, there )]TJ
-0.0015 Tc 0.0015 Tw T*
[(have been report)-4 (s)-2 ( of preg)9 (nancy)29 ( from)-4 ( wom)-4 (e)2 (n who have used com)-4 (b)-1 (i)-4 (n)-1 (ed oral)-4 ( cont)-4 (racept)-4 (i)-4 (v)-1 (es, as )]TJ
-0.001 Tc 0.001 Tw T*
(well as injectable/implantable contraceptive products.  These reports ar\e more frequent for )Tj
-0.0004 Tc 0.0004 Tw T*
[(women who use only)30 ( a sing)10 (le method of contraception.  I)23 (t)-3 ( is not known if hormonal )]TJ
-0.0018 Tc 0.0018 Tw T*
[(cont)-4 (racept)-4 (i)-4 (v)-2 (es di)-4 (ffer i)-4 (n)-2 ( t)-4 (h)-2 (ei)-4 (r effect)-4 (i)-4 (v)-2 (eness when used wi)-4 (t)-4 (h)-2 ( Accut)-4 (a)2 (ne. Therefore, i)-4 (t)-4 ( i)-4 (s)-3 ( )]TJ
0.0011 Tc -0.0011 Tw 0 -1.14 TD
[(c)5 (r)4 (itic)5 (a)5 (lly)31 ( impor)4 (ta)5 (nt f)4 (o)1 (r)4 ( wome)5 (n of)4 ( c)5 (h)1 (ildbe)5 (a)5 (r)4 (ing)11 ( pote)5 (n)1 (tia)5 (l to se)5 (le)5 (c)5 (t)-1 ( a)5 (nd c)5 (o)1 (mmit to use)5 ( 2 f)4 (o)1 (r)4 (m)-1 (s )]TJ
-0.0014 Tc 0.0014 Tw 0 -1.15 TD
[(of effect)-4 (i)-4 (v)-1 (e cont)-4 (racept)-4 (i)-4 (on si)-4 (m)-4 (u)-1 (l)-4 (t)-4 (a)2 (neousl)-4 (y)29 (, at)-4 ( l)-4 (east)-4 ( 1 of whi)-4 (c)2 (h m)-4 (u)-1 (st)-4 ( be a pri)-4 (m)-4 (a)2 (ry)29 ( form)-4 (, unl)-4 (ess )]TJ
-0.0008 Tc 0.0008 Tw T*
[(absolute abstinence is the chosen method, or the patient has underg)9 (one a hy)29 (sterectomy)29 ( \(see )]TJ
-0.0015 Tc 0.0015 Tw 0 -1.16 TD
[(box)-11 (ed C)-4 (ONTR)-4 (A)1 (I)22 (NDI)22 (C)-4 (A)1 (TI)22 (ONS)-5 ( AND W)-8 (A)1 (R)-4 (N)1 (I)22 (NGS)-5 (\).  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT1 1 Tf
-0.0012 Tc 1.5 0 Td
[(Phenyt)-3 (oi)-3 (n:)]TJ
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 4.38 0 Td
[( Accutane has not been shown to alter the pharmacokinetics of pheny)29 (toin in a )]TJ
-0.0004 Tc 0.0004 Tw -4.38 -1.14 Td
[(study)30 ( in seven healthy)30 ( volunteers. These results are consistent with the in vitro finding)10 ( that )]TJ
0 Tc 0 Tw 0 -1.15 TD
[(neither isotretinoin nor its metabolites induce or inhibit the activity)30 ( of the CYP 2C9 human )]TJ
-0.0004 Tc 0.0004 Tw T*
[(hepatic P450 enz)-7 (y)30 (me. Pheny)30 (t)-3 (oin is known to cause osteomalacia.  No formal clinical studies )]TJ
-0.0008 Tc 0.0008 Tw T*
[(have been conducted to assess if there is an interactive effect on bone \loss between pheny)29 (toin )]TJ
-0.001 Tc 0.001 Tw 0 -1.16 TD
[(and Accutane. Therefore, caution should be ex)-11 (ercised when using)9 ( these drug)9 (s tog)9 (e)3 (ther.  )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj141 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 142/Width 76>>stream
H얁 !gwJ	HLCKB$Ƌ}cUh2}^\1MB|W#ͱf:|Ok23=~b-"^tn/e^l/?@XX>B p+y
endstreamendobj410 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 411 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 412 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj412 0 obj<</Font 413 0 R>>endobj413 0 obj<</ArialRoundedMTBold 231 0 R>>endobj411 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj409 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj405 0 obj<</Length 7243>>stream
q
1 0 0 1 -10.823334 17.149017 cm
0 0 612 792 re
W n
1 0 0 1 10.823334 -17.149017 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/T1_0 1 Tf
-0.0022 Tc 9.96 0 0 9.96 61.2173 655.429 Tm
(\002\003)Tj
/TT0 1 Tf
0.004 Tc -0.001 Tw 1.807 0 Td
[(Pat)5 (i)5 (e)2 (n)10 (t)5 (s)8 ( m)23 (a)2 (y)22 ( report)5 ( m)23 (e)2 (n)10 (t)5 (al)5 ( h)10 (eal)5 (t)5 (h)10 ( probl)5 (em)23 (s)8 ( or f)12 (a)2 (m)23 (i)5 (l)5 (y)22 ( h)10 (i)5 (s)8 (t)5 (ory)22 ( of)12 ( ps)8 (y)22 (c)2 (h)10 (i)5 (at)5 (ri)5 (c di)5 (s)8 (o)-2 (rders)8 (.)1 ( T)-12 (h)10 (es)8 (e report)5 (s)8 ( s)8 (h)10 (ou)10 (l)5 (d)-2 ( be )]TJ
0.0007 Tc 0.0023 Tw 0 -1.157 TD
[(d)-5 (i)1 (scu)7 (ssed)-5 ( w)24 (ith)7 ( th)7 (e p)-5 (a)-1 (tien)7 (t)1 ( an)7 (d)-5 (/)1 (o)-5 (r)-4 ( th)7 (e p)-5 (a)-1 (tien)7 (t)1 (\222)8 (s)4 ( f)8 (a)-1 (m)20 (ily)19 (. A)12 ( ref)8 (e)-1 (rral to)-5 ( a m)20 (e)-1 (n)7 (t)1 (al h)7 (ealth)7 ( p)-5 (r)-4 (o)-5 (f)8 (essio)-5 (n)7 (al m)20 (a)-1 (y)19 ( b)-5 (e)-1 ( )]TJ
0.0009 Tc 0.0021 Tw T*
[(n)7 (ecessary)19 (.  T)-15 (h)7 (e p)-5 (h)7 (y)19 (s)5 (ician)7 ( sh)7 (o)-5 (u)7 (ld)-5 ( co)-5 (n)7 (s)5 (id)-5 (er w)24 (h)7 (eth)7 (e)-1 (r o)-5 (r)-3 ( n)7 (o)-5 (t A)12 (ccu)7 (tan)7 (e)-1 ( th)7 (erap)-5 (y)19 ( is ap)-5 (p)-5 (r)-3 (o)-5 (p)-5 (r)-3 (iate in)7 ( th)7 (is settin)7 (g)7 ( \(see )]TJ
-0.0002 Tc 0 Tw 0 -1.145 TD
[(W)-8 (A)11 (RNINGS: )]TJ
/TT1 1 Tf
-0.0001 Tc 5.916 0 Td
[(Psych)-6 (ia)-6 (tric)]TJ
/TT0 1 Tf
0.0037 Tc (\). )Tj
/T1_0 1 Tf
-0.0022 Tc -7.723 -1.831 Td
(\002\003)Tj
/TT0 1 Tf
0.0021 Tc 0.0009 Tw 1.807 0 Td
[(P)-8 (atien)8 (t)3 (s)6 ( s)6 (h)8 (ou)8 (ld be in)8 (f)10 (o)-4 (rm)21 (ed th)8 (at th)8 (ey)20 ( m)21 (u)8 (s)6 (t)3 ( n)8 (o)-4 (t s)6 (h)8 (are A)13 (ccu)8 (tan)8 (e w)26 (ith)8 ( an)8 (y)20 (o)-4 (n)8 (e els)6 (e becau)8 (s)6 (e of)10 ( th)8 (e ris)6 (k)8 ( of)10 ( birth)8 ( )]TJ
0.0029 Tc 0.0001 Tw 0 -1.157 TD
[(def)11 (ects)7 ( an)9 (d oth)9 (e)1 (r s)7 (e)1 (riou)9 (s)7 ( adv)9 (e)1 (rs)7 (e ev)9 (en)9 (ts)7 (.  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw 12 0 0 12 61.2173 570.949 Tm
(\002\003)Tj
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw 1.5 0 Td
[(Patients should not donate blood during)10 ( therapy)30 ( and for 1 month following)10 ( discontinuance of )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.14 TD
[(the drug)9 ( because the blood mig)9 (ht be g)9 (i)-3 (ven to a preg)9 (nant woman whose fetus must not be )]TJ
-0.0011 Tc 0.0011 Tw 0 -1.16 TD
[(ex)-11 (posed to Accutane.  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
(Patients should be reminded to take Accutane with a meal \(see DOSAGE AN\D )Tj
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(ADMI)22 (N)2 (I)22 (S)-4 (TRATI)22 (ON\). To decrease the risk of esophag)9 (eal irritation, patients should swallow )]TJ
0.0009 Tc -0.0009 Tw 0 -1.16 TD
[(the)5 ( c)5 (a)5 (p)1 (sule)5 (s with a)5 ( f)4 (u)1 (ll g)11 (l)-1 (a)5 (ss of)4 ( liquid. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0009 Tc 0.0009 Tw 1.5 0 Td
[(P)-5 (a)3 (tients should be informed that transient ex)-11 (acerbation \(flare\) of acne has been seen, )]TJ
0.0009 Tc -0.0009 Tw 0 -1.15 TD
[(g)11 (e)5 (ne)5 (r)4 (a)5 (lly)31 ( dur)4 (ing)11 ( the)5 ( initia)5 (l pe)5 (r)4 (i)-1 (od of)4 ( the)5 (r)4 (a)5 (p)1 (y)31 (.)1 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0009 Tc 0.0009 Tw 1.5 0 Td
[(W)-7 (a)3 (x)-11 ( epilation and skin resurfacing)9 ( procedures \(such as dermabrasion, laser\) should be )]TJ
0.0007 Tc -0.0007 Tw T*
[(a)5 (voide)5 (d dur)4 (ing)11 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( the)5 (r)4 (a)5 (p)1 (y)31 ( a)5 (nd f)4 (o)1 (r)4 ( a)5 (t)-1 ( le)5 (a)5 (st 6 months the)5 (r)4 (e)5 (a)5 (f)4 (te)5 (r)4 ( due)5 ( to the)5 ( possibility)31 ( of)4 ( )]TJ
-0.0014 Tc 0.0014 Tw 0 -1.16 TD
[(scarring)9 ( \(see ADVER)-4 (S)-5 (E R)-4 (E)-1 (AC)-4 (TI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 16.28 0 Td
(Skin and Appendages)Tj
/TT0 1 Tf
-0.0015 Tc 0 Tw (\). )Tj
/T1_0 1 Tf
0 Tc -17.78 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 1.5 0 Td
[(Patients should be advised to avoid prolong)10 (ed ex)-10 (posure to UV ray)30 (s)-1 ( or sunlig)10 (ht. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0009 Tc 0.0009 Tw 1.5 0 Td
[(Patients should be informed that they)29 ( may)29 ( ex)-11 (perience decreased tolerance to contact lenses )]TJ
-0.002 Tc 0.002 Tw T*
[(duri)-4 (n)-2 (g)8 ( and aft)-4 (e)2 (r t)-4 (h)-2 (erapy)28 (.)-2 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 1.5 0 Td
[(Patients should be informed that approx)-10 (imately)30 ( 16% of patients treated with Accutane in a )]TJ
0.0011 Tc -0.0011 Tw 0 -1.14 TD
[(c)5 (linic)5 (a)5 (l)-1 ( tr)4 (ia)5 (l de)5 (ve)5 (lope)5 (d musc)5 (uloske)5 (le)5 (ta)5 (l sy)31 (mptoms \()4 (i)-1 (nc)5 (luding)11 ( a)5 (r)4 (thr)4 (a)5 (lg)11 (ia)5 (\))4 ( dur)4 (ing)11 ( tr)4 (e)5 (a)5 (tme)5 (nt. I)24 (n)1 ( )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(g)10 (e)3 (neral, these sy)30 (mptoms were mild to moderate, but occasionally)30 ( required discontinuation of )]TJ
0.0009 Tc -0.0009 Tw T*
[(the)5 ( dr)4 (ug)11 (. Tr)4 (a)5 (n)1 (sie)5 (n)1 (t pa)5 (in in the)5 ( c)5 (h)1 (e)5 (st ha)5 (s be)5 (e)5 (n)1 ( r)4 (e)5 (por)4 (te)5 (d le)5 (ss f)4 (r)4 (e)5 (que)5 (ntly)31 (. I)24 (n)1 ( the)5 ( c)5 (linic)5 (a)5 (l)-1 ( tr)4 (ia)5 (l, )]TJ
-0.0006 Tc 0.0006 Tw T*
[(these sy)29 (mptoms g)9 (e)3 (nerally)29 ( cleared rapidly)29 ( after discontinuation of Accutane, but in some )]TJ
-0.0013 Tc 0.0013 Tw T*
[(cases persisted \(see ADVER)-4 (S)-5 (E R)-4 (EAC)-4 (TI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
-0.0007 Tc 0 Tw (Musculoskeletal)Tj
/TT0 1 Tf
-0.002 Tc 0.002 Tw 25.47 0 Td
(\). There have been rare )Tj
-0.0002 Tc 0.0002 Tw -25.47 -1.15 Td
[(postmarketing)10 ( reports of rhabdomy)30 (oly)30 (sis, some associated with strenuous phy)30 (sical activity)30 ( )]TJ
-0.0027 Tc 0 Tw 0 -1.16 TD
(\(see )Tj
/TT1 1 Tf
0 Tc 1.85 0 Td
(Laboratory Tests: )Tj
/TT0 1 Tf
0.0017 Tc 7.45 0 Td
[(CPK)4 (\))5 (. )]TJ
/T1_0 1 Tf
0 Tc -10.8 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(Pediatric patients and their careg)9 (ivers should be informed that approx)-11 (imately)29 ( 29% \(104/358\) )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.14 TD
[(of pediatric patients treated with Accutane developed back pain. B)6 (ack pain was severe in )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(13.5% \(14/104\) of the cases and occurred at a hig)9 (h)-1 (er frequency)29 ( in female than male patients. )]TJ
T*
[(Arthralg)9 (ias were ex)-11 (perienced in 22% \(79/358\) of pediatric )]TJ
ET
q
1 0 0 1 -10.823334 17.149017 cm
370.241 115.08 3 -0.6 re
f
Q
BT
0.0006 Tc -0.0006 Tw 12 0 0 12 362.4173 129.1091 Tm
[(pa)4 (tie)4 (nts. Ar)4 (thr)4 (a)4 (lg)11 (ia)4 (s we)4 (r)4 (e)4 ( se)4 (ve)4 (r)4 (e)4 ( )]TJ
-0.0003 Tc 0.0003 Tw -23.6 -1.15 Td
[(in 7.6% \(6/79\) of patients. Appropriate evaluation of the musculoskele\tal sy)30 (stem should be )]TJ
-0.0007 Tc 0.0007 Tw T*
[(done in patients who present with these sy)29 (mptoms during)9 ( or after a course of Accutane. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj140 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 152/Width 76>>stream
H엁 ])YD.?@)9C!Hs`͈RADQmd~Cc`ΞNVhO6S0{b}/?6o#kUm	`jF2x5ZU
!@ nȚN
endstreamendobj407 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 414 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 415 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj415 0 obj<</Font 416 0 R>>endobj416 0 obj<</ArialRoundedMTBold 231 0 R>>endobj414 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj406 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj402 0 obj<</Length 6179>>stream
q
1 0 0 1 -8.538605 9.702667 cm
0 0 612 792 re
W n
1 0 0 1 8.538605 -9.702667 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0013 Tc 12 0 0 12 63.502 646.9027 Tm
[(Gen)-5 (e)3 (ral)]TJ
/TT1 1 Tf
0 Tc 3.33 0 Td
(:)Tj
/TT2 1 Tf
-0.0004 Tc 0.0004 Tw 0.33 0 Td
[(  Althoug)10 (h an effect of Accutane on bone loss is not established, phy)30 (sicians should use )]TJ
0.0008 Tc -0.0008 Tw -3.66 -1.15 Td
[(c)5 (a)5 (u)1 (tion whe)5 (n)1 ( pr)4 (e)5 (sc)5 (r)4 (ibing)11 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( to pa)5 (tie)5 (nts with a)5 ( g)11 (e)5 (ne)5 (tic)5 ( pr)4 (e)5 (d)1 (isposition f)4 (o)1 (r)4 ( a)5 (g)11 (e)5 (-)4 (r)4 (e)5 (la)5 (te)5 (d )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.15 TD
[(osteoporosis, a history)30 ( of childhood osteoporosis conditions, osteomalacia, or other disorders \of )]TJ
-0.0005 Tc 0.0005 Tw T*
[(bone metabolism. This would include patients diag)10 (nosed with anorex)-10 (ia nervosa and those who )]TJ
-0.0009 Tc 0.0009 Tw T*
[(are on chronic drug)9 ( therapy)29 ( that causes drug)9 (-induced osteoporosis/osteomalacia and/or affects )]TJ
-0.0002 Tc 0.0002 Tw T*
[(vitamin D metabolism, such as sy)30 (stemic corticosteroids and any)30 ( anticonvulsant. )]TJ
0 Tc 0 Tw T*
( )Tj
0.0009 Tc -0.0009 Tw T*
[(Pa)5 (tie)5 (nts ma)5 (y)31 ( be)5 ( a)5 (t)-1 ( inc)5 (r)4 (e)5 (a)5 (se)5 (d)1 ( r)4 (i)-1 (sk whe)5 (n)1 ( pa)5 (r)4 (tic)5 (ipa)5 (ting)11 ( in spor)4 (ts with r)4 (e)5 (pe)5 (titive)5 ( impa)5 (c)5 (t)-1 ( whe)5 (r)4 (e)5 ( the)5 ( )]TJ
-0.0002 Tc 0.0002 Tw T*
[(risks of spondy)30 (lolisthesis with and without pars fractures and hip g)10 (r)3 (owth plate injuries in early)30 ( )]TJ
-0.0013 Tc 0.0013 Tw T*
[(and late adolescence are known.  There are spontaneous reports of fractu\res and/or delay)29 (e)3 (d )]TJ
0.0008 Tc -0.0008 Tw T*
[(he)5 (a)5 (ling)11 ( in pa)5 (tie)5 (nts while)5 ( on tr)4 (e)5 (a)5 (tme)5 (nt with Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( or)4 ( f)4 (o)1 (llowing)11 ( c)5 (e)5 (ssa)5 (tion of)4 ( tr)4 (e)5 (a)5 (tme)5 (nt with )]TJ
-0.0005 Tc 0.0005 Tw T*
[(Accutane while involved in these activities. W)-7 (hile causality)30 ( to Accutane has not been )]TJ
-0.0008 Tc 0.0008 Tw T*
(established, an effect cannot be ruled out. )Tj
0 Tc 0 Tw T*
( )Tj
/TT0 1 Tf
0.0005 Tc -0.0005 Tw 0 -1.18 TD
[(Inform)-12 (ation for Patients and Prescribers:)]TJ
/TT3 1 Tf
0 Tc 0 Tw 17.19 0 Td
( )Tj
/T1_0 1 Tf
-17.19 -2.28 Td
(\002\003)Tj
/TT2 1 Tf
-0.0005 Tc 0.0005 Tw 1.5 0 Td
[(Patients should be instructed to read the Medication Guide supplied as r\equired by)30 ( law when )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.14 TD
[(Accutane is dispensed. The complete tex)-11 (t)-3 ( of the Medication Guide is reprinted at the end of )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.15 TD
[(this document. F)6 (or additional information, patients should also read the )]TJ
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 28.81 0 Td
(Patient Product )Tj
-28.81 -1.23 Td
[(Information, Important Information Concerning Y)-14 (our Treatment with)]TJ
/TT2 1 Tf
0 Tc 0 Tw 27.83 0 Td
( )Tj
/TT1 1 Tf
-0.0012 Tc [(Accut)-3 (ane)]TJ
/T1_1 1 Tf
0 Tc 3.96 0 Td
(\001)Tj
/TT1 1 Tf
( )Tj
0.0006 Tc -31.79 -1.16 Td
[(\()14 (i)-2 (sotretinoin\))]TJ
/TT2 1 Tf
-0.0001 Tc 0.0001 Tw 5.26 0 Td
[(.  All patients should sig)10 (n the I)23 (nformed Consent/Patient Ag)10 (reement. )]TJ
/TT3 1 Tf
0 Tc 0 Tw 27.39 0 Td
( )Tj
/T1_0 1 Tf
-34.15 -2.3 Td
(\002\003)Tj
/TT2 1 Tf
-0.0004 Tc 0.0004 Tw 1.5 0 Td
[(F)6 (e)3 (males of childbearing)10 ( potential should be instructed that they)30 ( must not be preg)10 (nant when )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.14 TD
[(Accutane therapy)29 ( is initiated, and that they)29 ( should use 2 forms of effective contraception 1 )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(month before starting)9 ( Accutane, while taking)9 ( Accutane, and for 1 month after Accutane has )]TJ
-0.0007 Tc 0.0007 Tw T*
[(been stopped. They)29 ( should also sig)9 (n)-1 ( a consent form prior to beg)9 (i)-3 (nning)9 ( Accutane therapy)29 (.)-1 ( )]TJ
T*
[(They)29 ( should be g)9 (i)-3 (ven an opportunity)29 ( to enroll in the Accutane Survey)29 ( and to review the )]TJ
T*
[(patient videotape provided by)29 ( the manufacturer to the prescriber. I)22 (t)-3 ( includes information )]TJ
T*
(about contraception, the most common reasons that contraception fails, a\nd the importance of )Tj
-0.0014 Tc 0.0014 Tw T*
[(usi)-4 (n)-1 (g)9 ( 2 form)-4 (s of effect)-4 (i)-4 (v)-1 (e cont)-4 (racept)-4 (i)-4 (on when t)-4 (a)2 (ki)-4 (ng)9 ( t)-4 (e)2 (rat)-4 (o)-1 (g)9 (e)2 (ni)-4 (c drug)9 (s. Fem)-4 (a)2 (l)-4 (e)2 ( pat)-4 (i)-4 (e)2 (nt)-4 (s )]TJ
-0.0009 Tc 0.0009 Tw T*
[(should be seen by)29 ( their prescribers monthly)29 ( and have a urine or serum preg)9 (nancy)29 ( test )]TJ
-0.0016 Tc 0.0016 Tw T*
[(perform)-4 (ed each m)-4 (ont)-4 (h duri)-4 (n)-2 (g)8 ( t)-4 (r)1 (eat)-4 (m)-4 (e)2 (nt)-4 ( t)-4 (o)-2 ( confi)-4 (r)1 (m)-4 ( neg)8 (a)2 (t)-4 (i)-4 (v)-2 (e preg)8 (nancy)28 ( st)-4 (at)-4 (us before anot)-4 (her )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.16 TD
[(Accutane prescription is written \(see box)-11 (ed CONTRAI)22 (NDI)22 (CATI)22 (ONS AND W)-7 (A)1 (RNI)22 (NGS\).)]TJ
/TT3 1 Tf
0 Tc 0 Tw 36.67 0 Td
( )Tj
/T1_0 1 Tf
-38.17 -2.31 Td
(\002\003)Tj
/TT2 1 Tf
-0.0006 Tc 0.0006 Tw 1.5 0 Td
[(Accutane is found in the semen of male patients taking)9 ( Accutane, but the amount delivered to )]TJ
0 -1.14 TD
[(a female partner would be about 1 million times lower than an oral dose \of 40 mg)9 (. W)-7 (h)-1 (ile the )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(no-effect limit for isotretinoin-induced embry)30 (opathy)30 ( is unknown, 20 y)30 (e)3 (ars of postmarketing)10 ( )]TJ
-0.0006 Tc 0.0006 Tw T*
[(reports include 4 with isolated defects compatible with features of reti\noid ex)-11 (posed fetuses. )]TJ
T*
(None of these cases had the combination of malformations characteristic \of retinoid )Tj
-0.0009 Tc 0.0009 Tw 0 -1.16 TD
[(ex)-11 (posure, and all had other possible ex)-11 (planations for the defects observed.  )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj139 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 148/Width 76>>stream
Hׁ CٙuXдw(ΙRJIҀtiQu,]b_%Vź|jԝO]"\	gwi#wkg&ӿ+=;y~{W	) Cw
endstreamendobj404 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 417 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 418 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj418 0 obj<</Font 419 0 R>>endobj419 0 obj<</ArialRoundedMTBold 231 0 R>>endobj417 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj403 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj399 0 obj<</Length 5629>>stream
q
1 0 0 1 -8.479492 7.122681 cm
0 0 612 792 re
W n
1 0 0 1 8.479492 -7.122681 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 12 0 0 12 81.5611 644.3227 Tm
[(The Prescriber Checklist attests that Accutane prescribers know the risk\ and severity)29 ( of )]TJ
0 -1.15 TD
[(injury)29 (/birth defects from Accutane; know how to diag)9 (nose and treat the various presentations )]TJ
-0.0013 Tc 0.0013 Tw T*
[(of acne; know the risk factors for unplanned preg)9 (nancy)29 ( and the effective measures for )]TJ
-0.0008 Tc 0.0008 Tw T*
[(avoidance; will refer the patient for, or provide, detailed preg)9 (nancy)29 ( prevention counseling)9 ( to )]TJ
-0.0002 Tc 0.0002 Tw T*
[(help the patient have knowledg)10 (e and tools needed to fulfill their ultimate responsibility)30 ( to )]TJ
-0.0008 Tc 0.0008 Tw T*
[(avoid becoming)9 ( preg)9 (nant; understand and properly)29 ( use throug)9 (hout the Accutane treatment )]TJ
-0.0009 Tc 0.0009 Tw T*
[(course, the revised risk manag)9 (e)3 (ment procedures, including)9 ( monthly)29 ( preg)9 (nancy)29 ( avoidance )]TJ
-0.0006 Tc 0.0006 Tw T*
[(counseling)9 (,)-1 ( preg)9 (nancy)29 ( testing)9 (,)-1 ( and use of qualified prescriptions with the y)29 (e)3 (llow self-)]TJ
-0.0008 Tc 0.0008 Tw 0 -1.16 TD
(adhesive Accutane Qualification Sticker. )Tj
-0.0007 Tc 0.0007 Tw -1.5 -2.22 Td
[(3\) )-420 (The y)29 (e)3 (llow self-adhesive Accutane Qualification Sticker is used as documentati\on that the )]TJ
-0.0019 Tc 0.0019 Tw 1.5 -1.15 Td
[(prescri)-4 (b)-2 (er has qual)-4 (i)-4 (f)1 (i)-4 (e)2 (d t)-4 (h)-2 (e fem)-4 (a)2 (l)-4 (e)2 ( pat)-4 (i)-4 (e)2 (nt)-4 ( accordi)-4 (n)-2 (g)8 ( t)-4 (o)-2 ( t)-4 (h)-2 (e qual)-4 (i)-4 (f)1 (i)-4 (cat)-4 (i)-4 (on cri)-4 (t)-4 (e)2 (ri)-4 (a \(see box)-12 (ed )]TJ
-0.0018 Tc 0.0018 Tw T*
[(C)-5 (ONTR)-5 (AI)21 (NDI)21 (C)-5 (ATI)21 (ONS)-6 ( AND W)-8 (AR)-5 (NI)21 (NGS)-6 (\). )]TJ
0.0013 Tc -0.0013 Tw -1.5 -2.23 Td
[(4\))4 ( )-420 (A)4 (c)5 (c)5 (u)1 (ta)5 (ne)5 ( Pr)4 (e)5 (g)11 (na)5 (nc)5 (y)31 ( Pr)4 (e)5 (v)1 (e)5 (n)1 (tion Pr)4 (og)11 (r)4 (a)5 (m \()4 (PPP\))4 ( is a)5 ( sy)31 (ste)5 (m)-1 (a)5 (tic)5 ( a)5 (ppr)4 (oa)5 (c)5 (h)1 ( to c)5 (o)1 (mpr)4 (e)5 (he)5 (nsive)5 ( )]TJ
-0.0005 Tc 0.0005 Tw 1.5 -1.15 Td
(patient education about their responsibilities and includes education fo\r contraception )Tj
0.001 Tc -0.001 Tw 0 -1.15 TD
[(c)5 (o)1 (mplia)5 (nc)5 (e)5 ( a)5 (nd r)4 (e)5 (inf)4 (o)1 (r)4 (c)5 (e)5 (m)-1 (e)5 (n)1 (t of)4 ( e)5 (duc)5 (a)5 (tiona)5 (l me)5 (ssa)5 (g)11 (e)5 (s. The)5 ( PPP inc)5 (l)-1 (ude)5 (s inf)4 (o)1 (r)4 (m)-1 (a)5 (tion on the)5 ( )]TJ
-0.0007 Tc 0.0007 Tw T*
(risks and benefits of Accutane which is linked to the Accutane Medicatio\n Guide dispensed )Tj
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
[(by)30 ( pharmacists with each prescription. )]TJ
-0.0007 Tc 0.0007 Tw 0 -2.22 TD
(Male and female patients are provided with separate booklets. Each bookl\et contains )Tj
0 -1.15 TD
[(information on Accutane therapy)29 (,)-1 ( including)9 ( precautions and warning)9 (s)-1 (, an I)22 (n)-1 (formed )]TJ
T*
[(Consent/Patient Ag)9 (reement form, and a toll-free line which provides Accutane information i\n )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(13 lang)10 (uag)10 (e)3 (s.  )]TJ
-0.0007 Tc 0.0007 Tw 0 -2.22 TD
(The booklet for male patients, )Tj
/TT1 1 Tf
-0.0008 Tc 0.0008 Tw 12.26 0 Td
(Be Smart, Be Safe, Be Sure, Accutane Risk Management )Tj
-0.0003 Tc 0.0003 Tw -12.26 -1.15 Td
(Program for Men,)Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 7.3 0 Td
[( also includes information about male reproduction, a warning)9 ( not to share )]TJ
-7.3 -1.15 Td
[(Accutane with others or to donate blood during)9 ( Accutane therapy)29 ( and for 1 month following)9 ( )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
(discontinuation of Accutane.  )Tj
-0.0008 Tc 0.0008 Tw 0 -2.22 TD
(The booklet for female patients, )Tj
/TT1 1 Tf
-0.0009 Tc 0.0009 Tw 13.03 0 Td
(Be Smart, Be Safe, Be Sure, Accutane Pregnancy Prevention )Tj
-0.0004 Tc 0.0004 Tw -13.03 -1.15 Td
[(and Risk Management Program for W)23 (omen,)]TJ
/TT0 1 Tf
-0.0021 Tc 0.0021 Tw 17.68 0 Td
[( al)-4 (so i)-4 (n)-2 (cl)-4 (udes a referral)-4 ( prog)8 (ram)-4 ( t)-4 (h)-2 (at)-4 ( offers )]TJ
-0.0011 Tc 0.0011 Tw -17.68 -1.15 Td
[(females free contraception counseling)9 (,)-1 ( reimbursed by)29 ( the manufacturer, by)29 ( a reproductive )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(specialist; a second Patient I)23 (nformation/Consent form concerning)10 ( birth defects, obtaining)10 ( her )]TJ
0.001 Tc -0.001 Tw T*
[(c)5 (onse)5 (n)1 (t to be)5 ( tr)4 (e)5 (a)5 (t)-1 (e)5 (d)1 ( within this a)5 (g)11 (r)4 (e)5 (e)5 (m)-1 (e)5 (n)1 (t; a)5 (n)1 ( e)5 (n)1 (r)4 (o)1 (llme)5 (nt f)4 (o)1 (r)4 (m)-1 ( f)4 (o)1 (r)4 ( the)5 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( Sur)4 (v)1 (e)5 (y)31 (; a)5 (nd )]TJ
-0.0008 Tc 0.0008 Tw T*
[(a qualification checklist affirming)9 ( the conditions under which female patients may)29 ( receive )]TJ
-0.0006 Tc 0.0006 Tw T*
[(Accutane. I)22 (n)-1 ( addition, there is information on the ty)29 (pes of contraceptive methods, the )]TJ
-0.001 Tc 0.001 Tw T*
(selection and use of appropriate, effective contraception, and the rates\ of possible )Tj
-0.0008 Tc 0.0008 Tw T*
[(contraceptive failure; a toll-free contraception counseling)9 ( line; and a video about the most )]TJ
-0.001 Tc 0.001 Tw 0 -1.16 TD
[(common reasons for unplanned preg)9 (nancies. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj138 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 142/Width 76>>stream
H얁@gw_	4P='zN)!.T/Zƛ1ԋ6k<߫d슊VzoW 6xfcQ{<as@$v<${	Ԙ^bvO>fL3bfZQ\q)%{ er)
endstreamendobj401 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 420 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 421 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj421 0 obj<</Font 422 0 R>>endobj422 0 obj<</ArialRoundedMTBold 231 0 R>>endobj420 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj400 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj396 0 obj<</Length 7008>>stream
q
1 0 0 1 -8.000854 15.522766 cm
0 0 612 792 re
W n
1 0 0 1 8.000854 -15.522766 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw 12 0 0 12 64.0397 652.7228 Tm
(Premature Epiphyseal Closure)Tj
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw [(: There are spontaneous reports of premature epiphy)29 (seal closure )]TJ
-0.0009 Tc 0.0009 Tw 0 -1.15 TD
[(in acne patients receiving)9 ( recommended doses of Accutane.  The effect of multiple courses of )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.16 TD
[(Accutane on epiphy)29 (seal closure is unknown. )]TJ
/TT2 1 Tf
0.0009 Tc -0.0009 Tw 0 -2.22 TD
[(V)18 (i)-1 (sion Im)-11 (pairm)-11 (ent)]TJ
/TT3 1 Tf
0 Tc 0 Tw 7.83 0 Td
(:)Tj
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 0.33 0 Td
[( Visual problems should be carefully)30 ( monitored. All Accutane patients )]TJ
-0.0006 Tc 0.0006 Tw -8.16 -1.15 Td
[(ex)-11 (periencing)9 ( visual difficulties should discontinue Accutane treatment and have an )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.16 TD
[(ophthalmolog)10 (i)-2 (cal ex)-10 (amination \(see ADVERSE REACTI)23 (ONS: )]TJ
/TT0 1 Tf
-0.001 Tc 0.001 Tw (Special Senses)Tj
/TT1 1 Tf
-0.0015 Tc 0 Tw 31.12 0 Td
(\). )Tj
/TT0 1 Tf
0.001 Tc -0.001 Tw -31.12 -2.23 Td
[(Corne)5 (a)1 (l Opac)5 (itie)5 (s:)]TJ
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 7.69 0 Td
[( Corneal opacities have occurred in patients receiving)9 ( Accutane for acne and )]TJ
-0.0006 Tc 0.0006 Tw -7.69 -1.15 Td
[(more frequently)29 ( when hig)9 (h)-1 (er drug)9 ( dosag)9 (es were used in patients with disorders of keratiniz)-7 (ation. )]TJ
0.0008 Tc -0.0008 Tw 0 -1.15 TD
[(The)5 ( c)5 (o)1 (r)4 (n)1 (e)5 (a)5 (l)-1 ( opa)5 (c)5 (itie)5 (s tha)5 (t)-1 ( ha)5 (ve)5 ( be)5 (e)5 (n)1 ( obse)5 (r)4 (ve)5 (d in c)5 (linic)5 (a)5 (l)-1 ( tr)4 (ia)5 (l pa)5 (tie)5 (nts tr)4 (e)5 (a)5 (t)-1 (e)5 (d)1 ( with Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( )]TJ
-0.0006 Tc 0.0006 Tw T*
[(have either completely)29 ( resolved or were resolving)9 ( at follow-up 6 to 7 weeks after discontinuation )]TJ
-0.0013 Tc 0.0013 Tw 0 -1.16 TD
[(of the drug)9 ( \(see ADVER)-4 (S)-5 (E R)-4 (EAC)-4 (TI)22 (ONS)-5 (: )]TJ
/TT0 1 Tf
-0.001 Tc 0.001 Tw (Special Senses)Tj
/TT1 1 Tf
-0.003 Tc 0 Tw 23.3 0 Td
(\).)Tj
/TT3 1 Tf
0 Tc 0.58 0 Td
( )Tj
/TT0 1 Tf
-0.0002 Tc 0.0002 Tw -23.88 -2.22 Td
(Decreased Night Vision:)Tj
/TT1 1 Tf
-0.001 Tc 0.001 Tw 9.88 0 Td
[( Decreased nig)9 (h)-1 (t vision has been reported during)9 ( Accutane therapy)29 ( and )]TJ
-0.0016 Tc 0.0016 Tw -9.88 -1.15 Td
[(i)-4 (n)-2 ( som)-4 (e)2 ( i)-4 (n)-2 (st)-4 (ances t)-4 (h)-2 (e event)-4 ( has persi)-4 (s)-2 (t)-4 (e)2 (d aft)-4 (e)2 (r t)-4 (h)-2 (erapy)28 ( was di)-4 (scont)-4 (i)-4 (nued. Because t)-4 (h)-2 (e onset)-4 ( i)-4 (n)-2 ( )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.15 TD
(some patients was sudden, patients should be advised of this potential p\roblem and warned to be )Tj
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
[(cautious when driving)10 ( or operating)10 ( any)30 ( vehicle at nig)10 (ht.)]TJ
/TT3 1 Tf
0 Tc 0 Tw 22.27 0 Td
( )Tj
-0.0016 Tc -22.27 -2.22 Td
[(P)9 (R)1 (E)-5 (CAUT)-5 (IONS)-5 (: )]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 7.85 0 Td
[(The Accutane Preg)9 (nancy)29 ( Prevention and Risk Manag)9 (e)3 (ment Prog)9 (rams consist )]TJ
-0.0012 Tc 0.0012 Tw -7.85 -1.15 Td
(of the )Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 2.55 0 Td
(System to Manage Accutane Related Teratogenicity)Tj
/TT1 1 Tf
-0.0009 Tc 0.0009 Tw 20.66 0 Td
( \(S.M.A.R.T.\) and the Accutane )Tj
0.0001 Tc -0.0001 Tw -23.21 -1.15 Td
[(Pre)4 (g)10 (na)4 (nc)4 (y)30 ( Pre)4 (ve)4 (ntion Prog)10 (ra)4 (m \(PPP\). S.M.A.R.T. should be)4 ( followe)4 (d for pre)4 (s)-1 (c)4 (r)3 (ibing)10 ( Ac)4 (c)4 (uta)4 (ne)4 ( )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(with the g)10 (oal of preventing)10 ( fetal ex)-10 (posure to isotretinoin. I)23 (t)-3 ( consists of: 1\) reading)10 ( the booklet )]TJ
0.0016 Tc 0 Tw T*
[(e)5 (n)2 (title)5 (d )]TJ
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 3.25 0 Td
(System to Manage Accutane Related Teratogenicity)Tj
/TT1 1 Tf
-0.0001 Tc 0.0001 Tw 20.66 0 Td
( \(S.M.A.R.T.\) )Tj
/TT0 1 Tf
0.0003 Tc -0.0003 Tw [(Guide)4 ( to Be)4 (st )]TJ
-0.0022 Tc 0 Tw -23.91 -1.15 Td
[(Pract)-4 (i)-4 (ces)]TJ
/TT1 1 Tf
0.0008 Tc -0.0008 Tw 3.77 0 Td
[(, 2\))4 ( sig)11 (n)1 (ing)11 ( a)5 (nd r)4 (e)5 (tur)4 (n)1 (ing)11 ( the)5 ( c)5 (o)1 (mple)5 (te)5 (d S.M.A.R.T. )]TJ
/TT0 1 Tf
0.0002 Tc -0.0002 Tw 21.18 0 Td
(Letter of Understanding)Tj
/TT1 1 Tf
0 Tc 0 Tw 9.67 0 Td
( )Tj
-0.0007 Tc 0.0007 Tw -34.62 -1.15 Td
[(containing)9 ( the Prescriber Checklist, 3\) a y)29 (e)3 (llow self-adhesive Accutane Qualification Sticker to )]TJ
-0.0005 Tc 0.0005 Tw T*
[(be affix)-10 (e)3 (d to the prescription pag)10 (e)3 (.  I)23 (n addition, the patient educational material, )]TJ
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 32.31 0 Td
(Be Smart, Be )Tj
-0.0005 Tc 0.0005 Tw -32.31 -1.16 Td
(Safe, Be Sure)Tj
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 5.35 0 Td
(, should be used with each patient. )Tj
0.0026 Tc 9.96 0 0 9.96 64.0397 258.4029 Tm
[(T)-13 (h)9 (e f)10 (o)-3 (llow)26 (i)3 (n)9 (g)9 ( f)10 (u)9 (rth)9 (e)1 (r des)6 (c)1 (ribes)6 ( each)9 ( com)21 (pon)9 (en)9 (t: )]TJ
-0.0004 Tc 0.4204 Tw 12 0 0 12 64.0397 239.0828 Tm
[(1\) The )420 (S.M.A.R.T. )]TJ
/TT0 1 Tf
0.0004 Tc -0.0004 Tw 8.25 0 Td
[(Guide)4 ( to Be)4 (st Prac)4 (tic)4 (e)4 (s )]TJ
/TT1 1 Tf
0.001 Tc -0.001 Tw 9.71 0 Td
[(inc)5 (l)-1 (ude)5 (s: Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( te)5 (r)4 (a)5 (tog)11 (e)5 (nic)5 ( pote)5 (n)1 (tia)5 (l, )]TJ
-0.0008 Tc 0.0008 Tw -16.46 -1.15 Td
[(information on preg)9 (nancy)29 ( testing)9 (,)-1 ( specific information about effective contraception, the )]TJ
-0.0006 Tc 0.0006 Tw T*
(limitations of contraceptive methods and behaviors associated with an in\creased risk of )Tj
-0.001 Tc 0.001 Tw T*
[(contraceptive failure and preg)9 (nancy)29 (,)-1 ( the methods to evaluate preg)9 (nancy)29 ( risk, and the method )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.16 TD
(to complete a qualified Accutane prescription.  )Tj
-0.0004 Tc 0.4204 Tw -1.5 -2.23 Td
[(2\) The )420 (S.M.A.R.T. )]TJ
/TT0 1 Tf
0.0002 Tc -0.0002 Tw 8.25 0 Td
(Letter of Understanding)Tj
/TT1 1 Tf
-0.0007 Tc 0.0007 Tw 9.67 0 Td
( attests that Accutane prescribers understand that )Tj
-0.001 Tc 0.001 Tw -16.42 -1.15 Td
[(Accutane is a teratog)9 (e)3 (n, have read the S.M.A.R.T. )]TJ
/TT0 1 Tf
0.0004 Tc -0.0004 Tw [(Guide)4 ( to Be)4 (st Prac)4 (tic)4 (e)4 (s,)]TJ
/TT1 1 Tf
-0.0007 Tc 0.0007 Tw 30.04 0 Td
( understand their )Tj
-0.0009 Tc 0.0009 Tw -30.04 -1.15 Td
[(responsibilities in preventing)9 ( ex)-11 (posure of preg)9 (nant females to Accutane and the procedures )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(for qualify)29 (i)-3 (ng)9 ( female patients as defined in the box)-11 (ed C)-4 (ONTR)-4 (A)1 (I)22 (NDI)22 (C)-4 (A)1 (TI)22 (ONS)-5 ( AND )]TJ
-0.0013 Tc 0 Tw 0 -1.16 TD
[(W)-7 (A)1 (R)-4 (N)1 (I)22 (NGS)-5 (. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj137 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 146/Width 76>>stream
H	 g"Iw1J)HxPe#s\	XqY߽YӨU;.` t7NycCZ,qhvx6b/|pbLľcX)e Sg
endstreamendobj398 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 423 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 424 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj424 0 obj<</Font 425 0 R>>endobj425 0 obj<</ArialRoundedMTBold 231 0 R>>endobj423 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj397 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj15 0 obj<</Contents 426 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 173 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 427 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 186 0 R/TT2 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 428 0 R>>>>/Rotate 0/Thumb 132 0 R/Type/Page>>endobj17 0 obj<</Contents 429 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 173 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 430 0 R>>/Font<</T1_0 188 0 R/TT0 105 0 R/TT1 112 0 R/TT2 186 0 R/TT3 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 431 0 R>>>>/Rotate 0/Thumb 133 0 R/Type/Page>>endobj19 0 obj<</Contents 432 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 173 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 433 0 R>>/Font<</T1_0 108 0 R/TT0 186 0 R/TT1 112 0 R/TT2 187 0 R/TT3 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 434 0 R>>>>/Rotate 0/Thumb 134 0 R/Type/Page>>endobj21 0 obj<</Contents 435 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 173 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 436 0 R>>/Font<</TT0 186 0 R/TT1 112 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 437 0 R>>>>/Rotate 0/Thumb 135 0 R/Type/Page>>endobj23 0 obj<</Contents 438 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 173 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 439 0 R>>/Font<</TT0 105 0 R/TT1 112 0 R/TT2 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 440 0 R>>>>/Rotate 0/Thumb 136 0 R/Type/Page>>endobj438 0 obj<</Length 6117>>stream
q
1 0 0 1 -8.346436 14.442749 cm
0 0 612 792 re
W n
1 0 0 1 8.346436 -14.442749 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0025 Tc 12 0 0 12 63.6942 651.6427 Tm
[(S)-6 (k)-2 (el)-5 (et)-5 (al)-5 (:)]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 3.61 0 Td
( Bone Mineral Density: )Tj
/TT2 1 Tf
0.0006 Tc -0.0006 Tw 9.65 0 Td
[(Ef)4 (f)4 (e)4 (c)4 (t)-2 (s of)4 ( multiple)4 ( c)4 (our)4 (se)4 (s of)4 ( Ac)4 (c)4 (u)1 (ta)4 (ne)4 ( on the)4 ( de)4 (ve)5 (loping)11 ( )]TJ
-0.0006 Tc 0.0006 Tw -13.26 -1.15 Td
[(musculoskeletal sy)29 (stem are unknown.  There is some evidence that long)9 (-term, hig)9 (h)-1 (-dose, or )]TJ
0.0007 Tc -0.0007 Tw 0 -1.15 TD
[(multiple)5 ( c)5 (our)4 (se)5 (s of)4 ( the)5 (r)4 (a)5 (p)1 (y)31 ( with isotr)4 (e)5 (tinoin ha)5 (ve)5 ( mor)4 (e)5 ( of)4 ( a)5 (n)1 ( e)5 (f)4 (f)4 (e)5 (c)5 (t)-1 ( tha)5 (n)1 ( a)5 ( sing)11 (le)5 ( c)5 (our)4 (se)5 ( of)4 ( )]TJ
-0.0006 Tc 0.0006 Tw T*
[(therapy)29 ( on the musculoskeletal sy)29 (stem. I)22 (n)-1 ( an open-label clinical trial \(N=217\) of a sing)9 (le course )]TJ
-0.001 Tc 0.001 Tw T*
[(of therapy)29 ( with Accutane for severe recalcitrant nodular acne, bone density)29 ( measurements at )]TJ
-0.0007 Tc 0.0007 Tw T*
[(several skeletal sites were not sig)9 (n)-1 (ificantly)29 ( decreased \(lumbar spine chang)9 (e)3 ( >-4% and total hip )]TJ
-0.0012 Tc 0.0012 Tw T*
[(chang)9 (e)3 ( >-5%\) or were increased in the majority)29 ( of patients.  One patient had a decrease in )]TJ
-0.0006 Tc 0.0006 Tw T*
[(lumbar spine bone mineral density)29 ( >4% based on unadjusted data.  Six)-11 (t)-3 (een \(7.9%\) patients had )]TJ
T*
[(decreases in lumbar spine bone mineral density)29 ( >4%, and all the other patients \(92%\) did not )]TJ
-0.0008 Tc 0.0008 Tw T*
[(have sig)9 (n)-1 (ificant decreases or had increases \(adjusted for body)29 ( mass index)-11 (\))2 (.  Nine patients \(4.5%\) )]TJ
-0.0007 Tc 0.0007 Tw T*
[(had a decrease in total hip bone mineral density)29 ( >5% based on unadjusted data.  Twenty)29 (-one )]TJ
-0.0005 Tc 0.0005 Tw T*
[(\(10.6%\) patients had decreases in total hip bone mineral density)30 ( >5%, and all the other patients )]TJ
-0.0008 Tc 0.0008 Tw T*
[(\(89%\) did not have sig)9 (n)-1 (ificant decreases or had increases \(adjusted for body)29 ( mass index)-11 (\))2 (.  )]TJ
-0.0005 Tc 0.0005 Tw T*
[(F)6 (ollow-up studies performed in 8 of the patients with decreased bone mine\ral density)30 ( for up to )]TJ
T*
[(11 months thereafter demonstrated increasing)10 ( bone density)30 ( in 5 patients at the lumbar spine, )]TJ
-0.0006 Tc 0.0006 Tw T*
[(while the other 3 patients had lumbar spine bone density)29 ( measurements below baseline values.  )]TJ
T*
[(Total hip bone mineral densities remained below baseline \(rang)9 (e \2261.6% to -7.6%\) in 5 of 8 )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
(patients \(62.5%\). )Tj
-0.0009 Tc 0.0009 Tw 0 -2.22 TD
[(I)22 (n)-1 ( a separate open-label ex)-11 (tension study)29 ( of 10 patients, ag)9 (es 13-18 y)29 (ears, who started a second )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
(course of Accutane 4 months after the first course, two patients showed \a decrease in mean )Tj
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(lumbar spine bone mineral density)30 ( up to 3.25% \(adjusted for body)30 ( mass index)-10 (\))3 (. )]TJ
-0.0007 Tc 0.0007 Tw 0 -2.22 TD
[(Spontaneous reports of osteoporosis, osteopenia, bone fractures, and del\ay)29 (e)3 (d healing)9 ( of bone )]TJ
-0.0008 Tc 0.0008 Tw 0 -1.15 TD
[(fractures have been seen in the Accutane population.  W)-7 (h)-1 (ile causality)29 ( to Accutane has not been )]TJ
-0.0007 Tc 0.0007 Tw T*
[(established, an effect cannot be ruled out.  L)20 (ong)9 (er term effects have not been studied.  I)22 (t)-3 ( is )]TJ
-0.0009 Tc 0.0009 Tw T*
[(important that Accutane be g)9 (i)-3 (ven at the recommended doses for no long)9 (er than the recommended )]TJ
-0.0002 Tc 0 Tw 0 -1.16 TD
(duration. )Tj
/TT1 1 Tf
-0.0001 Tc 0 -2.23 TD
(Hyperostosis)Tj
/TT2 1 Tf
-0.0006 Tc 0.0006 Tw 5.22 0 Td
[(: A hig)9 (h)-1 ( prevalence of skeletal hy)29 (perostosis was noted in clinical trials for disorders )]TJ
-0.0003 Tc 0.0003 Tw -5.22 -1.15 Td
[(of keratiniz)-6 (ation with a mean dose of 2.24 mg)10 (/kg)10 (/)-2 (day)30 (. Additionally)30 (, skeletal hy)30 (perostosis was )]TJ
0 -1.15 TD
[(noted in 6 of 8 patients in a prospective study)30 ( of disorders of keratiniz)-7 (ation.)]TJ
0 Tc 0 Tw 8.04 0 0 8.04 426.3342 231.7628 Tm
(6)Tj
-0.0017 Tc 0.0017 Tw 12 0 0 12 430.4142 226.2427 Tm
[( Mi)-4 (ni)-4 (m)-4 (a)2 (l)-4 ( skel)-4 (et)-4 (al)-4 ( )]TJ
-0.0006 Tc 0.0006 Tw -30.56 -1.15 Td
[(hy)29 (perostosis and calcification of lig)9 (aments and tendons have also been observed by)29 ( x)-11 (-ray)29 ( in )]TJ
-0.0008 Tc 0.0008 Tw T*
[(prospective studies of nodular acne patients treated with a sing)9 (le course of therapy)29 ( at )]TJ
0.0008 Tc -0.0008 Tw T*
[(r)4 (e)5 (c)5 (o)1 (mme)5 (nde)5 (d dose)5 (s. The)5 ( ske)5 (l)-1 (e)5 (t)-1 (a)5 (l)-1 ( e)5 (f)4 (f)4 (e)5 (c)5 (t)-1 (s of)4 ( multiple)5 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( tr)4 (e)5 (a)5 (tme)5 (nt c)5 (our)4 (se)5 (s f)4 (o)1 (r)4 ( a)5 (c)5 (n)1 (e)5 ( a)5 (r)4 (e)5 ( )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.16 TD
(unknown.  )Tj
-0.0008 Tc 0.0008 Tw 0 -2.22 TD
[(I)22 (n)-1 ( a clinical study)29 ( of 217 pediatric patients \(12 to 17 y)29 (ears\) with severe recalcitrant nodular acne, )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(hy)30 (perostosis was not observed after 16 to 20 weeks of treatment with appro\x)-10 (imately)30 ( 1 mg)10 (/kg)10 (/)-3 (day)30 ( )]TJ
0.0005 Tc -0.0005 Tw T*
[(of)4 ( Ac)4 (c)4 (u)1 (ta)4 (ne)4 ( g)11 (i)-2 (ve)4 (n in two divide)4 (d dose)4 (s.  Hy)31 (pe)4 (r)4 (o)1 (stosis ma)4 (y)31 ( r)4 (e)4 (quir)4 (e)4 ( a)4 ( long)11 (e)4 (r)4 ( time)4 ( f)4 (r)4 (a)4 (me)4 ( to )]TJ
-0.001 Tc 0.001 Tw 0 -1.16 TD
[(appear.  The clinical course and sig)9 (n)-1 (ificance remain unknown. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj136 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 146/Width 76>>stream
H0gYJQ('p!C^gxjqI$):t$	Yiнh;x^dq~EZTI˷WQ)NNWL?+S)-x=h= S/
endstreamendobj440 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 441 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 442 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj442 0 obj<</Font 443 0 R>>endobj443 0 obj<</ArialRoundedMTBold 231 0 R>>endobj441 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj439 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj435 0 obj<</Length 6732>>stream
q
1 0 0 1 -6.703552 7.12265 cm
0 0 612 792 re
W n
1 0 0 1 6.703552 -7.12265 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 12 0 0 12 65.337 644.3227 Tm
[(reduction in weig)10 (ht, restriction of dietary)30 ( fat and alcohol, and reduction in dose while continuing)10 ( )]TJ
-0.0023 Tc 0 Tw 0 -1.16 TD
[(Accut)-4 (a)2 (ne.)]TJ
0 Tc 8.04 0 0 8.04 113.457 635.9226 Tm
(5)Tj
12 0 0 12 117.537 630.4026 Tm
( )Tj
-0.0006 Tc 0.0006 Tw -4.35 -2.22 Td
[(B)6 (l)-3 (ood lipid determinations should be performed before Accutane is g)9 (i)-3 (ven and then at intervals )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.15 TD
[(until the lipid response to Accutane is established, which usually)30 ( occurs within 4 weeks. )]TJ
-0.0005 Tc 0.0005 Tw T*
[(Especially)30 ( careful consideration must be g)10 (i)-3 (ven to risk/benefit for patients who may)30 ( be at hig)10 (h )]TJ
T*
[(risk during)10 ( Accutane therapy)30 ( \(patients with diabetes, obesity)30 (, increased alcohol intake, lipid )]TJ
0.0011 Tc -0.0011 Tw T*
[(me)5 (ta)5 (bolism disor)4 (d)1 (e)5 (r)4 ( or)4 ( f)4 (a)5 (milia)5 (l histor)4 (y)31 ( of)4 ( lipid me)5 (ta)5 (bolism disor)4 (d)1 (e)5 (r)4 (\))4 (.)1 ( I)24 (f)4 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( the)5 (r)4 (a)5 (p)1 (y)31 ( is )]TJ
-0.0007 Tc 0.0007 Tw T*
[(instituted, more frequent checks of serum values for lipids and/or blood\ sug)9 (a)3 (r are recommended )]TJ
-0.0015 Tc 0.0015 Tw 0 -1.16 TD
[(\(see P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
0.0002 Tc -0.0002 Tw 9.25 0 Td
(Laboratory Tests)Tj
/TT0 1 Tf
-0.0015 Tc 0 Tw 6.87 0 Td
(\). )Tj
-0.0019 Tc 0.0019 Tw -16.12 -2.23 Td
[(The cardi)-4 (ovascul)-4 (ar consequences of hy)28 (pert)-4 (ri)-4 (g)8 (l)-4 (y)28 (ceri)-4 (d)-2 (em)-4 (i)-4 (a)2 ( associ)-4 (at)-4 (ed wi)-4 (t)-4 (h)-2 ( Accut)-4 (a)2 (ne are )]TJ
-0.0002 Tc 0.0002 Tw 0 -1.15 TD
(unknown.  )Tj
/TT1 1 Tf
-0.0001 Tc 0.0001 Tw (Animal Studies)Tj
/TT0 1 Tf
0 Tc 0 Tw 10.5 0 Td
[(:  I)23 (n rats g)10 (i)-2 (ven 8 or 32 mg)10 (/kg)10 (/)-2 (day)30 ( of isotretinoin \(1.3 to 5.3 times the )]TJ
-0.0009 Tc 0.0009 Tw -10.5 -1.15 Td
[(recommended clinical dose of 1.0 mg)9 (/kg)9 (/)-3 (day)29 ( after normaliz)-7 (ation for total body)29 ( surface area\) for )]TJ
-0.0005 Tc 0.0005 Tw T*
[(18 months or long)10 (er, the incidences of focal calcification, fibrosis and inflammation of \the )]TJ
-0.0008 Tc 0.0008 Tw T*
[(my)29 (ocardium, calcification of coronary)29 (, pulmonary)29 ( and mesenteric arteries, and metastatic )]TJ
0.0008 Tc -0.0008 Tw T*
[(c)5 (a)5 (l)-1 (c)5 (i)-1 (f)4 (i)-1 (c)5 (a)5 (tion of)4 ( the)5 ( g)11 (a)5 (str)4 (i)-1 (c)5 ( muc)5 (o)1 (sa)5 ( we)5 (r)4 (e)5 ( g)11 (r)4 (e)5 (a)5 (t)-1 (e)5 (r)4 ( tha)5 (n)1 ( in c)5 (ontr)4 (o)1 (l r)4 (a)5 (ts of)4 ( simila)5 (r)4 ( a)5 (g)11 (e)5 (.)1 ( F)7 (o)1 (c)5 (a)5 (l)-1 ( )]TJ
-0.0021 Tc 0.0021 Tw T*
[(endocardi)-4 (al)-4 ( and m)-4 (y)28 (ocardi)-4 (al)-4 ( cal)-4 (ci)-4 (fi)-4 (cat)-4 (i)-4 (ons associ)-4 (at)-4 (ed wi)-4 (t)-4 (h)-2 ( cal)-4 (ci)-4 (fi)-4 (cat)-4 (i)-4 (on of t)-4 (h)-2 (e coronary)28 ( art)-4 (e)2 (ri)-4 (es )]TJ
-0.0004 Tc 0.0004 Tw T*
[(were observed in two dog)10 (s after approx)-10 (imately)30 ( 6 to 7 months of treatment with isotretinoin at a )]TJ
T*
[(dosag)10 (e of 60 to 120 mg)10 (/kg)10 (/)-3 (day)30 ( \(30 to 60 times the recommended clinical dose of 1.0 mg)10 (/kg)10 (/)-3 (day)30 (, )]TJ
-0.001 Tc 0.001 Tw T*
[(respectively)29 (,)-1 ( after normaliz)-7 (ation for total body)29 ( surface area\). )]TJ
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 0 -2.23 TD
(Hearing Impairment: )Tj
/TT0 1 Tf
8.82 0 Td
[(I)22 (m)-3 (paired hearing)9 ( has been reported in patients taking)9 ( Accutane; in some )]TJ
-0.0008 Tc 0.0008 Tw -8.82 -1.15 Td
[(cases, the hearing)9 ( impairment has been reported to persist after therapy)29 ( has been discontinued. )]TJ
0.0009 Tc -0.0009 Tw 0 -1.15 TD
[(Me)5 (c)5 (h)1 (a)5 (n)1 (ism\()4 (s\))4 ( a)5 (nd c)5 (a)5 (u)1 (sa)5 (lity)31 ( f)4 (o)1 (r)4 ( this e)5 (v)1 (e)5 (n)1 (t ha)5 (ve)5 ( not be)5 (e)5 (n)1 ( e)5 (sta)5 (blishe)5 (d. Pa)5 (tie)5 (nts who e)5 (x)-9 (pe)5 (r)4 (i)-1 (e)5 (n)1 (c)5 (e)5 ( )]TJ
-0.0006 Tc 0.0006 Tw T*
[(tinnitus or hearing)9 ( impairment should discontinue Accutane treatment and be referred for )]TJ
-0.0014 Tc 0.0014 Tw 0 -1.16 TD
[(specializ)-8 (ed care for further evaluation \(see ADVER)-4 (S)-5 (E R)-4 (E)-1 (AC)-4 (TI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
-0.001 Tc 0.001 Tw 28.2 0 Td
(Special Senses)Tj
/TT0 1 Tf
-0.0015 Tc 0 Tw 5.85 0 Td
(\). )Tj
/TT1 1 Tf
-0.0005 Tc -34.05 -2.22 Td
(Hepatotoxicity:)Tj
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 6.21 0 Td
[( Clinic)5 (a)5 (l)-1 ( he)5 (pa)5 (titis c)5 (onside)5 (r)4 (e)5 (d)1 ( to be)5 ( possibly)31 ( or)4 ( pr)4 (oba)5 (bly)31 ( r)4 (e)5 (la)5 (te)5 (d to Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( )]TJ
0.0009 Tc -0.0009 Tw -6.21 -1.15 Td
[(the)5 (r)4 (a)5 (p)1 (y)31 ( ha)5 (s be)5 (e)5 (n)1 ( r)4 (e)5 (por)4 (te)5 (d. Additiona)5 (lly)31 (, mild to mode)5 (r)4 (a)5 (te)5 ( e)5 (l)-1 (e)5 (v)1 (a)5 (tions of)4 ( live)5 (r)4 ( e)5 (n)1 (zy)31 (me)5 (s ha)5 (ve)5 ( be)5 (e)5 (n)1 ( )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(observed in approx)-10 (imately)30 ( 15% of individuals treated during)10 ( clinical trials, some of which )]TJ
T*
[(normaliz)-7 (ed with dosag)10 (e reduction or continued administration of the drug)10 (. I)23 (f)3 ( normaliz)-7 (ation does )]TJ
-0.0005 Tc 0.0005 Tw T*
[(not readily)30 ( occur or if hepatitis is suspected during)10 ( treatment with Accutane, the drug)10 ( should be )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.16 TD
[(discontinued and the etiolog)10 (y)30 ( further investig)10 (ated. )]TJ
/TT1 1 Tf
0.0007 Tc -0.0007 Tw 0 -2.22 TD
[(I)4 (n)1 (flammatory)5 ( Bowe)5 (l Dise)5 (ase)5 (:)]TJ
/TT0 1 Tf
-0.0017 Tc 0.0017 Tw 11.93 0 Td
[( Accut)-4 (a)2 (ne has been associ)-4 (at)-4 (ed wi)-4 (t)-4 (h)-2 ( i)-4 (n)-2 (fl)-4 (am)-4 (m)-4 (a)2 (t)-4 (o)-2 (ry)28 ( bowel)-4 ( di)-4 (sease )]TJ
-0.0002 Tc 0.0002 Tw -11.93 -1.15 Td
[(\(including)10 ( reg)10 (i)-2 (onal ileitis\) in patients without a prior history)30 ( of intestinal disorders. I)23 (n some )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(instances, sy)29 (mptoms have been reported to persist after Accutane treatment has been s\topped. )]TJ
T*
[(Patients ex)-11 (periencing)9 ( abdominal pain, rectal bleeding)9 ( or severe diarrhea should discontinue )]TJ
0 -1.16 TD
[(Accutane immediately)29 ( \(see ADVERSE REACTI)22 (ONS: )]TJ
/TT1 1 Tf
0.0008 Tc 0 Tw 22.06 0 Td
[(Gastrointe)5 (stinal)]TJ
/TT0 1 Tf
-0.0015 Tc 6.51 0 Td
(\). )Tj
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj135 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 139/Width 76>>stream
H0B;eM٪sZkIz>O$(GF_Kl]4&+lFlm!w`9!꒳*6~Lصu%3]=e:b]Wqv>iLT،.2]}=:Zs ]L3
endstreamendobj437 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 444 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 445 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj445 0 obj<</Font 446 0 R>>endobj446 0 obj<</ArialRoundedMTBold 231 0 R>>endobj444 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj436 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj432 0 obj<</Length 7816>>stream
q
1 0 0 1 -7.624023 20.922699 cm
0 0 612 792 re
W n
1 0 0 1 7.624023 -20.922699 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 12 0 0 12 64.4166 658.1227 Tm
(should not be initiated until at least 8 weeks after completion of the f\irst course, because )Tj
0.0007 Tc -0.0007 Tw 0 -1.15 TD
[(e)5 (x)-9 (pe)5 (r)4 (i)-1 (e)5 (n)1 (c)5 (e)5 ( ha)5 (s shown tha)5 (t)-1 ( pa)5 (tie)5 (nts ma)5 (y)31 ( c)5 (ontinue)5 ( to impr)4 (ove)5 ( while)5 ( of)4 (f)4 ( Ac)5 (c)5 (u)1 (ta)5 (ne)5 (. The)5 ( optima)5 (l )]TJ
-0.0008 Tc 0.0008 Tw T*
(interval before retreatment has not been defined for patients who have n\ot completed skeletal )Tj
-0.0009 Tc 0.0009 Tw T*
[(g)9 (r)2 (owth \(see W)-7 (A)1 (RNI)22 (NGS:)]TJ
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 10.57 0 Td
( Skeletal: Bone Mineral Density, Hyperostosis, )Tj
/TT0 1 Tf
-0.001 Tc 0 Tw 19.03 0 Td
(and )Tj
/TT1 1 Tf
(Premature )Tj
0.0002 Tc -0.0002 Tw -29.6 -1.16 Td
(Epiphyseal Closure)Tj
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 7.86 0 Td
(\).   )Tj
/TT2 1 Tf
-0.0014 Tc 0.0014 Tw -7.86 -2.24 Td
[(CONT)-4 (RAINDICAT)-4 (IONS)-5 (: P)9 (regn)-5 (a)-1 (n)-5 (c)2 (y: Category X. S)-5 (ee b)-5 (oxed)-5 ( CONT)-4 (RAINDICAT)-4 (IONS)-5 ( )]TJ
-0.0017 Tc 0.0017 Tw 0 -1.16 TD
[(AND WARNING)6 (S)-5 (.)-2 ( )]TJ
/TT1 1 Tf
0.0008 Tc -0.0008 Tw 0 -2.21 TD
[(Alle)5 (rgic)5 ( Re)5 (ac)5 (tions:)4 ( )]TJ
/TT0 1 Tf
7.99 0 Td
[(Ac)5 (c)5 (u)1 (ta)5 (ne)5 ( is c)5 (ontr)4 (a)5 (indic)5 (a)5 (t)-1 (e)5 (d)1 ( in pa)5 (tie)5 (nts who a)5 (r)4 (e)5 ( hy)31 (pe)5 (r)4 (se)5 (n)1 (sitive)5 ( to this )]TJ
-0.0005 Tc 0.0005 Tw -7.99 -1.15 Td
[(medication or to any)30 ( of its components. Accutane should not be g)10 (i)-3 (ven to patients who are )]TJ
0.0007 Tc -0.0007 Tw 0 -1.15 TD
[(se)5 (nsitive)5 ( to pa)5 (r)4 (a)5 (be)5 (ns, whic)5 (h a)5 (r)4 (e)5 ( use)5 (d)1 ( a)5 (s pr)4 (e)5 (se)5 (r)4 (va)5 (tive)5 (s in the)5 ( g)11 (e)5 (la)5 (tin c)5 (a)5 (p)1 (sule)5 ( \()4 (se)5 (e)5 ( )]TJ
-0.0009 Tc 0 Tw 0 -1.16 TD
[(P)-5 (R)-4 (EC)-4 (AUTI)22 (ONS)-5 (: )]TJ
/TT1 1 Tf
0.0009 Tc [(Hy)5 (pe)5 (rse)5 (nsitiv)5 (ity)]TJ
/TT0 1 Tf
-0.0015 Tc 13.89 0 Td
(\). )Tj
/TT2 1 Tf
-13.89 -2.24 Td
[(WARNING)6 (S)-5 (:)2 ( )]TJ
/TT3 1 Tf
0 Tc 6.18 0 Td
(Psychiatric Disorders:)Tj
/TT2 1 Tf
-0.0001 Tc 0.0001 Tw 9.19 0 Td
[( Accutane m)13 (ay cause depression, psychosis and, rarely, )]TJ
0.0003 Tc -0.0003 Tw -15.37 -1.15 Td
[(suicidal ideation, suicide attem)13 (p)-3 (ts, suicide, and aggressive and/or violent behaviors.  )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.15 TD
[(Discontinuation of)-7 ( Accutane therapy m)13 (ay be insuf)-7 (f)-7 (i)-2 (cient; f)-7 (u)-4 (rther evaluation m)13 (ay be )]TJ
-0.0015 Tc 0.0015 Tw T*
[(n)-5 (ecessary. No m)12 (ech)-5 (an)-5 (ism)12 ( of)-8 ( action)-5 ( h)-5 (a)-1 (s b)-5 (een)-5 ( estab)-5 (lish)-5 (e)2 (d)-5 ( f)-8 (o)-1 (r th)-5 (ese even)-5 (ts \(see ADVE)-4 (RS)-5 (E)-4 ( )]TJ
-0.0017 Tc 0 Tw T*
[(RE)-5 (ACT)-5 (IONS)-5 (: )]TJ
/TT3 1 Tf
0.0012 Tc 6.53 0 Td
[(Psy)5 (c)5 (h)-3 (iatric)]TJ
/TT2 1 Tf
-0.002 Tc 0.002 Tw 4.61 0 Td
[(\). P)9 (rescri)-4 (b)-6 (ers sh)-6 (ou)-6 (l)-4 (d)-6 ( read)-6 ( th)-6 (e b)-6 (r)2 (och)-6 (u)-6 (re, )]TJ
/TT3 1 Tf
0.0014 Tc -0.0014 Tw 17.25 0 Td
[(Re)5 (c)5 (ognizing Psy)5 (c)5 (h)-2 (iatric)5 ( )]TJ
-0.0012 Tc 0.0012 Tw -28.39 -1.23 Td
[(Di)-3 (sorders i)-3 (n)-5 ( A)-4 (dol)-3 (escen)-5 (t)-3 (s)-2 ( an)-5 (d Y)-10 (o)-1 (u)-5 (n)-5 (g)-1 ( A)-4 (d)-1 (u)-5 (l)-3 (t)-3 (s)-2 (: A)-4 ( Gu)-5 (i)-3 (d)-1 (e for Prescri)-3 (b)-1 (ers of A)-4 (ccu)-5 (t)-3 (a)-1 (n)-5 (e)]TJ
/T1_0 1 Tf
0 Tc 0 Tw 33.58 0 Td
(\002)Tj
-0.02 -0.02 Td
[(\002)780 (\002)]TJ
0 0.02 TD
(\002)Tj
/TT3 1 Tf
( )Tj
0.002 Tc -33.56 -1.15 Td
[(\()5 (isotre)6 (tinoin\))5 (.)]TJ
/TT2 1 Tf
0 Tc 5.65 0 Td
( )Tj
/TT3 1 Tf
0.0006 Tc -0.0006 Tw -5.65 -2.23 Td
[(Pseudotum)-12 (or Cerebri:)]TJ
/TT2 1 Tf
-0.0016 Tc 0.0016 Tw 9.21 0 Td
[( Accu)-5 (tan)-5 (e)2 ( u)-5 (s)-2 (e h)-5 (a)-2 (s b)-5 (een)-5 ( associ)-4 (ated)-5 ( w)-9 (i)-4 (th)-5 ( a n)-5 (u)-5 (m)11 (b)-5 (er of)-9 ( cases of)-9 ( )]TJ
-0.0019 Tc 0.0019 Tw -9.21 -1.15 Td
[(p)-6 (s)-3 (eu)-6 (d)-6 (o)-2 (tu)-6 (m)11 (o)-2 (r cereb)-6 (ri)-4 ( \(b)-6 (en)-6 (i)-4 (g)-2 (n)-6 ( i)-4 (n)-6 (tracran)-6 (i)-4 (al)-4 ( h)-6 (y)-2 (p)-6 (erten)-6 (si)-4 (on)-6 (\), som)11 (e)2 ( of)-9 ( w)-10 (h)-6 (i)-4 (c)2 (h)-6 ( i)-4 (n)-6 (vol)-4 (ved)-6 ( )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(concom)12 (itant use of)-8 ( tetracyclines. Concom)12 (itant treatm)12 (ent w)-8 (i)-3 (th tetracyclines should )]TJ
-0.0011 Tc 0.0011 Tw T*
[(th)-5 (eref)-8 (ore b)-5 (e)3 ( avoid)-5 (e)3 (d)-5 (.)-1 ( Early sign)-5 (s an)-5 (d)-5 ( sym)12 (p)-5 (tom)12 (s)-2 ( of)-8 ( p)-5 (s)-2 (eu)-5 (d)-5 (o)-1 (tu)-5 (m)12 (o)-1 (r cereb)-5 (ri in)-5 (clu)-5 (d)-5 (e)3 ( )]TJ
0.0018 Tc -0.0018 Tw T*
[(papille)6 (de)6 (m)15 (a, he)6 (adac)6 (he)6 (, nause)6 (a)2 ( and vom)15 (it)5 (ing, and visual dist)5 (ur)6 (banc)6 (e)6 (s)1 (. P)13 (a)2 (t)5 (ie)6 (n)-2 (t)5 (s)1 ( w)-6 (it)5 (h)-2 ( t)5 (h)-2 (e)6 (s)1 (e)6 ( )]TJ
0.0003 Tc -0.0003 Tw T*
[(sym)13 (p)-3 (tom)13 (s should be screened f)-7 (or papilledem)13 (a and, if)-7 ( present, they should be told to )]TJ
-0.0017 Tc 0.0017 Tw T*
[(d)-5 (i)-4 (scon)-5 (ti)-4 (n)-5 (u)-5 (e)2 ( Accu)-5 (tan)-5 (e)2 ( i)-4 (m)11 (m)11 (e)2 (d)-5 (i)-4 (atel)-4 (y an)-5 (d)-5 ( b)-5 (e)2 ( ref)-9 (erred)-5 ( to a n)-5 (e)2 (u)-5 (r)2 (ol)-4 (ogi)-4 (st f)-9 (o)-2 (r f)-9 (u)-5 (rth)-5 (er d)-5 (i)-4 (agn)-5 (osi)-4 (s)-2 ( )]TJ
-0.0021 Tc 0.0021 Tw 0 -1.16 TD
[(an)-6 (d)-6 ( care \(see ADVE)-5 (RS)-6 (E)-5 ( RE)-5 (ACT)-5 (IONS)-6 (:)]TJ
/TT3 1 Tf
-0.0001 Tc 0.0001 Tw 17.1 0 Td
( Neurological)Tj
/TT2 1 Tf
-0.0015 Tc 0 Tw 5.64 0 Td
(\). )Tj
/TT1 1 Tf
0.0009 Tc -22.74 -2.2 Td
[(Panc)5 (re)5 (atitis:)4 ( )]TJ
/TT2 1 Tf
-0.0031 Tc 0.0031 Tw 5.47 0 Td
[(Acu)-7 (te p)-7 (a)-3 (n)-7 (creati)-5 (ti)-5 (s)]TJ
ET
q
1 0 0 1 -7.624023 20.922699 cm
137.681 211.2 93.48 -1.2 re
f
Q
BT
/TT3 1 Tf
0 Tc 0 Tw 12 0 0 12 223.5366 233.4428 Tm
( )Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw (has been reported in patients with either elevated or normal )Tj
0.0014 Tc -0.0014 Tw -13.26 -1.15 Td
[(se)5 (r)4 (u)1 (m tr)4 (ig)11 (ly)31 (c)5 (e)5 (r)4 (ide)5 ( le)5 (ve)5 (ls. )]TJ
/TT2 1 Tf
-0.0018 Tc 0.0018 Tw 10.33 0 Td
[(In)-6 ( rare i)-4 (n)-6 (stan)-6 (ces, f)-9 (a)-2 (tal)-4 ( h)-6 (e)2 (m)11 (o)-2 (rrh)-6 (agi)-4 (c p)-6 (a)-2 (n)-6 (creati)-4 (ti)-4 (s h)-6 (a)-2 (s b)-6 (een)-6 ( )]TJ
-0.0031 Tc 0 Tw -10.33 -1.15 Td
[(rep)-7 (orted)-7 (.)]TJ
/TT0 1 Tf
-0.0007 Tc 0.0007 Tw 3.96 0 Td
[( Accutane should be stopped if hy)29 (pertrig)9 (l)-3 (y)29 (ceridemia cannot be controlled at an )]TJ
-3.96 -1.16 Td
[(acceptable level or if sy)29 (mptoms of pancreatitis occur.  )]TJ
/TT1 1 Tf
0.0015 Tc 0 Tw 0 -2.22 TD
(Lipids:)Tj
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 2.84 0 Td
[( Elevations of serum trig)9 (ly)29 (cerides have been reported in patients treated with Accutane. )]TJ
-2.84 -1.15 Td
[(Marked elevations of serum trig)9 (ly)29 (cerides in ex)-11 (cess of 800 mg)9 (/dL)20 ( were reported in approx)-11 (imately)29 ( )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.15 TD
[(25% of patients receiving)10 ( Accutane in clinical trials. I)23 (n addition, approx)-10 (imately)30 ( 15% developed )]TJ
-0.0007 Tc 0.0007 Tw T*
[(a decrease in hig)9 (h)-1 (-density)29 ( lipoproteins and about 7% showed an increase in cholesterol levels.  )]TJ
T*
[(I)22 (n)-1 ( clinical trials, the effects on trig)9 (ly)29 (cerides, HDL)20 (, and cholesterol were reversible upon )]TJ
-0.0009 Tc 0.0009 Tw T*
[(cessation of Accutane therapy)29 (.)-1 (  Some patients have been able to reverse trig)9 (ly)29 (ceride elevation by)29 ( )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj134 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 155/Width 76>>stream
HQ
0CuUCCŒw5cBp"z	zybM̪M(+8k|jM0T*²k^d1?b.ܻB\ZDM6è!B
t^(ZH.Z !R?
endstreamendobj434 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 447 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 448 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj448 0 obj<</Font 449 0 R>>endobj449 0 obj<</ArialRoundedMTBold 231 0 R>>endobj447 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj433 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj429 0 obj<</Length 10494>>stream
q
1 0 0 1 -8.215881 18.222748 cm
0 0 612 792 re
W n
1 0 0 1 8.215881 -18.222748 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0013 Tc -0.0013 Tw 12 0 0 12 63.8247 655.4227 Tm
[(Spe)5 (c)5 (i)-1 (al Patie)5 (nt Populations:)]TJ
/TT1 1 Tf
-0.0002 Tc 0.0002 Tw 11.74 0 Td
( Pediatric Patients)Tj
/TT2 1 Tf
-0.0006 Tc 0.0006 Tw 7.5 0 Td
(: The pharmacokinetics of isotretinoin were )Tj
0.0008 Tc -0.0008 Tw -19.24 -1.15 Td
[(e)5 (v)1 (a)5 (l)-1 (ua)5 (te)5 (d a)5 (f)4 (te)5 (r)4 ( sing)11 (le)5 ( a)5 (nd multiple)5 ( dose)5 (s in 38 pe)5 (dia)5 (t)-1 (r)4 (i)-1 (c)5 ( pa)5 (tie)5 (nts \()4 (12 to 15 y)31 (e)5 (a)5 (r)4 (s\))4 ( a)5 (nd 19 a)5 (dult )]TJ
0.0001 Tc -0.0001 Tw 0 -1.23 TD
(patients \()Tj
/T1_0 1 Tf
0 Tc 0 Tw 3.69 0 Td
(\006)Tj
/TT2 1 Tf
-0.0013 Tc 0.0013 Tw 0.55 0 Td
[(18 y)29 (ears\) who received Accutane for the treatment of severe recalcitrant no\dular acne. )]TJ
-0.0007 Tc 0.0007 Tw -4.24 -1.14 Td
[(I)22 (n)-1 ( both ag)9 (e g)9 (r)2 (oups, 4-)]TJ
/TT1 1 Tf
-0.0019 Tc 0 Tw (oxo)Tj
/TT2 1 Tf
0.0011 Tc -0.0011 Tw 10.19 0 Td
[(-)4 (i)-1 (sotr)4 (e)5 (tinoin wa)5 (s the)5 ( ma)5 (jor)4 ( me)5 (ta)5 (bolite)5 (; tr)4 (e)5 (tinoin a)5 (nd 4-)]TJ
/TT1 1 Tf
-0.0019 Tc 0 Tw 21.9 0 Td
(oxo)Tj
/TT2 1 Tf
-0.0001 Tc 1.44 0 Td
(-tretinoin )Tj
-0.0008 Tc 0.0008 Tw -33.53 -1.15 Td
[(were also observed. The dose-normaliz)-7 (ed pharmacokinetic parameters for isotretinoin following)9 ( )]TJ
0.0008 Tc -0.0008 Tw 0 -1.15 TD
[(sing)11 (le)5 ( a)5 (nd multiple)5 ( dose)5 (s a)5 (r)4 (e)5 ( summa)5 (r)4 (i)-1 (ze)5 (d in Ta)5 (ble)5 ( 3 f)4 (o)1 (r)4 ( pe)5 (dia)5 (t)-1 (r)4 (i)-1 (c)5 ( pa)5 (tie)5 (nts. The)5 (r)4 (e)5 ( we)5 (r)4 (e)5 ( no )]TJ
-0.0005 Tc 0.0005 Tw T*
[(statistically)30 ( sig)10 (nificant differences in the pharmacokinetics of isotretinoin between ped\iatric and )]TJ
0.0002 Tc -0.0002 Tw 0 -1.16 TD
(adult patients. )Tj
/TT3 1 Tf
0.002 Tc -0.002 Tw 0.56 -2.25 Td
[(Table)6 ( 3. P)13 (h)-2 (ar)6 (m)15 (a)2 (c)6 (o)2 (kine)6 (t)5 (ic)6 ( P)13 (a)2 (r)6 (a)2 (m)15 (e)6 (t)5 (e)6 (r)6 (s)1 ( of Isot)5 (r)6 (e)6 (t)5 (inoin F)13 (o)2 (llowing Single)6 ( and M)6 (u)-2 (lt)5 (iple)6 ( D)4 (o)2 (se)6 ( )]TJ
-0.0004 Tc 0.0004 Tw 6.43 -1.15 Td
[(Adm)13 (i)-3 (nistration in P)10 (e)3 (diatric P)10 (atients, 12 to 15 Years of)-7 ( Age )]TJ
-0.0025 Tc 0.0025 Tw 8.14 -1.23 Td
[(Mean)-6 ( \()]TJ
/T1_0 1 Tf
0 Tc 0 Tw 3.04 0 Td
(\007)Tj
-0.02 -0.02 Td
[(\007)529 (\007)]TJ
0 0.02 TD
(\007)Tj
/TT3 1 Tf
-0.0003 Tc 0.0003 Tw 0.56 0 Td
( SD\), N=38* )Tj
-0.0119 Tc 0 Tw -15.57 -2.29 Td
[(Pa)-12 (r)-8 (a)-12 (me)-8 (t)-9 (e)-8 (r)]TJ
0 Tc 8.04 0 0 8.04 155.6247 480.3427 Tm
( )Tj
0.0003 Tc -0.0003 Tw 12 0 0 12 240.8247 474.8227 Tm
(Isotretinoin  )Tj
-0.0021 Tc 0.0021 Tw -0.29 -1.15 Td
[(\(S)-6 (i)-4 (n)-6 (gl)-4 (e Dose\) )]TJ
0.0003 Tc -0.0003 Tw 12.66 1.15 Td
(Isotretinoin  )Tj
-0.001 Tc 0 Tw -0.52 -1.15 Td
(\(Steady-State\) )Tj
ET
q
1 0 0 1 -8.215881 18.222748 cm
66.281 468.36 140.4 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
206.681 468.36 0.72 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
207.401 468.36 143.28 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 468.36 0.72 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
351.401 468.36 152.28 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
206.681 467.64 0.72 -27.6 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 467.64 0.72 -27.6 re
f
Q
BT
/TT2 1 Tf
0 Tc 12 0 0 12 96.3447 446.7427 Tm
(C)Tj
-0.0017 Tc 8.04 0 0 8.04 104.3847 445.1827 Tm
[(ma)-6 (x)]TJ
-0.0004 Tc 0.0004 Tw 12 0 0 12 118.1847 446.7427 Tm
[( \(ng)10 (/mL)20 (\) )]TJ
9.51 0 Td
(573.25 \(278.79\) )Tj
12.38 0 Td
(731.98 \(361.86\) )Tj
ET
q
1 0 0 1 -8.215881 18.222748 cm
66.281 440.04 140.4 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
206.681 440.04 0.72 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
207.401 440.04 143.28 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 440.04 0.72 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
351.401 440.04 152.28 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
206.681 439.32 0.72 -13.8 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 439.32 0.72 -13.8 re
f
Q
BT
-0.0022 Tc 0 Tw 12 0 0 12 78.1047 431.9827 Tm
(AUC)Tj
-0.0047 Tc 8.04 0 0 8.04 103.4247 430.4227 Tm
[(\(0)-12 (-1)-12 (2)-12 (\))]TJ
-0.001 Tc 0.001 Tw 12 0 0 12 123.5847 431.9827 Tm
( \(ng)Tj
/T1_0 1 Tf
0 Tc 0 Tw 1.57 0 Td
(\005)Tj
/TT2 1 Tf
0.0013 Tc [(hr)4 (/mL)22 (\))4 ( )]TJ
-0.0004 Tc 0.0004 Tw 6.99 0.08 Td
[(3033.37 \(1394.17\) )-4720 (5082.00 \(2184.23\) )]TJ
ET
q
1 0 0 1 -8.215881 18.222748 cm
206.681 425.52 0.72 -14.76 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 425.52 0.72 -14.76 re
f
Q
BT
-0.0022 Tc 0 Tw 12 0 0 12 78.1047 417.2227 Tm
(AUC)Tj
-0.0047 Tc 8.04 0 0 8.04 103.4247 415.6627 Tm
[(\(0)-12 (-2)-12 (4)-12 (\))]TJ
-0.001 Tc 0.001 Tw 12 0 0 12 123.5847 417.2227 Tm
( \(ng)Tj
/T1_0 1 Tf
0 Tc 0 Tw 1.57 0 Td
(\005)Tj
/TT2 1 Tf
0.0013 Tc [(hr)4 (/mL)22 (\))4 ( )]TJ
-0.0003 Tc 0.0003 Tw 6.99 0.08 Td
[(6003.81 \(2885.67\) )-8170 (\226 )]TJ
ET
q
1 0 0 1 -8.215881 18.222748 cm
206.681 410.76 0.72 -14.64 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 410.76 0.72 -14.64 re
f
Q
BT
0 Tc 0 Tw 12 0 0 12 104.9847 403.5427 Tm
(T)Tj
-0.0017 Tc 8.04 0 0 8.04 112.3047 401.9827 Tm
[(ma)-6 (x)6 ( )]TJ
-0.0008 Tc 0.0008 Tw 12 0 0 12 128.1447 403.5427 Tm
[(\(hr\)\206)-11 ( )]TJ
8.396 0 Td
(6.00 \(1.00-24.60\) )Tj
12.996 0 Td
(4.00 \(0-12.00\) )Tj
ET
q
1 0 0 1 -8.215881 18.222748 cm
206.681 396.12 0.72 -13.8 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 396.12 0.72 -13.8 re
f
Q
BT
0.0019 Tc 0 Tw 12 0 0 12 92.2647 389.7427 Tm
(Css)Tj
-0.0017 Tc 8.04 0 0 8.04 109.6647 388.1827 Tm
[(mi)-7 (n)]TJ
-0.0003 Tc 0.0003 Tw 12 0 0 12 122.2647 389.7427 Tm
[( \(ng)10 (/mL)21 (\) )]TJ
12.131 0 Td
(\226 )Tj
9.42 0 Td
(352.32 \(184.44\) )Tj
ET
q
1 0 0 1 -8.215881 18.222748 cm
206.681 382.32 0.72 -13.8 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 382.32 0.72 -13.8 re
f
Q
BT
0 Tc 0 Tw 12 0 0 12 109.3047 375.9427 Tm
(T)Tj
0.0066 Tc 8.04 0 0 8.04 116.6247 374.3827 Tm
(1/2)Tj
-0.0009 Tc 0.0009 Tw 12 0 0 12 127.0647 375.9427 Tm
( \(hr\) )Tj
11.735 0 Td
(\226 )Tj
10.169 0 Td
(15.69 \(5.12\) )Tj
ET
q
1 0 0 1 -8.215881 18.222748 cm
206.681 368.52 0.72 -13.8 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 368.52 0.72 -13.8 re
f
Q
BT
-0.0003 Tc 0.0003 Tw 12 0 0 12 100.4247 362.1427 Tm
[(CL)21 (/F)6 ( \(L)21 (/hr\) )]TJ
13.95 0 Td
(\226 )Tj
10.17 0 Td
(17.96 \(6.27\) )Tj
ET
q
1 0 0 1 -8.215881 18.222748 cm
66.281 340.92 140.4 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
206.681 354.72 0.72 -13.8 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
206.681 340.92 0.72 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
207.401 340.92 143.28 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 354.72 0.72 -13.8 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
350.681 340.92 0.72 -0.72 re
f
Q
q
1 0 0 1 -8.215881 18.222748 cm
351.401 340.92 152.28 -0.72 re
f
Q
BT
-0.0005 Tc 0.0005 Tw 12 0 0 12 63.8247 347.6227 Tm
[(*The sing)10 (le and multiple dose data in this table were obtained following)10 ( a non-standardiz)-7 (ed meal )]TJ
-0.0004 Tc 0.0004 Tw 0 -1.15 TD
[(that is not comparable to the hig)10 (h-fat meal that was used in the study)30 ( in Table 2.  )]TJ
-0.0017 Tc 0.0017 Tw 0 -1.16 TD
[(\206)-12 (M)-2 (edian \(rang)8 (e\) )]TJ
-0.0008 Tc 0.0008 Tw 0 -2.31 TD
[(I)22 (n)-1 ( pediatric patients \(12 to 15 y)29 (ears\), the mean )]TJ
/T1_0 1 Tf
0 Tc 0 Tw 18.8 0 Td
(\007)Tj
/TT2 1 Tf
0.001 Tc -0.001 Tw 0.55 0 Td
[( SD e)5 (limina)5 (tion ha)5 (lf)4 (-)4 (live)5 (s \()4 (t)]TJ
0.0067 Tc 0 Tw 8.04 0 0 8.04 430.6647 290.6228 Tm
(1/2)Tj
-0.0002 Tc 0.0002 Tw 12 0 0 12 441.1047 292.1828 Tm
(\) of isotretinoin )Tj
-0.0006 Tc 0.0006 Tw -31.44 -1.22 Td
(and 4-)Tj
/TT1 1 Tf
-0.0019 Tc 0 Tw 2.52 0 Td
(oxo)Tj
/TT2 1 Tf
-0.0005 Tc 0.0005 Tw 1.44 0 Td
(-isotretinoin were 15.7 )Tj
/T1_0 1 Tf
0 Tc 0 Tw 9.32 0 Td
(\007)Tj
/TT2 1 Tf
-0.0003 Tc 0.0003 Tw 0.55 0 Td
( 5.1 hours and 23.1 )Tj
/T1_0 1 Tf
0 Tc 0 Tw 7.91 0 Td
(\007)Tj
/TT2 1 Tf
-0.0008 Tc 0.0008 Tw 0.55 0 Td
[( 5.7 hours, respectively)29 (.)-1 ( The )]TJ
-0.0004 Tc 0.0004 Tw -22.29 -1.16 Td
[(accumulation ratios of isotretinoin rang)10 (ed from 0.46 to 3.65 for pediatric patients. )]TJ
/TT3 1 Tf
-0.0014 Tc 0.0014 Tw 0 -2.22 TD
[(INDICAT)-4 (IONS)-5 ( AND US)-5 (AG)6 (E)-4 (:)]TJ
/TT1 1 Tf
-0.0007 Tc 0.0007 Tw 13.21 0 Td
( Severe Recalcitrant Nodular Acne:)Tj
/TT2 1 Tf
-0.001 Tc 0.001 Tw 14.25 0 Td
( Accutane is indicated for )Tj
-0.0009 Tc 0.0009 Tw -27.46 -1.15 Td
[(the treatment of severe recalcitrant nodular acne. Nodules are inflammat\ory)29 ( lesions with a )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(diameter of 5 mm or g)9 (r)2 (eater. The nodules may)29 ( become suppurative or hemorrhag)9 (ic. \223Severe,\224 by)29 ( )]TJ
0.0002 Tc 0 Tw T*
(definition,)Tj
0.0075 Tc 8.04 0 0 8.04 113.5047 201.1028 Tm
(2 )Tj
-0.0009 Tc 0.0009 Tw 12 0 0 12 119.6247 195.5827 Tm
[(means \223many)29 (\224)3 ( as opposed to \223few or several\224 nodules. B)6 (ecause of sig)9 (n)-1 (ificant )]TJ
ET
q
1 0 0 1 -8.215881 18.222748 cm
394.121 176.04 106.2 -0.6 re
f
Q
BT
12 0 0 12 63.8247 181.7827 Tm
(adverse effects associated with its use, Accutane should be reserved for\ patients with severe )Tj
ET
q
1 0 0 1 -8.215881 18.222748 cm
72.041 162.24 440.16 -0.6 re
f
Q
BT
-0.0006 Tc 0.0006 Tw 12 0 0 12 63.8247 167.9827 Tm
[(nodular acne who are unresponsive to conventional therapy)29 (,)-1 ( including)9 ( sy)29 (stemic antibiotics)]TJ
ET
q
1 0 0 1 -8.215881 18.222748 cm
72.041 148.44 433.56 -0.6 re
f
Q
BT
0 Tc 0 Tw 12 0 0 12 497.3847 167.9827 Tm
[(. I)23 (n )]TJ
-0.001 Tc 0.001 Tw -36.13 -1.15 Td
[(addition, Accutane is indicated only)29 ( for those females who are not preg)9 (nant, because Accutane )]TJ
-0.0015 Tc 0.0015 Tw T*
[(can cause severe birth defects \(see box)-11 (ed C)-4 (ONTR)-4 (A)1 (I)22 (NDI)22 (C)-4 (A)1 (TI)22 (ONS)-5 ( AND W)-8 (A)1 (R)-4 (N)1 (I)22 (NGS)-5 (\). )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0006 Tc 0.0006 Tw T*
[(A sing)9 (le course of therapy)29 ( for 15 to 20 weeks has been shown to result in complete and )]TJ
-0.0003 Tc 0.0003 Tw T*
[(prolong)10 (ed remission of disease in many)30 ( patients.)]TJ
0.0056 Tc 0 Tw 8.04 0 0 8.04 297.4647 104.5028 Tm
(1,3,4)Tj
-0.0009 Tc 0.0009 Tw 12 0 0 12 313.7847 98.9827 Tm
[( I)22 (f)2 ( a second course of therapy)29 ( is needed, it )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj133 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 210/Width 76>>stream
HK DzNuY$:&6eT|Z+(\80z^fLfu½$*ژ!J"/ȥ)IJZQEe8G^[-0/CuHP	z:59朑=y4f7´	Rކ7r-;@h8HxP)?D?1'j."6q_l d
endstreamendobj431 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 450 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 451 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj451 0 obj<</Font 452 0 R>>endobj452 0 obj<</ArialRoundedMTBold 231 0 R>>endobj450 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj430 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj426 0 obj<</Length 12244>>stream
q
1 0 0 1 -8.127075 18.512695 cm
0 0 612 792 re
W n
1 0 0 1 8.127075 -18.512695 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0017 Tc 0.0017 Tw 12 0 0 12 144.7935 647.6727 Tm
[(T)-5 (a)-2 (b)-5 (l)-4 (e 2. P)9 (h)-5 (arm)11 (a)-2 (cok)-5 (i)-4 (n)-5 (e)2 (ti)-4 (c P)9 (a)-2 (ram)11 (e)2 (ters of)-9 ( Isotreti)-4 (n)-5 (oi)-4 (n)-5 ( )]TJ
-0.0015 Tc 0.0015 Tw 6.93 -1.17 Td
[(Mean)-5 ( \(%)-11 (CV\), N=74 )]TJ
-0.0024 Tc 0.0024 Tw -12.43 -1.19 Td
[(Accu)-6 (tan)-6 (e)1 (  )]TJ
0 Tc 0 Tw -0.04 -1.15 Td
[(2 x 40 m)13 (g )]TJ
0.0027 Tc 0.12 -1.15 Td
[(C)5 (a)3 (psule)7 (s)2 ( )]TJ
-0.0022 Tc 7.69 2.22 Td
(AUC)Tj
0.0075 Tc 8.04 0 0 8.04 197.9535 616.8327 Tm
(0-)Tj
/T1_0 1 Tf
0 Tc 0.866 0 Td
(\004)Tj
-0.03 -0.03 Td
[(\004)683 (\004)]TJ
0 0.03 TD
(\004)Tj
/TT0 1 Tf
12 0 0 12 210.5535 618.3927 Tm
( )Tj
-0.003 Tc -3.98 -1.22 Td
[(\(n)-7 (g)]TJ
/T1_0 1 Tf
0 Tc 1.41 0 Td
(\005)Tj
-0.23 Tc -0.02 -0.02 Td
(\005\005)Tj
0 Tc 0 0.02 TD
(\005)Tj
/TT0 1 Tf
0.003 Tc 0.26 0 Td
[(hr)7 (/m)16 (L\))6 ( )]TJ
0 Tc 7.14 1.3 Td
(C)Tj
-0.027 Tc 8.04 0 0 8.04 276.9135 617.7927 Tm
[(ma)-34 (x)]TJ
0 Tc 12 0 0 12 291.4335 619.3527 Tm
( )Tj
-0.002 Tc -2.71 -1.15 Td
[(\(n)-6 (g/)-4 (m)11 (L)-5 (\) )]TJ
0 Tc 8.09 1.15 Td
(T)Tj
-0.027 Tc 8.04 0 0 8.04 364.0335 617.7927 Tm
[(ma)-34 (x)]TJ
0 Tc 12 0 0 12 378.5535 619.3527 Tm
( )Tj
-0.0032 Tc -1.77 -1.15 Td
[(\(h)-7 (r\) )]TJ
0 Tc 7.58 1.15 Td
(t)Tj
0.0067 Tc 8.04 0 0 8.04 452.2335 617.7927 Tm
(1/2)Tj
0 Tc 12 0 0 12 462.6735 619.3527 Tm
( )Tj
-0.0032 Tc -1.43 -1.15 Td
[(\(h)-7 (r\) )]TJ
ET
q
1 0 0 1 -8.127075 18.512695 cm
66.281 612.36 0.12 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.401 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.881 612.36 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
154.961 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
155.441 612.36 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
243.521 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
244.001 612.36 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.081 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.561 612.36 85.8 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.361 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.841 612.36 89.4 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.241 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 612.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.401 611.88 0.48 -41.4 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
154.961 611.88 0.48 -41.4 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
243.521 611.88 0.48 -41.4 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.081 611.88 0.48 -41.4 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.361 611.88 0.48 -41.4 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 611.88 0.48 -41.4 re
f
Q
BT
/TT1 1 Tf
-0.0011 Tc 0.0011 Tw 12 0 0 12 90.7935 577.7127 Tm
[(F)5 (e)3 (d* )-3390 (10,004 \(22%\) )-2270 (862 \(22%\) )-2920 (5.3 \(77%\) )-3230 (21 \(39%\) )]TJ
ET
q
1 0 0 1 -8.127075 18.512695 cm
66.401 570.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.881 570.48 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
154.961 570.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
155.441 570.48 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
243.521 570.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
244.001 570.48 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.081 570.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.561 570.48 85.8 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.361 570.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.841 570.48 89.52 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 570.48 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.401 570 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
154.961 570 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
243.521 570 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.081 570 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.361 570 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 570 0.48 -13.8 re
f
Q
BT
12 0 0 12 87.1935 563.4327 Tm
[(F)5 (a)3 (sted )-3330 (3,703 \(46%\) )-2520 (301 \(63%\) )-2920 (3.2 \(56%\) )-3230 (21 \(30%\) )]TJ
ET
q
1 0 0 1 -8.127075 18.512695 cm
66.401 556.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.881 556.2 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
154.961 556.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
155.441 556.2 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
243.521 556.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
244.001 556.2 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.081 556.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.561 556.2 85.8 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.361 556.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.841 556.2 89.52 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 556.2 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.401 555.72 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
154.961 555.72 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
243.521 555.72 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.081 555.72 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.361 555.72 0.48 -13.8 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 555.72 0.48 -13.8 re
f
Q
BT
-0.0019 Tc 0.0019 Tw 12 0 0 12 63.9135 541.1127 Tm
[(*Eat)-4 (i)-4 (n)-2 (g)8 ( a st)-4 (andardi)-4 (z)-8 (ed hi)-4 (g)8 (h)-2 (-fat)-4 ( m)-4 (eal)-4 ( )]TJ
ET
q
1 0 0 1 -8.127075 18.512695 cm
66.281 541.92 0.12 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.401 541.92 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
66.881 541.92 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
154.961 541.92 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
155.441 541.92 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
243.521 541.92 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
244.001 541.92 88.08 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.081 541.92 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
332.561 541.92 85.8 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.361 541.92 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
418.841 541.92 89.4 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.241 541.92 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 541.92 0.48 -0.48 re
f
Q
q
1 0 0 1 -8.127075 18.512695 cm
508.361 541.92 0.48 -0.48 re
f
Q
BT
/TT2 1 Tf
0.0008 Tc 0 Tw 12 0 0 12 63.9135 519.2727 Tm
(Distribution:)Tj
/TT1 1 Tf
0 Tc 5.23 0 Td
[( I)23 (s)-1 (otretinoin is more than 99.9% bound to plasma proteins, primarily)30 ( albumin. )]TJ
/TT2 1 Tf
0.0003 Tc -5.23 -2.23 Td
[(M)3 (e)4 (tabolism:)]TJ
/TT1 1 Tf
0.001 Tc -0.001 Tw 5.05 0 Td
[( F)7 (o)1 (llowing)11 ( or)4 (a)5 (l)-1 ( a)5 (d)1 (ministr)4 (a)5 (tion of)4 ( isotr)4 (e)5 (tinoin, a)5 (t)-1 ( le)5 (a)5 (st thr)4 (e)5 (e)5 ( me)5 (ta)5 (bolite)5 (s ha)5 (ve)5 ( be)5 (e)5 (n)1 ( )]TJ
-5.05 -1.15 Td
[(ide)5 (n)1 (tif)4 (ie)5 (d in huma)5 (n)1 ( pla)5 (sma)5 (:  4-)]TJ
/TT2 1 Tf
-0.0019 Tc 0 Tw 12.52 0 Td
(oxo)Tj
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 1.44 0 Td
(-isotretinoin, retinoic acid \(tretinoin\), and 4-)Tj
/TT2 1 Tf
-0.0019 Tc 0 Tw 17.67 0 Td
(oxo)Tj
/TT1 1 Tf
-0.0022 Tc 0.0022 Tw 1.44 0 Td
[(-ret)-4 (i)-4 (noi)-4 (c aci)-4 (d )]TJ
-0.0015 Tc 0 Tw -33.07 -1.15 Td
(\(4-)Tj
/TT2 1 Tf
-0.0019 Tc 1.16 0 Td
(oxo)Tj
/TT1 1 Tf
-0.0004 Tc 0.0004 Tw 1.44 0 Td
(-tretinoin\). Retinoic acid and 13-)Tj
/TT2 1 Tf
-0.0038 Tc 0 Tw 13.12 0 Td
[(ci)-6 (s)]TJ
/TT1 1 Tf
-0.0019 Tc 0.0019 Tw 1.11 0 Td
[(-ret)-4 (i)-4 (noi)-4 (c aci)-4 (d are g)8 (e)2 (om)-4 (et)-4 (ri)-4 (c i)-4 (s)-3 (om)-4 (ers and show )]TJ
-0.0005 Tc 0.0005 Tw -16.83 -1.15 Td
[(reversible interconversion. The administration of one isomer will g)10 (i)-3 (ve rise to the other. )]TJ
0 Tc 0 Tw 0 -1.15 TD
[(I)23 (s)-1 (otretinoin is also irreversibly)30 ( ox)-10 (idiz)-6 (ed to 4-)]TJ
/TT2 1 Tf
-0.0019 Tc 18.01 0 Td
(oxo)Tj
/TT1 1 Tf
-0.0002 Tc 0.0002 Tw 1.44 0 Td
[(-isotretinoin, which forms its g)10 (e)4 (ometric isomer )]TJ
0 Tc 0 Tw -19.45 -1.16 Td
(4-)Tj
/TT2 1 Tf
-0.0019 Tc 0.83 0 Td
(oxo)Tj
/TT1 1 Tf
-0.0001 Tc 0.0001 Tw 1.44 0 Td
(-tretinoin.  )Tj
-0.0007 Tc 0.0007 Tw -2.27 -2.22 Td
[(After a sing)9 (le 80 mg)9 ( oral dose of Accutane to 74 healthy)29 ( adult subjects, concurrent )]TJ
-0.0005 Tc 0.0005 Tw T*
[(administration of food increased the ex)-10 (tent of formation of all metabolites in plasma when )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.16 TD
[(compared to the ex)-11 (tent of formation under fasted conditions. )]TJ
0.001 Tc -0.001 Tw 0 -2.22 TD
[(All of)4 ( the)5 (se)5 ( me)5 (ta)5 (bolite)5 (s posse)5 (ss r)4 (e)5 (tinoid a)5 (c)5 (tivity)31 ( tha)5 (t)-1 ( is in some)5 ( in vitr)4 (o mode)5 (ls mor)4 (e)5 ( tha)5 (n)1 ( tha)5 (t)-1 ( of)4 ( )]TJ
-0.0007 Tc 0.0007 Tw 0 -1.15 TD
[(the parent isotretinoin. However, the clinical sig)9 (n)-1 (ificance of these models is unknown.  After )]TJ
0.0011 Tc -0.0011 Tw 0 -1.23 TD
[(multiple)5 ( or)4 (a)5 (l)-1 ( dose)5 ( a)5 (d)1 (ministr)4 (a)5 (tion of)4 ( isotr)4 (e)5 (tinoin to a)5 (dult c)5 (y)31 (stic)5 ( a)5 (c)5 (n)1 (e)5 ( pa)5 (tie)5 (nts \()]TJ
/T1_0 1 Tf
0 Tc 0 Tw 30.98 0 Td
(\006)Tj
/TT1 1 Tf
-0.0013 Tc 0.0013 Tw 0.55 0 Td
[(18 y)29 (ears\), the )]TJ
-0.0007 Tc 0.0007 Tw -31.53 -1.15 Td
[(ex)-11 (posure of patients to 4-)]TJ
/TT2 1 Tf
-0.0019 Tc 0 Tw (oxo)Tj
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 11.6 0 Td
[(-isotretinoin at steady)29 (-)2 (state under fasted and fed conditions was )]TJ
0 Tc 0 Tw -11.6 -1.16 Td
[(approx)-10 (imately)30 ( 3.4 times hig)10 (her than that of isotretinoin.  )]TJ
-0.0002 Tc 0.0002 Tw 0 -2.22 TD
[(I)23 (n vitro studies indicate that the primary)30 ( P450 isoforms involved in isotretinoin metabolism are )]TJ
0.0008 Tc -0.0008 Tw 0 -1.15 TD
[(2C8, 2C9, 3A4, a)5 (nd 2B)8 (6. I)24 (sotr)4 (e)5 (tinoin a)5 (nd its me)5 (ta)5 (bolite)5 (s a)5 (r)4 (e)5 ( f)4 (u)1 (r)4 (t)-1 (he)5 (r)4 ( me)5 (ta)5 (bolize)5 (d)1 ( into c)5 (onjug)11 (a)5 (t)-1 (e)5 (s, )]TJ
-0.0021 Tc 0.0021 Tw 0 -1.16 TD
[(whi)-4 (c)2 (h are t)-4 (h)-2 (en ex)-12 (cret)-4 (ed i)-4 (n)-2 ( uri)-4 (n)-2 (e and feces. )]TJ
/TT2 1 Tf
0.0007 Tc 0 Tw 0 -2.23 TD
(Elimination:)Tj
/TT1 1 Tf
-0.0002 Tc 0.0002 Tw 5.06 0 Td
[( F)6 (ollowing)10 ( oral administration of an 80 mg)10 ( dose of )]TJ
0.0075 Tc 0 Tw 8.04 0 0 8.04 372.1935 210.5127 Tm
(14)Tj
0 Tc 12 0 0 12 380.3535 204.9927 Tm
(C-isotretinoin as a liquid )Tj
0.0001 Tc -26.37 -1.15 Td
(suspension, )Tj
0.0075 Tc 8.04 0 0 8.04 122.5935 196.7127 Tm
(14)Tj
-0.0004 Tc 0.0004 Tw 12 0 0 12 130.7535 191.1928 Tm
[(C-activity)30 ( in blood declined with a half-life of 90 hours. The metabolites of )]TJ
-0.0007 Tc 0.0007 Tw -5.57 -1.15 Td
[(isotretinoin and any)29 ( conjug)9 (ates are ultimately)29 ( ex)-11 (creted in the feces and urine in relatively)29 ( equal )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.15 TD
[(amounts \(total of 65% to 83%\). After a sing)10 (le 80 mg)10 ( oral dose of Accutane to 74 healthy)30 ( adult )]TJ
-0.0006 Tc 0.0006 Tw 0 -1.23 TD
(subjects under fed conditions, the mean )Tj
/T1_0 1 Tf
0 Tc 0 Tw 16.06 0 Td
(\007)Tj
/TT1 1 Tf
0.001 Tc -0.001 Tw 0.55 0 Td
[( SD e)5 (limina)5 (tion ha)5 (lf)4 (-)4 (live)5 (s \()4 (t)]TJ
0.0067 Tc 0 Tw 8.04 0 0 8.04 397.8735 147.2727 Tm
(1/2)Tj
-0.0003 Tc 0.0003 Tw 12 0 0 12 408.3135 148.8327 Tm
(\) of isotretinoin and 4-)Tj
/TT2 1 Tf
-0.0019 Tc 0 Tw -28.7 -1.22 Td
(oxo)Tj
/TT1 1 Tf
-0.0005 Tc 0.0005 Tw 1.44 0 Td
(-isotretinoin were 21.0 )Tj
/T1_0 1 Tf
0 Tc 0 Tw 9.32 0 Td
(\007)Tj
/TT1 1 Tf
-0.0003 Tc 0.0003 Tw 0.55 0 Td
( 8.2 hours and 24.0 )Tj
/T1_0 1 Tf
0 Tc 0 Tw 7.91 0 Td
(\007)Tj
/TT1 1 Tf
-0.0006 Tc 0.0006 Tw 0.55 0 Td
[( 5.3 hours, respectively)29 (.)-1 ( After both sing)9 (le and )]TJ
-0.0003 Tc 0.0003 Tw -19.77 -1.15 Td
[(multiple doses, the observed accumulation ratios of isotretinoin rang)10 (ed from 0.90 to 5.43 in )]TJ
0.001 Tc -0.001 Tw 0 -1.16 TD
[(pa)5 (tie)5 (nts with c)5 (y)31 (stic)5 ( a)5 (c)5 (n)1 (e)5 (.)1 (  )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj132 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 187/Width 76>>stream
HK0D{uOu% 4[ڊB鈡J`6DIL,eRTr8(_g]zfVcP)eJJ*9JZ{ּ,O#ftpjfH(GG!4qk-a_^q^9'zrf ܜ
endstreamendobj428 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 453 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 454 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj454 0 obj<</Font 455 0 R>>endobj455 0 obj<</ArialRoundedMTBold 231 0 R>>endobj453 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj427 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj185 0 obj<</Contents 456 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 172 0 R/Resources<</ColorSpace<</CS0 202 0 R/CS1 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 457 0 R>>/Font<</T1_0 188 0 R/TT0 186 0 R/TT1 187 0 R>>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject<</Fm0 458 0 R/Im0 203 0 R/Im1 199 0 R>>>>/Rotate 0/Thumb 126 0 R/Type/Page>>endobj1 0 obj<</Contents 459 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 172 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 460 0 R>>/Font<</T1_0 188 0 R/T1_1 108 0 R/T1_2 110 0 R/TT0 187 0 R/TT1 105 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 461 0 R>>>>/Rotate 0/Thumb 127 0 R/Type/Page>>endobj6 0 obj<</Contents 462 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 172 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 463 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 464 0 R>>>>/Rotate 0/Thumb 128 0 R/Type/Page>>endobj8 0 obj<</Contents 465 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 172 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 466 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 467 0 R>>>>/Rotate 0/Thumb 129 0 R/Type/Page>>endobj10 0 obj<</Contents 468 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 172 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 469 0 R>>/Font<</T1_0 188 0 R/TT0 187 0 R/TT1 105 0 R/TT2 186 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 470 0 R>>>>/Rotate 0/Thumb 130 0 R/Type/Page>>endobj12 0 obj<</Contents 471 0 R/CropBox[0 0 612 792]/MediaBox[0 0 612 792]/Parent 172 0 R/Resources<</ColorSpace<</CS0 190 0 R>>/ExtGState<</GS0 196 0 R/GS1 472 0 R>>/Font<</TT0 186 0 R/TT1 112 0 R/TT2 187 0 R/TT3 105 0 R>>/ProcSet[/PDF/Text/ImageB]/XObject<</Fm0 473 0 R/Im0 14 0 R>>>>/Rotate 0/Thumb 131 0 R/Type/Page>>endobj471 0 obj<</Length 4852>>stream
q
1 0 0 1 -5.320251 -35.477295 cm
0 0 612 792 re
W n
1 0 0 1 5.320251 35.477295 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 12 0 0 12 66.7203 601.7227 Tm
[(f)4 (o)1 (llowing)11 ( dy)31 (e)5 ( sy)31 (ste)5 (m)-1 (s: 10 mg)11 ( \227 ir)4 (on ox)-9 (ide)5 ( \()4 (r)4 (e)5 (d\))4 ( a)5 (nd tita)5 (nium diox)-9 (ide)5 (;)-1 ( 20 mg)11 ( \227 F)7 (D)3 (&)9 (C)-2 ( Re)5 (d )]TJ
0.0001 Tc -0.0001 Tw 0 -1.15 TD
[(No. 3, F)6 (D)2 (&)8 (C)-3 ( B)7 (l)-2 (ue)4 ( No. 1, a)4 (nd tita)4 (nium diox)-10 (ide)4 (;)-2 ( 40 mg)10 ( \227 F)6 (D)2 (&)8 (C)-3 ( Ye)4 (llow No. 6, D&)8 (C Ye)4 (llow )]TJ
0 -1.16 TD
[(No. 10, and titanium diox)-10 (ide. )]TJ
0.0003 Tc -0.0003 Tw 0 -2.22 TD
[(Chemically)30 (, isotretinoin is 13-)]TJ
/TT1 1 Tf
-0.0038 Tc 0 Tw 12.14 0 Td
[(ci)-6 (s)]TJ
/TT0 1 Tf
-0.0006 Tc 0.0006 Tw 1.11 0 Td
(-retinoic acid and is related to both retinoic acid and retinol )Tj
-13.25 -1.15 Td
[(\(vitamin A\). I)22 (t)-3 ( is a y)29 (e)3 (llow to orang)9 (e)3 ( cry)29 (s)-1 (talline powder with a molecular weig)9 (ht of 300.44. The )]TJ
-0.0019 Tc 0.0019 Tw 0 -1.16 TD
[(st)-4 (ruct)-4 (ural)-4 ( form)-4 (ul)-4 (a i)-4 (s)-3 (:)-4 ( )]TJ
ET
q
1 0 0 1 -5.320251 -35.477295 cm
72.041 539.16 144 -39 re
f*
Q
q
/CS0 cs 1 1 1  scn
144 0 0 39 66.7203526 464.6827087 cm
/Im0 Do
Q
BT
/TT2 1 Tf
0 Tc 0 Tw 12 0 0 12 210.7203 464.6827 Tm
( )Tj
-0.0015 Tc 0.0015 Tw -12 -1.98 Td
[(CL)-4 (INICAL)-4 ( P)9 (H)-4 (ARMACOL)-4 (O)-4 (G)6 (Y)1 (:)]TJ
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw [( I)23 (s)-1 (otretinoin is a retinoid, which when administered in )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(pharmacolog)9 (i)-3 (c dosag)9 (es of 0.5 to 1.0 mg)9 (/kg)9 (/)-3 (day)29 ( \(see DOSAGE AND ADMI)22 (N)1 (I)22 (S)-5 (TRATI)22 (ON\), )]TJ
-0.0006 Tc 0.0006 Tw T*
[(inhibits sebaceous g)9 (l)-3 (and function and keratiniz)-7 (ation. The ex)-11 (act mechanism of action of )]TJ
0.0002 Tc -0.0002 Tw 0 -1.16 TD
(isotretinoin is unknown. )Tj
/TT3 1 Tf
0.001 Tc -0.001 Tw 0 -2.22 TD
(Nodular Acne)Tj
/TT1 1 Tf
0 Tc 0 Tw 5.81 0 Td
(:)Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw 0.33 0 Td
( Clinical improvement in nodular acne patients occurs in association wit\h a )Tj
-0.0008 Tc 0.0008 Tw -6.14 -1.15 Td
[(reduction in sebum secretion. The decrease in sebum secretion is tempora\ry)29 ( and is related to the )]TJ
0 -1.15 TD
[(dose and duration of treatment with Accutane, and reflects a reduction i\n sebaceous g)9 (l)-3 (and siz)-7 (e)3 ( )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
[(and an inhibition of sebaceous g)10 (l)-3 (and differentiation.)]TJ
0.0075 Tc 0 Tw 8.04 0 0 8.04 316.5603 336.7627 Tm
(1 )Tj
/TT3 1 Tf
0 Tc 12 0 0 12 66.7203 304.4827 Tm
[(Pharm)-12 (acokinetics:  )]TJ
/TT1 1 Tf
0.0005 Tc (Absorption:)Tj
/TT0 1 Tf
0.0002 Tc -0.0002 Tw 13.07 0 Td
[( Due to its hig)10 (h lipophilicity)30 (, oral absorption of isotretinoin is )]TJ
-0.0007 Tc 0.0007 Tw -13.07 -1.15 Td
[(enhanced when g)9 (i)-3 (ven with a hig)9 (h)-1 (-fat meal. I)22 (n)-1 ( a crossover study)29 (, 74 healthy)29 ( adult subjects )]TJ
-0.001 Tc 0.001 Tw 0 -1.15 TD
[(received a sing)9 (le 80 mg)9 ( oral dose \(2 x)-11 ( 40 mg)9 ( capsules\) of Accutane under fasted and fed )]TJ
-0.0005 Tc 0.0005 Tw T*
[(conditions. B)7 (oth peak plasma concentration \(C)]TJ
-0.0017 Tc 0 Tw 8.04 0 0 8.04 291.7203 261.5228 Tm
[(ma)-6 (x)]TJ
-0.0008 Tc 0.0008 Tw 12 0 0 12 305.5203 263.0828 Tm
[(\) and the total ex)-11 (posure \(AUC\) of isotretinoin )]TJ
-19.9 -1.14 Td
[(were more than doubled following)9 ( a standardiz)-7 (ed hig)9 (h)-1 (-fat meal when compared with Accutane )]TJ
-0.0009 Tc 0.0009 Tw T*
[(g)9 (i)-3 (ven under fasted conditions \(see Table 2 below\). The observed eliminat\ion half-life was )]TJ
-0.0006 Tc 0.0006 Tw T*
[(unchang)9 (ed. This lack of chang)9 (e)3 ( in half-life sug)9 (g)9 (e)3 (sts that food increases the bioavailability)29 ( of )]TJ
-0.0001 Tc 0.0001 Tw T*
[(isotretinoin without altering)10 ( its disposition. The time to peak concentration \(T)]TJ
-0.0017 Tc 0 Tw 8.04 0 0 8.04 440.1603 206.4427 Tm
[(ma)-6 (x)]TJ
-0.0011 Tc 0.0011 Tw 12 0 0 12 453.9603 208.0028 Tm
(\) was also )Tj
-32.27 -1.15 Td
[(increased with food and may)29 ( be related to a long)9 (er absorption phase. Therefore, Accutane )]TJ
-0.0008 Tc 0.0008 Tw T*
[(capsules should alway)29 (s)-2 ( be taken with food \(see DOSAGE AND ADMI)22 (N)1 (I)22 (S)-5 (TRATI)22 (ON\). Clinical )]TJ
-0.0007 Tc 0.0007 Tw T*
(studies have shown that there is no difference in the pharmacokinetics o\f isotretinoin between )Tj
-0.0003 Tc 0.0003 Tw 0 -1.16 TD
[(patients with nodular acne and healthy)30 ( subjects with normal skin. )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj131 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 148/Width 76>>stream
HA
0~ǃx*&6aG(`2[[;B&^hȇtk	p%l9{tzNr8OPZjJؿ^Kjf\ޜV!#^yL"?8{
/G-l"! 7d
endstreamendobj473 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 474 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 475 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj14 0 obj<</BitsPerComponent 1/DecodeParms<</BlackIs1 false/Columns 600/EncodedByteAlign true/EndOfLine false/K -1/Rows 163>>/Filter/CCITTFaxDecode/Height 163/ImageMask true/Length 948/Subtype/Image/Type/XObject/Width 600>>stream
&$S<6?O_______DQIa8Ah89&ay8a&Ay0&I$AAaAl $ܠ$ Ia6ai7a I80l &aAMnAMaÀaAMnAMaÀaAMnAn8aA04paam"
! ]pAC4
$&&iCl &aal06  al0l7	0i0al8al6Mࠛ	m& ah&a m& $aAAÀh&a m&$nimal66a$aaim$l8a l0a࠘Bm(6À	0h0	i0ab؆>al6|l0|l6|l0|l6|l6i"-p<0@L!܂D0AlG	MVUu{||u÷~uuMki6i|0ڱLS k0F͈L8A	AMA	8	AM0MAML87L8AIං@H`PPP
P 
endstreamendobj475 0 obj<</Font 476 0 R>>endobj476 0 obj<</ArialRoundedMTBold 231 0 R>>endobj474 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj472 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj468 0 obj<</Length 7276>>stream
q
1 0 0 1 -4.390961 14.252686 cm
0 0 612 792 re
W n
1 0 0 1 4.390961 -14.252686 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0022 Tc -0.0022 Tw 12 0 0 12 75.0896 651.2127 Tm
[(pr)6 (e)6 (s)1 (c)6 (r)6 (ibe)6 (r)6 ( and pat)5 (ie)6 (n)-2 (t)5 ( should disc)6 (uss t)5 (h)-2 (e)6 ( de)6 (sir)6 (a)2 (bilit)5 (y of c)6 (o)2 (nt)5 (inuing t)5 (h)-2 (e)6 ( pr)6 (e)6 (g)2 (nanc)6 (y. )]TJ
-0.0019 Tc 0.0019 Tw 0 -1.15 TD
[(P)9 (rescri)-4 (b)-6 (ers are stron)-6 (g)-2 (l)-4 (y)-2 ( en)-6 (cou)-6 (r)2 (aged)-6 ( to rep)-6 (ort al)-4 (l)-4 ( cases of)-9 ( p)-6 (regn)-6 (a)-2 (n)-6 (c)2 (y to Roch)-6 (e )]TJ
-0.0005 Tc 0.0005 Tw T*
[(@ 1-800-526-6367 w)-8 (h)-4 (ere a Roche P)10 (regnancy P)10 (revention P)10 (r)3 (ogram)13 ( Specialist w)-8 (ill be )]TJ
-0.0019 Tc 0.0019 Tw T*
[(avai)-4 (l)-4 (a)-2 (b)-6 (l)-4 (e to d)-6 (i)-4 (scu)-6 (ss Roch)-6 (e p)-6 (regn)-6 (a)-2 (n)-6 (c)2 (y i)-4 (n)-6 (f)-9 (o)-2 (rm)11 (ati)-4 (o)-2 (n)-6 (,)-2 ( or p)-6 (rescri)-4 (b)-6 (ers m)11 (ay con)-6 (t)1 (act th)-6 (e )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.16 TD
[(F)11 (ood and Drug Adm)13 (i)-2 (nistration MedWatch P)11 (r)4 (ogram)13 ( @ 1-800-F)11 (DA-1088. )]TJ
-0.0017 Tc 0.0017 Tw 0 -2.22 TD
[(Accu)-5 (tan)-5 (e)2 ( sh)-5 (ou)-5 (l)-4 (d)-5 ( b)-5 (e)2 ( p)-5 (rescri)-4 (b)-5 (e)2 (d)-5 ( on)-5 (l)-4 (y)-2 ( b)-5 (y)-2 ( p)-5 (rescri)-4 (b)-5 (ers w)-9 (h)-5 (o h)-5 (ave d)-5 (e)2 (m)11 (o)-2 (n)-5 (s)-2 (trated)-5 ( sp)-5 (eci)-4 (al)-4 ( )]TJ
-0.0021 Tc 0.0021 Tw 0 -1.15 TD
[(com)11 (p)-6 (eten)-6 (ce i)-4 (n)-6 ( th)-6 (e d)-6 (i)-4 (agn)-6 (osi)-4 (s)-3 ( an)-6 (d)-6 ( treatm)11 (en)-6 (t of)-9 ( severe recal)-4 (c)2 (i)-4 (t)1 (ran)-6 (t)1 ( n)-6 (o)-2 (d)-6 (u)-6 (l)-4 (ar acn)-6 (e)2 (, are )]TJ
T*
[(exp)-6 (eri)-4 (en)-6 (ced)-6 ( i)-4 (n)-6 ( th)-6 (e u)-6 (s)-3 (e of)-9 ( system)11 (i)-4 (c)2 ( reti)-4 (n)-6 (oi)-4 (d)-6 (s)-3 (, h)-6 (ave read)-6 ( th)-6 (e S)-6 (.)-2 (M.A.R.T)-5 (.)]TJ
/TT1 1 Tf
0.0013 Tc -0.0013 Tw [( Guide)5 ( to Be)5 (st )]TJ
-0.0015 Tc 0 Tw T*
[(Pract)-4 (i)-4 (ces,)]TJ
/TT0 1 Tf
0.0026 Tc -0.0026 Tw [( signe)6 (d)-1 ( and r)6 (e)6 (t)6 (ur)6 (ne)6 (d t)6 (h)-1 (e)6 ( )]TJ
/TT1 1 Tf
0.0015 Tc 0 Tw [(c)5 (o)2 (m)-11 (p)2 (le)5 (te)5 (d )]TJ
/TT0 1 Tf
-0.0014 Tc 19.14 0 Td
[(S)-5 (.)-1 (M.A.R.T)-4 (.)-1 ( )]TJ
/TT1 1 Tf
0.0004 Tc -0.0004 Tw 5.11 0 Td
(Letter of Understanding)Tj
/TT0 1 Tf
0 Tc 0 Tw 9.95 0 Td
(, )Tj
0.002 Tc -0.002 Tw -34.2 -1.15 Td
[(and obt)5 (a)2 (ine)6 (d)-2 ( ye)6 (llow)-6 ( se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Qualific)6 (at)5 (ion St)5 (ic)6 (ke)6 (r)6 (s)1 (.  Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( should )]TJ
0.0024 Tc -0.0024 Tw T*
[(not)5 ( be)6 ( pr)6 (e)6 (s)2 (c)6 (r)6 (ibe)6 (d or)6 ( dispe)6 (n)-1 (se)6 (d wit)5 (h)-1 (out)5 ( a ye)6 (llow se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( A)5 (c)6 (c)6 (u)-1 (t)5 (a)2 (ne)6 ( )]TJ
0 -1.16 TD
[(Qualific)6 (at)6 (ion St)6 (ic)6 (ke)6 (r)6 (.)]TJ
/TT2 1 Tf
0 Tc 0 Tw 9.18 0 Td
( )Tj
ET
q
1 0 0 1 -4.390961 14.252686 cm
71.801 648 0.48 -191.64 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
519.161 648 0.48 -191.64 re
f
Q
BT
/TT0 1 Tf
-0.0016 Tc 0.0016 Tw 12 0 0 12 75.0896 458.9727 Tm
[(INF)9 (O)-4 (RMAT)-5 (ION F)9 (O)-4 (R P)9 (H)-4 (ARMACIS)-5 (T)-5 (S)-5 (:)]TJ
ET
q
1 0 0 1 -4.390961 14.252686 cm
79.481 443.4 212.88 -1.2 re
f
Q
BT
0 Tc 0 Tw 12 0 0 12 287.9696 458.9727 Tm
( )Tj
-0.0016 Tc 0.0016 Tw -17.74 -2.23 Td
[(ACCUT)-5 (ANE)-5 ( MUS)-5 (T)-5 ( ONL)-5 (Y)1 ( B)-5 (E)-5 ( DIS)-5 (P)9 (E)-5 (N)1 (S)-5 (E)-5 (D: )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -0.6 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0014 Tc 0.0014 Tw 1.5 0 Td
[(IN NO MORE)-4 ( T)-4 (H)-4 (AN A 30-DAY S)-5 (U)1 (P)9 (P)9 (L)-4 (Y )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
-0.0008 Tc 0.0008 Tw 1.5 0 Td
[(ONL)-4 (Y)1 ( ON P)10 (R)1 (E)-4 (S)-5 (E)-4 (N)1 (T)-4 (A)1 (T)-4 (I)-2 (ON OF)10 ( AN ACCUT)-4 (ANE)-4 ( P)10 (R)1 (E)-4 (S)-5 (CRIP)10 (T)-4 (ION WIT)-4 (H)-3 ( A )]TJ
0.0004 Tc -0.0004 Tw 0 -1.15 TD
[(YELLOW SELF)11 (-ADHESIVE ACCUTANE QUALIF)11 (ICATION STICK)8 (E)-3 (R  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
0.0007 Tc -0.0007 Tw 1.5 0 Td
[(WRITTEN WITHIN THE P)12 (R)3 (EVIOUS 7 DAYS )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
0.002 Tc -0.002 Tw 1.5 0 Td
[(R)4 (E)-1 (F)13 (I)1 (LLS R)4 (E)-1 (QU)4 (IR)4 (E A)4 ( N)4 (E)-1 (W P)13 (R)4 (ESC)4 (R)4 (I)1 (P)13 (T)-1 (ION)4 ( WITH A)4 ( Y)4 (ELLOW SELF)13 (-)]TJ
-0.0012 Tc 0.0012 Tw T*
[(ADHE)-4 (S)-5 (IVE)-4 ( ACCUT)-4 (ANE)-4 ( QUAL)-4 (IF)10 (ICAT)-4 (ION S)-5 (T)-4 (ICK)7 (E)-4 (R  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
0.0022 Tc -0.0022 Tw 1.5 0 Td
[(N)4 (O TELEP)13 (HON)4 (E OR)4 ( C)4 (OM)6 (P)13 (U)4 (TER)4 (IZ)9 (ED)4 ( P)13 (R)4 (ESC)4 (R)4 (I)1 (P)13 (T)-1 (ION)4 (S)-2 ( A)4 (R)4 (E)-1 ( )]TJ
0.0018 Tc 0 Tw T*
[(P)13 (E)-1 (R)4 (M)6 (ITTED)4 (. )]TJ
-0.0017 Tc 0.0017 Tw -0.9 -2.23 Td
[(AN ACCUT)-5 (ANE)-5 ( ME)-5 (DICAT)-5 (ION G)6 (U)1 (IDE)-5 ( MUS)-5 (T)-5 ( B)-5 (E)-5 ( G)6 (I)-2 (VE)-5 (N T)-5 (O)-4 ( T)-5 (H)-4 (E)-5 ( P)9 (A)1 (T)-5 (I)-2 (E)-5 (N)1 (T)-5 ( )]TJ
-0.0009 Tc 0.0009 Tw T*
[(E)-4 (ACH T)-4 (I)-2 (ME)-4 ( ACCUT)-4 (ANE)-4 ( IS)-5 ( DIS)-5 (P)10 (E)-4 (N)1 (S)-5 (E)-4 (D, AS)-5 ( RE)-4 (QUIRE)-4 (D)1 ( B)-4 (Y)1 ( L)-4 (A)1 (W.  T)-4 (H)-3 (IS)-5 ( )]TJ
-0.0013 Tc 0.0013 Tw T*
[(ACCUT)-4 (ANE)-4 ( ME)-4 (DICAT)-4 (ION G)7 (U)1 (IDE)-4 ( IS)-5 ( AN IMP)10 (O)-3 (RT)-4 (ANT)-4 ( P)10 (ART)-4 ( OF)10 ( T)-4 (H)-3 (E)-4 ( RIS)-5 (K)7 ( )]TJ
-0.0016 Tc 0.0016 Tw 0 -1.16 TD
[(MANAG)6 (E)-5 (M)2 (E)-5 (N)1 (T)-5 ( P)9 (R)1 (OG)6 (RAM F)9 (O)-4 (R T)-5 (H)-4 (E)-5 ( P)9 (A)1 (T)-5 (I)-2 (E)-5 (N)1 (T)-5 (.)-2 ( )]TJ
ET
q
1 0 0 1 -4.390961 14.252686 cm
71.801 456.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
72.281 456.36 446.88 -0.48 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
519.161 456.36 0.48 -0.48 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
71.801 455.88 0.48 -301.44 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
71.801 154.44 0.48 -0.48 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
71.801 154.44 0.48 -0.48 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
72.281 154.44 446.88 -0.48 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
519.161 455.88 0.48 -301.44 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
519.161 154.44 0.48 -0.48 re
f
Q
q
1 0 0 1 -4.390961 14.252686 cm
519.161 154.44 0.48 -0.48 re
f
Q
BT
-0.001 Tc 0 Tw 12 0 0 12 67.6496 144.3327 Tm
[(DE)-4 (S)-5 (CRIP)10 (T)-4 (ION:)]TJ
/TT2 1 Tf
-0.0004 Tc 0.0004 Tw 7.27 0 Td
[( I)23 (s)-1 (otretinoin, a retinoid, is available as Accutane in 10-mg)10 (, 20-mg)10 ( and 40-mg)10 ( )]TJ
-0.0006 Tc 0.0006 Tw -7.27 -1.15 Td
[(soft g)9 (e)3 (latin capsules for oral administration. Each capsule contains beeswax)-11 (,)-1 ( buty)29 (l)-3 (ated )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.15 TD
[(hy)30 (drox)-10 (y)30 (a)3 (nisole, edetate disodium, hy)30 (drog)10 (enated soy)30 (bean oil flakes, hy)30 (drog)10 (enated veg)10 (e)3 (table oil, )]TJ
-0.0006 Tc 0.0006 Tw T*
[(and soy)29 (b)-1 (ean oil. Gelatin capsules contain g)9 (l)-3 (y)29 (cerin and parabens \(methy)29 (l and propy)29 (l\), with the )]TJ
ET
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj130 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 186/Width 76>>stream
HQ
0CwrAζfm/YǨT*ʊ=t yɬ\/ֽ #+˳tHVzE{^v3u^dU$tey*ɲ}Q,:)^HMeYH/$:{wҋey{Yk^zKI/t\liU* |)
endstreamendobj470 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 477 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 478 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj478 0 obj<</Font 479 0 R>>endobj479 0 obj<</ArialRoundedMTBold 231 0 R>>endobj477 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj469 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj465 0 obj<</Length 14067>>stream
q
1 0 0 1 3.168243 21.072021 cm
0 0 612 792 re
W n
1 0 0 1 -3.168243 -21.072021 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
-0.0019 Tc 0.0019 Tw 12 0 0 12 89.8488 657.552 Tm
[(P)9 (a)-2 (ti)-4 (en)-6 (ts m)11 (u)-6 (st recei)-4 (ve w)-10 (r)2 (i)-4 (tten)-6 ( w)-10 (a)-2 (rn)-6 (i)-4 (n)-6 (gs ab)-6 (ou)-6 (t th)-6 (e rates of)-9 ( p)-6 (o)-2 (ssi)-4 (b)-6 (l)-4 (e con)-6 (t)1 (racep)-6 (ti)-4 (on)-6 ( )]TJ
0.0028 Tc -0.0028 Tw 0 -1.15 TD
[(failur)7 (e)7 ( \()6 (i)1 (nc)7 (lude)7 (d in pat)6 (i)1 (e)7 (n)-1 (t)6 ( e)7 (duc)7 (at)6 (ion kit)6 (s)2 (\))6 (.)3 ( )]TJ
0 Tc 0 Tw T*
( )Tj
-0.0018 Tc 0.0018 Tw T*
[(P)9 (rescri)-4 (b)-6 (ers are ad)-6 (vi)-4 (sed)-6 ( to con)-6 (s)-3 (u)-6 (l)-4 (t th)-6 (e p)-6 (a)-2 (ck)-6 (age i)-4 (n)-6 (sert of)-9 ( an)-6 (y m)11 (e)2 (d)-6 (i)-4 (cati)-4 (on)-6 ( )]TJ
-0.0015 Tc 0.0015 Tw T*
[(ad)-5 (m)12 (i)-4 (n)-5 (i)-4 (stered)-5 ( con)-5 (c)2 (om)12 (i)-4 (t)2 (an)-5 (tl)-4 (y w)-9 (i)-4 (th)-5 ( h)-5 (o)-1 (rm)12 (on)-5 (al)-4 ( con)-5 (t)2 (racep)-5 (ti)-4 (ves, si)-4 (n)-5 (ce som)12 (e)2 ( m)12 (e)2 (d)-5 (i)-4 (cati)-4 (on)-5 (s )]TJ
-0.0018 Tc 0.0018 Tw T*
[(m)11 (ay d)-6 (ecrease th)-6 (e ef)-9 (f)-9 (ecti)-4 (v)-2 (en)-6 (ess of)-9 ( th)-6 (ese b)-6 (i)-4 (rth)-6 ( con)-6 (t)1 (rol)-4 ( p)-6 (r)2 (od)-6 (u)-6 (c)2 (ts. P)9 (a)-2 (ti)-4 (en)-6 (ts sh)-6 (ou)-6 (l)-4 (d)-6 ( b)-6 (e)2 ( )]TJ
0.0021 Tc -0.0021 Tw T*
[(pr)6 (ospe)6 (c)6 (t)5 (ive)6 (ly c)6 (a)2 (ut)5 (ione)6 (d not)5 ( t)5 (o)2 ( se)6 (lf-)5 (m)15 (e)6 (d)-2 (ic)6 (at)5 (e)6 ( wit)5 (h)-2 ( t)5 (h)-2 (e)6 ( he)6 (r)6 (b)-2 (al supple)6 (m)15 (e)6 (n)-2 (t)5 ( St)5 (. John\222)5 (s )]TJ
-0.0017 Tc 0.0017 Tw T*
[(Wort b)-5 (ecau)-5 (s)-2 (e a p)-5 (o)-2 (ssi)-4 (b)-5 (l)-4 (e i)-4 (n)-5 (teracti)-4 (o)-2 (n)-5 ( h)-5 (a)-2 (s b)-5 (een)-5 ( su)-5 (ggested)-5 ( w)-9 (i)-4 (th)-5 ( h)-5 (o)-2 (rm)11 (on)-5 (al)-4 ( )]TJ
-0.0001 Tc 0.0001 Tw T*
[(contraceptives based on reports of)-7 ( breakthrough bleeding on oral contraceptives )]TJ
-0.0003 Tc 0.0003 Tw T*
[(shortly af)-7 (ter starting St. John's Wort.  P)11 (regnancies have been reported by users of)-7 ( )]TJ
-0.0001 Tc 0.0001 Tw T*
[(com)13 (b)-4 (ined horm)13 (onal contraceptives w)-8 (h)-4 (o also used som)13 (e)4 ( f)-7 (orm)13 ( of)-7 ( St. John's Wort )]TJ
-0.0017 Tc 0.0017 Tw 0 -1.16 TD
[(\(see P)9 (R)1 (E)-5 (CAUT)-5 (IONS)-5 (\).  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.2 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0015 Tc 1.5 0 Td
[(Mu)-5 (st)]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
90.281 455.64 26.64 -1.2 re
f
Q
BT
0 Tc 12 0 0 12 120.0888 478.032 Tm
[( have signed a P)11 (atient Inf)-7 (orm)13 (ation/Consent f)-7 (orm)13 ( that contains w)-8 (arnings )]TJ
0.0022 Tc -0.0022 Tw -2.22 -1.15 Td
[(about)5 ( t)5 (h)-2 (e)6 ( r)6 (isk of pot)5 (e)6 (nt)5 (ial bir)6 (t)5 (h de)6 (fe)6 (c)6 (t)5 (s if t)5 (h)-2 (e)6 ( fe)6 (t)5 (u)-2 (s is e)6 (x)2 (pose)6 (d t)5 (o)2 ( isot)5 (r)6 (e)6 (t)5 (inoin. )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
-0.0015 Tc 1.5 0 Td
[(Mu)-5 (st)]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
90.281 414.12 26.64 -1.2 re
f
Q
BT
0.0001 Tc -0.0001 Tw 12 0 0 12 120.0888 436.512 Tm
[( have been inf)-7 (orm)13 (ed of)-7 ( the purpose and im)13 (portance of)-7 ( participating in the )]TJ
0.0018 Tc -0.0018 Tw -2.22 -1.14 Td
[(A)4 (c)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Sur)6 (ve)6 (y and have)6 ( be)6 (e)6 (n)-2 ( give)6 (n t)5 (h)-2 (e)6 ( oppor)6 (t)5 (unit)5 (y)2 ( t)5 (o)2 ( e)6 (n)-2 (r)6 (o)2 (ll \()5 (s)1 (e)6 (e)6 ( )]TJ
-0.0013 Tc 0 Tw T*
[(P)10 (R)1 (E)-4 (CAUT)-4 (IONS)-5 (\). )]TJ
0.0022 Tc -0.0022 Tw -0.9 -2.22 Td
[(The)6 ( ye)6 (llow)-6 ( se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Qualific)6 (at)5 (ion St)5 (ic)6 (ke)6 (r)6 ( doc)6 (u)-2 (m)15 (e)6 (nt)5 (s t)5 (h)-2 (at)5 ( t)5 (h)-2 (e)6 ( fe)6 (m)15 (a)2 (le)6 ( )]TJ
0.0024 Tc -0.0024 Tw 0 -1.15 TD
[(pat)5 (ie)6 (n)-1 (t)5 ( is qualifie)6 (d, and inc)6 (lude)6 (s t)5 (h)-1 (e)6 ( dat)5 (e)6 ( of qualific)6 (at)5 (ion, pat)5 (ie)6 (n)-1 (t)5 ( ge)6 (nde)6 (r)6 (,)2 ( c)6 (u)-1 (t)5 (-)5 (o)2 (ff )]TJ
0.0019 Tc -0.0019 Tw 0 -1.16 TD
[(dat)5 (e)6 ( for)6 ( filling t)5 (h)-2 (e)6 ( pr)6 (e)6 (s)1 (c)6 (r)6 (ipt)5 (ion, and up t)5 (o)2 ( a 30-)5 (day supply lim)15 (it)5 ( wit)5 (h)-2 ( no r)6 (e)6 (f)-5 (ills. )]TJ
0.002 Tc -0.002 Tw 0 -2.22 TD
[(The)6 (s)1 (e)6 ( ye)6 (llow)-6 ( se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Qualific)6 (at)5 (ion St)5 (ic)6 (ke)6 (r)6 (s)1 ( should also be)6 ( use)6 (d)-2 ( for)6 ( )]TJ
-0.0018 Tc 0.0018 Tw 0 -1.16 TD
[(m)11 (a)-2 (l)-4 (e)2 ( p)-6 (a)-2 (ti)-4 (en)-6 (ts. )]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 648 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 648 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
72.281 648 446.88 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 648 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 648 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 647.52 0.48 -370.32 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 647.52 0.48 -370.32 re
f
Q
BT
12 0 0 12 91.8888 287.232 Tm
[(T)-5 (a)-2 (b)-5 (l)-4 (e 1. Use of)-9 ( P)9 (regn)-5 (a)-2 (n)-5 (c)2 (y T)-5 (e)2 (sts an)-5 (d)-5 ( Accu)-5 (tan)-5 (e)2 ( Q)-4 (u)-5 (al)-4 (i)-4 (f)-9 (i)-4 (c)2 (ati)-4 (o)-2 (n)-5 ( S)-5 (t)1 (i)-4 (c)2 (k)-5 (ers f)-9 (o)-2 (r P)9 (a)-2 (ti)-4 (en)-5 (ts )]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 277.2 0.48 -13.8 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 277.2 0.48 -13.8 re
f
Q
BT
0.0032 Tc -0.0002 Tw 9.96 0 0 9.96 82.6488 263.232 Tm
[(Patien)5 (t T)8 (y)-3 (p)5 (e)1 ( )]TJ
0.0003 Tc 0 Tw 9.157 1.157 Td
[(P)-3 (reg)-6 (na)-6 (ncy)-6 ( )]TJ
-0.004 Tc 1.373 -1.157 Td
[(Te)-6 (st)-8 ( )]TJ
0 Tc -1.084 -1.157 Td
(Required )Tj
0.0005 Tc 0.0025 Tw 6.373 1.157 Td
[(Q)7 (u)2 (a)-5 (lifica)-5 (t)-4 (io)-5 (n Da)-5 (te )]TJ
0.0016 Tc 0 Tw 11.651 1.157 Td
(Accutane )Tj
-0.0001 Tc -0.807 -1.157 Td
[(Q)7 (u)2 (a)-6 (lifica)-6 (t)-4 (io)-6 (n )]TJ
0.0018 Tc 0.0012 Tw -0.988 -1.157 Td
[(Stick)16 (er Neces)5 (s)5 (a)-4 (ry )]TJ
-0.0016 Tc 0.0046 Tw 9.916 2.313 Td
[(Dispe)-3 (nse)-3 ( Wit)-6 (hin )]TJ
0.0054 Tc -0.0024 Tw 1.53 -1.157 Td
[(7 D)5 (ays)9 ( of )]TJ
0.0005 Tc 0.0025 Tw -1.964 -1.157 Td
[(Q)7 (u)2 (a)-5 (lifica)-5 (t)-4 (io)-5 (n Da)-5 (te )]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 263.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
72.281 263.4 89.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 263.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
162.281 263.4 62.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 263.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
225.281 263.4 102.12 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 263.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.881 263.4 90.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 263.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.841 263.4 100.32 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 263.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 262.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 262.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 262.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 262.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 262.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 262.92 0.48 -34.56 re
f
Q
BT
0.0003 Tc 0.0027 Tw 9.96 0 0 9.96 82.6488 239.712 Tm
[(All M)-20 (a)-6 (les )]TJ
10.837 0 Td
[(No)-6 ( )-3675 (Da)-6 (te Prescriptio)-6 (n )]TJ
0.002 Tc 0 Tw 7.223 -1.145 Td
[(Written)4 ( )]TJ
-0.0012 Tc 7.8235 Tw 10.639 1.145 Td
(Yes Yes )Tj
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 228.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
72.281 228.36 89.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 228.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
162.281 228.36 62.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 228.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
225.281 228.36 102.12 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 228.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.881 228.36 90.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 228.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.841 228.36 100.32 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 228.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 227.88 0.48 -22.92 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 227.88 0.48 -22.92 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 227.88 0.48 -22.92 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 227.88 0.48 -22.92 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 227.88 0.48 -22.92 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 227.88 0.48 -22.92 re
f
Q
BT
0.0028 Tc 0.0002 Tw 9.96 0 0 9.96 82.6488 216.3121 Tm
[(Fem)29 (a)-3 (les)6 ( of )]TJ
-0.0008 Tc 0 Tw 0 -1.157 TD
[(Childbea)-7 (r)-3 (ing)-7 ( )]TJ
0.0013 Tc T*
[(Po)-5 (tentia)-5 (l )]TJ
0.0007 Tc 5.7252 Tw 10.675 2.313 Td
[(Yes Da)-5 (te )5723 (o)-5 (f)-4 ( )]TJ
0.0017 Tc 0 Tw 6.108 -1.157 Td
[(Co)-4 (nfirm)28 (a)-4 (to)-4 (ry)-4 ( )]TJ
0.003 Tc -1.313 -1.157 Td
(Negative Pregnancy )Tj
-0.004 Tc 3.374 -1.157 Td
[(Te)-6 (st)-8 ( )]TJ
-0.0012 Tc 7.8235 Tw 9.855 3.47 Td
(Yes Yes )Tj
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 204.96 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
72.281 204.96 89.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 204.96 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
162.281 204.96 62.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 204.96 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
225.281 204.96 102.12 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 204.96 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.881 204.96 90.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 204.96 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.841 204.96 100.32 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 204.96 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 204.48 0.48 -46.08 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 204.48 0.48 -46.08 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 204.48 0.48 -46.08 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 204.48 0.48 -46.08 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 204.48 0.48 -46.08 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 204.48 0.48 -46.08 re
f
Q
BT
0.0023 Tc 0.0007 Tw 9.96 0 0 9.96 82.6488 169.7521 Tm
[(Fem)28 (a)-4 (les)6 (*)-4 ( Not)]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
121.721 147.6 15.6 -0.96 re
f
Q
BT
0.0044 Tc -0.0014 Tw 9.96 0 0 9.96 140.4888 169.7521 Tm
( of )Tj
-0.0008 Tc 0 Tw -5.807 -1.157 Td
[(Childbea)-7 (r)-3 (ing)-7 ( )]TJ
0.0013 Tc T*
[(Po)-5 (tentia)-5 (l )]TJ
0.0019 Tc 3.6758 Tw 10.831 2.313 Td
[(No Date )3675 (Pres)6 (cription )]TJ
0.002 Tc 0 Tw 7.229 -1.157 Td
[(Written)4 ( )]TJ
-0.0012 Tc 7.8235 Tw 10.639 1.157 Td
(Yes Yes )Tj
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 158.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
72.281 158.4 89.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 158.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
162.281 158.4 62.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 158.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
225.281 158.4 102.12 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 158.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.881 158.4 90.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 158.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.841 158.4 100.32 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 158.4 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 157.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 157.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 157.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 157.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 157.92 0.48 -34.56 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 157.92 0.48 -34.56 re
f
Q
BT
0.0027 Tc 0.0003 Tw 9.96 0 0 9.96 82.6488 134.712 Tm
[(*Fem)29 (ales)6 ( w)-10 (h)5 (o have had a hys)6 (t)-2 (erectom)29 (y or w)-10 (h)5 (o are pos)6 (t)-2 (m)29 (e)1 (nopaus)6 (al are not cons)6 (idered to be of )]TJ
0 Tc 0.003 Tw 0.506 -1.145 Td
[(childbea)-6 (r)-2 (ing)-6 ( po)-6 (tentia)-6 (l. )]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 123.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
72.281 123.36 89.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
161.801 123.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
162.281 123.36 62.52 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
224.801 123.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
225.281 123.36 102.12 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.401 123.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
327.881 123.36 90.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.361 123.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
418.841 123.36 100.32 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 123.36 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 122.88 0.48 -22.92 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 122.88 0.48 -22.92 re
f
Q
BT
-0.0019 Tc 0.0019 Tw 12 0 0 12 82.6488 96.9121 Tm
[(If)-9 ( a p)-6 (regn)-6 (a)-2 (n)-6 (c)2 (y d)-6 (o)-2 (es occu)-6 (r d)-6 (u)-6 (r)2 (i)-4 (n)-6 (g treatm)11 (en)-6 (t of)-9 ( a w)-10 (o)-2 (m)11 (a)-2 (n)-6 ( w)-10 (i)-4 (th)-6 ( Accu)-6 (tan)-6 (e)2 (, th)-6 (e )]TJ
ET
q
1 0 0 1 3.168243 21.072021 cm
71.801 99.96 0.48 -26.88 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 73.08 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
71.801 73.08 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
72.281 73.08 446.88 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 99.96 0.48 -26.88 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 73.08 0.48 -0.48 re
f
Q
q
1 0 0 1 3.168243 21.072021 cm
519.161 73.08 0.48 -0.48 re
f
Q
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj129 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 271/Width 76>>stream
Hk ::nVPܚ%&dZ=,W(KҗVV-/6AVCJ}kAX\)_^BXi
U-_,I_,%9; [b,ޗdZYH\OdNB%6^GVswXqϹs?'6|Yly%s8?q,1T.ksטO嚶j\"^V{f:]d}*/1%Yrh2i> 6
endstreamendobj467 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 480 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 481 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj481 0 obj<</Font 482 0 R>>endobj482 0 obj<</ArialRoundedMTBold 231 0 R>>endobj480 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj466 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj462 0 obj<</Length 9935>>stream
q
1 0 0 1 2.265167 16.812073 cm
0 0 612 792 re
W n
1 0 0 1 -2.265167 -16.812073 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0021 Tc -0.0021 Tw 12 0 0 12 81.7458 653.2921 Tm
[(F)13 (o)2 (r)6 ( fe)6 (m)15 (a)2 (le)6 ( pat)5 (ie)6 (n)-2 (t)5 (s)1 (, t)5 (h)-2 (e)6 ( ye)6 (llow)-6 ( se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Qualific)6 (at)5 (ion St)5 (ic)6 (ke)6 (r)6 ( signifie)6 (s )]TJ
-0.0005 Tc 0.0005 Tw 0 -1.16 TD
(that she: )Tj
/T1_0 1 Tf
0 Tc 0 Tw -0.6 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0015 Tc 1.5 0 Td
[(Mu)-5 (st)]TJ
ET
q
1 0 0 1 2.265167 16.812073 cm
90.281 593.64 26.64 -1.2 re
f
Q
BT
-0.0002 Tc 0.0002 Tw 12 0 0 12 119.1858 611.7721 Tm
[( have had 2 negative urine or serum)13 ( pregnancy tests w)-8 (i)-2 (th a sensitivity of)-7 ( at )]TJ
-0.0023 Tc 0.0023 Tw -2.22 -1.14 Td
[(l)-4 (e)2 (ast 25 m)11 (I)-3 (U/)-4 (m)11 (L)-5 ( b)-6 (e)2 (f)-9 (o)-2 (re recei)-4 (vi)-4 (n)-6 (g)-2 ( th)-6 (e i)-4 (n)-6 (i)-4 (t)1 (i)-4 (a)-2 (l)-4 ( Accu)-6 (tan)-6 (e)2 ( p)-6 (rescri)-4 (p)-6 (t)1 (i)-4 (o)-2 (n)-6 (.)-2 ( T)-5 (h)-6 (e f)-9 (i)-4 (rst test )]TJ
-0.0021 Tc 0.0021 Tw 0 -1.15 TD
[(\(a screen)-6 (i)-4 (n)-6 (g test\) i)-4 (s)-3 ( ob)-6 (tai)-4 (n)-6 (ed)-6 ( b)-6 (y)-2 ( th)-6 (e p)-6 (rescri)-4 (b)-6 (er w)-10 (h)-6 (en)-6 ( th)-6 (e d)-6 (eci)-4 (si)-4 (on)-6 ( i)-4 (s)-3 ( m)11 (a)-2 (d)-6 (e)2 ( to )]TJ
0.0024 Tc -0.0024 Tw T*
[(pur)6 (sue)6 ( qualific)6 (at)5 (ion of t)5 (h)-1 (e)6 ( pat)5 (ie)6 (n)-1 (t)5 ( for)6 ( A)5 (c)6 (c)6 (u)-1 (t)5 (a)2 (ne)6 (. The)6 ( se)6 (c)6 (o)2 (nd pr)6 (e)6 (g)2 (nanc)6 (y t)5 (e)6 (st)5 ( \()5 (a)2 ( )]TJ
0.0001 Tc -0.0001 Tw T*
[(conf)-7 (irm)13 (ation test\) should be done during the f)-7 (i)-2 (rst 5 days of)-7 ( the m)13 (e)4 (nstrual period )]TJ
-0.0021 Tc 0.0021 Tw T*
[(i)-4 (m)11 (m)11 (e)2 (d)-6 (i)-4 (atel)-4 (y p)-6 (reced)-6 (i)-4 (n)-6 (g th)-6 (e b)-6 (e)2 (gi)-4 (n)-6 (n)-6 (i)-4 (n)-6 (g)-2 ( of)-9 ( Accu)-6 (tan)-6 (e)2 ( th)-6 (erap)-6 (y. F)9 (o)-2 (r p)-6 (a)-2 (ti)-4 (en)-6 (ts w)-10 (i)-4 (th)-6 ( )]TJ
-0.0005 Tc 0.0005 Tw T*
[(am)13 (enorrhea, the second test should be done at least 11 days af)-7 (ter the last act of)-7 ( )]TJ
-0.0006 Tc 0.0006 Tw T*
[(unprotected sexual intercourse \(w)-8 (ithout using 2 ef)-8 (f)-8 (ective f)-8 (o)-1 (rm)12 (s of)-8 ( contraception\).)]TJ
/TT1 1 Tf
0 Tc 0 Tw 34.65 0 Td
( )Tj
/TT0 1 Tf
-0.0003 Tc 0.0003 Tw -34.65 -1.15 Td
[(Each m)13 (onth of)-7 ( therapy, the patient m)13 (u)-4 (st have a negative result f)-7 (r)4 (om)13 ( a urine or )]TJ
-0.002 Tc 0.002 Tw T*
[(seru)-6 (m)11 ( p)-6 (regn)-6 (a)-2 (n)-6 (c)2 (y test. A p)-6 (regn)-6 (a)-2 (n)-6 (c)2 (y test m)11 (u)-6 (st b)-6 (e)2 ( rep)-6 (eated)-6 ( every m)11 (o)-2 (n)-6 (t)1 (h)-6 ( p)-6 (r)2 (i)-4 (o)-2 (r to )]TJ
-0.0003 Tc 0.0003 Tw T*
[(the f)-7 (e)4 (m)13 (ale patient receiving each prescription. The m)13 (anuf)-7 (acturer w)-8 (ill m)13 (ake )]TJ
-0.0022 Tc 0.0022 Tw T*
[(avai)-4 (l)-4 (a)-2 (b)-6 (l)-4 (e u)-6 (r)2 (i)-4 (n)-6 (e p)-6 (regn)-6 (a)-2 (n)-6 (c)2 (y test k)-6 (i)-4 (ts f)-9 (o)-2 (r f)-9 (e)2 (m)11 (a)-2 (l)-4 (e)2 ( Accu)-6 (tan)-6 (e)2 ( p)-6 (a)-2 (ti)-4 (en)-6 (ts f)-9 (o)-2 (r th)-6 (e i)-4 (n)-6 (i)-4 (t)1 (i)-4 (a)-2 (l)-4 (,)-2 ( )]TJ
0.0023 Tc -0.0023 Tw T*
[(se)6 (c)6 (o)2 (nd and m)15 (o)2 (nt)5 (hly t)5 (e)6 (st)5 (ing dur)6 (ing t)5 (h)-1 (e)6 (r)6 (a)2 (py.)]TJ
/TT1 1 Tf
0 Tc 0 Tw ( )Tj
-1.5 -1.13 Td
( )Tj
/T1_0 1 Tf
0 -1.25 TD
(\002\003)Tj
/TT0 1 Tf
-0.0015 Tc 1.5 0 Td
[(Mu)-5 (st)]TJ
ET
q
1 0 0 1 2.265167 16.812073 cm
90.281 399.6 26.64 -1.2 re
f
Q
BT
-0.002 Tc 0.002 Tw 12 0 0 12 119.1858 417.7321 Tm
[( h)-6 (ave sel)-4 (ected)-6 ( an)-6 (d)-6 ( h)-6 (ave com)11 (m)11 (i)-4 (tted)-6 ( to u)-6 (s)-3 (e 2 f)-9 (o)-2 (rm)11 (s of)-9 ( ef)-9 (f)-9 (ecti)-4 (v)-2 (e con)-6 (t)1 (racep)-6 (ti)-4 (on)-6 ( )]TJ
0.0001 Tc -0.0001 Tw -2.22 -1.15 Td
[(sim)13 (u)-4 (ltaneously, at least 1 of)-7 ( w)-8 (h)-4 (ich m)13 (u)-4 (st be a prim)13 (ary f)-7 (orm)13 (, unless absolute )]TJ
-0.002 Tc 0.002 Tw 0 -1.15 TD
[(ab)-6 (sti)-4 (n)-6 (en)-6 (ce i)-4 (s)-3 ( th)-6 (e ch)-6 (osen)-6 ( m)11 (e)2 (th)-6 (od)-6 (, or th)-6 (e p)-6 (a)-2 (ti)-4 (en)-6 (t h)-6 (a)-2 (s u)-6 (n)-6 (d)-6 (ergon)-6 (e a h)-6 (y)-2 (sterectom)11 (y. )]TJ
-0.0019 Tc 0.0019 Tw 0 -1.14 TD
[(P)9 (a)-2 (ti)-4 (en)-6 (ts m)11 (u)-6 (st u)-6 (s)-3 (e 2 f)-9 (o)-2 (rm)11 (s of)-9 ( ef)-9 (f)-9 (ecti)-4 (v)-2 (e con)-6 (t)1 (racep)-6 (ti)-4 (on)-6 ( f)-9 (o)-2 (r at l)-4 (e)2 (ast 1 m)11 (o)-2 (n)-6 (t)1 (h)-6 ( p)-6 (r)2 (i)-4 (o)-2 (r to )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.15 TD
[(initiation of)-7 ( Accutane therapy, during Accutane therapy, and f)-7 (or 1 m)13 (onth af)-7 (ter )]TJ
0.0004 Tc -0.0004 Tw T*
(discontinuing Accutane therapy. Counseling about contraception and behav\iors )Tj
-0.0014 Tc 0.0014 Tw T*
[(associ)-4 (ated)-5 ( w)-9 (i)-4 (th)-5 ( an)-5 ( i)-4 (n)-5 (creased)-5 ( ri)-4 (sk)-5 ( of)-8 ( p)-5 (regn)-5 (a)-1 (n)-5 (c)2 (y m)12 (u)-5 (st b)-5 (e)2 ( rep)-5 (eated)-5 ( on)-5 ( a m)12 (o)-1 (n)-5 (t)2 (h)-5 (l)-4 (y )]TJ
0.0013 Tc 0 Tw 0 -1.16 TD
(basis. )Tj
-0.0017 Tc 0.0017 Tw -0.3 -2.23 Td
[(E)-5 (f)-9 (f)-9 (ecti)-4 (v)-2 (e f)-9 (o)-2 (rm)11 (s of)-9 ( con)-5 (t)1 (racep)-5 (ti)-4 (on)-5 ( i)-4 (n)-5 (cl)-4 (u)-5 (d)-5 (e)2 ( b)-5 (o)-2 (th)-5 ( p)-5 (r)2 (i)-4 (m)11 (ary an)-5 (d)-5 ( secon)-5 (d)-5 (a)-2 (ry f)-9 (o)-2 (rm)11 (s of)-9 ( )]TJ
0 -1.15 TD
[(con)-6 (t)1 (racep)-6 (ti)-4 (on)-6 (.  P)9 (r)2 (i)-4 (m)11 (ary f)-9 (o)-2 (rm)11 (s of)-9 ( con)-6 (t)1 (racep)-6 (ti)-4 (on)-6 ( i)-4 (n)-6 (cl)-4 (u)-6 (d)-6 (e)2 (: tu)-6 (b)-6 (a)-2 (l)-4 ( l)-4 (i)-4 (gati)-4 (o)-2 (n)-6 (,)-2 ( p)-6 (a)-2 (rtn)-6 (er\222s )]TJ
0.0019 Tc -0.0019 Tw T*
[(vase)6 (c)6 (t)5 (om)15 (y, int)5 (r)6 (aut)5 (e)6 (r)6 (ine)6 ( de)6 (vic)6 (e)6 (s)1 (, bir)6 (t)5 (h c)6 (o)2 (nt)5 (r)6 (o)2 (l pills, and )]TJ
0.0022 Tc -0.0022 Tw T*
[(inj)5 (e)6 (c)6 (t)5 (able)6 (/im)15 (plant)5 (a)2 (ble)6 (/inse)6 (r)6 (t)5 (able)6 ( hor)6 (m)15 (onal bir)6 (t)5 (h c)6 (o)2 (nt)5 (r)6 (o)2 (l pr)6 (oduc)6 (t)5 (s)1 (. Se)6 (c)6 (o)2 (ndar)6 (y )]TJ
-0.0015 Tc 0.0015 Tw T*
[(f)-8 (o)-1 (rm)12 (s of)-8 ( con)-5 (t)2 (racep)-5 (ti)-4 (on)-5 ( i)-4 (n)-5 (cl)-4 (u)-5 (d)-5 (e)2 ( d)-5 (i)-4 (ap)-5 (h)-5 (r)2 (agm)12 (s, l)-4 (a)-1 (tex con)-5 (d)-5 (o)-1 (m)12 (s)-2 (, an)-5 (d)-5 ( cervi)-4 (c)2 (al)-4 ( cap)-5 (s)-2 (; each)-5 ( )]TJ
T*
[(m)12 (u)-5 (st b)-5 (e)2 ( u)-5 (s)-2 (ed)-5 ( w)-9 (i)-4 (th)-5 ( a sp)-5 (erm)12 (i)-4 (c)2 (i)-4 (d)-5 (e. )]TJ
0 Tc 0 Tw T*
( )Tj
-0.002 Tc 0.002 Tw T*
[(An)-6 (y b)-6 (i)-4 (rth)-6 ( con)-6 (t)1 (rol)-4 ( m)11 (e)2 (th)-6 (od)-6 ( can)-6 ( f)-9 (a)-2 (i)-4 (l)-4 (.)-2 ( T)-5 (h)-6 (eref)-9 (ore, i)-4 (t)1 ( i)-4 (s)-3 ( cri)-4 (ti)-4 (cal)-4 (l)-4 (y)-2 ( i)-4 (m)11 (p)-6 (o)-2 (rtan)-6 (t th)-6 (at w)-10 (o)-2 (m)11 (e)2 (n)-6 ( )]TJ
-0.0016 Tc 0.0016 Tw T*
[(of)-9 ( ch)-5 (i)-4 (l)-4 (d)-5 (b)-5 (e)2 (ari)-4 (n)-5 (g p)-5 (o)-2 (ten)-5 (t)1 (i)-4 (a)-2 (l)-4 ( u)-5 (s)-2 (e 2 ef)-9 (f)-9 (ecti)-4 (v)-2 (e f)-9 (o)-2 (rm)11 (s of)-9 ( con)-5 (t)1 (racep)-5 (ti)-4 (on)-5 ( si)-4 (m)11 (u)-5 (l)-4 (t)1 (an)-5 (eou)-5 (s)-2 (l)-4 (y.  A )]TJ
-0.0018 Tc 0.0018 Tw T*
[(d)-6 (r)2 (u)-6 (g)-2 ( i)-4 (n)-6 (teracti)-4 (o)-2 (n)-6 ( th)-6 (at d)-6 (ecreases ef)-9 (f)-9 (ecti)-4 (v)-2 (en)-6 (ess of)-9 ( h)-6 (o)-2 (rm)11 (on)-6 (al)-4 ( con)-6 (t)1 (racep)-6 (ti)-4 (ves h)-6 (a)-2 (s n)-6 (o)-2 (t )]TJ
-0.0021 Tc 0.0021 Tw T*
[(b)-6 (een)-6 ( en)-6 (ti)-4 (rel)-4 (y ru)-6 (l)-4 (e)2 (d)-6 ( ou)-6 (t f)-9 (o)-2 (r Accu)-6 (tan)-6 (e)2 (.  Al)-4 (th)-6 (ou)-6 (gh)-6 ( h)-6 (o)-2 (rm)11 (on)-6 (al)-4 ( con)-6 (t)1 (racep)-6 (ti)-4 (ves are )]TJ
-0.0018 Tc 0.0018 Tw T*
[(h)-6 (i)-4 (gh)-6 (l)-4 (y)-2 ( ef)-9 (f)-9 (ecti)-4 (v)-2 (e, th)-6 (ere h)-6 (ave b)-6 (een)-6 ( rep)-6 (orts of)-9 ( p)-6 (regn)-6 (a)-2 (n)-6 (c)2 (y f)-9 (r)2 (om)11 ( w)-10 (o)-2 (m)11 (e)2 (n)-6 ( w)-10 (h)-6 (o h)-6 (ave u)-6 (s)-3 (ed)-6 ( )]TJ
-0.0002 Tc 0.0002 Tw T*
[(oral contraceptives, as w)-8 (e)4 (ll as injectable/im)13 (plantable contraceptive products.  )]TJ
-0.0025 Tc 0.0025 Tw T*
[(T)-5 (h)-6 (ese rep)-6 (orts occu)-6 (rred)-6 ( w)-10 (h)-6 (i)-5 (l)-5 (e)1 ( th)-6 (ese p)-6 (a)-2 (ti)-5 (en)-6 (ts w)-10 (ere tak)-6 (i)-5 (n)-6 (g)-2 ( Accu)-6 (tan)-6 (e)1 (. T)-5 (h)-6 (ese rep)-6 (orts )]TJ
-0.0033 Tc 0.0033 Tw T*
[(are m)10 (o)-3 (re f)-10 (r)1 (e)]TJ
ET
q
1 0 0 1 2.265167 16.812073 cm
86.681 82.08 395.76 13.32 re
W n
1 0 0 1 -2.265167 -16.812073 cm
BT
0 Tc 0 Tw 12 0 0 12 152.5458 101.1721 Tm
(q)Tj
ET
Q
BT
0.003 Tc -0.003 Tw 12 0 0 12 159.2658 101.1721 Tm
[(ue)7 (nt)6 ( for)7 ( wom)16 (e)7 (n who use)7 ( onl)]TJ
ET
q
1 0 0 1 2.265167 16.812073 cm
86.681 82.08 395.76 13.32 re
W n
1 0 0 1 -2.265167 -16.812073 cm
BT
0 Tc 0 Tw 12 0 0 12 303.1458 101.1721 Tm
(y)Tj
ET
Q
BT
0.0006 Tc -0.0006 Tw 12 0 0 12 309.1458 101.1721 Tm
( a sin)Tj
ET
q
1 0 0 1 2.265167 16.812073 cm
86.681 82.08 395.76 13.32 re
W n
1 0 0 1 -2.265167 -16.812073 cm
BT
0 Tc 0 Tw 12 0 0 12 335.9058 101.1721 Tm
(g)Tj
ET
Q
BT
-0.0006 Tc 0.0006 Tw 12 0 0 12 341.9058 101.1721 Tm
[(le m)12 (e)3 (thod of)-8 ( contrace)]TJ
ET
q
1 0 0 1 2.265167 16.812073 cm
86.681 82.08 395.76 13.32 re
W n
1 0 0 1 -2.265167 -16.812073 cm
BT
0 Tc 0 Tw 12 0 0 12 451.9458 101.1721 Tm
(p)Tj
ET
Q
BT
0.0005 Tc 0 Tw 12 0 0 12 458.6658 101.1721 Tm
(tion. )Tj
ET
q
1 0 0 1 2.265167 16.812073 cm
71.801 648 0.48 -0.48 re
f
Q
q
1 0 0 1 2.265167 16.812073 cm
71.801 648 0.48 -0.48 re
f
Q
q
1 0 0 1 2.265167 16.812073 cm
72.281 648 446.88 -0.48 re
f
Q
q
1 0 0 1 2.265167 16.812073 cm
519.161 648 0.48 -0.48 re
f
Q
q
1 0 0 1 2.265167 16.812073 cm
519.161 648 0.48 -0.48 re
f
Q
q
1 0 0 1 2.265167 16.812073 cm
71.801 647.52 0.48 -565.92 re
f
Q
q
1 0 0 1 2.265167 16.812073 cm
519.161 647.52 0.48 -565.92 re
f
Q
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj128 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 176/Width 76>>stream
HQ C::Fe#[
+=kD[QE+.+e/ViC{*-x,dǸ*j^;xwdBG֎^kT'JloGhv{bB=]f-OWB~ҽ8ۑNجZ/(' #D
endstreamendobj464 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 483 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 484 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj484 0 obj<</Font 485 0 R>>endobj485 0 obj<</ArialRoundedMTBold 231 0 R>>endobj483 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj463 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj459 0 obj<</Length 7627>>stream
q
1 0 0 1 7.1474 15.281281 cm
0 0 612 792 re
W n
1 0 0 1 -7.1474 -15.281281 cm
BT
/CS0 cs 0 0 0  scn
/GS0 gs
/TT0 1 Tf
0.0002 Tc -0.0002 Tw 12 0 0 12 86.628 651.6413 Tm
[(m)13 (eets all of)-7 ( the f)-7 (ollow)-8 (i)-2 (ng conditions: )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -0.6 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0015 Tc 1.5 0 Td
[(Mu)-5 (st)]TJ
ET
q
1 0 0 1 7.1474 15.281281 cm
90.281 607.44 26.64 -1.2 re
f
Q
BT
0 Tc 12 0 0 12 124.068 624.0413 Tm
[( NOT be pregnant or breast f)-7 (eeding. )]TJ
/T1_0 1 Tf
-3.72 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
-0.0015 Tc 1.5 0 Td
[(Mu)-5 (st)]TJ
ET
q
1 0 0 1 7.1474 15.281281 cm
90.281 579.72 26.64 -1.2 re
f
Q
BT
-0.0018 Tc 0.0018 Tw 12 0 0 12 124.068 596.3213 Tm
[( b)-6 (e)2 ( cap)-6 (a)-2 (b)-6 (l)-4 (e of)-9 ( com)11 (p)-6 (l)-4 (y)-2 (i)-4 (n)-6 (g w)-10 (i)-4 (th)-6 ( th)-6 (e m)11 (a)-2 (n)-6 (d)-6 (a)-2 (tory con)-6 (t)1 (racep)-6 (ti)-4 (ve m)11 (e)2 (asu)-6 (res )]TJ
-2.22 -1.14 Td
[(req)-6 (u)-6 (i)-4 (red)-6 ( f)-9 (o)-2 (r Accu)-6 (tan)-6 (e)2 ( th)-6 (erap)-6 (y)-2 ( an)-6 (d)-6 ( u)-6 (n)-6 (d)-6 (erstan)-6 (d)-6 ( b)-6 (e)2 (h)-6 (avi)-4 (ors associ)-4 (ated)-6 ( w)-10 (i)-4 (th)-6 ( an)-6 ( )]TJ
-0.0014 Tc 0.0014 Tw 0 -1.16 TD
[(i)-4 (n)-5 (creased)-5 ( ri)-4 (sk)-5 ( of)-8 ( p)-5 (regn)-5 (a)-1 (n)-5 (c)2 (y.  )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.3 Td
(\002\003)Tj
/TT0 1 Tf
-0.0015 Tc 1.5 0 Td
[(Mu)-5 (st)]TJ
ET
q
1 0 0 1 7.1474 15.281281 cm
90.281 524.52 26.64 -1.2 re
f
Q
BT
0.0021 Tc -0.0021 Tw 12 0 0 12 124.068 541.1213 Tm
[( be)6 ( r)6 (e)6 (liable)6 ( in unde)6 (r)6 (s)1 (t)5 (a)2 (nding and c)6 (a)2 (r)6 (r)6 (y)2 (ing out)5 ( inst)5 (r)6 (u)-2 (c)6 (t)5 (ions. )]TJ
-0.0026 Tc 0.0026 Tw -3.12 -2.23 Td
[(Accu)-6 (tan)-6 (e)1 ( m)10 (u)-6 (st b)-6 (e)1 ( p)-6 (rescri)-5 (b)-6 (e)1 (d)-6 ( u)-6 (n)-6 (d)-6 (er th)-6 (e )]TJ
/TT1 1 Tf
0 Tc 0 Tw 17.03 0 Td
[(System)-12 ( to Manage Accutane Related )]TJ
0.0011 Tc -17.03 -1.23 Td
[(Te)5 (ratoge)5 (nic)5 (ity)]TJ
/T1_1 1 Tf
0 Tc 5.96 0 Td
(\001)Tj
-0.02 -0.02 Td
[(\001)760 (\001)]TJ
0 0.02 TD
(\001)Tj
/TT0 1 Tf
-0.0004 Tc 0.0004 Tw ( \(S.M.A.R.T.)Tj
/T1_2 1 Tf
0 Tc 0 Tw 6.24 0 Td
(\001)Tj
-0.02 -0.02 Td
[(\001)760 (\001)]TJ
T*
(\001)Tj
/TT0 1 Tf
-0.001 Tc 0.001 Tw (\).  )Tj
-0.0017 Tc 0.0017 Tw -12.16 -2.23 Td
[(T)-5 (o)-2 ( p)-5 (rescri)-4 (b)-5 (e)2 ( Accu)-5 (tan)-5 (e)2 (, th)-5 (e p)-5 (rescri)-4 (b)-5 (er m)11 (u)-5 (st ob)-5 (tai)-4 (n)-5 ( a su)-5 (p)-5 (p)-6 (l)-4 (y)-2 ( of)-9 ( yel)-4 (l)-4 (o)-2 (w)-9 ( sel)-4 (f)-9 (-ad)-5 (h)-5 (e)2 (si)-4 (ve )]TJ
0.002 Tc -0.002 Tw 0 -1.16 TD
[(Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Qualific)6 (at)5 (ion St)5 (ic)6 (ke)6 (r)6 (s)1 (. To obt)5 (a)2 (in t)5 (h)-2 (e)6 (s)1 (e)6 ( st)5 (ic)6 (ke)6 (r)6 (s)1 (:)5 ( )]TJ
-0.0005 Tc 0.0005 Tw -0.6 -2.22 Td
[(1\) )-420 (Read the booklet entitled )]TJ
/TT1 1 Tf
-0.0001 Tc 0.0001 Tw 12.44 0 Td
[(System)-12 ( to Manage Accutane Related Teratogenicity )]TJ
/TT0 1 Tf
-0.0006 Tc 0 Tw -10.94 -1.16 Td
(\(S.M.A.R.T.\) )Tj
/TT1 1 Tf
0.0011 Tc -0.0011 Tw 5.77 0 Td
[(Guide)5 ( to Be)5 (st Prac)5 (tic)5 (e)5 (s.)]TJ
/TT0 1 Tf
0 Tc 0 Tw 9.83 0 Td
( )Tj
0.0024 Tc -0.0024 Tw -17.1 -2.22 Td
[(2\))5 ( )-420 (Sign and r)6 (e)6 (t)5 (ur)6 (n t)5 (h)-1 (e)6 ( c)6 (o)2 (m)15 (p)-1 (le)6 (t)5 (e)6 (d S.M)6 (.)2 (A)5 (.)2 (R)5 (.)2 (T. )]TJ
/TT1 1 Tf
0.0003 Tc -0.0003 Tw (Letter of Understanding )Tj
/TT0 1 Tf
0.0022 Tc -0.0022 Tw 30.05 0 Td
[(c)6 (o)2 (nt)5 (aining t)5 (h)-2 (e)6 ( )]TJ
-0.003 Tc 0.003 Tw -28.55 -1.16 Td
[(f)-10 (o)-3 (l)-5 (l)-5 (o)-3 (w)-11 (i)-5 (n)-7 (g)-3 ( P)8 (rescri)-5 (b)-7 (er Ch)-7 (eck)-7 (l)-5 (i)-5 (s)-4 (t: )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -2.31 Td
(\002\003)Tj
/TT0 1 Tf
-0.0017 Tc 0.0017 Tw 1.5 0 Td
[(I k)-5 (n)-5 (o)-2 (w)-9 ( th)-5 (e ri)-4 (sk)-5 ( an)-5 (d)-5 ( severi)-4 (ty of)-9 ( f)-9 (e)2 (tal)-4 ( i)-4 (n)-5 (ju)-5 (ry/)-4 (b)-5 (i)-4 (r)2 (th)-5 ( d)-5 (e)2 (f)-9 (ects f)-9 (r)2 (om)11 ( Accu)-5 (tan)-5 (e)2 ( )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.22 Td
(\002\003)Tj
/TT0 1 Tf
1.5 0 Td
[(I know)-8 ( how)-8 ( to diagnose and treat the various presentations of)-7 ( acne )]TJ
/T1_0 1 Tf
-1.5 -1.22 Td
(\002\003)Tj
/TT0 1 Tf
0.0027 Tc -0.0027 Tw 1.5 0 Td
[(I know t)6 (h)-1 (e)7 ( r)7 (i)1 (sk fac)7 (t)6 (or)7 (s for)7 ( unplanne)7 (d pr)7 (e)7 (g)3 (nanc)7 (y and t)6 (h)-1 (e)7 ( e)7 (ffe)7 (c)7 (t)6 (ive)7 ( m)16 (e)7 (asur)7 (e)7 (s)2 ( for)7 ( )]TJ
0.0021 Tc -0.0021 Tw 0 -1.14 TD
[(avoidanc)6 (e)6 ( of)-5 ( unplanne)6 (d pr)6 (e)6 (g)2 (nanc)6 (y )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
0.0001 Tc -0.0001 Tw 1.5 0 Td
[(It is the inf)-7 (orm)13 (ed patient\222s responsibility to avoid pregnancy during Accutane )]TJ
0.002 Tc -0.002 Tw T*
[(t)5 (h)-2 (e)6 (r)6 (a)2 (py and for)6 ( 1 m)15 (o)2 (nt)5 (h aft)5 (e)6 (r)6 ( st)5 (opping A)4 (c)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 (. To he)6 (lp pat)5 (ie)6 (n)-2 (t)5 (s)1 ( have)6 ( t)5 (h)-2 (e)6 ( )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.15 TD
[(know)-8 (l)-2 (edge and tools to do so: Bef)-7 (ore beginning treatm)13 (ent of)-7 ( f)-7 (e)4 (m)13 (ale patients w)-8 (i)-2 (th )]TJ
0.0022 Tc -0.0022 Tw T*
[(Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( I w)-6 (ill r)6 (e)6 (f)-5 (e)6 (r)6 ( for)6 ( e)6 (x)2 (pe)6 (r)6 (t)5 (, de)6 (t)5 (a)2 (ile)6 (d pr)6 (e)6 (g)2 (nanc)6 (y pr)6 (e)6 (v)2 (e)6 (n)-2 (t)5 (ion c)6 (o)2 (unse)6 (ling and )]TJ
-0.0023 Tc 0.0023 Tw T*
[(p)-6 (rescri)-4 (b)-6 (i)-4 (n)-6 (g, rei)-4 (m)11 (b)-6 (u)-6 (r)2 (sed)-6 ( b)-6 (y)-2 ( th)-6 (e m)11 (a)-2 (n)-6 (u)-6 (f)-9 (actu)-6 (rer, O)-4 (R I h)-6 (ave th)-6 (e exp)-6 (erti)-4 (s)-3 (e to p)-6 (erf)-9 (orm)11 ( )]TJ
0.0004 Tc -0.0004 Tw T*
[(this f)-7 (unction and elect to do so )]TJ
/T1_0 1 Tf
0 Tc 0 Tw -1.5 -1.23 Td
(\002\003)Tj
/TT0 1 Tf
0.0021 Tc -0.0021 Tw 1.5 0 Td
[(I unde)6 (r)6 (s)1 (t)5 (a)2 (nd, and w)-6 (ill pr)6 (ope)6 (r)6 (ly use)6 ( t)5 (h)-2 (r)6 (o)2 (ughout)5 ( t)5 (h)-2 (e)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( t)5 (r)6 (e)6 (a)2 (t)5 (m)15 (e)6 (n)-2 (t)5 ( c)6 (o)2 (ur)6 (se)6 (, )]TJ
-0.0001 Tc 0.0001 Tw 0 -1.14 TD
[(the S.M.A.R.T. procedures f)-7 (or Accutane, including m)13 (onthly pregnancy avoidance )]TJ
0.0022 Tc -0.0022 Tw 0 -1.15 TD
[(c)6 (o)2 (unse)6 (ling, pr)6 (e)6 (g)2 (nanc)6 (y t)5 (e)6 (st)5 (ing and use)6 ( of t)5 (h)-2 (e)6 ( ye)6 (llow se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( A)4 (c)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( )]TJ
0.0025 Tc -0.0025 Tw T*
[(Qualific)6 (at)6 (ion St)6 (ic)6 (ke)6 (r)6 (s)2 ( )]TJ
0 Tc 0 Tw -0.9 -1.15 Td
( )Tj
0.0019 Tc -0.0019 Tw -0.6 -1.15 Td
[(3\))5 ( )-420 (To use)6 ( t)5 (h)-2 (e)6 ( ye)6 (llow)-6 ( se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Qualific)6 (at)5 (ion St)5 (ic)6 (ke)6 (r)6 (:)5 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( should )]TJ
-0.0002 Tc 0.0002 Tw 1.5 -1.15 Td
[(not be prescribed or dispensed to any patient \(m)13 (ale or f)-7 (e)4 (m)13 (ale\) w)-8 (i)-2 (thout a yellow)-8 ( )]TJ
0.0022 Tc -0.0022 Tw 0 -1.16 TD
[(se)6 (lf-)5 (a)2 (dhe)6 (sive)6 ( Ac)6 (c)6 (u)-2 (t)5 (a)2 (ne)6 ( Qualific)6 (at)5 (ion St)5 (ic)6 (ke)6 (r)6 (.)2 ( )]TJ
ET
q
1 0 0 1 7.1474 15.281281 cm
71.801 648 0.48 -0.48 re
f
Q
q
1 0 0 1 7.1474 15.281281 cm
71.801 648 0.48 -0.48 re
f
Q
q
1 0 0 1 7.1474 15.281281 cm
72.281 648 446.88 -0.48 re
f
Q
q
1 0 0 1 7.1474 15.281281 cm
519.161 648 0.48 -0.48 re
f
Q
q
1 0 0 1 7.1474 15.281281 cm
519.161 648 0.48 -0.48 re
f
Q
q
1 0 0 1 7.1474 15.281281 cm
71.801 647.52 0.48 -566.4 re
f
Q
q
1 0 0 1 7.1474 15.281281 cm
519.161 647.52 0.48 -566.4 re
f
Q
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj127 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 200/Width 76>>stream
H0YSB<PIE<FJR#tX,cIʋ
.>#~/RkpYY^b.b^HUYמI:YJ/%~bXJ/!L$Kdazey~q^JwX^m[zLǨo4ne#^K%dQϘd)dJO9 "(l
endstreamendobj461 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 486 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 487 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj487 0 obj<</Font 488 0 R>>endobj488 0 obj<</ArialRoundedMTBold 231 0 R>>endobj486 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj110 0 obj<</BaseFont/TT674o00/Encoding 5 0 R/FirstChar 1/FontDescriptor 4 0 R/LastChar 1/Subtype/Type1/Type/Font/Widths[780]>>endobj5 0 obj<</Differences[1/Ge4]/Type/Encoding>>endobj4 0 obj<</Ascent 0/CapHeight 0/Descent 0/Flags 4/FontBBox[0 0 720 670]/FontFile3 3 0 R/FontName/TT674o00/ItalicAngle 0/StemV 0/Type/FontDescriptor>>endobj3 0 obj<</Filter/FlateDecode/Length 154/Subtype/Type1C>>stream
Hbd`ad`dd	13770 q~uw˰aa[a@##{	\;c;H٥OvTwUQ#DlJ~O)]oʏWlb-;+?Tv 7

endstreamendobj460 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj456 0 obj<</Length 6955>>stream
q
1 0 0 1 5.904694 17.430969 cm
0 0 612 792 re
W n
q
/GS0 gs
61.8000031 0 0 31.9199982 72.0406036 616.0800934 cm
/Im0 Do
Q
1 0 0 1 -5.904694 -17.430969 cm
BT
/CS1 cs 1 1 1  scn
/GS0 gs
/TT0 1 Tf
12 0 0 12 139.7453 633.511 Tm
( )Tj
0 0 0  scn
/TT1 1 Tf
-0.0022 Tc -5.15 -2.08 Td
[(ACCUT)-5 (ANE)]TJ
/T1_0 1 Tf
0 Tc 8.04 0 0 8.04 146.1053 614.071 Tm
(\001)Tj
-0.03 -0.03 Td
[(\001)760 (\001)]TJ
0 0.03 TD
(\001)Tj
/TT1 1 Tf
12 0 0 12 152.3453 608.551 Tm
( )Tj
/TT0 1 Tf
-0.0001 Tc 0.0001 Tw -6.2 -1.13 Td
(\(isotretinoin\)  )Tj
/TT1 1 Tf
-0.0022 Tc 0 Tw 0 -1.18 TD
[(CAP)9 (S)-6 (UL)-5 (E)-5 (S)-6 ( )]TJ
-0.0014 Tc 0.0014 Tw 0 -2.22 TD
[(CAUS)-5 (E)-4 (S)-5 ( B)-4 (I)-2 (RT)-4 (H DE)-4 (F)9 (E)-4 (CT)-4 (S)]TJ
0 Tc 0 Tw 9.96 0 0 9.96 225.4253 554.191 Tm
( )Tj
ET
q
1 0 0 1 5.904694 17.430969 cm
72.041 534 39 -67.92 re
f*
Q
q
/CS1 cs 1 1 1  scn
39 0 0 67.9199982 77.9452976 483.5110624 cm
/Im1 Do
Q
BT
/TT0 1 Tf
12 0 0 12 116.9453 483.511 Tm
( )Tj
/TT1 1 Tf
-0.001 Tc 0.001 Tw -3.25 -0.94 Td
[(DO NOT)-4 ( G)7 (E)-4 (T)-4 ( P)10 (R)1 (E)-4 (G)7 (NANT)-4 ( )]TJ
-0.0015 Tc 0.0015 Tw 0.62 -3.35 Td
[(CONT)-4 (RAINDICAT)-4 (IONS)-5 ( AND WARNING)6 (S)-5 (:)2 ( Accu)-5 (tan)-5 (e)2 ( m)12 (u)-5 (st n)-5 (o)-1 (t b)-5 (e)2 ( u)-5 (s)-2 (ed)-5 ( b)-5 (y)-1 ( )]TJ
0 -1.14 TD
[(f)-8 (e)2 (m)12 (a)-1 (l)-4 (e)2 (s w)-9 (h)-5 (o are p)-5 (regn)-5 (a)-1 (n)-5 (t)2 (. Al)-4 (th)-5 (ou)-5 (gh)-5 ( n)-5 (o)-1 (t every f)-8 (e)2 (tu)-5 (s exp)-5 (o)-1 (sed)-5 ( to Accu)-5 (tan)-5 (e)2 ( h)-5 (a)-1 (s )]TJ
-0.002 Tc 0.002 Tw 0 -1.15 TD
[(resu)-6 (l)-4 (ted)-6 ( i)-4 (n)-6 ( a d)-6 (e)2 (f)-9 (o)-2 (rm)11 (ed)-6 ( ch)-6 (i)-4 (l)-4 (d)-6 (, th)-6 (ere i)-4 (s)-3 ( an)-6 ( extrem)11 (el)-4 (y h)-6 (i)-4 (gh)-6 ( ri)-4 (sk)-6 ( th)-6 (at a d)-6 (e)2 (f)-9 (o)-2 (rm)11 (ed)-6 ( i)-4 (n)-6 (f)-9 (a)-2 (n)-6 (t)1 ( )]TJ
-0.0016 Tc 0.0016 Tw T*
[(can)-5 ( resu)-5 (l)-4 (t i)-4 (f)-9 ( p)-5 (regn)-5 (a)-2 (n)-5 (c)2 (y occu)-5 (rs w)-9 (h)-5 (i)-4 (l)-4 (e)2 ( tak)-5 (i)-4 (n)-5 (g)-2 ( Accu)-5 (tan)-5 (e)2 ( i)-4 (n)-5 ( an)-5 (y am)11 (ou)-5 (n)-5 (t)1 ( even)-5 ( f)-9 (o)-2 (r sh)-5 (ort )]TJ
0.0002 Tc -0.0002 Tw T*
[(periods of)-7 ( tim)13 (e)4 (. P)11 (otentially any f)-7 (e)4 (tus exposed during pregnancy can be af)-7 (f)-7 (ected. )]TJ
-0.002 Tc 0.002 Tw T*
[(P)9 (resen)-6 (tl)-4 (y, th)-6 (ere are n)-6 (o)-2 ( accu)-6 (rate m)11 (e)2 (an)-6 (s of)-9 ( d)-6 (e)2 (term)11 (i)-4 (n)-6 (i)-4 (n)-6 (g, af)-9 (ter Accu)-6 (tan)-6 (e)2 ( exp)-6 (o)-2 (su)-6 (re, )]TJ
0.003 Tc -0.003 Tw 0 -1.16 TD
[(whic)7 (h fe)7 (t)6 (u)-1 (s has be)7 (e)7 (n)-1 ( affe)7 (c)7 (t)6 (e)7 (d)-1 ( and whic)7 (h fe)7 (t)6 (u)-1 (s has not)6 ( be)7 (e)7 (n)-1 ( affe)7 (c)7 (t)6 (e)7 (d)-1 (.  )]TJ
-0.0015 Tc 0.0015 Tw 0 -2.22 TD
[(Major h)-5 (u)-5 (m)12 (an)-5 ( f)-8 (e)2 (tal)-4 ( ab)-5 (n)-5 (o)-1 (rm)12 (al)-4 (i)-4 (t)2 (i)-4 (e)2 (s rel)-4 (ated)-5 ( to Accu)-5 (tan)-5 (e)2 ( ad)-5 (m)12 (i)-4 (n)-5 (i)-4 (strati)-4 (on)-5 ( i)-4 (n)-5 ( f)-8 (e)2 (m)12 (a)-1 (l)-4 (e)2 (s )]TJ
-0.0013 Tc 0.0013 Tw 0 -1.15 TD
[(h)-5 (ave b)-5 (een)-5 ( d)-5 (o)-1 (cu)-5 (m)12 (e)3 (n)-5 (t)2 (ed)-5 (. T)-4 (h)-5 (ere i)-3 (s)-2 ( an)-5 ( i)-3 (n)-5 (creased)-5 ( ri)-3 (sk)-5 ( of)-8 ( sp)-5 (on)-5 (tan)-5 (e)3 (ou)-5 (s ab)-5 (orti)-3 (on)-5 (. In)-5 ( )]TJ
-0.0003 Tc 0.0003 Tw 0 -1.16 TD
[(addition, prem)13 (ature births have been reported. )]TJ
-0.0019 Tc 0.0019 Tw 0 -2.23 TD
[(Docu)-6 (m)11 (e)2 (n)-6 (t)1 (ed)-6 ( extern)-6 (al)-4 ( ab)-6 (n)-6 (o)-2 (rm)11 (al)-4 (i)-4 (t)1 (i)-4 (e)2 (s i)-4 (n)-6 (cl)-4 (u)-6 (d)-6 (e)2 (: sk)-6 (u)-6 (l)-4 (l)-4 ( ab)-6 (n)-6 (o)-2 (rm)11 (al)-4 (i)-4 (t)1 (y; ear ab)-6 (n)-6 (o)-2 (rm)11 (al)-4 (i)-4 (t)1 (i)-4 (e)2 (s )]TJ
0.0001 Tc -0.0001 Tw 0 -1.15 TD
[(\(including anotia, m)13 (i)-2 (cropinna, sm)13 (all or absent external auditory canals\); eye )]TJ
0.0018 Tc -0.0018 Tw T*
[(abnor)6 (m)15 (alit)5 (ie)6 (s \()5 (inc)6 (luding m)15 (ic)6 (r)6 (o)2 (pht)5 (halm)15 (ia\))5 (;)5 ( fac)6 (ial dysm)15 (or)6 (phia;)5 ( c)6 (le)6 (f)-5 (t)5 ( palat)5 (e)6 (.  )]TJ
-0.0021 Tc 0.0021 Tw T*
[(Docu)-6 (m)11 (e)2 (n)-6 (t)1 (ed)-6 ( i)-4 (n)-6 (tern)-6 (al)-4 ( ab)-6 (n)-6 (o)-2 (rm)11 (al)-4 (i)-4 (t)1 (i)-4 (e)2 (s i)-4 (n)-6 (cl)-4 (u)-6 (d)-6 (e)2 (: CNS)-6 ( ab)-6 (n)-6 (o)-2 (rm)11 (al)-4 (i)-4 (t)1 (i)-4 (e)2 (s \(i)-4 (n)-6 (c)2 (l)-4 (u)-6 (d)-6 (i)-4 (n)-6 (g)-2 ( cereb)-6 (ral)-4 ( )]TJ
T*
[(ab)-6 (n)-6 (o)-2 (rm)11 (al)-4 (i)-4 (t)1 (i)-4 (e)2 (s, cereb)-6 (el)-4 (l)-4 (a)-2 (r m)11 (a)-2 (l)-4 (f)-9 (orm)11 (a)-2 (ti)-4 (on)-6 (, h)-6 (y)-2 (d)-6 (r)2 (ocep)-6 (h)-6 (a)-2 (l)-4 (u)-6 (s, m)11 (i)-4 (crocep)-6 (h)-6 (a)-2 (l)-4 (y, cran)-6 (i)-4 (a)-2 (l)-4 ( n)-6 (e)2 (rve )]TJ
-0.0012 Tc 0.0012 Tw T*
[(d)-5 (e)3 (f)-8 (i)-3 (cit\); card)-5 (iovascu)-5 (lar ab)-5 (n)-5 (o)-1 (rm)12 (alities; th)-5 (ym)12 (u)-5 (s)-2 ( glan)-5 (d)-5 ( ab)-5 (n)-5 (o)-1 (rm)12 (ality; p)-5 (a)-1 (rath)-5 (yroid)-5 ( )]TJ
-0.0018 Tc 0.0018 Tw T*
[(h)-6 (o)-2 (rm)11 (on)-6 (e d)-6 (e)2 (f)-9 (i)-4 (ci)-4 (en)-6 (cy. In)-6 ( som)11 (e)2 ( cases d)-6 (e)2 (ath)-6 ( h)-6 (a)-2 (s occu)-6 (rred)-6 ( w)-10 (i)-4 (th)-6 ( certai)-4 (n)-6 ( of)-9 ( th)-6 (e )]TJ
0.0017 Tc -0.0017 Tw 0 -1.16 TD
[(abnor)6 (m)15 (alit)5 (ie)6 (s pr)6 (e)6 (v)2 (iously not)5 (e)6 (d. )]TJ
0.0001 Tc -0.0001 Tw 0 -2.22 TD
[(Cases of)-7 ( IQ scores less than 85 w)-8 (i)-2 (th or w)-8 (i)-2 (thout obvious CNS abnorm)13 (alities have also )]TJ
-0.0028 Tc 0.0028 Tw 0 -1.16 TD
[(b)-7 (een)-7 ( rep)-7 (orted)-7 (.)-3 (  )]TJ
0.0026 Tc -0.0026 Tw 0 -2.22 TD
[(A)5 (c)6 (c)6 (u)-1 (t)6 (a)3 (ne)6 ( is c)6 (o)3 (nt)6 (r)6 (a)3 (indic)6 (a)3 (t)6 (e)6 (d in fe)6 (m)16 (a)3 (le)6 (s of c)6 (h)-1 (ildbe)6 (ar)6 (in)]TJ
ET
q
1 0 0 1 5.904694 17.430969 cm
98.681 84.48 402.6 13.32 re
W n
1 0 0 1 -5.904694 -17.430969 cm
BT
0 Tc 0 Tw 12 0 0 12 357.4253 104.191 Tm
(g)Tj
ET
Q
BT
0 Tc 0 Tw 12 0 0 12 363.4253 104.191 Tm
( )Tj
ET
q
1 0 0 1 5.904694 17.430969 cm
98.681 84.48 402.6 13.32 re
W n
1 0 0 1 -5.904694 -17.430969 cm
BT
12 0 0 12 366.4253 104.191 Tm
(p)Tj
ET
Q
BT
12 0 0 12 373.1453 104.191 Tm
(otential unless the )Tj
ET
q
1 0 0 1 5.904694 17.430969 cm
98.681 84.48 402.6 13.32 re
W n
1 0 0 1 -5.904694 -17.430969 cm
BT
12 0 0 12 468.1853 104.191 Tm
(p)Tj
ET
Q
BT
-0.0006 Tc 12 0 0 12 474.9053 104.191 Tm
(atient )Tj
ET
q
1 0 0 1 5.904694 17.430969 cm
71.801 439.2 0.48 -0.48 re
f
Q
q
1 0 0 1 5.904694 17.430969 cm
71.801 439.2 0.48 -0.48 re
f
Q
q
1 0 0 1 5.904694 17.430969 cm
72.281 439.2 446.88 -0.48 re
f
Q
q
1 0 0 1 5.904694 17.430969 cm
519.161 439.2 0.48 -0.48 re
f
Q
q
1 0 0 1 5.904694 17.430969 cm
519.161 439.2 0.48 -0.48 re
f
Q
q
1 0 0 1 5.904694 17.430969 cm
71.801 438.72 0.48 -354.72 re
f
Q
q
1 0 0 1 5.904694 17.430969 cm
519.161 438.72 0.48 -354.72 re
f
Q
/Artifact <</Contents (This label may not be the latest approved by FDA. \r\nFor current labeli\ng information, please visit https://www.fda.gov/drugsatfda)/Subtype /Header /Type /Pagination >>BDC 
Q
q
1 0 0 1 120.6970062 785.2004395 cm
/GS1 gs
/Fm0 Do
Q
EMC 

endstreamendobj126 0 obj<</BitsPerComponent 8/ColorSpace 103 0 R/Filter/FlateDecode/Height 99/Length 215/Width 76>>stream
H ۇ}Xԏ Q7lsvq^(!TR%ĕH¸}X *-h\%pWNp0mzQ.@ψ"v7||?7+U,O]36]Zי"]/euEθ&[=̮e5&u2.ex컿"Hiû矸 D'
endstreamendobj458 0 obj<</BBox[0.0 -22.0 370.606 2.20013]/LastModified(D:20240613110447-04'00')/Length 542/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/OC 227 0 R/PieceInfo<</ADBE_CompoundType<</DocSettings 489 0 R/LastModified(D:20240613110447-04'00')/Private/Header>>>>/Resources 490 0 R/Subtype/Form>>stream
0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts
BT
/ArialRoundedMTBold 10 Tf
0 0 1 rg
65.791 -7.9 Td
(This ) Tj
22.92 0 Td
(label ) Tj
26.055 0 Td
(may ) Tj
22.71 0 Td
(not ) Tj
18.12 0 Td
(be ) Tj
14.692 0 Td
(the ) Tj
18.023 0 Td
(latest ) Tj
29.595 0 Td
(approved ) Tj
48.974 0 Td
(by ) Tj
14.17 0 Td
(FDA.  ) Tj
-281.05 -12 Td
(For ) Tj
18.96 0 Td
(current ) Tj
38.765 0 Td
(labeling ) Tj
41.055 0 Td
(information, ) Tj
61.25 0 Td
(please ) Tj
34.707 0 Td
(visit ) Tj
22.299 0 Td
(https://www.fda.gov/drugsatfda) Tj
ET

endstreamendobj203 0 obj<</BitsPerComponent 8/ColorSpace 202 0 R/Filter/JPXDecode/Height 67/Length 2600/Subtype/Image/Type/XObject/Width 129>>stream
   jP  

   ftypjp2     jp2 jpxbjpx    rreq   @    -     jp2h   ihdr   C        colr      >pclr    fff"""333DDDUUUwww   cmap           jp2cOQ )        C              C         R     \ @@HHPHHPHHPHHPHHP 
     ! ߀{de]j.".]8 
     (:,4
LΫQE[ 
     K|(|'@| qL=ӳ][&()`l=np#b^O
0 
     |7#sQ@z
g-_[)50w$E뮥"UC߸:$EDرt5;S=)<3Ae%z4ٗ&Z%z&[g'=_-VlKNJB\:I\zŮH_(Cu0Է[	Q	 
    4ӗ$] VeQ8BBt8BTu?l?x+}ʾ'j䳄6nMcBSuvw@xq4 IeT>gaUK@BPPA|zވl;1Hv%ֺ꼊Y*%cNx7Bo^.oNFSzӘ2$QMtiF H^r=*Zw
57PʝH͍)	x\`߳v><h+nL[Wqt,HoŽQ ep`Y D o<ȹ,A"*kDi2HdeQ&攃c{=g#Q$_#/'{ny#FsJ$(ěyzjSazl_<0u.ܨƎ<>A` [E35؂ާю]vq)rPu+5d%y.>V^,(d 
    ~M7T7{Hqs~}M1v̔ȳ]O]x?B`!SeD:	6;5LpYzӺPgrŮ6m`5" |^]md9HϳN\ 2gt+K~mӹϹrjd݆bn~kZJ>%ǥ$qQq-&`muDHWa0,5翓J9N-$kRχ$q x$;〖+1Bko˾F$y*<~2'媓}xqk>N:I 07VhaMWgSK_#Wށ(cP_͢t aKSnC Q/2RUyVV*iuuM/й.3᠁70E}oYd4*UEs=Dij
A9ԔmOTpս;zMJ>Kᰕ< <T9j◙I5.ܭ> pZuq$ ZH"iB?O,_%V+y01bAkUɤ]!VʂOA(9M&x_F-ڜh" #\=Zj_@8Odr"ozt}uwP=-P5(>keĻ)RFZrxoVmIԻZ0g	nYڐ1o*'ʃtKMq6# oRH7脦;OE1QI1`0rzV-CS`zd}%n~t{"{$/g=m> w]hA+E}0ȶ.P^$]OTPI}T3ueq{V^
CQ	"z2zքU.z&8	*A(sZ$`޳$Mj^Q&q܆K֍4sIBùFL#K%00F:7qp,CGV@-d'hw6zbG&".$p<,tB|o
]yGsr.
-KSceI20ujqt=ң7W N_vjV_&N0|J~.['m睓sh\*'C@>$<ld zgQ6oB0XxbkDm t~O74s7w S,o<=@Qi{5F>]: Y-gRSib:S+O[YM~Q㻾4:/|[#,&?I;X(6
T8*%fcdCLR9G»,[͆.s& Th~*s6ӑw4j*Ǭߪ6"k/
endstreamendobj202 0 obj[/Indexed 190 0 R 15 201 0 R]endobj201 0 obj<</Length 48>>stream
   fff"""333DDDUUUwww
endstreamendobj490 0 obj<</Font 491 0 R>>endobj491 0 obj<</ArialRoundedMTBold 231 0 R>>endobj489 0 obj<</Length 717>>stream
﻿<?xml version = "1.0" encoding = "UTF-8" ?><HeaderFooterSettings version = "8.0"><Font size="10.0" name="ArialRoundedMTBold" type="TrueType"/><Color r="0.0" b="1.0" g="0.0"/><Margin left="0.0" right="0.0" top="28.7996" bottom="0.0"/><Appearance shrink="1" fixedprint="0"/><PageRange end="-1" start="-1" even="1" odd="1"/><Page offset = "0"><PageIndex format="1"/></Page><Date><Month format="1"/>/<Day format="1"/><Year format="0"/></Date><Header><Left></Left><Center>This label may not be the latest approved by FDA. 
For current labeling information, please visit https://www.fda.gov/drugsatfda</Center><Right></Right></Header><Footer><Left></Left><Center></Center><Right></Right></Footer></HeaderFooterSettings>
endstreamendobj457 0 obj<</CA 1.0/Type/ExtGState/ca 1.0>>endobj211 0 obj[]endobj209 0 obj<</BaseFont/Helvetica/Encoding 208 0 R/Name/Helv/Subtype/Type1/Type/Font>>endobj210 0 obj<</BaseFont/ZapfDingbats/Name/ZaDb/Subtype/Type1/Type/Font>>endobj208 0 obj<</Differences[24/breve/caron/circumflex/dotaccent/hungarumlaut/ogonek/ring/tilde 39/quotesingle 96/grave 128/bullet/dagger/daggerdbl/ellipsis/emdash/endash/florin/fraction/guilsinglleft/guilsinglright/minus/perthousand/quotedblbase/quotedblleft/quotedblright/quoteleft/quoteright/quotesinglbase/trademark/fi/fl/Lslash/OE/Scaron/Ydieresis/Zcaron/dotlessi/lslash/oe/scaron/zcaron 160/Euro 164/currency 166/brokenbar 168/dieresis/copyright/ordfeminine 172/logicalnot/.notdef/registered/macron/degree/plusminus/twosuperior/threesuperior/acute/mu 183/periodcentered/cedilla/onesuperior/ordmasculine 188/onequarter/onehalf/threequarters 192/Agrave/Aacute/Acircumflex/Atilde/Adieresis/Aring/AE/Ccedilla/Egrave/Eacute/Ecircumflex/Edieresis/Igrave/Iacute/Icircumflex/Idieresis/Eth/Ntilde/Ograve/Oacute/Ocircumflex/Otilde/Odieresis/multiply/Oslash/Ugrave/Uacute/Ucircumflex/Udieresis/Yacute/Thorn/germandbls/agrave/aacute/acircumflex/atilde/adieresis/aring/ae/ccedilla/egrave/eacute/ecircumflex/edieresis/igrave/iacute/icircumflex/idieresis/eth/ntilde/ograve/oacute/ocircumflex/otilde/odieresis/divide/oslash/ugrave/uacute/ucircumflex/udieresis/yacute/thorn/ydieresis]/Type/Encoding>>endobj182 0 obj<</Author(HHS/FDA)/CreationDate(D:20020621145523-04'00')/Creator(AdobePS5.dll Version 5.1)/Keywords(accutane, isotretinoin, casules, roche)/ModDate(D:20240613110447-04'00')/Producer(Etymon PJ 1.10, Copyright \(C\) 1998-2000 Etymon Systems, Inc. <http://www.etymon.com/>. )/Subject(label)/Title(Accutane \(isotretinoin\) Capsules Label)>>endobjxref
0 492
0000000000 65535 f
0000434243 00000 n
0000000000 00000 f
0000491671 00000 n
0000491514 00000 n
0000491461 00000 n
0000434565 00000 n
0000000000 00000 f
0000434861 00000 n
0000000000 00000 f
0000435145 00000 n
0000000000 00000 f
0000435454 00000 n
0000000000 00000 f
0000441808 00000 n
0000378455 00000 n
0000000000 00000 f
0000378764 00000 n
0000000000 00000 f
0000379085 00000 n
0000000000 00000 f
0000379406 00000 n
0000000000 00000 f
0000379690 00000 n
0000000000 00000 f
0000334654 00000 n
0000000000 00000 f
0000334962 00000 n
0000000000 00000 f
0000335246 00000 n
0000000000 00000 f
0000335580 00000 n
0000000000 00000 f
0000335877 00000 n
0000000000 00000 f
0000287030 00000 n
0000000000 00000 f
0000287351 00000 n
0000000000 00000 f
0000287648 00000 n
0000000000 00000 f
0000287969 00000 n
0000000000 00000 f
0000288277 00000 n
0000000000 00000 f
0000246231 00000 n
0000000000 00000 f
0000246527 00000 n
0000000000 00000 f
0000246835 00000 n
0000000000 00000 f
0000247131 00000 n
0000000000 00000 f
0000247415 00000 n
0000000000 00000 f
0000205516 00000 n
0000000000 00000 f
0000205826 00000 n
0000000000 00000 f
0000206123 00000 n
0000000000 00000 f
0000206407 00000 n
0000000000 00000 f
0000206704 00000 n
0000000000 00000 f
0000167971 00000 n
0000000000 00000 f
0000168280 00000 n
0000000000 00000 f
0000168576 00000 n
0000000000 00000 f
0000168872 00000 n
0000000000 00000 f
0000169181 00000 n
0000000000 00000 f
0000120033 00000 n
0000000000 00000 f
0000120342 00000 n
0000000000 00000 f
0000120639 00000 n
0000000000 00000 f
0000120936 00000 n
0000000000 00000 f
0000141984 00000 n
0000141939 00000 n
0000133939 00000 n
0000000000 00000 f
0000121244 00000 n
0000000000 00000 f
0000131306 00000 n
0000131139 00000 n
0000005419 00000 n
0000000000 00000 f
0000005740 00000 n
0000000000 00000 f
0000006061 00000 n
0000000000 00000 f
0000006382 00000 n
0000000000 00000 f
0000073394 00000 n
0000049090 00000 n
0000006717 00000 n
0000000000 00000 f
0000047785 00000 n
0000047835 00000 n
0000105090 00000 n
0000214640 00000 n
0000105539 00000 n
0000214430 00000 n
0000214829 00000 n
0000491326 00000 n
0000214581 00000 n
0000104577 00000 n
0000105716 00000 n
0000245707 00000 n
0000245543 00000 n
0000245348 00000 n
0000245488 00000 n
0000000000 00000 f
0000129646 00000 n
0000130395 00000 n
0000112622 00000 n
0000112241 00000 n
0000073311 00000 n
0000043442 00000 n
0000043348 00000 n
0000498968 00000 n
0000489298 00000 n
0000479563 00000 n
0000467425 00000 n
0000451239 00000 n
0000440685 00000 n
0000431822 00000 n
0000417435 00000 n
0000404853 00000 n
0000394966 00000 n
0000386156 00000 n
0000376430 00000 n
0000367348 00000 n
0000359639 00000 n
0000351376 00000 n
0000342059 00000 n
0000332642 00000 n
0000323590 00000 n
0000313655 00000 n
0000305100 00000 n
0000295687 00000 n
0000285006 00000 n
0000276703 00000 n
0000265629 00000 n
0000259271 00000 n
0000253090 00000 n
0000243379 00000 n
0000236329 00000 n
0000230993 00000 n
0000222160 00000 n
0000212463 00000 n
0000203558 00000 n
0000199550 00000 n
0000191539 00000 n
0000183191 00000 n
0000175812 00000 n
0000165938 00000 n
0000156137 00000 n
0000148069 00000 n
0000132851 00000 n
0000126814 00000 n
0000117999 00000 n
0000110282 00000 n
0000102594 00000 n
0000047461 00000 n
0000004420 00000 n
0000004540 00000 n
0000004642 00000 n
0000004739 00000 n
0000004836 00000 n
0000004933 00000 n
0000005030 00000 n
0000005127 00000 n
0000005224 00000 n
0000005321 00000 n
0000000302 00000 n
0000505346 00000 n
0000000000 00000 f
0000000016 00000 n
0000433888 00000 n
0000077752 00000 n
0000077178 00000 n
0000076999 00000 n
0000000000 00000 f
0000073357 00000 n
0000078529 00000 n
0000079318 00000 n
0000078816 00000 n
0000078984 00000 n
0000078698 00000 n
0000096782 00000 n
0000078367 00000 n
0000000000 00000 f
0000127965 00000 n
0000073496 00000 n
0000502960 00000 n
0000502913 00000 n
0000500158 00000 n
0000000000 00000 f
0000000000 00000 f
0000000167 00000 n
0000043258 00000 n
0000504153 00000 n
0000503983 00000 n
0000504075 00000 n
0000503963 00000 n
0000112842 00000 n
0000119982 00000 n
0000118282 00000 n
0000105938 00000 n
0000112791 00000 n
0000110541 00000 n
0000096948 00000 n
0000105887 00000 n
0000102877 00000 n
0000043580 00000 n
0000096897 00000 n
0000048243 00000 n
0000006951 00000 n
0000043529 00000 n
0000007976 00000 n
0000008823 00000 n
0000042489 00000 n
0000008868 00000 n
0000008903 00000 n
0000008952 00000 n
0000010139 00000 n
0000010407 00000 n
0000076230 00000 n
0000076146 00000 n
0000076181 00000 n
0000103808 00000 n
0000103724 00000 n
0000103759 00000 n
0000111472 00000 n
0000111388 00000 n
0000111423 00000 n
0000119213 00000 n
0000119129 00000 n
0000119164 00000 n
0000158158 00000 n
0000167920 00000 n
0000166220 00000 n
0000150074 00000 n
0000158107 00000 n
0000156407 00000 n
0000142998 00000 n
0000150023 00000 n
0000148323 00000 n
0000131535 00000 n
0000142947 00000 n
0000133092 00000 n
0000121585 00000 n
0000131484 00000 n
0000127118 00000 n
0000128877 00000 n
0000128793 00000 n
0000128828 00000 n
0000142178 00000 n
0000142094 00000 n
0000142129 00000 n
0000149254 00000 n
0000149170 00000 n
0000149205 00000 n
0000157338 00000 n
0000157254 00000 n
0000157289 00000 n
0000167151 00000 n
0000167067 00000 n
0000167102 00000 n
0000201563 00000 n
0000205465 00000 n
0000203765 00000 n
0000193563 00000 n
0000201512 00000 n
0000199812 00000 n
0000185213 00000 n
0000193512 00000 n
0000191812 00000 n
0000177848 00000 n
0000185162 00000 n
0000183462 00000 n
0000169478 00000 n
0000177797 00000 n
0000176097 00000 n
0000177028 00000 n
0000176944 00000 n
0000176979 00000 n
0000184393 00000 n
0000184309 00000 n
0000184344 00000 n
0000192743 00000 n
0000192659 00000 n
0000192694 00000 n
0000200743 00000 n
0000200659 00000 n
0000200694 00000 n
0000204696 00000 n
0000204612 00000 n
0000204647 00000 n
0000238322 00000 n
0000246180 00000 n
0000243648 00000 n
0000233053 00000 n
0000238271 00000 n
0000236571 00000 n
0000224226 00000 n
0000233002 00000 n
0000231302 00000 n
0000215468 00000 n
0000224175 00000 n
0000222475 00000 n
0000207013 00000 n
0000215417 00000 n
0000212730 00000 n
0000213661 00000 n
0000213577 00000 n
0000213612 00000 n
0000223406 00000 n
0000223322 00000 n
0000223357 00000 n
0000232233 00000 n
0000232149 00000 n
0000232184 00000 n
0000237502 00000 n
0000237418 00000 n
0000237453 00000 n
0000244579 00000 n
0000244495 00000 n
0000244530 00000 n
0000278747 00000 n
0000286979 00000 n
0000285279 00000 n
0000267601 00000 n
0000278696 00000 n
0000276996 00000 n
0000261270 00000 n
0000267550 00000 n
0000265850 00000 n
0000255110 00000 n
0000261219 00000 n
0000259519 00000 n
0000247687 00000 n
0000255059 00000 n
0000253359 00000 n
0000254290 00000 n
0000254206 00000 n
0000254241 00000 n
0000260450 00000 n
0000260366 00000 n
0000260401 00000 n
0000266781 00000 n
0000266697 00000 n
0000266732 00000 n
0000277927 00000 n
0000277843 00000 n
0000277878 00000 n
0000286210 00000 n
0000286126 00000 n
0000286161 00000 n
0000325610 00000 n
0000334603 00000 n
0000332903 00000 n
0000315683 00000 n
0000325559 00000 n
0000323859 00000 n
0000307117 00000 n
0000315632 00000 n
0000313932 00000 n
0000297713 00000 n
0000307066 00000 n
0000305366 00000 n
0000288573 00000 n
0000297662 00000 n
0000295962 00000 n
0000296893 00000 n
0000296809 00000 n
0000296844 00000 n
0000306297 00000 n
0000306213 00000 n
0000306248 00000 n
0000314863 00000 n
0000314779 00000 n
0000314814 00000 n
0000324790 00000 n
0000324706 00000 n
0000324741 00000 n
0000333834 00000 n
0000333750 00000 n
0000333785 00000 n
0000369369 00000 n
0000378404 00000 n
0000376704 00000 n
0000361666 00000 n
0000369318 00000 n
0000367618 00000 n
0000353407 00000 n
0000361615 00000 n
0000359915 00000 n
0000344080 00000 n
0000353356 00000 n
0000351656 00000 n
0000336198 00000 n
0000344029 00000 n
0000342329 00000 n
0000343260 00000 n
0000343176 00000 n
0000343211 00000 n
0000352587 00000 n
0000352503 00000 n
0000352538 00000 n
0000360846 00000 n
0000360762 00000 n
0000360797 00000 n
0000368549 00000 n
0000368465 00000 n
0000368500 00000 n
0000377635 00000 n
0000377551 00000 n
0000377586 00000 n
0000419524 00000 n
0000433837 00000 n
0000432137 00000 n
0000406887 00000 n
0000419473 00000 n
0000417773 00000 n
0000396984 00000 n
0000406836 00000 n
0000405136 00000 n
0000388181 00000 n
0000396933 00000 n
0000395233 00000 n
0000379986 00000 n
0000388130 00000 n
0000386430 00000 n
0000387361 00000 n
0000387277 00000 n
0000387312 00000 n
0000396164 00000 n
0000396080 00000 n
0000396115 00000 n
0000406067 00000 n
0000405983 00000 n
0000406018 00000 n
0000418704 00000 n
0000418620 00000 n
0000418655 00000 n
0000433068 00000 n
0000432984 00000 n
0000433019 00000 n
0000491960 00000 n
0000503912 00000 n
0000499311 00000 n
0000481618 00000 n
0000491909 00000 n
0000489626 00000 n
0000469575 00000 n
0000481567 00000 n
0000479867 00000 n
0000453304 00000 n
0000469524 00000 n
0000467824 00000 n
0000443910 00000 n
0000453253 00000 n
0000451553 00000 n
0000435780 00000 n
0000443859 00000 n
0000440961 00000 n
0000443090 00000 n
0000443006 00000 n
0000443041 00000 n
0000452484 00000 n
0000452400 00000 n
0000452435 00000 n
0000468755 00000 n
0000468671 00000 n
0000468706 00000 n
0000480798 00000 n
0000480714 00000 n
0000480749 00000 n
0000490557 00000 n
0000490473 00000 n
0000490508 00000 n
0000503143 00000 n
0000503059 00000 n
0000503094 00000 n
trailer
<</Size 492/Root 184 0 R/Info 182 0 R/ID[<4C452D867A47EEE3296AF704AA75E926><E1EA773575D43F4EA366DE345EF043EB>]>>
startxref
505701
%%EOF
